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Natural products and their derivatives are very often used as lead compounds for the development 
of biologically active molecules.[1] The percentage of medicinal compounds derived from natural 
products is about 25%.[2-3] A wide plethora of natural products exist, despite the limited amount of 
building blocks used by organisms to synthesize their primary and secondary metabolites. An 
example of a commonly used class of building blocks are the amino acids, which can be linked to 
form proteins or can be transformed into complex secondary metabolites via specialized synthetic 
pathways.  
When two amino acids undergo a double condensation, cyclic dipeptides 1 are formed, which are 
known as piperazin-2,5-diones or 2,5-diketopiperazines (DKPs). These are the smallest cyclic peptides 
(Figure 1). These compounds were recognized as a separate class of compounds around 1900. The 
first synthetic diketopiperazine, cyclo(Gly, Gly), was made in 1888[4] and many of the simpler 
members of this class were synthesized soon thereafter.[5]  
 
Figure 1: General 2,5-diketopiperazine structure 1. 
2,5-Diketopiperazines were originally found in hydrolysates of proteins and processed food and 
drinks, where they can influence the flavor.[6] Therefore, these compounds were considered to be 
side products from terminal proteolysis during fermentation and food processing. However, since 
then they have been recognized as secondary metabolites. They are mostly present in fungi, but they 
can also be found in animals and plants. New additions to the family are commonly isolated from 
cultures of fungi. 
The 2,5-diketopiperazines possess several properties that make them attractive as a scaffold for 
medicinal chemistry. The restricted conformational freedom as a result of their cyclic structure 
endows them with several benefits when compared to their linear dipeptide counterparts. Most 
importantly they are more resistant to enzymatic degradation by proteases with respect to linear 
dipeptides, which results in a longer preservation of their biological activity. Diketopiperazines can be 
used as scaffolds to synthesize peptidomimetic drugs with enhanced activity. Moreover, their 
constrained structure can result in higher receptor selectivity or higher binding affinities in their 
interaction with receptors. Their rigid structure can also be used to determine the active 
conformation of a protein.[7] 
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The class of 2,5-diketopiperazines is thus promising for the development of new drugs. The number 
of possible cyclic dipeptides is rather extensive. Using merely the 20 most abundant L-amino acids 
already gives rise to 200 different diketopiperazines, but there is no limitation to the use of D-isomers 
or other unnatural amino acids. So, where to start? 
Through evolution, conservation of certain structural features has arisen among natural products, 
which results in overrepresentation of a limited number of scaffolds in a large number of different 
secondary metabolite classes.[8] These entities entail specific biological activities and can be 
considered ‘privileged (sub)structures’.[9] Their presence often endows the molecule with a high 
affinity for its receptor, and the same privileged scaffold can do so for parent molecules targeting 
totally unrelated receptors.[10] These privileged (sub)structures are a good indication to look for 
interesting scaffolds.[11] An example is the cyclo(L-Trp, L-Pro) scaffold, also known as brevianamide F 
2a (Figure 2). This structural unit, which displays biological activity on its own, can be found in many 
fungal secondary metabolites with a variety of activities. 
 
Figure 2: Brevianamide F 2a. 
Scaffold 2a constitutes the core structure in the families of the brevianamides (2a, 3) 
(antibacterial),[12] austamides (4),[13-14] spirotryprostatins (5) (cell cycle inhibitor),[15] tryprostatins (6) 
(microtubule inhibitor),[16-17] fumitremorgins (7) (BCRP inhibitor),[18] versicolamides (8),[19] 
paraherquamides (9) (antihelminthic, insecticidal),[20-21] sclerotamides (10),[22-23] notoamides (11),[24-
26] avrainvillamides (12),[27] malbrancheamides (13) (calmodulin inhibitor),[28-29] stephacidins (14) 
(antitumor)[30], aspergamides (16)[31] and VM55599 (15) (Figure 3). These are all fungal secondary 
metabolites that are produced by different Aspergillus and Penicillium species.  
The amino acids that make up the cyclic dipeptide will influence the activity of the final compound. 
Proline differs from the other amino acids because of its secondary amino group that is embedded in 
a cyclic sidechain. When it forms an amide bond it can no longer act as a hydrogen bond donor, only 
as a hydrogen bond acceptor. The cyclic sidechain also influences the conformation and promotes 
the cyclization tendency of dipeptides.  
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Figure 3: Fungal secondary metabolites made up of cyclo(L-Trp, L-Pro) 2a. 
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Tryptophan possesses the indole moiety, a structural unit which is associated with several bioactive 
compounds like the neurotransmitter serotonin 17, the hormone melatonin 18, and the auxins, plant 
hormones like indol-3-ylacetic acid 19 (Figure 4).[32] 
 
Figure 4: Indoles with important activity in animals and plants. 
The natural products in Figure 3 mostly have a multifunctionalized and rather complex 
diketopiperazine skeleton. In view of the broad range of their biological activities (anticancer, 
antibacterial, insecticidal), it is very appealing to study synthetic analogues with a less complex 
structure. Scaffold 2 can be seen as the key intermediate towards these different natural products. 
Therefore, it was chosen as the starting material in the present research. The aim was to decorate 
the basic skeleton 2 through the application of various synthetic methodologies to generate novel 
analogues. 
The first part of the research will focus on the synthesis of the basic skeleton 2 from the amino acids 
tryptophan and proline. These two amino acids frequently occur in natural diketopiperazines (Figure 
3). Different synthetic strategies will be evaluated, after which the basic skeleton will be used for the 
synthesis of analogues with a diverse substitution pattern. 
 
Figure 5: Possible sites of modification in the cyclo(Trp, Pro) scaffold 2.  
The arrows in Figure 5 show the different positions of scaffold 2, which can be modified using 
straightforward synthetic methodologies. The use of amino acids with an opposite chirality will lead 
to the study of the activity of the unnatural counterparts (Figure 5, modification a). Natural 
diketopiperazines are primarily made up from natural L-amino acids. Consequently, they are chiral 
molecules that mainly exist in the cis-configuration. Nonetheless, some piperazin-2,5-diones 
consisting of D-amino acids have been found to occur naturally.[7, 33] Moreover, tadalafil 20, 
a commercially available diketopiperazine-based drug for the treatment of erectile dysfunction, also 
contains the unnatural D-isomer of tryptophan (Figure 6).[34] Thus, the incorporation of unnatural 
amino acids does not exclude the possibility of displaying biological activity. 
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Figure 6: Tadalafil 20. 
The use of hydroxyproline units (Figure 5, modification b) will allow for the decoration of the basic 
scaffold later on in the synthesis, through the introduction of substituents important in medicinal 
chemistry (heterocyclic nuclei, fluorine containing substituents, morpholines, cyclopropyl 
substituents). In this way, starting from a basic diketopiperazine scaffold, a diverse set of analogues 
may be prepared in a highly efficient, divergent way. 
From the basic scaffold 2, different strategies can be adopted to prepare annulated (Figure 5, 
modification c) as well as spiro-derivatives (Figure 5, modification d) with different ring sizes. The 
introduction of a supplementary ring in the basic skeleton will enhance the conformational rigidity of 
the scaffold, which may lead to increased receptor specificity. In research towards active analogues 
from natural products, conformational restriction is often evaluated.[35-39]  
Next to the synthesis of the compounds, attention will be paid to the testing of their bioactivity. 
Compounds will be evaluated in collaboration with the department of Radiotherapy and 
Experimental Cancerology (UZ Gent), the Laboratory of Microbiology (UGent) or by Cerep (France). 
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1. Introduction 
The 2,5-diketopiperazines are abundantly present in nature.[33, 40-42] The most widespread and 
structurally diverse 2,5-diketopiperazine subclass is made up from the amino acids tryptophan and 
proline. Several modes of (iso)prenylation of the simple cyclic dipeptide precursor cyclo(L-Trp, L-Pro) 
or brevianamide F 2a lead to the development of a diverse family of diketopiperazines. Further 
heterocyclization of nonannulated compounds has resulted in the formation of annulated and spiro-
annulated diketopiperazines, while some compounds possess a more complex 
diazabicyclo[2.2.2]octane core.[42]  
The brevianamides are a group of mould metabolites and were the first tryptophan-proline based 
diketopiperazines to be isolated. Over the years numerous new compounds have been found (Figure 
3). This literature study focuses on the brevianamides, which include nonannulated, annulated and 
bridged diazabicyclo[2.2.2]octane-based products. Additionally, the (spiro- and cyclo-)tryprostatins 
and fumitremorgins are discussed, because of their interesting bioactivity, which makes them 
promising leads for anticancer drugs. 
2. Brevianamides 
The brevianamides A-F are secondary metabolites that were originally isolated by Birch et al. in 1969 
from the mould Penicillium brevi-compactum, and were the first examples of this new class of fungal 
alkaloids.[43-45] The structures of brevianamide A-F are shown in Figure 7.  
 
Figure 7: Structures of brevianamides A-F. 
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Brevianamide A 3 was the most abundant of the reported metabolites, isolated from Penicillium 
brevi-compactum. Its relative and absolute stereochemistry were established through X-ray 
crystallographical analysis of its 5-bromo derivative.[46] In addition, brevianamide A 3 was also found 
in other cultures, such as Penicillium viridicatum[47] and Penicillium ochraceum.[48]  
Brevianamide A 3 failed to display antibiotic or antifungal properties.[47] However, it possesses 
antifeedant and insecticidal activities.[49] The compound was evaluated against Drosophila 
melanogaster for feeding inhibition and against Spodoptora littoralis for feeding inhibition and 
mortality. At a concentration of 27 nM, it displayed a significant effect in all three assays. Similar 
antifeedant activity was detected against Spodoptera frugiperda and Heliothis virescens.[50] 
Brevianamide A 3 is thus a mycopesticide (a pesticide produced by fungi). Preliminary toxicity studies 
of brevianamide A 3 showed no acute toxicity in mice upon oral or intraperitoneal administration. 
However, the molecule induced cytotoxicity and inflammatory lung response in intratracheally 
exposed mice, which prohibits its application as an insecticide in food crops.[51-52] 
Brevianamide B 21 is a diastereomer of brevianamide A 3, with all centres but the spirocarbon 
inverted. They are enantiomorphs with respect to the diazabicyclo[2.2.2]octane ring.[53] The natural 
occurring (+)-brevianamide A 3 can be interconverted into the unnatural (-)-enantiomer of 
brevianamide B 21 (Scheme 1). Reduction of brevianamide A 3 with sodium borohydride and acidic 
dehydration of the resulting hydroxyindoline with concomitant rearrangement results in 
deoxybrevianamide A 25.[44] Subsequent re-oxidation to the hydroxyindolenine and rearrangement 
with base yields (-)-brevianamide B 21.[45] Brevianamide A and B are found to appear after 
conidiation and are mainly present in the aerial hyphae of the fungus.[54-55] 
 
Scheme 1: Interconversion of (+)-brevianamide A 3 in (-)-brevianamide B 21. 
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Characterization studies revealed that brevianamides C 22 and D 23 are in fact photochemical 
artifacts formed during fermentation and isolation, and not true metabolites of enzymatic origin. 
Both can be prepared by irradiation of brevianamide A 3 and they were not detected in P. brevi-
compactum when grown in the dark.[45] 
The absolute configuration of brevianamide E 24 was determined on the basis of its first 
enantioselective total synthesis.[56-57] Reduction of brevianamide E 24 with zinc in acetic acid gave 
deoxybrevianamide E 26 (Scheme 2).[43-44] Deoxybrevianamide E 26 has been isolated as a metabolite 
in cultures of Aspergillus ustus and is a natural product on its own.[13, 58] Deoxybrevianamide E 26 
slowly converts into brevianamide E 24 by aerial oxidation, leading to the suspicion of 
brevianamide E 24 being an artifact.[59] However, if this should be the case, brevianamide E 24 would 
have been detected in the cultures of A. ustus alongside of deoxybrevianamide E 26. Since no trace 
of brevianamide E 24 was present, the compound cannot be an artifact, but represents a dead end in 
the biosynthetic pathway.[60] 
 
Scheme 2: Relation between brevianamide E 24 and deoxybrevianamide E 26. 
Brevianamide F 2a, the simplest of the brevianamides, is the condensation product of L-tryptophan 
and L-proline. Its biological activity has been studied most extensively. Preliminary investigations 
have shown the potential of cyclo(L-Trp, L-Pro) 2a as an antimicrobial substance.  
Compound 2a also showed potential for use in the treatment of cardiovascular dysfunction, since it 
affected sodium, calcium and potassium channels.[61] The effects of all four isomers of 2 on the heart 
and ion-channel activity were examined (Table 1).  
Cyclo(D-Trp, L-Pro) 2b displayed an antagonistic effect on the calcium channel thus inhibiting the 
influx of Ca2+ (blocking the current), while the other isomers acted as agonists increasing the inward 
current of Ca2+. All four isomers exhibited antagonistic effects on the sodium ion channel. No effect 
was noted on the inward rectifier potassium current for cyclo(L-Trp, D-Pro) 2c and cyclo(D-Trp, D-Pro) 
2d, while cyclo(L-Trp, L-Pro) 2a and cyclo(D-Trp, L-Pro) 2b behaved as antagonists.  
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Table 1: Qualitative representation of the effects of the isomers on Ca
2+
-, K
+
-, Na
+
-channel activity. 
Cyclic dipeptide Effect on: 
Ca2+ channels[a] 
100 µM 
Na+ channels[b] 
100 µM 
K+ channels[c] 
10 µM 
Cyclo(L-Trp, L-Pro) 2a agonist antagonist antagonist 
Cyclo(D-Trp, L-Pro) 2b antagonist antagonist antagonist  
Cyclo(L-Trp, D-Pro) 2c agonist antagonist no significant effect 
Cyclo(D-Trp, D-Pro) 2d agonist antagonist no significant effect 
[a] Holding potential -90 mV and test potential 5 mV. [b] Holding potential -90 mV and test 
potential -30 mV. [c] Holding potential -80 mV and test potential between -140 mV and -50 mV. 
The cis-isomers (2a and 2d) showed no significant effect on the heart rate. In contrast, cyclo(L-Trp, D-
Pro) 2c increased the heart rate and cyclo(D-Trp, L-Pro) 2b exhibited a decrease in heart rate. The 
coronary flow rate was not influenced by any of the isomers. In addition, all isomers significantly 
reduced the duration of ventricular tachycardia (rapid heartbeat) and arrhythmia (irregular 
heartbeat, too fast or too slow), as well as the time to sinus rhythm (normal heartrate) thus showing 
antiarrhythmic potential.[62] However, further studies revealed the hepatotoxicity of the isomers.[63] 
The administration of the compounds involves potential harm, which may limit their potential usage 
in the treatment of various diseases.  
Also antifungal activity has been recorded.[64] Moreover, brevianamide F 2a gave potent inhibition of 
seedling growth. A possible explanation for this behavior lies in the structural similarity between 
brevianamide F 2a and indol-3-ylacetic acid 19, a plant hormone involved in plant growth and 
development. Brevianamide F 2a might block the interaction of indol-3-ylacetic acid 19 with its auxin 
receptor, resulting in plant growth inhibition. Brevianamide F 2a might lead the way to a natural, 
eco-friendly herbicide.[65] 
Later studies have reported on the isolation of new members of the brevianamide family such as 
brevianamide J 27, a dimer, and brevianamide K 28. Both were isolated from the fungus Aspergillus 
versicolor.[66] Brevianamides Q 29 and R 30 were also obtained from the solid-state fermented rice 
culture of the fungus Aspergillus versicolor (Figure 8).[67] Several other diketopiperazine alkaloids 
were isolated, namely brevianamides L-P. In contrast to the earlier discussed members of the 
brevianamide class, these metabolites do not bear a cyclo(Trp, Pro) core. 
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Figure 8: Structures of brevianamides J, K, Q and R. 
The latest addition to the brevianamide series are the brevianamides S-V (Figure 9).[68] These 
alkaloids were found in an Aspergillus versicolor isolated from sediment obtained in the Bohai Sea, 
China. Brevianamide S 31 displayed no significant inhibitory activity against several Gram-positive 
and -negative bacteria and the fungus Candida albicans. However, a significant antibacterial acivity 
against Bacille Calmette-Guérin was reported. Selectivity towards the latter, a screening surrogate 
for Mycobacterium tuberculosis, is indicative of a new mechanism of action and might thus constitute 
a very appealing hit in the search for new antitubercular drugs. Brevianamide J 27 and 
brevianamide S 31 are the only two hitherto discovered brevianamides, which are members of the 
class of dimeric diketopiperazines. 
 
Figure 9: Brevianamides S-V. 
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3. Biosynthetic pathway 
In the following part, the current knowledge on the biosynthesis of brevianamides A 3 and B 21 will 
be discussed. Their structural complexity arises from the presence of both the spirocyclic junction 
and the bicyclic structure, and several mechanisms to their origin have been proposed. 
During the structural elucidation of brevianamide A 3, the presence of an indole group and a 
diketopiperazine ring suggested tryptophan as a biological precursor, with a link to another amino 
acid. Moreover, mass and NMR spectra indicated the presence of an isoprene unit. Feeding 
experiments with 14C-labeled tryptophan, proline and mevalonic acid lactone resulted in significant 
incorporation into brevianamide A 3 by P. brevi-compactum, confirming that brevianamide A 3 may 
be biosynthetically derived from proline, tryptophan and mevalonic acid. On the basis of this work, a 
biosynthetic precursor in the form of deoxybrevianamide E 26 was suggested.[44] Additionally, a 
feeding experiment with 14C-labeled cyclo(L-Trp, L-Pro) 2a proved that brevianamide F 2a is 
incorporated into brevianamide A 3.[69] 
As a result, a biosynthetic sequence was proposed starting with the coupling of the amino acids 
L-proline and L-tryptophan. A gene encoding for a brevianamide F synthetase enzyme has been 
identified.[70] Brevianamide F 2a is subsequently converted in brevianamide A 3 via the intermediate 
deoxybrevianamide E 26 (Scheme 3).[69]  
 
Scheme 3: Biosynthetic pathway to brevianamide A 3. 
Radio-labeled [8-3H]deoxybrevianamide E 26 was used to validate the hypothesis that this molecule 
is an intermediate in the biosynthetic pathway of brevianamides A 3, B 21 and E 24.[60] The formation 
of deoxybrevianamide E 26 from brevianamide F 2a necessitates the introduction of an isoprenyl 
group at the C-2 position of the indole (Scheme 4). This isoprene unit is delivered by 
dimethylallylpyrophosphate (DMAPP), arising from the mevalonate pathway. The most recent report 
for the attachment of the isoprenyl group suggests the presence of a “reverse” prenyl transferase in 
which DMAPP undergoes electrophilic attack at C-3 via an SN2’ mechanism instead of at the 
phosphorylated end.[71] 
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Scheme 4: Introduction of the isoprene unit. 
The most intriguing feature is the diazabicyclo[2.2.2]octane core present in (among others) 
brevianamide A 3 and B 21. Porter and Sammes postulated that the bridged architecture was the 
result of an intramolecular Diels-Alder reaction (Scheme 5).[72]. Such a [4+2] cycloaddition reaction 
has rarely been proven to occur in the biosynthesis of natural products. Hence, it is not surprising 
that the biosynthetic origin of the tricyclic framework has received a lot of attention.[23, 60, 73-80] Two 
possible routes for the transformation of deoxybrevianamide E 26 into brevianamide A 3 and B 21 
have been investigated. The two pathways differ in the order in which the intramolecular Diels-Alder 
reaction and the formation of the spiro-indoxyl group take place. 
 
Scheme 5: Proposed biosynthetic Diels-Alder reaction constructing the bicyclo[2.2.2] ring system. 
The original biosynthetic proposal included the formation of the achiral azadiene 35 by the oxidation 
of the tryptophan unit and enolization of the proline unit from deoxybrevianamide E 26 (Scheme 6). 
Cycloaddition of 35 with the isoprenyl group can take place at both sides of the azadiene, resulting in 
a mixture of hexacyclic compounds 36. Taking into account that brevianamide A 3 and B 21 are 
produced by the fungi in different amounts, this would imply the formation of the enantiomers 36 in 
unequal amounts. Since compound 36 does not autoxidize to either brevianamide A 3 and B 21, this 
would imply an enzyme-mediated conversion of 36 into 3 or 21. A hydroxyl group would be 
introduced, proposedly by an (R)-selective indole oxidase. Then, a pinacol-type ring contraction of 
the hydroxyindolenines 37and 38 would lead to brevianamides A 3 and B 21.  
The main concern with this proposal was that the most abundant metabolite, brevianamide A 3, 
would be formed by oxidation at the most hindered side of the indole group (via 37), while the minor 
metabolite, brevianamide B 21, would arise from oxidation at the least hindered side of 36.[53, 81] 
When feeding experiments proved that structures 36 are not intermediates in the biosynthesis of 
brevianamides A 3 and B 21, this pathway was abandoned.[60]  
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Scheme 6: Original proposal for the biogenesis of brevianamide A 3 and B 21. 
Subsequently, a different biosynthetic pathway was proposed that also takes into account the 
formation of brevianamide E 24 (Scheme 7).[60, 74] In this proposal, deoxybrevianamide E 26 
undergoes an (R)-selective hydroxylation reaction at C-3 of the indole unit, furnishing 3-
hydroxyindolenine 39. Thereupon, compound 39 is either converted in brevianamide E 24 via an 
irreversible nucleophilic addition of the secondary amide-N to the iminium bond of 39 (pathway a) 
or, alternatively, via a stereospecific pinacol-type rearrangement of 3-hydroxyindolenine 39 
(pathway b) that affords an (R)-stereochemistry at the quaternary spiro-carbon of 40. The latter is 
subsequently transformed in brevianamide A 3 and B 21 through the oxidation and enolization of the 
diketopiperazine core (41) and an intramolecular Diels-Alder reaction.  
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Scheme 7: Current proposed biosynthetic route for brevianamides A, B and E. 
The transition state structures of the last step of this pathway (41) were further investigated to 
assess the possibility of a biological Diels-Alder reaction, during which the azadiene 41 would 
undergo a [4+2] cycloaddition with the isoprenyl group (Scheme 8). A priori, four diastereomers can 
be formed, but only (+)-brevianamide A 3 and B 21 are known natural products. The relative 
activation energies of the four stereoisomeric transition state structures 41 were calculated relative 
to 41a and are depicted in Scheme 8. Structures 41a and 41b lead to the formation of 
brevianamide A 3 and B 21, respectively, while structures 41c and 41d would lead to 42 and 43, 
diastereomers of 3 and 21, which are not known to occur in nature.[75]  
These calculations are made assuming compounds are in the gas phase, in the absence of solvent. 
This is in contrast to the natural, aqueous environment of the cells. It is known that a polar solvent 
like water can enhance the Diels-Alder reaction.[82] So these ab initio studies do not accurately 
mimick the biological environment. However, the findings concur with the observations and are 
helpful to rationalize what’s happening. 
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Scheme 8: The calculated relative energies for transition state structures 41 of the intramolecular [4+2] cycloaddition. 
The transition state structure for brevianamide A (41a) has the lowest potential energy barrier, which 
can be explained by the formation of an intramolecular hydrogen bond. This stabilizes the transition 
structure resulting in the major formation of brevianamide A 3 as the most abundant secondary 
metabolite in contrast to brevianamide B 21.[75] It has been shown that the intramolecular 
cycloaddition in these systems can proceed spontaneously at room temperature.[77] The potential 
energy barriers towards stereoisomers 42 and 43 is much higher, accordingly these compounds 
(presumably) do not occur in nature. Their higher activation energy is caused by the orientation of 
the vinyl group with respect to the azadiene, which is in turn influenced by the concomitant 
formation of the five-membered ring during the Diels-Alder reaction (Figure 10). This forces the vinyl 
group to twist around the forming C-C bonds 1-2 and 3-4. As a consequence these three bonds (1-2, 
2-3 and 3-4) are not in the same plane. The dihydral angle (1-2-3-4) is bigger for the transition 
structures leading to 42 and 43 than the one in the intermediates leading to brevianamides A 3 and 
B 21. This leads to an ineffective overlap in the structures 41c and 41d explaining their higher 
activation energies.  
 
Figure 10: Top and front view of the transition state structures to 3, 21, 42 and 43. 
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4. Syntheses 
The first asymmetric total synthesis of brevianamide E 24 was reported by Kametani et al. in 1980 
(Scheme 9).[56-57] This total synthesis of brevianamide E was the first one in the brevianamide series 
to be reported. This was partly due to the simpler structure of brevianamide E 24 with respect to that 
of brevianamide A 3 and B 21, and partly because its structure had not yet been confirmed by X-ray 
crystallography at the time, in contrast to brevianamide A 3.[59]  
The diketopiperazine core was synthesized starting from the acid chloride 44 of N-Cbz-L-proline, 
which was reacted with dimethyl 2-aminomalonate 45 under Schotten-Baumann conditions to 
give 46. Deprotection of the Cbz group by hydrogenolysis yielded the free amine 47, which was 
heated in the presence of hydroxypyridine to afford the diketopiperazine 48. Condensation of 48 
with isoprenylated gramine 49 using sodium hydride provided two diastereomers 50a and 50b. Both 
50a and 50b were subsequently converted to deoxybrevianamide E 26 and its epimer 51 by 
hydrolysis and decarboxylation of 50. In the final step, deoxybrevianamide E 26 was subjected to 
photo-oxidation in the presence of Rose Bengal followed by treatment with dimethyl sulfide, 
furnishing brevianamide E 24 and its diastereomer 52. 
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Scheme 9: Asymmetric total synthesis of brevianamide E 24. 
The synthesis of brevianamide E 24 has been studied by several groups over the past 35 years.[56-57, 59-
60, 83-84] The main challenge comprised the synthesis of the syn-cis configured 
hydroxypyrroloindolenine core (marked in red in 24, Scheme 10). The majority of the developed 
syntheses were based on an oxidative cyclization step using photo-oxidation (vide supra) or 
dimethyldioxirane (DMDO)[84] of deoxybrevianamide E 26, which always resulted in a mixture of 
diastereomers: syn-cis brevianamide E 24 and anti-cis epi-brevianamide E 52.  
The first stereoselective synthesis of brevianamide E 24 dates from 2012 (Scheme 10).[85] An 
isoprenyl group was introduced at C-2 of the indole in Nα-phthaloyl-tryptophan methyl ester 53 using 
prenyl-9-BBN. Removal of the phthaloyl and methyl groups from 54 under basic conditions gave the 
triethylammonium salt 55 after workup. Subsequent tritylation of 55 and coupling of proline methyl 
ester under standard conditions yielded dipeptide 56. The key step in the sequence was the selective 
DMDO-mediated oxidation of dipeptide 56, which yielded the syn-cis diastereomer 58 in high 
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selectivity (yield 82%, dr > 8:1). This contrasts with the poor diastereoselectivities obtained in DMDO-
mediated oxidations of various other dipeptides of the form N–Trt-Trp-AA-OMe (where AA is one of 
12 standard amino acids). The increased steric bulk of proline compared to other amino acids favors 
the formation of one diastereomeric transition state 57, in which DMDO-mediated oxidation and 
pyrrole ring closure are synchronized to favor the syn-cis product 58. The presence of the nitrogen 
from Trp may further promote the facial indole reactivity. Removal of the trityl group in the presence 
of hexafluoroisopropanol (HFIP) and treatment with DIPEA gave brevianamide E 24.  
 
Scheme 10: Stereoselective synthesis of brevianamide E 24. 
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The structure of brevianamide A 3 had already been confirmed by X-ray analysis of its 
5-bromo derivative.[46] Brevianamide B 21 was thought to be the stereoisomer of brevianamide A 3 
about the spiro-centre.[45] The first total synthesis of brevianamide B 21 did not only confirm its 
structure,[86] but also revealed that both the synthetic brevianamide B and the semisynthetic product 
derived from brevianamide A 3 were of the opposite absolute configuration of natural 
(+)-brevianamide B 21.[53, 81]  
This synthesis started from allylated proline derivative 60, which was reacted with lithium 
p-methoxybenzylamine to form the amide 61. Condensation of 61 with bromoacetyl bromide and 
subsequent ring closure yielded DKP 62. Ozonolysis of 62 furnished aldehyde 63, which was 
converted into allylic alcohol 64 by a Wittig reaction and a reduction. Allylic alcohol 64 was protected 
as the corresponding tert-butyldimethylsilyl ether 65. Next, methoxycarbonylation of 65 afforded a 
diastereomeric mixture of 66 (Scheme 11).  
 
Scheme 11: Synthesis of intermediate 66 towards (-)-brevianamide B 21. 
Following the methodology of Kametani the mixture of diastereomers 66 was treated with gramine 
and a single diastereomer 67 was obtained (Scheme 12).[56, 87] Demethoxycarbonylation of 67 
involved hydrolysis to the carboxylic acid and rapid thermal decarboxylation to furnish 68 with the 
desired syn-isomer 68a as the main product. Compound 69 was obtained by protection of the indole-
N and deprotection of the allylic alcohol of 68a. Conversion of allylic alcohol 69 into the allylic 
chloride 70 was followed by an intramolecular SN2’ cyclization to 71 and 72. This step is crucial for 
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setting the stereogenic center at the bridge. It was found that the cyclization of 70 in the presence of 
sodium hydride and 18-crown-6 ether resulted in the formation of mainly the desired isomer 71 (in a 
4.9:1 ratio) while the reaction performed with sodium hydride in benzene resulted in the highly 
stereoselective formation of the undesired isomer 72 in 82% yield (71:72 3:97 ratio). 
 
Scheme 12: Synthesis of intermediate 71 towards (-)-brevianamide B 21. 
The rationalization for this change in stereoselectivity is based on the assumption that the 
environment of the enolate that is generated during the reaction plays an important role in the 
formation of the two possible products 71 and 72 (Scheme 13). In good cation-solvating conditions a 
bulky solvent shell can be created around the sodium cation. This creates a sterically demanding 
environment around the enolate oxygen. As a result, the allylic chloride will fold over the enolate as 
depicted in transition state 73b to obtain the correct transition-state geometry for cyclization. 
However, cyclization in the nonpolar, poor ligating solvent benzene favors the formation of transition 
state 73a, which brings the sodium cation and the developing chloride anion in close proximity, 
resulting in the formation of 72. 
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Scheme 13: Rationalization for the change in stereochemistry leading to 71 and 72. 
To complete the synthesis of (-)-21, compound 71 was stirred with HCl in dioxane to effect 
concomitant removal of the N-Boc protecting group and cyclization to produce the hexacycle 74 
(Scheme 14). Oxidation of 74 with mCPBA at the least hindered side of the indole moiety led to 
hydroxy indolenine 75, which after a base-induced rearrangement furnished indoxyl 76. The final 
step in the synthesis of (-)-brevianamide 21 involved the removal of the p-methoxybenzyl group, 
which required deprotonation with tert-butyllithium and quenching of the benzylic anion with 
oxygen. 
 
Scheme 14: Final steps in the synthesis of (-)-brevianamide B 21. 
A shorter, diastereoselective synthesis of d,l-brevianamide B 21 has also been accomplished by the 
group of Williams (Scheme 15).[88] A different approach for the formation of the tricyclic core was 
used here. Michael addition of ethyl 1,3-dithiane-2-carboxylate to dienone 77 gave dithiane 78. 
Hydrolysis of the ester provided acid 79, which was coupled with L-prolinamide to compound 80. 
Oxidative deprotection of 80 gave a mixture of diketopiperazine 81 and 82. The mixture of 81 and 82 
was treated with AlCl3 leading to the desired enantiomeric Diels-Alder adducts 83 and side product 
84. After isolation of the enantiomers 83, the indole heterocycle was formed via a Fischer indole 
reaction. The final conversion of the 2,3-disubstituted indole 36 to the spiro-indoxyl moiety was 
similar to the final steps in the previously described synthesis of (-)-brevianamide B 21, including the 
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stereoselective epoxidation to 3-hydroxyindolenine 38 and pinacol-type rearrangement to form 
racemic brevianamide B 21.  
 
Scheme 15: Synthesis of a mixture of brevianamide B enantiomers. 
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5. Other Trp-Pro based diketopiperazines 
A family of prenylated Trp-Pro-based diketopiperazines has been isolated from the fermentation 
broth of the marine fungus Aspergillus fumigatus BM939 by Osada et al. These compounds include 
tryprostatin A, B,[15, 89-90] the cyclotryprostatins A-D,[91] spirotryprostatin A and B,[92-93] fumitremorgin 
C and demethoxyfumitremorgin C,[15] all of which cause cell cycle arrest at the G2/M phase (Table 2). 
Table 2: Inhibitory activity towards the cell cycle progression of tsFT210 cells. 
Cpd  IC50 (µM) MIC (µM) 
6 Tryprostatin A 78.7 16.4 
85 Tryprostatin B 18.8 4.4 
86 Spirotryprostatin A 197.5  
5 Spirotryprostatin B 14.0  
87 Cyclotryprostatin A 5.6  
88 Cyclotryprostatin B 19.5  
89 Cyclotryprostatin C 23.4  
90 Cyclotryprostatin D 25.3  
7 Fumitremorgin C 14.0 4.1 
91 Demethoxyfumitremorgin C 1.78 0.45 
5.1. Tryprostatins 
Tryprostatin A 6 and B 85 arrest cell cycle progression at the G2/M phase in tsFT210 cells (a cell line 
used to detect inhibitors of the mammalian cell cycle) with IC50 values of 78.7 µM for 6 and 18.8 µM 
for 85 (Figure 11, Table 2).[15, 89-90] Tryprostatin A 6 inhibits the formation of microtubules, which are 
essential for mitosis, by interfering with the interaction between microtubule-associated proteins 
(MAP) and the C-terminal domain of tubulin.[16, 94] This represents a novel mechanism, as most other 
antimitotic agents interact with tubulin.[95]  
 
Figure 11: Tryprostatin A 6 and B 85. 
II. Literature overview 
26 
 
Moreover, tryprostatin A 6 was inhibits the breast cancer resistance protein (BCRP).[17] BCRP is an 
energy-dependent (ATP) transmembrane drug-efflux pump, which contributes to the multidrug 
resistance (MDR) of cancers. An increased expression of BCRP causes resistance of certain cancer cell 
lines against antitumor drugs like mitoxantrone, topotecan and doxorubicin, by preventing the 
chemotherapeutic drugs from reaching lethal levels within the cells. Inhibitors of BCRP can thus be 
considered chemosensitizers. In normal tissues the expression of BCRP is limited, which makes 
inhibition of BCRP an attractive strategy to reverse MDR. Tryprostatin A 6 reverses a mitoxantrone-
resistant phenotype in the human gastric carcinoma cell line EPG85-257RNOV and the human breast 
cancer cell line MCF-7/AdrVp (both cell lines exhibited acquired BCRP-mediated MDR) at 
concentrations of 10–50 µM, so that the cellular mitoxantrone accumulation is no longer BCRP-
dependent. At these concentrations no cytotoxicity was observed.[17] The presence of the methoxy 
group in tryprostatin A 6 reduces the cytotoxicity compared to tryprostatin B 85 and enhances the 
specificity for inhibition of microtubule assembly. A MTT assay determined that the IC50 of 
tryprostatin A 6 was 400 µM whereas tryprostatin B 85 displayed an IC50 value of 4 µM.
[96] 
Tryprostatin A analogues may thus be considered a hit in the search for novel antimitotic and BCRP 
inhibiting agents. 
Despite their rather simple, nonannulated structure, the synthesis of 6 and 85 requires several steps 
to obtain the appropriately substituted tryptophan derivatives 105 and 106.[97-98] In a sequence 
reported by Cook et al., indoles 92 and 93 are protected by the introduction of a Boc group (Scheme 
16). Then, the protected 3-methylindoles 94 and 95 are reacted with NBS to afford the 
3-(bromomethyl)indoles 96 and 97. Reaction of brominated compounds with the anion of the 
Schöllkopf chiral auxiliary 98 provides the desired trans-diastereomers 99 and 100 with 100% 
diastereoselectivity. Next, using NBS, bromination of the indole C-2 position is accomplished. The 
resulting compounds 101 and 102 are treated with LDA and prenyl bromide to introduce the prenyl 
group. Hydrolysis of the dihydropyrazine unit in 103 and 104 under acidic conditions affords the 
substituted L-tryptophan derivatives 105 and 106. The coupling of the latter with N-Fmoc-L-prolyl 
chloride 107, together with removal of the Fmoc group, is accomplished by the addition of the base 
4-(aminomethyl)piperidine (4-AMP). Finally, the dipeptides 108 and 109 are heated in xylenes at 
reflux to yield tryprostatins A 6 and B 85.  
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Scheme 16: Enantiospecific total synthesis of tryprostatin A 6 and B 85.  
5.2. Spirotryprostatins 
The spirotryprostatins A 86 and B 5 possess a unique spiro-fusion to a pyrrolidine at the 3-position of 
the oxindole (Figure 12). This intriguing feature is characteristic for the spirotryprostatins and is not 
present in the brevianamide series. The spirotryprostatin A 86 displayed the weakest biological 
activity of the DKP family of cell cycle inhibitors (Table 2).  
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Figure 12: Spirotryprostatin A 86 and B 5. 
Different syntheses of spirotryprostatin B 5 have been developed, motivated by its unique structure 
and limited availability from natural sources (11 mg from a 400 L fermentation).[99-106] The main 
challenges were the introduction of the spirocyclic center and the prenyl-substituted carbon with the 
correct stereochemistry. The most recent total synthesis by Trost and Stiles affords the natural 
isomer of spirotryprostatin B 5 in eight steps.[107] 
The diketopiperazine core was constructed from N-Cbz-L-proline 111 and dimethyl aminomalonate 
hydrochloride 110. Next, the methyl ester in DKP 48 was transesterified with prenyl alcohol in the 
presence of Otera’s catalyst.  
The oxindole group, which was to be introduced on the diketopiperazine ring, was prepared by 
formylation of 113. The alcohol 114 was converted to the corresponding vinyl tosylate and the 
lithium salt of DKP 112 was added. The coupled product 115 was obtained as a 1:1.7 mixture of 
diastereomers (Scheme 17). 
 
Scheme 17: Synthesis of the key intermediate 115 towards spirotryprostatin B 5 by Trost and Stiles. 
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The diastereomers 115 were subjected to palladium catalysis to effect the concomitant 
decarboxylation-prenylation, which yielded a mixture of products 116 and 117. After a screening of 
different reaction conditions, the desired product 116 was present as the major compound (Scheme 
18). 
To accomplish the final cyclization, selenium chemistry was used on 116. The intermediately 
obtained selenide 116-int was oxidized and eliminated to provide the allylic acetate 118. The final 
cyclization to 5 was accomplished by generation of an aluminum amide on treatment with 
trimethylaluminum. Spirotryprostatin B 5 was obtained in 13% overall yield, together with minor 
amounts of isomers 119 and 120. 
 
Scheme 18: Total synthesis of spirotryprostatin B 5 via a diastereoselective prenylation. 
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5.3. Cyclotryprostatins 
Cyclotryprostatins A 87, B 88, C 89 and D 90, isolated from the secondary metabolites of Aspergillus 
fumigatus BM939, were also identified as inhibitors of the mammalian cell cycle (Figure 13). 
Compounds 87–90 inhibited the cell cycle progression of tsFT210 cells at the G2/M phase with 
IC50 values of 5.6 μM (87), 19.5 μM (88), 23.4 μM (89) and 25.3 μM (90), respectively. 
 
Figure 13: Cyclotryprostatins A-D. 
These compounds contain an annulated structure similar to the fumitremorgins. Cyclotryprostatin C 
89, for example, was synthesized as intermediate towards demethoxyfumitremorgin B 129 (Scheme 
19).[108] The annulated structure is obtained by a Pictet-Spengler reaction of L-tryptophan methyl 
ester 121a with aldehyde 122. The 1,3-cis-β-carboline 123a was formed as the major product, next to 
the trans-isomer 123b. Compound 123a was coupled with N-Troc-L-prolyl chloride derivative 124 to 
afford dipeptide 125. Next, dehydrogenation with DDQ was performed providing dipeptide analogue 
126. The prenyl group was achieved through dehydrosulfenylation of 126. Removal of the protecting 
group of 127 followed by cyclization yielded the pentacyclic compound 128. Finally, dihydroxylation 
of the double bond led to cyclotryprostatin C 89, which was further converted in 
demethoxyfumitremorgin B 129. 
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Scheme 19: Synthesis of cyclotryprostatin C 89 as intermediate towards demethoxyfumitremorgin B 129. 
5.4. Fumitremorgins 
Fumitremorgin C 7 and demethoxyfumitremorgin C 91 were also isolated from the fermentation 
broth of Aspergillus fumigatus BM939 by Osada et al. (Figure 14).[94] Fumitremorgin C 7 was 
identified as a BCRP-specific inhibitor and thus acts as a chemosensitizing agent, which reverses 
MDR.[18, 109] However, fumitremorgin C 7 has tremor-inducing activity[110] and causes cell-cycle arrest 
at the G2/M phase.[15] Therefore, fumitremorgin C analogues are required, which are more selective 
and display less toxicity.[111-112]  
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Figure 14: Fumitremorgin C 7 and demethoxyfumitremorgin C 91. 
Demethoxyfumitremorgin C 91 is the most effective inhibitor of the mammalian cell cycle of these 
natural diketopiperazines (Table 2). Removal of the methoxy group on the aromatic ring causes an 
increase in inhibitory activity with respect to 7, which is also observed for tryprostatin A 6 and B 85, 
and spirotryprostatin A 86 and B 5, respectively. The minimal inhibitory concentration (MIC) of 
0.45 µM for 91 is a tenfold lower than for fumitremorgin C 7 (MIC 4.1 µM). 
A concise three-step synthesis of demethoxyfumitremorgin C 91 was reported, which starts off by 
treating L-tryptophan methyl ester 121a with 3-methyl-2-butenal in pure trimethyl orthoformate to 
generate the imine 130 (Scheme 20).[113] The imine was acylated with N-Fmoc-L-prolyl choride 107 to 
afford a 1.4:1 diastereomeric mixture of the annulated dipeptides 131 and 132 via an acyliminium 
Pictet-Spengler condensation. After separation, the diastereomers were subjected to deprotection 
and simultaneous cyclization in the presence of piperidine to afford the natural product 91 and its 
diastereomer 133. 
 
Scheme 20: Synthesis of demethoxyfumitremorgin C 91. 
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5.5. Biosynthetic pathway 
The fumitremorgin biosynthetic pathway is responsible for the biosynthesis of the tryprostatins. 
Tryprostatins A 6 and B 85 are the biosynthetic intermediates towards fumitremorgin-type alkaloids 
and are the presumed precursors of the spirotryprostatins (Scheme 21).[114]  
The peptide synthetase FtmA is responsible for the formation of brevianamide F 2a from 
L-tryptophan and L-proline.[70] Next, the brevianamide F scaffold is decorated with a prenyl group by 
prenyltransferase FtmB, which leads to tryprostatin B 85.[115] FtmC effectuates aromatic 
hydroxylation of 85 yielding desmethyltryprostatin A 134,[116] which is subsequently methylated by 
FtmD resulting in tryprostatin A 6.[117] When tryprostatin A 6 is exposed to FtmE, the indole ring is 
fused to the diketopiperazine core to form the pentacyclic fumitremorgin C 7.[116] The mechanism for 
spiro-carbon formation, which is involved in the conversion of fumitremorgin C 7 into 
spirotryprostatin A 86, is supposedly mediated by FqzB.[118] FqzB is an FAD-containing monooxidase 
originating from an unrelated gene cluster. This crossover of biosynthetic pathways allows organisms 
to widen the range of metabolites that they can synthesize. The FqzB enzyme catalyzes a 
stereoselective epoxidation of the indole double bond between C-2 and C-3 in 7, which is followed by 
a semipinacol-type rearrangement resulting in spirotryprostatin A 86.  
Tryprostatin B 85 is also an intermediate in the biosynthesis of spirotryprostatin B 5. FtmE converts 
spirotryprostatin B 85 in demethoxyfumitremorgin C 91 through fusion of the indole ring and 
diketopiperazine moiety. FtmG and not FqzB is responsible for the formation of the spirocentre in 5 
from 91. Exposure of 91 to FtmG does not only afford spirotryprostatin B 5, but also compounds 135 
and 136, the mono- and dihydroxylated form of 91, respectively. Structure 136 resembles 
cyclotryprostatin C 89, however, the stereochemistry was not determined. 
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Scheme 21: Proposed biosynthesis of tryprostatins, fumitremorgins and spirotryprostatins in A. fumigatus BM939. 
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The proposed reaction mechanism for the working of enzyme FtmG involves a P450 heme-catalyzed 
initial radical formation (137) and subsequent hydroxylation of 91 (Scheme 22). Upon the second 
radical formation (138a), the radical can migrate to C-2 (138b). Hydroxylation of 138b results in 
compound 139, which undergoes a semipinacol-type rearrangement and dehydratation, with 
concomitant spiro-ring formation, leading to spirotryprostatin B 5. When the radical in 138a does not 
migrate, the subsequent hydroxylation will result in diol 136. 
 
Scheme 22: Proposed mechanism for spirocarbon formation in 5 and diol 136 via a radical route catalyzed by FtmG. 
Thus, spirotryprostatins A and B are the result of two different spiro-carbon formation mechanisms. 
On the one hand, the epoxide route catalyzed by FqzB, furnishes spirotryprostatin A 86, on the other 
hand a radical route catalyzed by FtmG, yields spirotryprostatin B 5. 
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6. Conclusion 
The interest in the diketopiperazine classes discussed above stems from their pharmaceutical 
importance and diverse, sophisticated structure.  
Many of these natural products display important biological activities (mitotic or BCRP inhibition). 
Fumitremorgin C 7 is a strong BCRP inhibitor, which reverses multidrug resistance of cancer cells. 
Some compounds display a new mode of action. Tryprostatin A 6, for example, inhibits microtubules 
formation by interfering with MAP instead of interacting with tubulin itself. Unfortunately, these 
compounds also cause negative side effects such as tremor-induction. Analogues are being 
investigated to find compounds with improved selectivity.[112, 119-122]  
Moreover, synthetic chemists have been attracted by the structural complexity of certain fungal 
metabolites such as the spirotryprostatins, and as a result these compounds were often chosen as 
the targets of total syntheses.[118] 
Despite the apparent common biosynthetic origin of these natural products, i.e. brevianamide F 2, 
uncertainties about the biological pathways leading to these alkaloids still exist. The mechanisms for 
the intramolecular Diels-Alder reaction remain to be unraveled. The study of the spiro-carbon 
formation in the biosynthesis of spirotryprostatins has revealed two different mechanisms for 
spiro-carbon formation. The investigation of the biosynthesis of these complex fungal metabolites 
may be aided by the development of structural analogues. Biomimetic total syntheses can provide 
valuable insights into the biosynthetic origin of the diketopiperazines and may aid in discovering the 
enzymes which are involved in the generation of these complex structures.[118]  
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1. Synthesis of the cyclo(Trp, Pro) scaffold 
The first objective was to develop an efficient route for the synthesis of the basic skeleton, 
cyclo(Pro, Trp) 2, starting from the L- and D-enantiomers of proline and tryptophan. Different 
synthetic routes to obtain the desired compounds were evaluated (Scheme 23). A key step was the 
coupling of the amino acids. Other aspects like the choice of the protecting group or the order in 
which to couple the amino acids was also examined. A first strategy was based on phosphorus-
assisted amide formation and microwave heating (i).[123] Secondly, benzotriazole activation was 
tested which involved the activation of the carboxylic group of the amino acids as acylbenzotriazole 
to perform the coupling (ii).[124] An alternative strategy commonly used in peptide chemistry 
comprised 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC∙HCl) as a coupling 
reagent (iii).[125]  
 
Scheme 23: Evaluated syntheses of cyclo(Trp, Pro) 2. 
In het course of this research many practical issues arose related to the foaming tendency and the 
poor solubility of the compounds. The poor solubility in combination with the polarity of certain 
reported compounds caused many difficulties during purification. The solubility issue is mentioned in 
the recent review by Sano and Nakao: “In most situations, 2,5-DKP is insoluble in reaction solvents 
and precipitates as it is formed,” and “In general, intermolecular hydrogen bond formation between 
the 2,5-DKP rings (C=O⋯H-N) is responsible for the low solubility of 2,5-DKP in water and various 
organic solvents.”[126] This was also mentioned by Palacin et al.: “In general, DKPs have a low 
solubility and dissolution required heating and large volumes of solvent.”[127] It was often observed 
that the DKP (or a derivative) after being formed, did not (completely) redissolve again after the 
solvent had been evaporated in vacuo. Even when the compound was synthesized in a certain 
solvent (e.g. CH2Cl2) and remained in solution during the reaction, attempts to redissolve the 
compound again after workup in the same solvent often failed. This behavior sometimes complicated 
purification. While an eluent mixture of a dissolved (and thus diluted) sample was deemed 
appropriate by TLC, the application of the same eluent mixture during column chromatography or 
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pTLC could cause formation of an insoluble layer. Subsequent use of a stronger eluent mixture would 
then result in co-elution of the different products. 
The analysis of crude mixtures mostly had to rely on HPLC-MS analysis since it was difficult to 
formulate conclusions based on 1H NMR data of the crude and purifications were cumbersome. In 
the case of the dipeptides, different rotamers made it difficult to interpret 1H NMR spectra. However, 
1H NMR analyses were performed on several dipeptides at elevated temperature (60 °C) in DMSO-d6. 
These results were reported by Delbeke and were not reproduced in this manuscript.[128]  
1.1. Diketopiperazine synthesis via methyl dichlorophosphite-assisted coupling 
A first strategy that was briefly investigated to obtain the diketopiperazine framework involves a 
phosphite-promoted single-step condensation of unprotected amino acids that uses microwave 
irradiation-induced heating according to the procedure of Jainta et al.[123] This procedure was appealing 
since it provides a straightforward route to the diketopiperazine ring system without the necessity of 
introducing protecting groups, which contributes to the atom economy of the reaction. The synthesis of 
symmetrical homo- and unsymmetrical heterodiketopiperazines was reported. To obtain the 
heterodiketopiperazines without the corresponding homodiketopiperazines, a small excess of 1.2 
equivalents of one amino acid was reported to be necessary.  
These reaction conditions were used to attempt the synthesis of different symmetrical and 
unsymmetrical diketopiperazines (Table 3). This methodology proved to be solely successful for the 
synthesis of homocoupled cyclo(Pro, Pro) 140 (entry 1). When performing the reaction with glycine 
or threonine, the desired homodiketopiperazines could not be detected on HPLC-MS (entries 2 and 
3). The reaction of tryptophan or glycine and proline did not provide the desired 
heterodiketopiperazine (entries 4-6). Instead the symmetrical cyclo(Pro, Pro) 140 was observed in all 
cases despite the addition of a slight excess of the other amino acid. Indeed, the substrates described 
by Jainta et al.[123] were primarily limited to proline and derivatives thereof. This limited substrate 
scope can explain why the procedure failed with the amino acids used in the present work. No 
conclusion can be formed about the fate of the starting materials (degradation or preservation) as 
these were not detected in the HPLC-MS analyses of the resulting crude mixtures. 
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Table 3: Synthesis of DKPs based on MeOPCl2-assisted coupling. 
 
Entry Cpd  AA1  AA2 Yield (%) 
1 140 1 equiv.  Pro 1 equiv.  Pro 51 
2 141 1 equiv. Gly 1 equiv. Gly - 
3 142 1 equiv. Thr 1 equiv. Thr - 
4 2a 1 equiv. Trp 1.2 equiv. Pro    -[a] 
5 2a 1.2 equiv. Trp 1 equiv. Pro    -[a] 
6 143 1.2 equiv. Gly 1 equiv. Pro    -[a] 
[a] Only the formation of cyclo(Pro, Pro) 140 was detected on HPLC-MS. 
1.2. Diketopiperazine synthesis via benzotriazole-assisted coupling 
The 1H-benzotriazole carboxylic acid activation methodology is well-known and was extensively 
investigated by Katritzky and coworkers.[129-133] The activation of amino acids with benzotriazole 
requires only the protection of the amino group and tolerates other functional groups.[134] Moreover, 
N-acylbenzotriazoles are stable crystalline compounds, which makes them easy to handle. 
Benzotriazole has been used as an efficient coupling reagent in the synthesis of peptides and 
derivatives thereof and was investigated in an alternative synthetic route towards the 
diketopiperazine scaffold (Scheme 24).[124]  
The benzotriazole-assisted approach was chosen because of the previous experience with this 
methodology at our department (SynBioC, Department of Sustainable Organic Chemistry and 
Technology, Faculty of Bioscience Engineering, Ghent University). Bt-activated amino acids were 
efficiently synthesized and coupled with heterocyclic amines and amino acids using microreactor 
technology.[135-136] Moreover, this methodology has already been used for the synthesis of 2,5-
diketopiperazines.[137] The planned synthesis starts with the N-protected amino acid 144, which 
undergoes activation of its carboxyl group via introduction of benzotriazole (145). The activated 
amino acid 145 is subsequently coupled to a second, unprotected amino acid. The resulting dipeptide 
146 is again activated by the introduction of benzotriazole at the C-terminus (147). Deprotection of 
the activated dipeptidoyl benzotriazole 147 should lead to 148, which eventually should result in the 
desired diketopiperazine 1. 
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Scheme 24: General synthetic route based on the benzotriazole methodology. 
Two protecting groups were evaluated for this synthesis, namely the 
fluorenylmethylcarbonyl- (Fmoc-)group and the benzyloxycarbonyl- (Cbz-)group. The frequently used 
tert-butyloxycarbonyl- (Boc-)group was not evaluated due to the incompatibility of the 
benzotriazole-activated dipeptide with acidic conditions typically used for deprotection.  
1.2.1. Fmoc protection 
The synthesis starts with the in situ formation of BtS(O)Bt from thionyl chloride and 
benzotriazole.[133] Subsequently, the Fmoc-protected amino acids tryptophan 149 or proline 150 
were added to yield the activated amino acids 151 and 152, respectively. Both compounds were 
obtained in good crude yield (Scheme 25). 
 
Scheme 25: Benzotriazole methodology using Fmoc-protected amino acids. 
In the next step, the activated amino acids 151 and 152 were coupled with the unprotected amino 
acids proline and tryptophan, respectively. The reactions were performed at room temperature and 
under microwave heating. In both cases the recovery of the desired dipeptide (153 or 154) after 
workup was very low. The poor recovery of dipeptides 153 and 154 in this reaction step can be 
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attributed to the use of base, which can cause deprotection of the Fmoc group resulting in side 
reactions.[138] Therefore, the use of Fmoc as protecting group was abandoned. 
1.2.2. Cbz protection 
Alternatively, the Cbz protecting group was used, which can be removed via hydrogenolysis and is 
stable in the presence of base. Two methods were compared to achieve the introduction of the 
protecting group on the unprotected amino acids. The first required the simultaneous addition of 
CbzCl and a sodium hydroxide solution to keep the pH stable,[139] which was not very convenient 
(Table 4, reaction conditions A). For the second method the amino acid was dissolved in an aqueous 
solution of NaHCO3 and K2CO3, and acetone (Table 4, reaction conditions B).
[140] Both procedures 
provided the desired compounds in pure form and with good yields (Table 4). The latter procedure 
was more practical. Moreover, the first procedure describes precipitation of the desired compounds 
upon acidification of the aqueous solution. However, in the case of the proline derivatives 111 and 
156 a viscous oil was obtained, which could not be filtered off.  
The chosen procedure B provided Cbz-Trp 155a or 155b as a strong foaming oil upon evaporation of 
the organic solvent after extractive workup, which made it difficult to remove all the solvent. Almost 
all products, which were synthesized during this PhD thesis were obtained as foams. In this case, co-
evaporation of residual volatiles from dichloromethane gave the amino acids 155a and 155b as 
white-grey powders making them easier to handle. 
Table 4: Cbz-protection of amino acids. 
 
Entry Cpd AA1 Reaction conditions Yield (%) Physical state 
1 155a L-Trp A 90 Powder 
2 155a L-Trp B 92 Powder 
3 155b D-Trp B 94 Powder 
4 111 L-Pro A 97 Oil 
5 111 L-Pro B 98 Oil 
6 156 L-Hyp B 88 Oil 
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1.2.3.  Benzotriazole-activation of N-protected amino acids 
Benzotriazole activation of the Cbz-protected amino acids was achieved using a procedure described 
by Katritzky et al. (Table 5).[133] The reaction provided the activated amino acids 157 and 158 in good 
crude yields. Occasionally, some traces of starting material could be found. The main impurity in the 
crude product consisted of some remaining benzotriazole. The presence of benzotriazole is no 
problem, since it will be released in the next step anyhow and added in excess in the second 
benzotriazole activation step. The Bt-activation of N-Cbz-hydroxyproline (Hyp) 156 failed to provide 
the desired compound 159 as the sole product and resulted in the formation of several products. 
HPLC-MS showed several more polar side products with higher mass than the expected compound. 
These may be the result of self condensation, by the reaction of 156 with another molecule of 
already activated 159, due to the presence of the unprotected hydroxyl group.   
Table 5: Benzotriazole activation of Cbz-protected amino acids. 
 
Cpd AA1 Crude yield (%) 
157a L-Trp 70 
157b D-Trp 94 
158 L-Pro 91 
159 L-Hyp Complex reaction 
mixture 
 
1.2.4. Dipeptide synthesis with benzotriazole-activated amino acids 
The condensation of the benzotriazole-activated monomers with an unprotected amino acid was 
accomplished according to a procedure from Katritzky et al. yielding the dipeptides 160 to 162.[133] 
The coupling of both amino acids was executed under microwave heating so a short reaction time of 
ten minutes sufficed. The crude products (160-162) were used as such in the second benzotriazole 
activation step.  
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Table 6: Condensation to the dipeptide. 
 
Cpd AA1 AA2 Crude yield (%) 
160 L-Trp  L-Pro 72 
161 D-Trp L-Pro 92 
162 L-Pro D-Trp 93 
  
1.2.5. Benzotriazole-activation of N-protected dipeptides 
In the next step the dipeptides were again activated via the introduction of a benzotriazole group at 
the C-terminus of the dipeptide with procedures from the Katritzky research group (Table 7).[130, 137] 
These procedures started with the in situ formation of BtS(O)Bt. A large excess of benzotriazole was 
used. When the reaction was started at lower temperature (-10 °C) (entry 3 versus entry 4),[137] 
the crude yield was slightly better. The activated dipeptides 163 and 164 were obtained in acceptable 
purity (more than 95% pure based on HPLC analysis) so no further purification was performed.  
Table 7: Benzotriazole activation of dipeptides. 
 
Entry Cpd AA1 AA2 Solvent T, t Crude yield (%) 
1 163a L-Trp L-Pro CH2Cl2 -10 °C, 1 h 
Then r.t., 1 h 
58 
2 163b D-Trp L-Pro CH2Cl2 -10 °C, 1 h 
then r.t., 1 h 
87 
3 164 L-Pro D-Trp CH2Cl2 -10 °C, 1 h 
then r.t., 1 h 
78 
4 164 L-Pro D-Trp THF 0 °C, 2 h 68 
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1.2.6.  Hydrogenolysis of N-Cbz-protected dipeptides 
Subsequently, the removal of the N-protecting group, whether or not followed by spontaneous ring 
closure, was aspired in accordance to the procedure described by Monbaliu et al. (Scheme 26).[137] 
The synthesis of the trans-diketopiperazines containing one unnatural amino acid was examined first 
because of the anticipated easier formation of the thermodynamically more stable trans-DKP. 
Dipeptide 164 was foremost investigated as this allows the introduction of the more expensive D-Trp 
later on in the pathway, which avoids losses during the first protection or activation steps. While the 
unnatural amino acid, D-Pro, could be introduced by the trans-selective cyclization/epimerization 
method of Monbaliu et al. (vide infra).[137] 
However, hydrogenolysis in ethanol did not lead to the desired cyclized product 2, nor did it provide 
the N-deprotected benzotriazole-activated dipeptide 165 or 166. Instead, the dipeptide esters 167 
and 168 were present as the main products, in which the benzotriazolyl moiety was replaced with an 
ethoxy group and no deprotection had taken place (Table 8, entries 1-2). The benzotriazole-activated 
carboxyl group reacts with the alcoholic solvent used, leading to the ester or with traces of water 
leading to the acid (162, entry 3). However, this was not a problem during the hydrogenolysis and 
cyclization of the dipeptides studied by Montbaliu et al.[137] No traces of deprotection were detected 
leading to the supposition that the palladium catalyst was inactivated by the nitrogen atoms present 
in benzotriazole, the indole or the amide bond. A larger amount of palladium catalyst was added 
(entry 4), but still no deprotection was detected. The reactions were also performed in the presence 
of a catalytic amount of acid without success (entries 5[141]-6). Since the reaction of the dipeptide 
with the alcoholic solvent proceeded so easily, EtOAc and CH2Cl2 were evaluated as solvent (entries 
7-8[142]). In these instances, the starting material 164 was recovered.  
 
Scheme 26: Desired products after removal of the Cbz protecting group from dipeptides 163-164. 
Cyclohexene and ammonium formate were evaluated as alternative sources of hydrogen 
(entries 9[143]-10). The use of ammonium formate was promising and led to the deprotected 
dipeptide 169b, which had also undergone reaction with the solvent methanol. The reaction with 
ammonium formate was repeated with several other non-alcoholic solvents (entries 11-14). No 
III. Results and discussion 
46 
 
desired product was formed and side reactions had taken place resulting in complex reaction 
mixtures of polar compounds. One of these side products was tentatively attributed as the dipeptide 
amide Trp-Pro-CONH2 resulting from the reaction of 164 with the ammonia released during 
decomposition of ammonium formate. 
As another catalyst, PdCl2, was used, which led to the removal of the Cbz group (entry 15) and 
concomitant esterification by the alcoholic solvent, yielding 169b. Switching the solvent to 
dichloromethane, to prevent esterification, led to precipitation of the product upon addition of 
hydrochloric acid, whereupon no reaction occurred (entry 16).  
Hydrogenolysis is the standard method for deprotection of the Cbz group.[144] There was no obvious 
reason why the hydrogenolysis should not work as this had been reported by Monbaliu et al. for 
related dipeptides. Therefore, only hydrogenolysis involving Pd catalysts were tested.  
Moreover, in view of the tentative idea of translating the DKP 2 synthesis into a continuous flow 
process, the removal of the Cbz group through hydrogenolysis was envisaged. Hydrogenolysis can be 
transferred into a flow process using specialized equipment e.g. the H-Cube Mini reactor, available at 
the department. This offers the possibility of pumping a dipeptide solution through a fixed bed of 
Pd/C catalyst, allowing the easy recuperation and reuse of this relatively expensive catalyst, while 
generating the explosive H2 in situ in small quantities. Unfortunately, the synthesis of DKP 2 from 
dipeptides 164 via hydrogenolysis did not look very promising.  
Acidic (e.g. HBr) or alkaline (e.g. KOH in MeOH) deprotection strategies were not tested as these 
could induce unwanted epimerization. However, other mild methods for Cbz removal (e.g. nBu4NF) 
can be suggested for further research.[145]  
In both cases where deprotection was successful (entries 10 and 15), an alcoholic solvent was used 
leading to esterification. The alkoxy group is a good leaving group permitting cyclization, so the 
desired DKP could be obtained from 169 under the right conditions. However, this would abolish the 
mere reason to use the benzotriazole-based synthetic route.  
During concomitant research, the synthesis of the benzotriazole activated L-tryptophan 157 using 
microreactor technology has been developed at our department as part of another PhD thesis.[136] 
The amino acid 157 was subsequently coupled in flow with L-ProOMe∙HCl 183a providing the 
dipeptide N-Cbz-L-Trp-L-ProOMe 181a. Unfortunately, substantial epimerization had occurred (6:1 
cis:trans) as a result of the elevated temperature (130 °C) required to obtain full conversion in the 
limited residence time (= reaction time) of 30 min in the reactor.  
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The dipeptide methyl ester can be formed without epimerization and in only one step with 
carbodiimide mediated coupling (vide infra). As a result, further steps towards the deprotection of 
163 or 164 were not investigated within the timeframe of this work.  
Table 8: N-deprotection of the dipeptides 163-164. 
 
Entry AA1 AA2 Reaction conditions Result 
1 L-Trp L-Pro 5 bar H2, 10 wt% Pd/C 
EtOH, r.t., 18 h 
163a/167 
2 L-Pro D-Trp 5 bar H2, 10 wt% Pd/C 
EtOH, r.t., 18 h 
164/168 
3 L-Pro D-Trp 5 bar H2, 10 wt% Pd/C 
EtOH, r.t., 23 h 
164/168/162 
4 L-Pro D-Trp 5 bar H2, 100 wt% Pd/C 
EtOH, r.t., 20 h 
168 
5 L-Pro D-Trp 5 bar H2, 10 wt% Pd/C, cat. HOAc 
EtOH, r.t., 20 h 
164/168 
6 L-Pro D-Trp 5 bar H2, 10 wt% Pd/C, cat. HCl 
EtOH, r.t., 1 d 
168 
7 L-Pro D-Trp 5 bar H2, 50 wt% Pd/C 
EtOAc, r.t., 65 h 
164 
8 L-Pro D-Trp 5 bar H2, 50 wt% Pd/C, 1 equiv. DIPEA 
CH2Cl2, r.t., 1 d 
164 
9 L-Pro D-Trp Cyclohexene, 50 wt% Pd/C 
EtOH, , 6 h 
164/168 
10 L-Pro D-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
MeOH, , 2 h 
169b 
11 L-Pro D-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
EtOAc, , 3 h 
Complex reaction 
 mixture 
12 L-Pro D-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
CH2Cl2, , 19 h 
Complex reaction 
 mixture 
13 L-Pro D-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
THF, , 1 h 
Complex reaction 
 mixture 
14 L-Pro D-Trp 4 equiv. HCOONH4, 5 wt% Pd/C 
iPrOH, MW, 83 °C, 10 min 
Complex reaction 
 mixture 
15 L-Pro D-Trp 5 bar H2, 0.3 equiv. PdCl2, 4 equiv. HCl 
MeOH, r.t., 3 d 
169b 
16 L-Pro D-Trp 5 bar H2, 0.3 equiv. PdCl2, 4 equiv. HCl 
CH2Cl2, r.t., 3 d 
164 
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A final overview of the benzotriazole synthetic pathway that was examined, is presented in Scheme 
27. 
 
Scheme 27: Overview of the synthetic pathway using the benzotriazole activation methodology starting from 
Cbz-protected amino acids. Crude yields are depicted between parentheses. 
1.2.7. Trans-selective cyclization/epimerization 
A tandem trans-selective cyclization/epimerization of N-Cbz-dipeptidoyl benzotriazoles has been 
described by Monbaliu et al.[137] The procedure allows ring formation of the benzotriazole-activated 
dipeptides without removal of the N-protecting group. With the required substrates already in hand, 
these conditions were applied on the compounds 163a and 163b (Table 9). Dipeptide 163a, made up 
from two L-amino acids, undergoes epimerization at the proline stereocenter under the current 
reaction conditions and the trans-diketopiperazine 170a was formed (entry 1). On the other hand, 
starting from the D,L-dipeptide 163b the stereochemistry of the amino acids was retained in the 
cyclized product 170b (entry 2).  
Table 9: Cyclization of Cbz-dipeptidoyl benzotriazoles 163a and 163b. 
 
Entry  AA1 AA2 Cpd AA1 AA2 Yield (%) 
1 163a L-Trp  L-Pro 170a L-Trp  D-Pro       96 
2 163b D-Trp  L-Pro 170b D-Trp  L-Pro 41[a] 
[a] Isolated yield after column chromatography. 
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Hydrogenolysis of compound 170b gave the desired DKP 2b (Scheme 28). However, this procedure is 
limited to the synthesis of trans-diketopiperazines. Moreover, it takes up to 6 steps to get the 
desired compounds.  
 
Scheme 28: Hydrogenolysis of Cbz-protected DKP 170b. 
1.3. Diketopiperazine synthesis via carbodiimide-assisted coupling 
A third strategy to obtain the desired diketopiperazines used EDC∙HCl as a coupling reagent. 
Carbodiimides are commonly used coupling reagents in standard peptide chemistry.[146-147] Scheme 
29 shows the envisaged synthetic route, which is notably shorter than the one using the 
benzotriazole methodology. However, the use of appropriate protecting groups is required. In the 
first step a N-protected amino acid 144 and the ester of a second amino acid 171 are coupled in the 
presence of EDC. Subsequently, the protecting group is removed from the dipeptide 172, upon which 
(spontaneous) cyclization of 173 affords the diketopiperazine 1.  
 
Scheme 29: General synthesis of the DKP scaffold 1 via EDC-assisted coupling. 
1.3.1. EDC-assisted coupling 
In the current synthetic route, several N-Cbz- and N-Boc-protected tryptophan, proline and 
hydroxyproline amino acids were submitted to EDC-mediated coupling with methyl or ethyl esters of 
these amino acids. These products were commercially available, only the N-Cbz-D-Trp 155b was 
synthesized from D-Trp.[125] Evaporation of the organic phase after extractive workup resulted again 
in strong foaming of the desired compounds 174-182. These compounds were already quite pure 
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(more than 95% pure based on HPLC analysis) and were used without further purification in the next 
step (Table 10 and Table 11). 
Table 10: EDC-assisted coupling starting from N-Boc-protected amino acids. 
 
Cpd AA1 AA2 R3 Crude yield (%) 
174 L-Pro L-Trp Me 85 
175 L-Hyp L-Trp Me 60 
176 L-Trp Gly Et 73 
177 L-Pro L-Pro Me 96 
178 L-Trp L-Hyp Me 67 
179 L-Hyp Gly Et 67 
 
Table 11: EDC-assisted coupling starting from N-Cbz-protected amino acids. 
 
Cpd AA1 AA2 Crude yield (%) 
180a L-Pro L-Trp 95 
180b L-Pro D-Trp 67 
181a L-Trp L-Pro 73 
181b L-Trp D-Pro 76 
181c D-Trp L-Pro 89 
181d D-Trp D-Pro 76 
182a L-Trp L-Hyp 91 
182b D-Trp L-Hyp 70 
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The procedure with EDC∙HCl was a straightforward method for the coupling of the amino acids. 
Unfortunately, the coupling reaction was performed in dichloromethane, a halogenated solvent. At 
SynBioC the use of these solvents is discouraged and avoided if possible to prevent any release into 
the environment. Firstly, water was used as a benign alternative solvent.[148] However, the starting 
material 155a did not dissolve in water. The desired dipeptide 181a was not detected via HPLC-MS, 
only a side product such as 184 or 185 resulting from O- to N-acyl-transfer during the activation of 
tryptophan with EDC was formed (Scheme 30).  
Scheme 30: EDC coupling in water. 
Next, methanol was screened as solvent to perform the coupling. The following hydrogenolysis and 
cyclization steps were also to be performed in methanol (vide infra: 1.3.3 and 1.3.4). Hence, if these 
three steps could be conducted in the same solvent, a one pot procedure might be possible, avoiding 
several workups.  
In the absence of additional base, esterification of N-Cbz-L-Trp 155a took place and only a trace of 
dipeptide 181a was present (Table 12, entry 1). The addition of base to the reaction gave more 
formation of dipeptide, alongside esterification to N-Cbz-L-TrpOMe 186 and formation of the side 
product 184/185 resulting from acyltransfer (entry 2). Performing the reaction at lower temperature 
eliminated the esterification side product 186, but still a significant amount of 184/185 was present 
(entry 3).  
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Table 12: EDC-coupling in methanol. 
 
Entry Reaction conditions Result[a] 
1 1 equiv. EDC∙HCl 
MeOH, r.t., 24 h 
Trace of 181a 
N-Cbz-L-TrpOMe 186 
2 1 equiv. EDC∙HCl, 
1 equiv. Et3N 
MeOH, r.t., 24 h 
181a/(184+185+186) 
1/1.25 
3 1 equiv. EDC∙HCl, 
1 equiv. Et3N 
MeOH, 0 °C-r.t., 24 h 
181a/(184+185) 
1/1 
[a] Ratio determined on the 280 nm UV-signals in the HPLC chromatogram. 
The coupling was also performed in THF. The crude yield was good, but more side products were 
formed (Scheme 31). After deprotection of the crude dipeptide 181c through hydrogenolysis (for the 
conditions vide infra) and spontaneous cyclization, cyclo(D-Trp, L-Pro) 2b could not be isolated by 
recrystallization. Using column chromatography the pure diketopiperazine 2b was recovered in low 
yield (34% over 2 steps). This yield was lower compared to the yield of 2b (79% over 2 steps, vide 
infra) obtained using dichloromethane as solvent for the amino acid coupling. Hence, this solvent 
was also abandoned.  
 
Scheme 31: EDC-mediated coupling in THF. 
Since the conversion to the desired product remained low in the alternative solvents, 
dichloromethane remained the solvent of choice for the coupling. However, other solvents are still 
possible, but were not investigated within the timeframe of this work. The use of other reagents or 
additives may still allow the amide bond formation in high yield and purity in other solvents than 
dichloromethane. 
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1.3.2. Boc deprotection 
The Boc protecting group was removed thermally or by means of a strong acid. In the first instance 
the deprotection of 174 was attempted at elevated temperature using microwave-assisted heating, 
with the aim of spontaneous cyclization to the DKP ring according to the procedure of Pérez-Picaso et 
al. (Table 13, entry 1).[149] The diketopiperazine 2 was isolated as a mixture of diastereomers. The 
diastereomeric ratio was 1:1.4 (cis:trans). The absolute stereochemistry was not determined.  
To avoid the undesired epimerization, the temperature was lowered to 150 °C. In compensation, the 
reaction time was augmented to 15 minutes. A mixture of cis- and trans-diastereomers 2 was still 
detected (entry 2). An alternative procedure involved deprotection in the microwave reactor in the 
presence of acetic acid, which again resulted in a mixture of diastereomers 2 (entry 3).[150] Next, the 
solvent was switched to aprotic solvents like acetonitrile (ACN) and dimethyl sulfoxide (DMSO). 
Indeed, a protic solvent like water can promote enolization of the carbonyl function, leading to 
epimerization and producing the thermodynamically more stable trans-configuration. The 
temperature was also lowered further to 130 °C. Only a trace of the desired DKP 2 was detected after 
reaction in ACN, and the starting material 174 was largely retrieved (entry 4). This reaction could not 
be reproduced. The DKP 2 was not detected again, even after prolonged reaction times or 
augmented temperature (entries 5, 6). In DMSO the DKP 2 was also detected after 15 minutes, 
besides starting material 174, unprotected dipeptide 169 and some unidentified side products (entry 
7). After prolonged heating all the starting material 174 was converted to degradation products 
(entry 8). A final attempt for thermal removal of the Boc moiety was based on refluxing the dipeptide 
in N-methyl-2-pyrrolidinone (NMP). No conversion of the starting material 174 took place (entry 
9).[151] 
  
III. Results and discussion 
54 
 
Table 13: Boc deprotection of 174 and cyclization under microwave heating. 
 
Entry Reaction conditions Crude yield 2 (%) 
1 
H2O 
MW, 250 °C, 10 min 
97 
dr = 1:1.4 cis:trans[a] 
cis: 38%[b] trans: 38%[b] 
2 H2O 
MW, 150 °C, 15 min 
87 
dr = 1:1.5 cis:trans[c] 
3 HOAc/H2O (1:1) 
MW, 160 °C, 5 min 
dr = 1:1.5 cis:trans[c] 
4 ACN 
MW, 130 °C, 15 min 
Trace 
5 ACN 
MW, 130 °C, 60 min 
No conversion 
6 ACN 
MW, 150 °C, 60 min 
No conversion 
7 DMSO 
MW, 130 °C, 15 min 
Trace  
8 DMSO 
MW, 130 °C, 45 min 
Degradation 
9 NMP, , 1.5 h No conversion 
[a] Ratio determined on the basis of 1H-NMR. 
[b] Isolated yield after pTLC. 
[c] Ratio determined on the 280 nm UV-signals in the HPLC chromatogram. 
As the thermal deprotection of the dipeptide 174 only provided the diketopiperazine 2 as a mixture 
of diastereomers, a switch was made to acid-mediated deprotection. Several protocols were 
evaluated on dipeptide 174, which used TFA to accomplish Boc-removal (Table 14). The crude 
dipeptide was subsequently cyclized in the presence of a base namely, morpholine,[152] Et3N, 
NaHCO3
[153] or 2-hydroxypyridine.[28]  
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Table 14: Boc removal in dipeptide 174 using TFA immediately followed by cyclization. 
 
Entry Reaction conditions Result 
1 1) 30% TFA 
CH2Cl2, 0 °C-r.t., 3 h 
2) 35 equiv. morpholine 
      CH2Cl2, r.t., 48 h 
Mixture of 2a/187 
6/1[a] 
1/1[b] 
2 1) 30% TFA 
CH2Cl2, 0 °C-r.t., 30 min 
2) 5% aq. NaHCO3 
      MeOH, r.t., 2 h 
Mixture of 169a/187, 
1/1[a] 
trace of 2a 
 
3 1) 30% TFA 
CH2Cl2, 0 °C-r.t., 3 h 
2) 2 equiv. Et3N 
       CH2Cl2, r.t., 48 h 
Mixture of 169a/187 
2/1[a] 
 
4 1) 10% TFA 
CH2Cl2, r.t., 3 h 
2) 0.2 equiv. 2-hydroxypyridine 
      toluene, , 12 h 
Mixture of 169a/187,[c] 
3/1[b] 
trace of 2a 
[a] Ratio determined on the 280 nm UV-signals in the HPLC chromatogram. 
[b] Ratio determined on the MS-signals in the HPLC-MS chromatogram. 
[c] Compound 187 was not detected by UV absorption in the HPLC    chromatogram. 
In all cases, the Boc group was removed by treatment with TFA. The addition of NaHCO3, Et3N or 
2-hydroxypyridine did not induce (complete) cyclization (entries 2-4). HPLC-MS analysis revealed the 
presence of the desired DKP 2a after treatment with excess morpholine (entry 1). However, in all 
experiments, a side product was detected in HPLC-MS. The mass indicated the addition of a tert-
butyl group to 2a, which may be alkylated DKP 187. This side product 187 would result from reaction 
of the indole moiety with the tert-butyl cation, which is released upon treatment of the Boc group 
with acid. This undesired side reaction was described by Lundt et al.[154] However, since the 
compound was never isolated, the exact structure of the side product (or position of the tert-butyl 
group in 187) can not be elucidated. 
To avoid this unwanted alkylation, 1,2-ethanedithiole was added as a scavenger to the reaction 
mixture (Table 15).[154] However, the undesired alkylated product 187 was still formed, even with 
excess scavenger. 
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Table 15: Boc removal using TFA in the presence of a scavenger. 
 
Entry Reaction conditions Result 
1 30% TFA, 1 equiv. 1,2-ethanedithiol 
CH2Cl2, 0 °C-r.t., 3 h 
Mixture of 187/169a 
4/1 
2 30% TFA, 2.5 equiv. 1,2-ethanedithiol 
CH2Cl2, 0 °C-r.t., 3 h 
Mixture of 187/169a 
5/1 
[b] Ratio determined on the MS-signals in the HPLC-MS chromatogram. 
Alternatively, HCl was used to remove the Boc group. The HCl was formed in situ via reaction of 
acetyl chloride and methanol.[155] The deprotection was also performed in an ethyl acetate solution 
saturated with HCl. In both cases no alkylated side product 187 was detected on HPLC-MS analysis 
and the reaction produced 169a in quantitative crude yield.  
Table 16: Boc removal using HCl. 
 
Entry Reaction conditions Crude yield 
1 5 equiv. MeOH, 5 equiv. acetyl chloride 
CH2Cl2, 0 °C, 3 h 
Quantitative 
2 HCl in EtOAc 
r.t., 5 h 
Quantitative 
1.3.3. Cbz deprotection 
The removal of the alternative N-Cbz protecting group was also investigated. The most 
straightforward way to accomplish this was through hydrogenolysis. Different hydrogen sources are 
possible (Table 17). For instance, ammonium formate was used. Complete conversion took place 
affording the DKP 2, but the higher temperatures were detrimental to the preservation of the 
stereochemistry (entry 1). However, switching to a lower boiling solvent probably did not effectuate 
the release of hydrogen gas from ammonium formate so 180a was retrieved (entry 2). Next, the 
reactions were performed under a hydrogen atmosphere. Again, the reaction did not result in full 
conversion in dichloromethane as a solvent, not even after prolonging the reaction time (entries 3 
and 4). The reactions in methanol with Pd(OH)2/C or Pd/C both gave full conversion to the dipeptide 
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169a (entries 5 and 6). No spontaneous cyclization to the DKP 2a was detected. The required 
reaction time was reduced by adding more catalyst (entry 7). The same conditions were applied to 
the other dipeptides (181-182), in which the order of amino acids was reversed (entries 8-13). Full 
conversions were also achieved. Under the present conditions the hydrogenolysis was a ‘clean’ 
reaction and no side reactions were detected. 
The observation was made that the ‘trans’-isomeric dipeptides 181b, 181c and 182b, undergo 
spontaneous cyclization to the DKP ring structure after Cbz-removal (entries 9, 10 and 13). This was 
not the case for the ‘trans’-dipeptide 169b having a reversed order of amino acids (entry 7). Hence, 
the order in which the amino acids are coupled is of importance for allowing spontaneous cyclization. 
Table 17: Cbz removal via hydrogenolysis. 
 
Entry Cpd AA1 AA2 Reaction conditions Result 
1 180a L-Pro L-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
MeOH, , 18 h 
2 
dr = 1.5:1 cis:trans[a]  
2 180a L-Pro L-Trp 4 equiv. HCOONH4, 50 wt% Pd/C 
CH2Cl2, , 18 h 
180a 
Trace of 169a 
3 180a L-Pro L-Trp 5 bar H2, 1 wt% Pd/C 
CH2Cl2, r.t., 18 h
[156] 
ratio 180a:169a = 1:2[a] 
4 180a L-Pro L-Trp 5 bar H2, 1 wt% Pd/C 
CH2Cl2, r.t., 3 d 
ratio 180a:169a = 1:1[a] 
5 180a L-Pro L-Trp 5 bar H2, 1 wt% Pd(OH)2/C 
MeOH, r.t., 18 h 
169a 
6 180a L-Pro L-Trp 5 bar H2, 1 wt% Pd/C 
MeOH, r.t., 18 h 
169a 
7 180b L-Pro D-Trp 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 2 h 
169b 
8 181a L-Trp L-Pro 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 2 h 
188a 
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9 181b L-Trp D-Pro 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 2 h 
2c 
10 181c D-Trp L-Pro 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 2 h 
2b 
11 181d D-Trp D-Pro 5 bar H2, 2 wt% Pd/C 
MeOH, r.t., 3 h 
188b 
12 182a L-Trp L-Hyp 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 3 h 
189 
13 182b D-Trp L-Hyp 5 bar H2, 5 wt% Pd/C 
MeOH, r.t., 3 h 
190b 
[a] Ratio determined on the basis of the MS signals in the HPLC-MS chromatogram. 
The Cbz protecting group was preferred over the Boc protecting group as the hydrogenolysis was 
considered a milder procedure than the acidic deprotection. Moreover, the acidic deprotection 
provides the HCl salt of the deprotected dipeptide so the spontaneous ring closure of the L,D- and D,L- 
dipeptides would unlikely occur and extra base would be necessary to induce cyclization for all 
isomers. 
In view of the tentative idea of translating the DKP 2 synthesis into a continuous flow process, the 
Cbz protecting group may also be preferred over the Boc protecting group. The hydrogenolysis of the 
Cbz protecting group can more readily be transferred into a flow process. In contrast, the acidic 
deprotection of the Boc protecting group in a closed system of tubing does not readily allow the 
escape of the tert-butyl cation (as 2-methylpropene). This could again result in the formation of 
alkylated side products. In that case, further research into the addition of scavengers to prevent 
alkylation of the indole would be required. The synthesis of DKP 2 in a continuous process was not 
the topic of this dissertation. 
1.3.4. Cyclization 
The final step consisted of the cyclization of the dipeptides that did not spontaneously form the DKP. 
Table 18 shows the evaluated reaction conditions for dipeptide 169a. The addition of 
hydroxypyridine did not effectuate the ring formation using DMF or methanol as solvents, and the 
starting material 169a remained (entries 1-2).[57] The cyclized product 2a was obtained after 
prolonged refluxing of 169a in toluene, nevertheless some dipeptide 169a was still present 
(entry 3).[28] Incomplete conversion was also found for the reaction in the presence of NaHCO3 
(entry 4).[153] The addition of piperidine resulted in the desired diketopiperazine 2a at reflux (entry 5) 
and also at room temperature (entry 6), only a longer reaction time was needed in the latter case.[155] 
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Cyclization also occurred in the presence of morpholine (entry 7). However, repeated washing with 
1 M HCl could not mediate complete removal of morpholine.[152] Although the desired product 2a 
was obtained, the yields were still low. Finally, the dipeptide 169a was dissolved in a solution of 
7 M NH3 in methanol.
[84] The reaction was monitored with HPLC-MS until all starting material was 
converted. Recrystallization yielded the DKP in 63% yield as the sole product. 
Table 18: Reaction conditions for inducing cyclization. 
 
 Reaction conditions Yield 2a (%) 
1 0.2 equiv. 2-hydroxypyridine 
DMF, 70 °C, 3 h 
No conversion 
2 0.2 equiv. 2-hydroxypyridine 
MeOH, , 3 h 
No conversion 
3 0.2 equiv. 2-hydroxypyridine 
toluene, , 12 h[28] 
Not isolated 
4 5% aq. NaHCO3 
MeOH, r.t., 2 h 
Not isolated 
5 3 equiv. piperidine 
DMF, , 2 h 
20[a] 
6 3 equiv. piperidine 
DMF, r.t., 40 h 
34[a] 
7 Morpholine 
CH2Cl2, r.t., 48 h 
37[a] 
8 7 M NH3  
MeOH, r.t., 1 d 
63[a] 
[a] Isolated yield after recrystallization. 
The same procedure was applied on dipeptides 188a, 188b and 182a, which also provided the 
corresponding DKPs 2a, 2d and 190a in quantitative yield (Scheme 32).  
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Scheme 32: Cyclization of 188 and 182a using ammonia in methanol. Crude yields for this step are depicted between 
parentheses. 
A spontaneous ring closure took place for the D,L- and L,D-isomers of Trp-ProOMe, while an extra 
cyclization step was needed to convert the L,L- and D,D-isomers 188a and 188b to the DKP ring. No 
spontaneous ring formation occured with the L,D-isomer of Pro-TrpOMe 169 (vide supra, Table 8), so 
all isomers of 169 would require an extra cyclization step. Therefore the sequence starting from Cbz-
Trp 155 was preferred. 
The reason for the difference in cyclization tendency between the Trp-ProOMe and Pro-TrpOMe 
dipeptide esters can be attributed to the position of the proline amino acid in the dipeptide. An 
amide bond has a partial double bond character around the C-N bond as a result of delocalization of 
the electron lone pair on nitrogen. The partial double bond character results in hindered rotation of 
the amide bond and a distinction can be made between the cis- and trans-amide conformations 
(Scheme 33). In primary amino acids (R=H) an increased sterical hindrance is present in the cis-amide 
bond so the trans-amide isomer, which allows maximum separation, is favoured. However, proline 
forms an exception as a result of its secondary amine group. In proline (R-Cα=(CH2)3) sterical 
hindrance will be present for both the cis- and trans-amide conformation resulting in a less 
pronounced energy difference between the two forms. Therefore, the amide bond in AA1-Pro will 
more easily adopt a cis-conformation and a larger fraction will be present as the cis-isomer compared 
to primary amino acids.[157-158] This will increase the probability for cyclization of the dipeptide Trp-
ProOMe as the cis-amide conformation is required for the formation of the diketopiperazine ring.  
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Scheme 33: Cis- and trans-amide conformations. 
1.4. Collagen invasion assay  
Several 2,5-diketopiperazines modulate tumor cell invasion in vitro. Some diketopiperazines 191-193 
possessing anti-invasive properties are depicted in Figure 15.[159-161] Although the structures of these 
compounds differ considerably from each other, they all have the same piperazin-2,5-dione core. 
Since our group runs several projects on the development of anti-invasive molecules, we were 
intrigued to investigate our compounds in an in vitro model of invasion.  
Moreover, the inhibition of invasion by HCCLM3 cells on treatment with the different stereoisomers 
of AIPZ 192 was configuration-dependent.[160] Hence, with all four isomers of 2 available, it was 
decided to investigate the influence of the different configurations of 2 on their inhibitory activity for 
invasion. 
 
Figure 15: 2,5-Diketopiperazines with anti-invasive properties. 
In a first set of experiments, the different isomers 2a-d and 190b were tested for their effectivity in 
inhibiting the invasive phenotype of cancer cells at the Laboratory of Experimental Cancer Research, 
Ghent University. This was done using a collagen assay on human N-Cadherin positive (PC3) and 
negative (DU145) prostate carcinoma cell lines.  
A detailed protocol for the collagen invasion assay can be found in the reference of De Wever et al. 
(Figure 16).[162] Collagen type I gels as well as a single-cell suspension were prepared as described 
herein. Type I collagen is the main interstitial matrix component in solid tumors invasion. The tested 
compounds were diluted into DMSO and added to the single-cell suspension. This solution was 
deposited on top of the collagen type I gels. After incubation for 24 hours, invasive cells presenting 
invasive extensions into the collagen gel and non-invading cells were counted in 10–15 randomly 
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selected microscope fields. The results are reported as the mean invasion index, which is the ratio of 
the number of invasive cells over the total number of cells. 
 
Figure 16: Schematic representation of the collagen invasion assay. 
Isomers 2b and 2d were tested in four concentrations (0.01, 0.1, 1, 10 µM), while the other isomers 
were tested at 1 and 10 µM concentrations (Table 19). Cyclo(D-Trp, L-Pro) 2b displayed a significant 
inhibitory effect for PC3 (p<0.001). For the DU145 cell line, the difference between the conditions 
was only borderline significant (Table 20). In both cases a dose-response behavior was noted (Chart 
1). The outcome of this experiment was promising. In both cases a reduction of 75% of the mean 
invasion index was noted augmenting the concentration from 0.1 µM to 10 µM. However, as this 
experiment was only performed once, a confirmatory repeat experiment was necessary.  
Table 19: PC3 cell line invasion index measured at 24 h for all compounds (in triplo), in the collagen invasion test. 
 
0.01 µM 0.1 µM 1 µM 10 µM 
Cpd Inv. index Mean SD Inv. index Mean SD Inv. index Mean SD Inv. index Mean SD 
cyclo(L-Trp, L-Pro) 2a 
    
25.31 8.58 23.26 9.76 
cyclo(D-Trp, L-Pro) 2b 33.98 6.55 31.54 6.05 22.14 9.34 8.64 6.84 
cyclo(L-Trp, D-Pro) 2c     21.47 10.55 24.23 9.49 
cyclo(D-Trp, D-Pro) 2d 33.15 6.46 41.89 12.56 39.97 17.97 30.91 16.35 
cyclo(D-Trp, L-Hyp) 190b 
    
35.64 9.4 32.57 13.38 
Table 20: DU145 cell line invasion index measured at 24 h for 2b and 2d (in triplo), in the collagen invasion test. 
 
0.01 µM 0.1 µM 1 µM 10 µM 
Cpd Inv.index Mean SD Inv. index Mean SD Inv. index Mean SD Inv. index Mean SD 
cyclo(D-Trp, L-Pro) 2b 6.4 4.77 4.83 3.1 3.95 1.98 1.36 1.88 
cyclo(D-Trp, D-Pro) 2d 25.86 6.19 21.64 4.74 17.94 7.69 15.51 3.94 
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Chart 1: Mean invasion index for cyclo(D-Trp, L-Pro) 2b for the PC3 and DU145 cell line with 95% confidence interval, in 
the collagen invasion test. 
In the second run of experiments, four different cell lines were chosen to explore cell line-dependent 
behavior: LNCaP as a non-invasive, N-Cadherine positive cell line, PTKI as a non-invasive, N-Cadherine 
negative cell line, PC3 as an invasive, N-Cadherine positive cell line and MDA-MB231 as an invasive, 
N-Cadherine negative cell line.  
Overall, there was no significant inhibition by cyclo(D-Trp, L-Pro) 2b for the PTKI cell line (Table 21, b), 
and the diketopiperazine 2b also proved largely ineffective against invasion of MDA-MB cells (Table 
21, d). For the LNCaP cell line, all values were significant, but there was no dose-response behavior 
(Table 21, a). Moreover, the difference with the DMSO control is too small to warrant further 
investigation. 
Table 21: The invasion index for different cell lines measured at 24 h for cyclo(D-Trp, L-Pro) 2b (in triplo) in the collagen 
invasion test. 
 
 
DMSO control 0.1 µM 1 µM 10 µM 
 Cell line Inv. index Inv. index p-value Inv.index p-value Inv.index p-value 
a LNCaP 0.407 0.245 < 0.001 0.272 < 0.001 0.275 < 0.001 
b PTKI 2.798 2.327 0.095 2.041 0.002 2.78 0.996 
c PC3 0.46 0.37 0.046 0.325 0.003 0.557 0.009 
d MDA-MB231 2.871 1.93 0.008 2.179 0.043 2.197 0.081 
Unfortunately, contrary to the result obtained in the first experiment, the mean invasion index values 
against PC3 for compound 2b at the tested concentrations fluctuate around the value for DMSO 
(Table 21, c and Chart 2). Hence, the anti-invasive effect of 2b against invasion of PC3 cells in collagen 
could not be demonstrated in a reproducible manner within the timeframe of this work. 
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Chart 2: : Mean invasion index for cyclo(D-Trp, L-Pro) 2b for the PC3 cell line in the collagen invasion test. 
In all, no striking or reproducible anti-invasive behavior could be noted for diketopiperazines 
cyclo(Trp, Pro) 2a-d and cyclo(D-Trp, L-Hyp) 190b in the collagen invasion assay against the evaluated 
cell lines. 
1.5. Conclusion 
The phosphite-promoted condensation of unprotected amino acids did not provide the desired 
scaffold 2, since only homocoupling of the Pro units occurred. The synthetic route based on the 
benzotriazole methodology required more steps than EDC-mediated coupling, resulting in lower 
overall yields. Overviews for the EDC- and benzotriazole-mediated coupling starting from D-Trp or 
L-Pro to accomplish the synthesis of cyclo(D-Trp, L-Pro) 2b are shown in Scheme 35 and Scheme 36. 
The procedure with EDC∙HCl appears to be the best strategy of the ones investigated for the coupling 
of the amino acids, and eventually all four diastereomers 2a-d could be synthesized in good yields 
(Scheme 34, Table 22). As a protecting group, the Cbz group was chosen. Carbobenzyloxy-protected 
D-tryptophan 155b was obtained by treating D-tryptophan with benzyl chloroformate (CbzCl) in an 
aqueous solution of potassium carbonate and sodium bicarbonate.[140] The carbobenzyloxy (Cbz)-
protected tryptophan 155 was coupled with proline methyl ester hydrochloride (ProOMe∙HCl) 183 in 
the presence of EDC∙HCl.[125] Subsequent hydrogenolysis of the crude dipeptides 181 with Pd/C under 
a H2-atmosphere resulted in the deprotection of the dipeptides.  
For the D,L- and L,D- dipeptides 181b and 181c, spontaneous cyclization towards the 
piperazin-2,5-dione 2b and 2c occurred. This was not observed for the analogous L,D-dipeptide 169b 
having a reversed order of amino acids, which indicates the influence of the order in which the amino 
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acids are coupled and which led to the choice of starting the synthesis from Cbz-Trp. The cyclization 
of the other dipeptide isomers 188a and 188b into the respective diketopiperazines 2a and 2d 
required stirring with ammonia in methanol.  
 
Scheme 34: Synthesis of the cyclo(Trp, Pro) 2 isomers. 
 
Table 22: Isomers of cyclo(Trp, Pro) 2 and cyclo(Trp, Hyp) 190. 
Cpd 
 
Yield (%) 
2a Cyclo(L-Trp, L-Pro) 70[a],[c] 
2b Cyclo(D-Trp, L-Pro) 79[b],[c] 
2c Cyclo(L-Trp, D-Pro) 74[b],[c] 
2d Cyclo(D-Trp, D-Pro) 63[a],[c] 
190a Cyclo(L-Trp, L-Hyp) 40[a],[d] 
190b Cyclo(D-Trp, L-Hyp) 40[b],[c] 
[a] Yield after 3 steps from 155. [b] Yield after 2 steps from 155.  
[c] After recrystallization. [d] Purification with column chromatography. 
The different isomers of cyclo(Trp, Pro) 2 and 190b were evaluated for their inhibitory activity of 
invasion by cancer cells using the collagen invasion assay. In the first experiment a promising 
anti-invasive effect of 2b against PC3 cells in collagen was detected. However, this effect could not be 
confirmed in a second series of experiments. 
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Having the diketopiperazine substrate in hand, it will be used as basic skeleton for the synthesis of 
analogues with a diverse substitution pattern to obtain a diverse set of functionalized brevianamide F 
analogues. The first goal was to synthesize annulated derivatives by means of a Pictet-Spengler 
reaction performed directly on DKP skeleton 2.  
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2. Modification of the diketopiperazine scaffold for the synthesis of 
brevianamide F analogues 
2.1. Synthesis of annulated analogues via the Pictet-Spengler reaction 
2.1.1. Introduction 
A plethora of fungal secondary metabolites possess cyclo(Trp, Pro) 2a as a basic skeleton and display 
attractive biological activities (vide supra). Therefore, these natural products are interesting lead 
compounds.  
When comparing the different DKP-based inhibitors of cell proliferation, it can be concluded that the 
annulated derivatives fumitremorgin C 7 and demethoxyfumitremorgin C 91 are more active than 
their non-annulated counterparts, tryprostatin A 6 and B 85 (Table 2). Demethoxyfumitremorgin C 91 
in particular has shown much promise in the development of anticancer drugs.[15, 90, 163] Similar to 
many of these fungal metabolites, demethoxyfumitremorgin C 91 also possesses a prenyl group that 
is connected to a 1,2,3,4-tetrahydro-β-carboline moiety. In synthetic chemistry, the Pictet-Spengler 
reaction, generally performed on arylethylamines,[164] can be used to introduce the 1,2,3,4-
tetrahydro-β-carboline moiety.[165-166]  
 
Figure 17: Demethoxyfumitremorgin C 91 and tadalafil 20. 
Demethoxyfumitremorgin C analogues have been synthesized and evaluated for their cytotoxic 
activity.[163] The different analogues were obtained by reacting tryptophan methyl ester 121 with 
different aldehydes and subsequently coupling each of the resulting tetrahydro-β-carbolines 194 
with proline or other amino acids to obtain the annulated DKPs 195 (Scheme 37).  
  
Scheme 37: Typical synthesis of DKPs 195 enclosing a tetrahydro-β-carboline moiety. 
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The Pictet-Spengler reaction is also a key step in the formation of tadalafil 20 (Figure 17). Similarly, 
when tadalafil 20 or analogues thereof are synthesized, the synthesis typically starts with a Pictet-
Spengler condensation of a tryptophan ester 121 and an aldehyde to yield the tetrahydro-β-carboline 
194.[34, 167-170] The diketopiperazine ring 195 is only completed at a later stage. So, to evaluate the 
influence of different R groups in annulated derivatives of the general form 195, different 
intermediates 194 have to be synthesized.  
No articles have reported on the synthesis of analogues starting from the diketopiperazine scaffold 2. 
Therefore, the goal of this chapter was to start to evaluate the Pictet-Spengler condensation on 
diketopiperazine 2 directly. This would reduce the number of required reactions when one wants to 
screen different R groups from different aldehydes while maintaining the same DKP skeleton 
(Scheme 38). The amide bond already present would lead to a N-acyliminium Pictet-Spengler 
reaction, which would proceed even faster than the normal Pictet-Spengler reaction (if the N-
acyliminium intermediate 196 can be formed).[171]  
 
Scheme 38: Retrosynthesis of annulated DKP 195 starting from DKP 2. 
2.1.2. Pictet-Spengler reaction conditions lead to dimers 
Initially diketopiperazine cyclo(Trp, Pro) 2 was subjected to Pictet-Spengler reaction conditions. To a 
solution of DKP 2 in dry dichloromethane was added the aldehyde in the presence of an excess 
amount of trifluoracetic acid at -40 °C (Scheme 39).[172] Both in the case of propionaldehyde and 
acetaldehyde, HPLC-MS analysis of the crude product revealed three signals. The mass of two peaks 
corresponded to the formation of the two isomers of the Pictet-Spengler product (197 or 198). 
Surprisingly, the HPLC-MS analysis showed a signal indicative of the formation of a high-in-mass, 
dimeric product next to the expected Pictet-Spengler product. However, during this research, a 
frequent observation was made that the DKPs studied, easily tend to form dimers in MS, so the 
presence of the high mass signal did not necessarily mean that such a dimeric product was present. 
Monitoring the reaction with HPLC-MS revealed that after only five minutes both the peaks of the 
Pictet-Spengler isomeric products (197 or 198) as well as the signal for the high-in-mass product 
were detectable. As the reaction proceeded, the conversion of the three products augmented 
simultaneously. The relative proportion did not change after depletion of DKP 2. From this 
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observation it was concluded that the product with high mass was not formed from the targeted 
Pictet-Spengler product. 
Attempts to selectively crystallize one of the formed compounds failed. Crystallization with 
dichloromethane/diethyl ether only resulted in a residue that was enriched with the mass of the 
Pictet-Spengler product (197 or 198) and a mother liquor that was enriched with the high molecular 
weight compound. Repeating this procedure did not result in the isolation of one of the products. 
Normal phase column chromatography with 2% methanol in dichloromethane as an eluent was used 
for the purification of the reaction mixtures after the reaction of cyclo(L-Trp, L-Pro) 2a with 
acetaldehyde or propionaldehyde. Only one fraction could be separated that contained pure 
products. Mass spectral analysis evidenced the m/z values of 607 and 593, after the reaction with 
propionaldehyde and acetaldehyde, respectively. Thus, the presumed dimers were isolated. 1H-NMR 
finally confirmed that dimeric structures 199 and 200 were indeed formed since the signals of the 
cyclo(Trp, Pro) moiety were present in duplicate.  
 
Scheme 39: Pictet-Spengler reaction of cyclo(Trp, Pro) 2 with an aldehyde. 
Beside the cis-isomer 2a, also the trans-fused DKP cyclo(D-Trp, L-Pro) 2b was investigated. The 
reaction of 2b with propionaldehyde and acetaldehyde again resulted in the formation of three 
products (Scheme 39). The results were similar for both diastereomers 2a and 2b so the 
configuration of the amino acids has no effect on the reaction. Several attempts were made to 
isolate the different fractions through chromatographic methods. The compounds could not be 
isolated from pTLC. Normal phase column chromatography did not furnish the desired products, due 
to partial degradation on silica. However, through reversed-phase automatic chromatography, the 
dimers were eventually obtained.  
The dimers are the result of the reaction of two equivalents of DKP with one equivalent of aldehyde. 
The isolated products were symmetrical. The presence of 2 NH signals around 8-9 ppm in 1H-NMR 
misleadingly indicated the retention of the indole-NH. This led to the false assignment of two 
cyclo(Trp, Pro) units linked at the amide nitrogens. Unfortunately, this was only rectified at the end 
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of this PhD by reanalyzing some products with the (new) 400 MHz NMR, which provided better 
spectra. Analysis of the COSY and HMBC spectra clearly demonstrated that these signals are in fact 
originating from the amide-NH, and have shifted significantly with respect to those in the monomeric 
substrates. The NH-singlets displayed coupling with the CH-9 (α to the carbonyl in tryptophan) in the 
COSY spectrum and they coupled with the carbonyl CC=O-17 in the HMBC spectrum. 
The structures of dimers 199 and 200 derived from cyclo(L-Trp, L-Pro) 2a and from cyclo(D-Trp, L-Pro) 
2b with acetaldehyde and propionaldehyde are depicted in Figure 18. Since each time only one 
product was detected for the different dimers and taking into account the low reaction temperature 
(-40 °C) and short reaction time (1 h), it is assumed that the stereochemistry of the starting DKP did 
not change during the reaction. Difficulties with the purification resulted in low isolated yields of the 
dimers (Figure 18).  
Figure 18: Dimeric products 199 and 200 obtained under Pictet-Spengler conditions. 
 
An analogous reaction has been reported by Tourwé et al. when performing the Pictet-Spengler 
reaction with tryptophan and formaldehyde (Scheme 40).[173] After tryptophan had undergone the 
Pictet-Spengler reaction (201), two units were linked through a carbon-bridge connecting the 
indole-nitrogens (203) via intermediate 202. The main difference with the previous results, is that the 
Pictet-Spengler reaction occurred first and the desired product was further converted into dimers. 
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Scheme 40: Pictet-Spengler reaction of tryptophan with formaldehyde reported by Tourwé et al.[173] 
2.1.3. Pictet-Spengler reaction conditions with aromatic aldehydes 
A difference in behavior of aliphatic and aromatic aldehydes was observed. The aliphatic 
acetaldehyde and propionaldehyde formed a bridge at the indole-nitrogens of the diketopiperazine 
ring. When the reaction was performed in the presence of benzaldehyde two products with a mass 
corresponding to the dimer were detected. Next to the expected dimer 205, connected via the indole 
nitrogens, a dimer 204 with the connection via the C-2 of the indole moiety was also formed. In case 
of the L,L-isomer only 204a could be isolated using normal-phase chromatography, but for the 
D,L-isomer both dimeric products 204b and 205 were isolated using reversed-phase chromatography 
(Figure 19). 
Figure 19: Dimeric products resulting from Pictet-Spengler conditions with benzaldehyde. 
 
A possible explanation for the formation of these alternative dimers 204 can be found in the research 
of Jackson et al.[174] They investigated the electrophilic substitution at the 2-position of the 
3-substituted indole nucleus and their findings are in agreement with the mechanism proposed in 
Scheme 41. The reaction starts with an initial attack at the 3-position of the indole (206) and is 
followed by a 1,2-shift of the substituent to the 2-position (207). The loss of a proton regenerates the 
aromatic indole moiety (208). The loss of water under acidic conditions (209) permits another 
molecule of diketopiperazine 2 to react in a similar fashion, providing the final dimer 204. 
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Scheme 41: Possible mechanism for the formation of dimer 204a. 
2.1.4. Screening different reaction conditions for aliphatic aldehydes 
Several conditions were tested to enhance the formation of either the assumed Pictet-Spengler 
products (197 or 198) or of the dimers (199 or 200) (Table 23). The influence of reaction time, 
temperature and equivalents of reagents were screened. 
The reaction conditions that were used initially, proved to be the best for the synthesis of the dimers 
(entries 1-3). A reaction time of one hour was preferred as a shorter reaction time gave incomplete 
conversion (entry 4). A longer reaction time presumably allowed the dimers to react further with 
aldehyde and products with a mass even higher than the mass of the dimers were detected (referred 
to as rest fraction in Table 23 ) (entry 5). At higher temperatures (0 °C to reflux) (entries 6-9), the 
fraction of these side products augmented as well. In entry 9, all starting material was converted to a 
mixture of many (ca. 10) non-polar, inseparable compounds, possibly degradation had occurred as a 
result of the high temperature. Lowering the temperature to -78 °C was promising as the largest 
fraction consisted of the assumed Pictet-Spengler product (entry 10).  
Reduction of the amount of TFA was detrimental for the reaction and a higher reaction temperature 
was necessary to improve the conversion (entries 11-13). Reducing the equivalents of aldehyde (to 
0.6 equivalents) mainly gave dimers but minor peaks of the other products remained visible 
(entries 14-15). Excess aldehyde (5 equivalents) surprisingly did not result in complete conversion. 
The crude mixture consisted for the largest part of dimers and no side products with high mass were 
detected (entries 16-17). Selective formation of one of both products could not be achieved by 
adjusting the amount of aldehyde used.  
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Reaction conditions involving other (Lewis) acids, instead of TFA, were screened as well 
(entries 18-24). Only the reactions with BF3∙Et2O gave conversion of the starting DKP, resulting in 
formation of the dimers. 
Table 23: Screening of reaction conditions for the selective synthesis of Pictet-Spengler products or dimers. 
 
Entry Substrate R Reaction conditions Result[a] 
1 2a Et 1.25 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1 h 
198a/200a 
1/1 (16%) 
2 2b Et 1.5 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1 h 
198b/200b 
2/3 (12%) 
3 2b Me 1.25 equiv. acetaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1 h 
197b/199b 
3/7 (32%) 
4 2b Et 1.25 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 50 min 
2/198b/200b 
4/50/46 
5 2b Et 1.25 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1.5 h  
198b/200b/rest fraction 
45/35/20 
6 2b Et 1.5 equiv. propionaldehyde, 
5 equiv. TFA 
CH2Cl2, 0 °C, 10h -> r.t., 10 h 
2/198b/200b/rest fraction 
1/2/5/2 
7 2b Et 1.5 equiv. propionaldehyde, 
5 equiv. TFA 
CH2Cl2, r.t., 20 h 
2/198b/200b/rest fraction 
1/2/3/4 
8 2b Et 1.5 equiv. propionaldehyde, 
5 equiv. TFA 
CH2Cl2, , 4 h 
2/198b/200b/rest fraction 
1/1/4/4 
9 2b Et 1.5 equiv. propionaldehyde, 
5 equiv. TFA 
toluene, , 1 d 
Complex reaction mixture, 
complete conversion of DKP 2b 
10 2b Et 1.25 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -78 °C, 2 h 
2/198b/200b 
1/5/4 
11 2b Et 1.05 equiv. propionaldehyde, 
1.05 equiv. TFA 
CH2Cl2, -40 °C, 3 h -> r.t., 3 d 
No conversion at -40 °C 
198b/200b/rest fraction 
2/3/5 
12 2b Et 1.05 equiv. propionaldehyde, 
1.05 equiv. TFA 
CH2Cl2, r.t., 9 d 
2/198b/200b 
2/3/5 
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13 2b Et 1.05 equiv. propionaldehyde, 
catalytic TFA 
CH2Cl2, -78 °C, 2 h 
No conversion 
14 2b Me 0.5 equiv. acetaldehyde, 
10 equiv. TFA² 
CH2Cl2, -40 °C, 1 h 
197b/199b/rest fraction 
2/4/4 
15 2b Et 0.6 equiv. propionaldehyde, 
0.6 equiv. TFA 
CH2Cl2, r.t., 22 h 
198b/200b/rest fraction 
1/4/5 
16 2a Et 5 equiv. propionaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1 h 
2/198a/200a 
2/3/5 
17 2a Me 5 equiv. acetaldehyde, 
10 equiv. TFA 
CH2Cl2, -40 °C, 1 h 
197a/199a 
2/3/5 
18 2b -(CH2)4CH3 4 equiv. hexanal, 
2.2 equiv. BF3∙Et2O 
CH2Cl2, -78 °C, 3 h
[175] 
2b/210/211 
2/3/5 
19 2b Et 4 equiv. propionaldehyde, 
2.2 equiv. BF3∙Et2O 
CH2Cl2, -78 °C, 3 h
[175] 
2b/198b/200b 
1/1/8 (10%) 
20 2b Et 1.5 equiv. propionaldehyde, 
1.5 equiv. Ti(OiPr)4 
CH2Cl2, r.t., 4 d
[176] 
No conversion 
21 2b Et 1.2 equiv. propionaldehyde, 
10 mol% AlCl3, 1 equiv. BtH 
THF, r.t., 4 d
[177] 
No conversion 
22 2b Et 1 equiv. propionaldehyde, 
0.1 equiv. H3PO4 
toluene, , 3 d
[178] 
No conversion 
23 2b Et 1 equiv. propionaldehyde, 
0.1 equiv. pTsOH 
toluene, , 3 d
[179] 
No conversion 
24 2b Et 1.5 equiv. propionaldehyde, 
1/1 w/w H3PO4/P2O5 
100 °C, 1 d[180] 
No conversion 
[a] Ratio obtained by integration of the 220 nm UV-signals in the HPLC chromatogram. 
 
  
III. Results and discussion 
 
77 
 
2.1.5. Rationalization and further attempts 
The presence of dimeric structures means that an inter- instead of intramolecular reaction took 
place. The limited formation of Pictet-Spengler product will most probably result from an insufficient 
formation of the N-acyliminium intermediate from the DKP 2 contrary to the easier formation of an 
intermediate imine from the primary amine in tryptophan. Ducrot and Thal also aimed at performing 
a Pictet-Spengler reaction involving an N-acyliminium intermediate.[181] They found that this 
intermediate was not formed at a temperature below 0 °C. Since the reactions were performed 
at -40 °C in our case, the impeded formation of the N-acyliminium intermediate explains the smooth 
formation of the dimers, but it does not agree with the results at -78 °C where the assumed 
Pictet-Spengler product is the major fraction (entry 10).  
Therefore, it is suggested that the nitrogen amide bond in the DKP is not nucleophilic enough to 
attack the aldehyde compared to the indole nitrogen. This also clarifies why at higher temperatures 
more side products are formed with masses exceeding the dimers. These products probably are 
dimers that have reacted with extra equivalents of aldehyde. Once the dimers are formed the alkyl 
bridge functions as a protecting group of the indole nitrogen leaving only the amide nitrogen to react 
with the aldehyde. This points out the need of a protecting group on the indole nitrogen for the 
reaction to succeed. Unfortunately, the assignment of the alkyl bridge connecting the two monomers 
through the indole nitrogens was not noticed sooner. Since it was assumed the amide was reactive 
enough, no protecting groups were tested in the timeframe of this PhD.  
An appropriate protecting group would have to be acid resistant as TFA is used and would ideally 
enhance the nucleophilicity of the indole nucleus. Carbamate protecting groups (e.g. Boc or Cbz), 
sulfonyl derivatives (e.g. mesitylenesulfonamide) or N-trialkylsilylamines (e.g. TBDMS) do not comply. 
Preference would be given to N-alkyl or N-aryl derivatives (e.g. benzyl group). The most elegant 
solution would be to see if the alkyl bridge indeed functions as protecting group and let the dimers 
react further with the aldehyde to compounds analogous to 203 (Scheme 40). Subsequent hydrolysis 
of the aminal group as described for 203 by the group of Tourwé, should provide the desired Pictet-
Spengler products. 
In addition, it can be speculated that the more rigid conformation of the DKP ring does not allow the 
expected intramolecular ring formation necessary for a Pictet-Spengler reaction.  
On the other hand, a product was detected with a mass in agreement with the Pictet-Spengler 
product. This can indicate that the N-acyliminium is being formed to a limited extent. But, despite 
several trials to purify these products with normal-phase chromatography using different eluent 
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mixtures (ethyl acetate, dichloromethane/methanol, ethyl acetate/petroleum ether mixtures), the 
suspected Pictet-Spengler products were not isolated in pure form, so the structure could not be 
validated. Reversed-phase chromatography did result in the isolation of a fraction containing both of 
the isomers having the same mass of the Pictet-Spengler product. Their 1H-NMR spectra showed too 
much signal overlap to assign a structure to the compounds. 
The low reactivity of the amide-nitrogen is probably the main reason why the side products are so 
easily formed. However, a similar reaction was demonstrated by Gonzalez et al.[182-184] They 
performed a Pictet-Spengler cyclization of a phenylalanine-based diketopiperazine with aldehyde 
dimethyl acetals in the presence of TMSOTf as the catalyst. The amide bond was first activated by 
adding TMSOTf to the piperazin-2,5-dione to form the O-trimethylsilyl derivative. 
These reaction conditions were tested on cyclo(D-Trp, L-Pro) 2b as a substrate. TMSOTf was added 
together with DIPEA in a first step to activate the amide bond (Scheme 42). The reaction was tested 
with propionaldehyde and with an acetal (1,1-dimethoxyethane) (Table 24). Following the procedure 
of Gonzalez et al.,[182] the mass of the intermediate hemiaminal ether 212 was detected in HPLC-MS. 
It was surprising that the hemiaminal 212 remained stable during the HPLC-MS analysis and did not 
readily undergo hydrolysis. However, subsequent treatment with formic acid returned the starting 
material 2b. Analysis of the intermediate mixture after the first steps (entry 1) showed that the 
assumed intermediate 212 was in fact compound 214. The indole nitrogen again proved to be more 
reactive. When propionaldehyde was used, no reaction took place.  
 
Scheme 42: Pictet-Spengler reaction with TMSOTf as catalyst. 
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Table 24: Pictet-Spengler reaction conditions using TMSOTf as catalyst.  
Entry R1 R2 Reaction conditions result 
1 -Me -Me a) 1 equiv. DKP 2b 
    1.1 equiv. DIPEA, 
    1.2 equiv. TMSOTf 
    CH2Cl2, -78 °C, 4 h 
b) 1.2 equiv. dimethoxyethane  
     CH2Cl2, -78 °C, 4 h 
c) HCOOH,  
Mixture of 2b/214/199b 
 
 
Recovery DKP 2b 
2 -Et -H a) 1 equiv. DKP 2b 
    1.1 equiv. DIPEA, 
    1.2 equiv. TMSOTf 
    CH2Cl2, -78 °C, 4 h 
b) 1.2 equiv. propionaldehyde, 
     CH2Cl2, -78 °C, 4 h 
No conversion, 
2b recuperated 
Dimeric diketopiperazines based on a cyclo(Trp, Pro) skeleton also form a rare class of natural 
compounds. Amongst others this class includes stephacidine B 215,[27, 30, 185] aspergilazine A 216[186-187] 
(Figure 20) and brevianamide S 31[68] and J 27.[66] In general the connection between the two 
diketopiperazine units takes place through a linkage of the tryptophan units. Thus, here too the 
indole moiety is more reactive than the amide. 
 
Figure 20: Dimeric diketopiperazines (+)-stephacidine B 215 and (-)-aspergilazine A 216. 
Brevianamide S 31 exhibits selective antibacterial activity against Bacille Calmette-Guerin (BCG). 
Therefore, the antimicrobial activity of compounds 199b and 200b was tested by BCCMTM/LMG 
(Laboratory of Microbiology, Ugent) against a panel of four bacterials strains: the Gram-negative 
Escherichia coli LMG 8063 and Klebsiella pneumonia LMG 2095, and the Gram-positive 
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Staphylococcus aureus LMG 8064 and Bacillus substilis LMG 13579. No antimicrobial effect was 
observed based on visual assessment of the turbidity caused by bacterial growth. 
2.1.6. Conclusion 
When subjecting a tryptophan-proline derived diketopiperazine to Pictet-Spengler conditions with 
aldehydes in the presence of trifluoracetic acid, dimeric products were isolated. These dimers are 
novel members of the class of dimeric diketopiperazines possessing a linkage between the two 
diketopiperazine units via an alkyl bridge between the indole nitrogens. In the case of aromatic 
aldehydes, another dimer was detected with the linkage at the C-2 carbon of the indole moieties. In 
all cases symmetrical dimers were obtained. 
Products were also formed with a mass coinciding with the expected Pictet-Spengler product as 
evidenced by HPLC-MS analysis. Despite several trials, the desired compounds could not be isolated. 
Cyclo(Trp, Pro) as such is not suited as a starting point for the formation of annulated DKP derivatives 
via a Pictet-Spengler condensation reaction. The indole nitrogen was more reactive towards the 
aldehyde than the amide nitrogen, even after attempted activation of the latter by the addition of 
TMSOTf. A possible solution would be to introduce a protecting group on the indole nitrogen. 
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2.2. Ring formation through metathesis of allyl groups 
The next objective consisted of the decoration of the diketopiperazine scaffold with allylic moieties 
analogous to the prenyl group, which is omnipresent in the natural products. Subsequently, 
metathesis reactions towards spiro or annulated derivatives would be pursued. By using unsaturated 
electrophiles such as allyl bromide, precursors (218, 220) can be prepared which are suitable for 
transformation by metathesis reactions, with formation of compounds such as 217 and 219 (Scheme 
43). Also dimerizations can be envisaged by metathesis reactions, which opens the way to prepare 
analogues of dimeric natural compounds. 
 
Scheme 43: Envisaged derivatives 217 and 219 through metathesis of allyl groups. 
2.2.1. Introduction of the allyl group at C-3 of the indole 
The synthesis of the spiro derivatives 217 required the introduction of an allylic moiety at the indole 
C-3-position. The formation of allylated compound 221 was aimed for. However, it was reasonable to 
expect that 221 would react intramolecularly and thus lead to the formation of an annulated 
derivative 222. Different procedures based on palladium catalysis were tested on the scaffold 
cyclo(L-Trp, L-Pro) 2a (Table 25).  
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Table 25: Procedures for the C-3 allylation of DKP 2a. 
 
Entry Reaction conditions Result 
1 3 equiv. allyl methyl carbonate, 
2.5 mol% Pd2(dba)3, 
5 mol% P(2-furyl)3 
CH2Cl2, r.t., 1 d 
No reaction 
2 1 equiv. allyl alcohol, 
5 mol% Pd(PPh3)4, 
1 equiv. Et3B 
THF, 50 °C, 5 h 
222a  
(76%) 
3 1 equiv. allyl alcohol, 
5 mol% Pd(PPh3)4 polymer bound, 
1 equiv. Et3B 
THF, 50 °C, 5 h 
No reaction 
A procedure from Kagawa et al. was used for the palladium-catalyzed β-allylation of 2,3-disubstituted 
indoles, using allyl methyl carbonate as allylation precursor.[188] When these reaction conditions were 
applied on 2a, no reaction took place (Table 25, entry 1). 
Kimura et al.[189] used a Pd-Et3B/allyl alcohol system for the C-3 selective allylation of indoles 
including L-tryptophan methyl ester 121a. A similar, enantioselective procedure was elaborated by 
Trost et al.[190] The achiral conditions were applied on 2a with full conversion of the starting material. 
The annulated product 222a was formed as could be expected (Table 25, entry 2). Again difficulties 
arose for the isolation of the product. The separation of 222a from the triphenylphosphine oxide 
byproduct could not be achieved by recrystallization, pTLC, column chromatography or filtration over 
silica plugs. Eventually, product 222a was purified by pHPLC (Table 26). To prevent the release of the 
oxidized ligand, the reaction was repeated with polymer-bound catalyst (Sigma Aldrich, product 
number 511579, 0.5-0.9 mmol/g loading). However, no reaction was observed (Table 25, entry 3). 
Remarkably, the reaction only proceeded with the catalyst from Sigma-Aldrich. No conversion 
occurred when the reaction was repeated with Pd(PPh3)4 from other suppliers, like Acros Organics or 
TCI. Serendipitously, the reaction was performed with the right catalyst the first time it was run.  
The reaction conditions of Kimura et al. were applied on all the isomers of cyclo(Trp, Pro) 2. The 
reaction was only successful for the cis-isomers 2a and 2d (Table 26). The trans-isomers 2b and 2c 
were not allylated. 
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Table 26: Yields for the isomers of allylated cyclo(Trp, Pro) 222. 
Cpd Starting compound Yield (%) 
222a Cyclo(L-Trp, L-Pro) 76 
222b Cyclo(D-Trp, L-Pro) No conversion 
222c Cyclo(L-Trp, D-Pro) No conversion 
222d Cyclo(D-Trp, D-Pro) 68 
Kimura et al. reported that only one diastereomer 223 was formed from L-tryptophan methyl ester 
121a. A similar stereochemistry is assumed at the newly formed stereogenic centers in 222a and 
222d as only one product was detected with HPLC and 1H-NMR for the conversion of 2a and 2d 
(Figure 21). This assumption was investigated with NOE experiments on compound 222a. 
 
Figure 21: Novel C-3 allylated and annulated derivatives 222a and 222d. 
NOE experiments clearly showed that H-2 and the allyl group are in each other’s vicinity in space and 
thus have to be positioned at the same side of the molecule, as was expected (Figure 22). A small 
NOE was present between H-2 and the overlapping signals for H-9 and H-12, indicating that H-2 is 
situated at the same side of the molecule as H-9 and/or H-12. The stereocenters of tryptophan and 
proline are known to have the (S)-configuration and the allylation reaction does not influence the 
stereochemistry of the amino acids. Despite the fact that it is unclear whether H-2 is in the proximity 
of H-9, H-12, or both, it can be concluded that H-2, H-9 and H-12 are located at the same side of the 
diketopiperazine ring. 
Additionally, a NOE was observed for both H-2 and H-19 with one and the same proton at position 8 
(Figure 22). To determine how this proton was situated relative to H-9, the dihedral angle with H-9 
was calculated from the JH-H coupling constant using the Karplus equation according to Haasnoot et 
al.[191-192] or Pachler.[193-194] From the 1H-NMR spectrum, the coupling constants for the CH2-8 protons 
were determined as 6.3 Hz and 11.1 Hz. The proton displaying a NOE with H-2 and H-19 has a 
coupling constant of 6.3 Hz. This corresponds to different angles, which were compared with a 
Dreiding model of the molecule. Therefore, it was concluded that the proton displaying a coupling 
constant of 6.3 Hz is Ha-8, positioned at a dihedral angle of 35-41° to H-9, and thus at the same side 
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as H-9. The proton Hb-8 has a coupling constant of 11.1 Hz and is positioned at an angle of 160-167°. 
These observations support the structure 222a, where H-2, the allyl group, Ha-8 and H-9 are situated 
in each other’s proximity on the same side of the molecule. 
 
Figure 22: NOE by irradiating H-2 and H-19. 
Table 27: Estimated torsion angles. 
 Estimated torsion angles according to  
3JH-H coupling constants Haasnoot et al.
[a] Pachler[a] 
6.3 Hz 41°, 135°, 230°, 324° 35°, 128°, 232°, 325° 
11.1 Hz 167°, 198° 160°, 201° 
[a] The values in bold are the possible angles according to the Dreiding model. 
Compounds 222a and 222d are novel brevianamide derivatives that have a similar structure as 
several other tryptophan-based diketopiperazines such as fructigenine A 224,[195] okaramine M 
225,[196] roquefortine D 226[197] or brevicompanine B 227, which are also annulated and possess an 
isoprenyl group at the C-3 (Figure 23).[198-199]  
 
Figure 23: C-3 prenylated diketopiperazines. 
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2.2.2. Towards a spiro derivative 
To prepare the desired spiro derivative 217 (Scheme 43), two allyl groups had to be introduced. In 
the first step it has been demonstrated that C-3 allylation is possible, but is accompanied by 
intramolecular ring formation through reaction of the amide with intermediate indolenine 221. To 
prevent this spontaneous ring closure, the secondary amide bond was alkylated towards the tertiary 
amide. Since the diallylated product was the desired metathesis precursor, an allyl group was 
introduced. 
With cyclo(Trp, Pro) 2 in hand, it was investigated whether selective monoallylation of the amide was 
possible in the presence of the free indole-NH. Reaction with one equivalent of base gave a mixture 
of mono- and di-allylated products, together with a significant amount of residual starting material 
(Scheme 44). When 2a was reacted with base, epimerization occurred giving a complex mixture (228, 
220). This was not the case when 2b was used, so 228b could be isolated via pTLC. In 228b, the allyl 
group was located at the amide position. The difference in pKa values of the amine and amide did 
not suffice to allow for a selective monoallylation, and the use of protecting groups was necessary. 
 
Scheme 44: Attempted monoallylation of cyclo(Trp, Pro) 2a and 2b. 
A Boc protective group was introduced on the indole amine of dipeptide 181a (Scheme 45). 
Subsequent removal of the Cbz group from 229 and cyclization provided the corresponding 
diketopiperazine 230. Deprotonation with a base in the presence of the electrophile allyl bromide 
resulted in the allyl derivative 231, which had undergone partial epimerization.[121] Pure product 231 
was isolated after column chromatography. Finally, selectively monoallylated DKP 228a was obtained 
after removal of the Boc group from 231.  
The epimerization during alkylation of Boc-protected cyclo(L-Trp, L-Pro) 230 to provide 231, can 
possibly lead to one of two thermodynamically more stable trans-isomers of 231. To confirm the 
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stereochemical assignment of the isolated allyl derivative 231, the stereochemistry of 228a was 
investigated.  
The two possible trans-configurations of the diketopiperazine core that are under consideration are 
cyclo(D-Trp, L-Pro) or cyclo(L-Trp, D-Pro). However, the trans-isomer 228b possessing the cyclo(D-Trp, 
L-Pro) ring was also obtained (vide supra) and the sign of the optical rotations of 228a and 228b are 
opposite. On the ground of the optical rotation, possible epimerization at the CHα from tryptophan 
was excluded. Consequently, if 228a was derived from epimerized 231 instead of its cis-isomer, the 
diketopiperazine ring would have epimerized at the CHα from proline.  
The possibility of 228a being a trans-isomer was indicated by the low value of the CHα from proline in 
1H-NMR (2.29 ppm). When looking at the different isomers of cyclo(Trp, Pro) 2a-d, CHα from proline 
(CH-12) has the same chemical shift as CHα from tryptophan (CH-9) (around 4.1 ppm) for the cis-
isomers 2a and 2d. In contrast, the trans-isomers 2b and 2c display a significant difference in shift for 
both CHα’s (2.8 ppm for CH-12 versus 4.1 ppm for CH-9) most probably as a result of shielding by the 
indole ring of tryptophan folding back over the diketopiperazine ring.[7, 200] However, the prenylated 
instead of allylated cyclo(L-Trp, L-Pro) analogue of 228a has been reported by the group of R. M. 
Williams.[121] This compound also displays a shift of only 2.18 ppm for CH-12 and has been 
investigated by NOE experiments. The spectral data of 228a and the prenylated compound from 
Williams are very similar apart from the methyl groups. The low chemical shift of CH-12 is thus 
possible and therefore will more likely result from the presence of the allyl group. Moreover, the 
procedure by the group of Williams[121] (as well as e.g. Scheme 9)[56-57] applies very similar reaction 
conditions and no epimerization at the proline CHα was mentioned. This indicates that epimerization 
will not happen so readily at this position. In case of epimerization at CH-12, the absolute value of 
the optical rotation should be the same as for 228b as they would then be enantiomers, which was 
not the case (75° versus 95°). Therefore, it was concluded at the time that 228a and 231 were indeed 
the cis-isomers.  
However, another report by Wang et al. also describes the formation of the cis- and trans-prenylated 
cyclo(Trp, Pro) scaffold.[163] This article provides other spectral data for the cis-product, which do not 
correspond to the data reported by the group of Williams. The 1H NMR data for the cis-product 
provided by the group of Williams concurs better with the 1H NMR data for the trans-product made 
by Wang et al. In retrospect, the data reported by Williams et al. are incorrect and will actually 
correspond to the trans-product. As a result, the wrong conclusion was initially made on the 
stereochemistry of 228a, which will actually be the epimerized trans-product. This was corrected, but 
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no alternative synthesis was possible within the timeframe of this work. The difference in optical 
rotation values can be explained as the result of small impurities in the sample. 
 
Scheme 45: Selective synthesis of monoallylated cyclo(L-Trp, L-Pro) 228a. 
The method of Kimura et al. for the C-3 selective allylation of the indole, which worked on cis-DKP’s 
2a and 2d, was only applied on trans-DKP 228a. As could be expected, no formation of 218 was 
observed (Scheme 46). No further investigations into the application of these reaction conditions on 
the other isomers or the use of other palladium catalysts were conducted within the timeframe of 
this work. 
 
Scheme 46: Pd-catalyzed allylation of monoallylated 228a. 
2.2.3. Towards a dimer and an annulated derivative 
When the selective monoallylation of 2b was attempted, mixtures of mono- and di-allylated products 
were obtained. Since the allylated products 228b and 220b were available, a brief investigation was 
made into their transformation to the corresponding dimers 232 or annulated derivative 219b 
through metathesis. Unfortunately, all attempts towards the desired metathesis reactions failed. 
Dimerization of mono-allylated 228b using Grubbs I catalyst gave no conversion after refluxing in 
dichloromethane. In toluene, only isomerization of the double bond occurred (233, Scheme 47).  
III. Results and discussion 
88 
 
 
Scheme 47: Desired formation of dimers via metathesis from 228b. 
Finally, the formation of the annulated compound 219b starting from di-allylated compound 220b 
was attempted. To get a better conversion to 220b, more equivalents of base were added.[121] The 
conversion to 220b improved, but still some monoallylated 228b remained. Attempts towards ring 
formation of the di-allylated product 220b gave no conversion, both with Grubbs II or Hoveyda-
Grubbs II catalysts (Scheme 48). The lack of reaction can be the result of an unfavorably positioning 
of the two allyl groups to undergo metathesis. Presumably, conformational rigidity of the ring 
systems does not allow enough flexibility for the double bonds to align properly.  
 
Scheme 48: Desired formation of annulated derivatives via metathesis from 220b. 
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2.3. Synthesis of annulated analogues via other electrophiles 
2.3.1. Introduction 
Many of the complex fungal metabolites containing the cyclo(Trp, Pro) skeleton are annulated (7), 
spiro-annulated (86) or have a bicyclic core (3) and thus possess an extra bridging structure 
connected to the diketopiperazine ring (Figure 24). Nature has most likely selected for the 
introduction of an extra ring system in these compounds to increase the conformational rigidity, 
which in its turn leads to a higher selectivity towards target proteins. 
 
Figure 24: Fungal metabolites containing the cyclo(L-Trp, L-Pro) moiety. 
To assess the possibility of introducing an extra ring via a carbonyl bridge between the amide-N and 
the indole group, difunctionalized electrophilic reagents including 1,1'-carbonylbis-1H-imidazole (CDI) 
and phosgene were reacted with cyclo(Trp, Pro). In the present chapter, an alternative bridging 
structure for the tryptophan-proline based diketopiperazine scaffold is described: the 3,5-bridged 
piperazine moiety.  
2.3.2. Screening different electrophiles leads to the novel 3,5-bridged 
α-chloroamine 
The synthesis of diketopiperazine 2 was performed using standard protocols (Scheme 34). In a first 
attempt to introduce an extra ring, cyclo(D-Trp, L-Pro) 2b was reacted with CDI (Table 28). The 
reaction proceeded, very slowly, towards one product. Conversion remained incomplete even after 
several days (entries 1-2). Dimer 234 was obtained, which was a similar result to the earlier reported 
dimers derived from the Pictet-Spengler reaction (Figure 18). Due to the sensitivity of CDI to water, 
any residual (or introduced during sampling) moisture in the solvents will result in loss of some CDI, 
which may have caused the limited conversion. Therefore, excess CDI was added to improve 
conversion and to possibly speed up the reaction (entry 3), but no improvement was noted.  
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Table 28: Screening of reaction conditions for the synthesis of compound 234. 
 
Entry Conditions Conversion to 234[a],[b] 
1 
1.1 equiv. CDI,  
2 equiv. Et3N 
CH2Cl2, , 3 d 
60% (15%) 
2 
0.6 equiv. CDI, 
1 equiv. Et3N 
CH2Cl2, , 7 d 
40% (8%) 
3 
10 equiv. CDI, 
3 equiv. Et3N 
CH2Cl2, , 9 d 
50% 
4 
10 equiv. CDI, 
CH2Cl2, , 5 d 
No conversion 
5 
1.1 equiv. CDI, 
3 equiv. Et3N 
CH2Cl2, , 5 d 
80% (65%) 
6 
1.1 equiv. CDI, 
2 equiv. Et3N 
CH2Cl2, MW: 60 °C, 1 h  
35% conversion to 
unidentified compound[a] 
7 
1.1 equiv. CDI, 
2 equiv. Et3N 
CH2Cl2, MW: 100 °C, 1 h  
60% conversion to 
unidentified compound[a] 
8 
1.1 equiv. CDI, 
2 equiv. Et3N 
CH2Cl2, MW: 100 °C, 2 h  
35% conversion to 
unidentified compound[a] 
9 
1.8 equiv. Me2CO3, 
3.6 equiv. DIPEA 
CH2Cl2, r.t., 1 d 
No conversion 
10 
1.8 equiv. 1,3-dioxolan-2-one 
3.6 equiv. DIPEA 
CH2Cl2, r.t., 1 d 
No conversion 
11 
1.2 equiv. ClCO2Me, 
1.2 equiv. DIPEA 
CH2Cl2, r.t., 5 d 
No conversion 
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12 
1. 5 equiv. (CO)2Cl2, 
3 equiv. Et3N 
CH2Cl2, r.t., 4 h 
Complex reaction mixture 
[a] Conversion obtained by integration of the 220 nm UV-signals  
in the HPLC chromatogram. [b] Isolated yields are indicated in parentheses. 
In the absence of Et3N, no reaction took place and DKP 2b could be retrieved (entry 4). As the base 
proved to play a vital role in the reaction, excess base was also evaluated and a good conversion was 
achieved (entry 5). In an effort to speed up the reaction, it was performed under microwave 
conditions at elevated temperature and pressure. Generally, reactions proceed faster using 
microwave synthesis simply because they are conducted at higher temperatures.[201] However, no 
conversion to the desired dimer was achieved (entries 6-8). Nonetheless, partial conversion of the 
starting material to another compound was detected by HPLC-MS. Unfortunately, despite several 
trials, this compound could not be isolated for identification using pTLC with several eluent mixtures, 
due to degradation on the stationary phase. 
Some other electrophiles were screened. Carbonates gave no reaction with DKP 2b under the current 
conditions (entries 9-11). The reaction with oxalyl chloride was irreproducible and mixtures of several 
polar and non-polar compounds were obtained (entry 12).  
Cyclo(D-Trp, L-Pro) 2b was reacted with triphosgene in the presence of N,N-di-isopropylethylamine 
(DIPEA), to assess the possibility of introducing a carbonyl bridge between the amide-N and the 
indole group (Scheme 49).[202] However, another, unknown compound was formed during this 
reaction and isolated via pTLC. Mass spectrometry analysis of the unknown compound showed two 
molecular ion peaks (m/z 302 and 304, [M + H]+) with peak heights in a 3:1 ratio, which indicated the 
presence of a chlorine atom in the structure. The molecular mass of the DKP starting materials 2 is 
283 Da. Replacing a hydrogen for a chlorine atom exceeds the recorded mass 
(M-H+Cl : 283-1+35 = 317). Hence, it was concluded that an oxygen atom was expelled from DKP 2 
(M–O+Cl : 283–16+35 = 302).  
 
Scheme 49: Reaction of cyclo(D-Trp, L-Pro) 2b with triphosgene. 
Phosgene is known to react with amides to afford an imidoyl chloride. However, this intermediate 
(235 or 236, Scheme 50) would not be stable and would have reacted with the indole moiety. 1H-
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NMR studies indeed indicated that reaction had taken place at C-2 of the indole, since the signal of 
that proton had disappeared. The proposed structures (237 and 238) for the unknown compound 
included the remarkable feature of an α-chloroamine. Since the reaction could have taken place at 
either amide function, two possible structures remained: 237 and 238 (Scheme 50). 
 
Scheme 50: Structural elucidation of the product from reaction of 2 with triphosgene. 
X-ray analysis was envisaged to solve the structure and the compound was dissolved in a minimal 
volume of CH2Cl2. Slow evaporation of the solvent provided several prism-shaped crystals. Using 
X-ray analysis, the structure was confirmed to be pentacyclic α-chloroamine 237b (Figure 25). 
Indeed, a C-C bond had been formed between the C-2 of the indole moiety and the carbonyl carbon 
originating from proline. From this analysis, it was clear that the relative stereochemistry of the DKP 
was retained during the reaction. Surprisingly, two different crystal packings, both determined as 
‘block’ shaped, were detected for two separate repetitions of crystallizations performed in the same 
manner. However, the speed of evaporation may have differed depending on the temperature in the 
laboratory. 
   
Figure 25: X-ray analysis of the newly formed pentacyclic α-chloroamine 237b (thermal ellipsoid contour probability level 
50%). 
In the first type, hydrogen bridges were present in the crystal packing between the indole-NH of one 
molecule and the C=O carbonyl of another molecule (Figure 26). 
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Figure 26: First type of crystal packing of 237b. 
The second type of crystal was composed of the same compound 237b , but the unit cell and packing 
were different. In this case, there were 3 molecules building up the asymmetric unit (Figure 27). Here 
too, hydrogen bridges in the crystal packing were detected between the indole NH of one molecule 
and the C=O carbonyl of another molecule. When the three molecules building up the asymmetric 
unit are fitted, it can be seen that one of the molecules is inverted (Figure 28). The indole NH is 
oriented to the opposite side of that in the other two molecules. 
 
Figure 27: Unit cell of second type of crystal packing of 237b. 
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Figure 28: Second type of crystal packing of 237b. 
2.3.3. Mechanistic discussion for the formation of the α-chloroamine 
It is assumed that formation of the α-chloroamine 237b resembles a Vilsmeier-Haack reaction. We 
propose that the reaction of tri- (or di)phosgene with the amide function of 2b leads to an 
intermediate imidoyl chloride 235b (Scheme 51), which is followed by an electrophilic aromatic 
substitution of the indole moiety with the imidoyl chloride. The latter transformation could be 
started via nucleophilic attack by either the C-2 (pathway a), or the C-3 atom of the indole function 
(pathway b). C-3 attack would lead to an intermediate spiroindolenine (int-b), which undergoes a 
1,2-shift giving rise to product 239, which can then readily lose a proton affording α-chloroamine 
237b.  
III. Results and discussion 
 
95 
 
 
Scheme 51: Reaction of piperazin-2,5-dione 2b with tri- (or di)phosgene to α-chloroamine 237b. 
Although most literature precedents suggest that the more favorable 6-endo-trig cyclization 
(pathway a)[203-204] may be preferred over the less favorable 5-endo-trig cyclization (pathway b), 
evidence for the formation of a spiroindolenine (int-b) intermediate can be found as well.[205-207] To 
investigate the mechanism of the observed reaction, both pathways were studied by density 
functional theory (DFT) calculations performed at the Center for Molecular Modeling, Ghent 
University, Belgium. Gibbs free energy profiles for the involved transformations are shown in Figure 
29. For both pathways, two different transition states - exo and endo - were found, leading to two 
different protonated α-chloroamines 239, which both give rise to the α-chloroamine 237b after 
deprotonation. 
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Figure 29: Free energy profiles (kJ/mol) for the reaction of the intermediate imidoyl chloride 235b to the protonated α-chloroamine 239 (PCM (ε = 8.93) M06-2X/6-31+G(d,p)). 
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Free activation energies show that pathway a (direct attack by the C-2 atom) is the kinetically 
preferred route - via TS-a-endo - (∆Gǂ = 58.2 kJ/mol at the M06-2X/ 6-31+G(d,p) level of theory). 
Product 239-endo is the kinetically preferred compound and is quickly deprotonated towards the 
neutral α-chloroamine 237b upon formation. Therefore, equilibration of 239-endo via 235b to the 
thermodynamically preferred spiroindolenines Int-b (pathway b, via C-3 attack) is not feasible. 
Moreover, various attempts to model the necessary 1,2-shift (via TS-b’) between the intermediate 
spiroindolenine int-b and the protonated product 239 failed, as was previously found by 
Maresh et al. as well.[204] Presumably, if the intermediate spiroindolenine int-b would be formed, it 
would not undergo a 1,2-shift with formation of the protonated α-chloroamine 239 under the 
current reaction conditions, since this would imply the involvement of a high-energy intermediate. It 
can thus be concluded that α-chloroamine 237b is most likely formed via direct attack by the C-2 
atom of the indole function and not via C-3 attack followed by a 1,2-shift.  
2.3.4. Improving conversion towards the α-chloroamine 
The reaction suffered from low yields, partly due to incomplete conversion of cyclo(D-Trp, L-Pro) 2b 
(Table 29). To improve the conversion, longer reaction times (entries 1-3) and higher temperatures 
(entry 4) were evaluated. A run with a larger excess of triphosgene was also attempted (entry 5). 
These modifications did, however, not lead to a dramatic increase in formation of 237b. The addition 
of more base was detrimental to the reaction (entry 6).  
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Table 29: Reaction conditions tested on cyclo(D-Trp, L-Pro) 2b for the synthesis of 237b. 
Entry Electrophile Base Solvent T t Ratio 2b/237b[a] 
1 1.2 equiv. 
triphosgene 
3 equiv. DIPEA CH2Cl2 r.t. 21 h 1/2 (16%) 
2 1.2 equiv. 
triphosgene 
3 equiv. DIPEA CH2Cl2 r.t. 2 d 1/3 (24%) 
3 1.2 equiv. 
triphosgene 
3.6 equiv. DIPEA CH2Cl2 r.t. 6 d 1/4 (15%) 
4 1.2 equiv. 
triphosgene 
3.6 equiv. DIPEA CH2Cl2 Δ 4 d 1/4 
5 1.5 equiv. 
triphosgene 
4.5 equiv. DIPEA CH2Cl2 r.t. 2 d 1/4 (22%) 
6 1.2 equiv. 
triphosgene 
7.2 equiv. DIPEA CH2Cl2 r.t. 2 d No conversion 
7 1.8 equiv. 
diphosgene 
3.6 equiv. DIPEA CH2Cl2 r.t. 1 d Full conversion (48%) 
8 1.8 equiv. 
diphosgene 
3.6 equiv. Et3N CH2Cl2 r.t. 2 d Complex reaction mixture 
9 1.8 equiv. 
diphosgene 
3.6 equiv. DBU CH2Cl2 r.t. 2 d Complex reaction mixture 
10 3 equiv. diphosgene 6 equiv. 
imidazole 
CH2Cl2 r.t. 3 d Complex reaction mixture 
11 3 equiv. diphosgene 6 equiv. K2CO3 CH2Cl2 r.t. 4 d 1/10 
12 3 equiv. diphosgene 6 equiv. DIPEA THF r.t. 19 h Complex reaction mixture 
13 3 equiv. diphosgene 6 equiv. DIPEA ACN r.t. 1 d Complex reaction mixture 
14 1.2 equiv. POCl3 3.6 equiv. DIPEA CH2Cl2 r.t. 4 d No conversion 
15 1.2 equiv. 
triphosgene 
- CH2Cl2 r.t. 
 
Δ 
1 d 
 
4 d 
No conversion 
 
1/1 
16 3 equiv. diphosgene - CH2Cl2 Δ 21 h Full conversion 
(50%) 
[a] Based on HPLC-MS, isolated yield between parentheses.  
Diphosgene was evaluated as an alternative source of phosgene and gave full conversion (entry 7). 
Nevertheless, a significant amount of side product, formed by reaction between DIPEA and excess 
tri- or diphosgene, impeded the purification which resulted in low yields. This side product was 
identified as 1,3-diethyl-1,3-diisopropylurea, formation of which was confirmed by mixing DIPEA with 
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diphosgene (see Experimental Procedures).[208] A related reaction of Et3N and phosgene mentions the 
formation of intermediate 1,1’-carbonylbis(triethylammonium)chloride. The urea can lead to 
acylation of an NH in the diketopiperazine starting material 2b or desired product 237b generating 
more side products and complicating the reaction mixture.[209] This also helps explain why other 
trialkylamine bases still resulted in complex mixtures consisting of more than 5 compounds, which 
could not be identified as starting material 2b or desired product 237b, as analogous urea side 
products can be formed (entries 8-10). Only K2CO3 gave satisfactory results (entry 11). The use of 
other solvents than dichloromethane also resulted in complex reaction mixtures consisting of several 
compounds, which could not be identified as starting material 2b or desired product 237b (entries 
12-13).  
Phosphoryl chloride (POCl3), known to react with amides to form imidoyl chlorides and therefore 
used in Vilsmeier-Haack reactions,[210-211] was examined as an alternative electrophile under similar 
reaction conditions. Its use did not result in an analogous reaction (entry 14).  
The reaction was also run in the absence of base. Considering the proposed reaction mechanism no 
base is needed. When the substrate was stirred at room temperature in the presence of triphosgene, 
no conversion was detected. Under reflux conditions, the reaction proceeded partly (entry 15) and 
the formation of the urea was avoided. Finally, full conversion was achieved by using an excess of 
diphosgene (entry 16). Under these conditions, α-chloroamine 237b was obtained as the major 
product in the crude mixture. Isolation by column chromatography lowered the final yield due to the 
polarity of the compounds, which were largely retained on the column. Several solvent mixtures for 
normal- (petroleumether/EtOAc (+Et3N)) and reversed-phase (H2O/ACN) chromatography were 
examined, but the purification still resulted in major product losses. 
The reaction proved successful for all four stereoisomers of cyclo(Trp, Pro) 2. Table 30 shows the 
isolated yields of the resulting pentacycles 237a-d. 
Table 30: Yields for the isomers of α-chloroamine 237. 
237 Starting compound Y (2-3 steps) 
a Cyclo(L-Trp, L-Pro) 40% 
b Cyclo(D-Trp, L-Pro) 50% 
c Cyclo(L-Trp, D-Pro) 24% 
d Cyclo(D-Trp, D-Pro) 46% 
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2.3.5.  Derivatization of the α-chloroamine 
Since trans-diastereomer 237b gave the best isolated yield, it was chosen as a substrate to develop a 
small library of compounds. In research on the cyclo(Trp, Pro) natural products, typically the cis 
configuration, originating from the natural L-amino acids, is studied. However, compounds containing 
unnatural D-amino acids also possess biological activity. Tadalafil 20 is an example of a commercially 
available drug used for the treatment of erectile dysfunction, which contains a D-tryptophan unit 
(Figure 6).[34]  
The most obvious position to try to derivatize structure 237b was at the chlorine atom. The goal was 
to replace the chlorine atom with various groups. Neutral nucleophiles were evaluated first. 
Dissolving 237b in methanol or water or stirring with 3 equivalents of allylamine gave no conversion 
of the starting material. To stimulate the substitution of chlorine with a methoxy group (240), silver 
nitrate was added as a Lewis acid to a solution of 237b in methanol. Precipitation of the formed silver 
chloride salts should drive the reaction to completion. After a week at room temperature, no 
reaction was detected, but two days of reflux engendered complete conversion (Scheme 52). The 
silver salts proved to be tedious to remove, even after several filtrations. Other Lewis acid catalysts 
can solve this problem. However, an alternative method was simultaneously being investigated and 
provided the desired substitution. Therefore, this method was not pursued any further within the 
timeframe of this thesis. 
 
Scheme 52: Initial derivatization of 237b. 
Some cyclic compounds that also contained an α-chloroamine are known to exhibit a remarkable 
reactivity towards nucleophiles under basic conditions.[212-218] In view of such exploration, a short 
screening of several protecting groups was performed (Table 31). Indeed, since there are two 
secondary amines present in 237b, the possibility exists that the nucleophile would merely react as a 
base if no protecting group was present.  
Several protecting groups were introduced. The reactions were followed up using HPLC-MS. The 
introduction of the protecting group on 237b was confirmed by the molecular mass. Tentative 
assignments for 242 and 246 are based on the 1H NMR spectra of the crudes showing the strong 
decrease in integration of the indole NH signal in comparison with the integration of the other indole 
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signals. In the case of 245, two indole NH signals were present, one corresponding to the starting 
material and one to the acylated product. The sum of the integration of these two signals 
corresponded to the integration of CH-4 or CH-7 on the indole and the retention of the indole NH 
was assigned. From this screening of different protecting groups, it became apparent that the indole 
NH generally reacts more easily with electrophiles and is protected first (entries 1, 2, 4, 7), except in 
the case of acetyl chloride (entry 5). It is rather counter-intuitive that the secondary amine is less 
nucleophilic than the indole amine function, which will probably be effectuated by the nearby 
chlorine atom. For the introduction of the methyl groups extra portions of reagents were added until 
complete conversion was obtained (entry 8). The first methylation, of the indole nitrogen, occurred 
very smoothly (entry 7). The introduction of a second methyl group, on the bridge nitrogen, required 
longer time and more reagents (entry 8). Hence, both selective protection of the indole nitrogen 
(generally) or the bridge nitrogen (acetyl) is possible. 
 
Table 31: Screening the conditions for the introduction of protecting groups on compound 237b. 
 
Entry Cpd R = Reaction conditions R1 R2 Result[a] 
1 241 Boc 3 equiv. Boc2O,  
0.2 equiv. DMAP 
ACN, r.t., 3 h 
Boc H 
 
Complete conversion 
(98%) 
2 242 MEM 5 equiv. MEMCl,  
6 equiv. DIPEA 
CH2Cl2/THF, r.t., 2 d 
MEM H 
 
Complete conversion 
(not isolated) 
3 243 Cbz 2.5 equiv. CbzCl,  
2.5 equiv. NaH 
DMF, r.t., 1 d 
- - No conversion 
4 244 Bn 2.5 equiv. BnBr,  
2.5 equiv. NaH 
DMF, r.t., 1 d 
Bn H 
 
Complete conversion  
(56%) 
5 245 Ac 2.2 equiv. AcCl,  
2.2 equiv. Et3N 
CH2Cl2, r.t., 2 h 
H Ac 
 
Conversion 50% 
(not isolated) 
6  Me 3.5 equiv. MeI,  
3 equiv. Ag2O 
Acetone, , 20 h 
- - Complex reaction mixture 
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7 246 Me 2.5 equiv. MeI,  
2.5 equiv. NaH 
ACN, r.t., 1 h 
Me H 
 
Complete conversion 
(not isolated) 
8 247 Me 3.5 equiv. MeI,  
3.5 equiv. NaH 
DMF, r.t., 1 d 
Me Me 
 
Complete conversion  
(48%) 
[a] Conversion obtained by integration of the 220 nm UV-signals in the HPLC chromatogram. Isolated 
yield between parentheses. 
When examining the substitution of the chlorine atom with basic nucleophiles, protecting groups 
were introduced on the secondary amines to prevent the basic nucleophiles from acting as a base. 
However, the introduction of such a protecting group was generally only accomplished on the indole 
nitrogen.  
Consequently, in a next step, some of the monoprotected compounds were reacted with a basic 
nucleophile. Grignard reagents were used (Table 32). In all cases, an excess amount of nucleophile 
was used to compensate for any loss of nucleophile by taking up a proton from the bridge amine NH 
and complete conversion was detected with HPLC-MS analysis (entries 1-3). In the case of entries 2 
and 3, HPLC-MS analysis indicated the presence of another product in the reaction mixture. 
According to the mass spectrum, this product (252) had lost the chlorine atom on the bridgehead. 
The introduction of a hydrogen atom replacing chlorine can be explained by a magnesium transfer 
reaction from the preformed Grignard reagent to the α-chloroamine, which is followed by 
protonation of the magnesium intermediate by residual water or another proton source. This implies 
the presence of a Grignard reagent derived from a magnesium-halogen exchange in the 
α-chloroamine. However, the experiment to use compound 241 itself as the starting material for the 
formation of a Grignard reagent failed (entry 4). No Grignard reagent was formed as the magnesium 
remained unaltered after refluxing the suspension and to confirm this observation, allyl bromide was 
added, which indeed gave no allylated product. 
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Table 32: Replacing the chlorine atom in monoprotected 237b derivatives using Grignard reagents. 
  
Entry R1  Reaction conditions Anticipated product Result[a],[b] 
1 Bn 
5 equiv. BnMgBr 
CH2Cl2, r.t., 3 h 
248 R1 = Bn, R2 = Bn Complete conversion to 
248 
2 Boc 
2 equiv. vinylmagnesium 
bromide 
THF, r.t., 1.5 h 
249 R1 = Boc, R2 = CHCH2 
 
Complete conversion 
mixture of 249 and 252 
3 Boc 
5 equiv. BnMgBr 
CH2Cl2, r.t., 2 h 
250 R1 = Boc, R2 = Bn 
 
Complete conversion 
mixture of 250 and 252 
4 Boc 
1.05 equiv. Mg,  
1.5 equiv. allyl bromide 
THF, r.t., 1.5 h – , 1.5 h 
251 R1 = Boc, R2 = CH2CH=CH2 No conversion 
[a] Conversion was determined by integration of the MS-signals in the HPLC-MS chromatogram.  
[b] Compounds were not isolated. 
Until now, protecting groups were introduced to prevent the loss of the added nucleophile. 
However, compound 237b as such was also reacted with several O-, N-, S- and C-nucleophiles 
without the use of protecting groups (Table 33). Since no protective groups were used, three 
equivalents of nucleophile were added. However, good conversion was also achieved using only 1.5 
equivalents of nucleophile in particular cases (255 , 257 and 260). Generally these reactions 
proceeded smoothly. Therefore, the introduction of protecting groups on the pentacyclic scaffold 
prior to the substititution of chlorine with basic nucleophiles was omitted as an unnecessary step.  
Unfortunately, separation of the desired products from excess reagent and/or remaining substrate 
proved tedious due to the polar nature of the materials. Therefore, when the compounds were not 
immediately obtained in pure form, they were only recovered in low yields by pTLC. Poor solubility of 
some derivatives was used to isolate these compounds by decanting the solvent from the insoluble 
pure product. For that reason the more bulky nucleophile 1-naphthylmethylamine was added to the 
series of derivatives. The naphthyl group may lower the solubility, however decantation also resulted 
in a low isolated yield of 261. In some cases the purification failed and the pure product could not be 
retrieved (e.g. 266 or 268). Eventually, it was found that these type of compounds could also be 
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purified with reversed-phase chromatography, but the isolated yields remained low (e.g. 270 and 
274). 
The use of sodium hydride to activate the nucleophiles was necessary since reaction did occur with 
allylamine when treated with sodium hydride, while it did not proceed with allylamine alone. Some 
of the reactions with nucleophiles such as cyanide or azide failed to proceed under the current 
conditions. Compounds as 253, 263 or 271 are appealing, since the introduced functionalities offer 
the possibility for further modification.  
Table 33: Derivatives of 237b. 
 
Cpd R Reaction conditions Yield 
253 OH 
2 M NaOH 
H2O, , 2 h 
65% 
240 OMe 
4 M NaOMe 
MeOH, , 2.5 h 
96% 
254  
3 equiv. allyl alcohol + 3 equiv. NaH 
THF, r.t., 1 h 
86% 
255 
 
1.5 equiv. prenyl alcohol + 1.5 equiv. NaH 
THF, r.t., 1 h 
33%[c] 
256 
 
3 equiv. phenol + 3 equiv. NaH 
THF, r.t., 3 d 
19%[b] 
257 
 
1.5 equiv. benzyl alcohol + 1.5 equiv. NaH 
THF, r.t., 40 min 
26%[a] 
258  
3 equiv. allylamine + 3 equiv. NaH 
THF, r.t., 30 min 
77% 
259 
 
1 equiv. aniline + 2 equiv. KOtBu 
THF, r.t., 1 h 
2%[a] 
259 
 
3 equiv. aniline + 3 equiv. NaH 
THF, r.t., 1 h 
24%[b] 
260 
 
1.5 equiv. benzylamine + 1.5 equiv. NaH 
THF, r.t., 1 h 
28%[a] 
261 
 
3 equiv. amine + 3 equiv. NaH 
THF, r.t., 3 h 36%
[c] 
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262 
 
3 equiv. tryptamine + 3 equiv. NaH 
THF, r.t., 4 h 31%
[c] 
263 NH2 
1.5 equiv. NaNH2 
THF, r.t., 2 h 
(Incomplete conversion) 
- 
264 N3 
1.5 equiv. NaN3 
THF, r.t., 4 d 
No conversion 
265  
3 equiv. allyl mercaptan + 3 equiv. NaH 
THF, r.t., 3 d 
32%[a] 
266 Me 
1.5 equiv. MeLi  
THF, -78 °C , 1 h 
(Complete conversion) 
Not isolated 
267 Bu 
3 equiv. nBuLi  
THF, -78 °C – r.t., 30 min 
12%[a] 
268 sBu 
3 equiv. sBuLi 
THF, -78 °C , 1 h 
(Complete conversion) 
Not isolated 
269 tBu 
3 equiv. tBuLi 
THF, -78 °C , 2 h 
No reaction 
270 Ph 
2 equiv. PhLi  
THF, -78 °C, 3 h 
(Complete conversion) 
12%[c] 
271 CN 
1.2 equiv. KCN 
DMSO, r.t., 11 d 
No reaction 
271 CN 
1.2 equiv. KCN 
DMSO, 60 °C, 1 h 
No reaction 
271 CN 
3 equiv. ACH +3 equiv. Et3N 
THF, 100 °C, 1 d 
No reaction 
272 CH2CN 
3 equiv. ACN +3 equiv. LDA 
0 °C, 4 h 
mixture of polar  
unseparable compounds 
273 Bn 
1.5 equiv. BnMgBr 
THF, r.t., 5 h 
(trace of product) 
- 
274 CHCH2 
3 equiv. vinylmagnesium bromide 
THF, r.t., 1 h 
(Complete conversion) 
27%[c] 
[a] Isolated yield after purification by pTLC. 
[b] Isolated yield after purification by decantation. 
[c] Isolated yield after purification by reversed-phase chromatography. 
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In a ‘typical’ Vilsmeier-Haack reaction the α-chloroamines are unstable intermediates and undergo 
hydrolysis to the final product. In this case the newly formed product 237 did not readily hydrolyze to 
give the eight-membered ketone ring system. Hydrolysis of the bridged structure 237b or 253 under 
acidic conditions proved unsuccessful with full recovery of the starting material (Scheme 53). Using 
sodium hydroxide, compound 253 was isolated (Table 33). The particular stability of the α-
chloroamine can be attributed to its bridged structure.  
 
Scheme 53: Ring opening reaction. 
2.3.6. Biological testing 
The reported structures are the first examples of a new class of brevianamide F analogues, bearing 
the 3,5-bridged piperazin-2-one core. A preliminary evaluation of the bioactivity of these interesting 
materials was conducted.  
The antimicrobial activity of compounds 237b and 240 was tested by BCCMTM/LMG (Laboratory of 
Microbiology, Ugent) against a panel of four bacterial strains: the Gram-negative Escherichia coli 
LMG 8063 and Klebsiella pneumonia LMG 2095, and the Gram-positive Staphylococcus aureus LMG 
8064 and Bacillus substilis LMG 13579. No antimicrobial effect was observed based on visual 
assessment of turbidity caused by bacterial growth.  
A subset of compounds was tested against different targets that were chosen based on the interest 
in the laboratory for those targets[219-220] and on the basis of biological activities displayed by natural 
product analogues of these compounds (Table 34).  
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Table 34: Screening of different targets. The values express the percentage inhibition (of the control). 
  237b 254 255 257 20 
a α2 
(non-selective)[a],[b] 
60 nM 6 µM 60 nM 6 µM   60 nM 6 µM   
  -7.1 -5.5 -8.4 -13.1   -9.6 -7.0   
b D1[a],[c] 2.5 
µM 
25 µM   2.5 µM 25 µM 2.5 
µM 
25 µM   
  -6 2   3 -6 2 3   
c N neuronal α7[a],[d] 7 µM 70 µM   7 µM 70 µM 6.1 
µM 
61 µM   
  2 -15   -8 -7 -8 -4   
d N muscle-type[a],[e] 20 µM 0.2 nM   20 µM 0.2 nM 17 µM 0.17 
nM 
  
  5 7   -6 -3 0 -5   
e Serotonin 5-HT1 
(non-selective)[f] 
11 µM 0.11 
nM 
  11 µM 0.11 
nM 
9.5 
µM 
95 µM   
  0 3   11 8 -4 -3   
f PDE5(h) 
(non-selective)[g] 
0.7 
µM 
70 µM 0.7 
µM 
70 µM   0.7 
µM 
70 µM 0.7 µM 70 µM 
  -1.0 7.2 0.0 16.8   0.9 18.7 101.8 100.9 
g Tubulin 
polymerization[h] 
12 nM 0.12 
mM 
  12 nM 0.12 
mM 
12 nM 0.12 
mM 
  
  -8 -14   -10 -8 -14 -10   
h BCRP (h) inhibition[i] 5 µM 50 µM   5 µM 50 µM 4.3 
µM 
43 µM   
  0.1 10.8   21.5 46.5 6.9 40.6   
All assays were run by Cerep, France. For more details, see Experimental procedures. All values are 
the mean of two replicates. The test concentrations that were used, are based on the IC50 values of 
the reference compounds and the hundredfold or tenfold thereof. [a] Antagonist radioligand. [b] 
Reference: yohimbine (IC50 = 58.7 nM). 
[c] Reference: SCH 23390 (IC50 = 0.242 nM). 
[d] Reference: 
α-bungarotoxin (IC50 =0.7 nM). 
[e] Reference: α-bungarotoxin (IC50 =2 nM). 
[f] Reference: serotonin 
(5-HT) (IC50 = 0.0011 µM). 
[g] Reference: dipyridamole (IC50 = 0.7 µM). 
[h] Reference: vinblastine 
(IC50 = 1200 nM). 
[i] Reference: KO143 (IC50 = 480 nM). 
The α-chloroamine 237b and two derivatives 254 and 257 were submitted to a competitive binding 
assay against the α2 receptor, an adrenergic receptor localized in the central nervous system (Table 
34, entry a). The α2-receptor was chosen since the scouting of the chemical space for the closest 
resemblance of the newly reported compounds pointed towards yohimbine, which contains a 
tryptamine unit enclosed in a pentacyclic structure. This molecule was used as a reference compound 
in the binding assay. Values are expressed as the decrease of radioligand specific binding in the 
presence of the compounds and were determined by scintillation counting.[221] As can be seen from 
Table 3, no significant binding to the α2-receptor could be detected for the selected compounds.  
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α-Chloroamine 237b and two derivatives 255 and 257 were also tested for binding against a set of 
receptors which were of interest to the laboratory: the D1 dopamine receptor which is found in the 
central nervous system (Table 34, entry b), the α7 nicotinic receptor and muscle-type nicotinic 
receptor which are both a type of nicotinic acetyl choline receptors (Table 34, entries c and d), and 
the 5-HT1 serotonin or 5-hydroxytryptamine receptor (Table 34, entry e). These receptors influence 
various biological and neurological processes. No significant binding to these receptors could be 
detected. 
The compounds were also tested for their inhibitory activity against the phosphodiesterase type 5 
(PDE5) enzyme, which plays an important role in the cardiovascular system. Tadalafil 20 is a potent 
inhibitor of these enzymes, and bears structural resemblance to the tested compounds.[222] Cyclic 
guanosine monophosphate (cGMP) is broken down by the enzyme into guanosine-5'-triphosphate 
(GMP). The decrease in conversion of radiolabeled cGMP to GMP in the presence of the compounds 
is reflected in the percentage inhibition measured by scintillation counting.[223] Unfortunately, 
α-chloroamine 237b and derivatives 254 and 257 exhibit a very low potency for PDE5 inhibition 
(Table 34, entry f). The best result was obtained for 257, containing an aromatic benzyl sidechain. Of 
the tested compounds 257 indeed displays the most resemblance with the 1,3-benzodioxole-bearing 
tadalafil 20.  
The fungal metabolite tryprostatin A 6 was identified as an inhibitor of tubulin polymerization and 
thus prevents cell cycle progression at the M-phase.[224] Compounds 237b, 255 and 257 do not impair 
the microtubule assembly at the tested concentrations (Table 34, entry g).  
Several diketopiperazines, including fumitremorgin C 7 and analogues reverse multidrug resistance in 
cells transfected with the breast cancer resistance protein (BCRP).[17-18, 109] The BCRP is a 
transmembrane transporter that contributes to the resistance of cancer cells to chemotherapeutic 
agents such as mitoxantrone, topotecan and methotrexate, by removing these substances from the 
cell. Interestingly, compounds 255 and 257 display a significant inhibition of BCRP (46.5% and 40.6% 
at 50 and 43 µM, respectively). The presence of a more bulky sidechain replacing the chlorine atom is 
required for activity, since 237b does not display a significant degree of inhibition. The IC50’s of 255 
and 257 are around a hundred fold of the reference compound Ko 143 (276), also a diketopiperazine 
(Figure 30).  
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Figure 30: Ko 143 (276). 
2.3.7. Carbamate and urea derivatives of the α-chloroamine 
The reaction conditions using an excess of diphosgene provided the α-chloroamine 237 as the major 
product in the crude mixture but some other (side) products were also formed. Based on HPLC-MS 
analysis during the reaction, it was found that one of these other peaks displayed a mass 
corresponding to the α-chloroamine 237 with an extra methoxycarbonyl group attached to it. Since 
the samples were dissolved in MeOH, this solvent was most probably responsible for this 
observation. During flash chromatography, sometimes a small fraction was collected that was not the 
expected product 237, and that did not resemble the starting material. Analysis with HPLC-MS and 
NMR spectroscopy again demonstrated the addition of the –COOMe unit to structure 237. From time 
to time some methanol was added to dissolve the crude product to coat it on silica for column 
chromatography. Thus, the methoxy group was derived from a reaction of methanol with a 
derivative of 237. Since methanol apparently reacted very easily with this unknown compound, the 
solvent used for the HPLC-MS samples was switched to acetonitrile.  
When the reaction of 2b with diphosgene was left to stir for a longer period of time the fraction of 
α-chloroamine 237 started to decline, as it was converted into another product. The HPLC-MS 
analysis revealed that the newly formed compound contained two chlorine atoms.  
We propose that the excess diphosgene that is added to the reaction, reacts with the bridging 
secondary amine to yield a carbamoyl chloride 277 (Scheme 54). Upon exposure to methanol, the 
methyl carbamate 278 is immediately formed. Nonetheless, the carbamoyl chloride 277 is rather 
stable, since the work-up involves water. It is curious that the carbamoyl chloride 277 does not 
readily react with water forming the unstable carbamic acid, which would result again in 237b, 
despite the swift reaction with methanol. 
The reaction of cyclo(D-Trp, L-Pro) 2b with diphosgene was stirred until all material was cleanly 
converted to the carbamoyl chloride 277. The product that was obtained was already quite pure 
(±90%) and the crude yield was high (90%). The newly formed carbamoyl chloride 277 offers an 
alternative site of modification and enables the synthesis of novel derivatives.  
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Scheme 54: Reaction of DKP 2b with diphosgene leading to carbamoyl chloride 277. 
To synthesize new carbamate or urea derivatives, several alcohols and amines were added to the 
carbamoyl chloride 277 (Table 35). Partial degradation of 277 during the reaction with alcohols and 
amines led to mixtures of the targeted carbamate compound and compound 237b.  
Table 35: Carbamate and urea derivatives of carbamoyl chloride 277. 
 
Entry Cpd R Reaction conditions Yield 
1 278 OMe MeOH, r.t. 65% 
2 279 
 
2 equiv. benzyl alcohol, 2 equiv. Et3N 
THF, r.t., 12 d 
33%[a] 
3 279 
 
1.5 equiv. benzyl alcohol, 1 equiv. Et3N 
THF, , 12 d 
29%[a] 
4 279 
 
1.5 equiv. benzyl alcohol, 1 equiv. Et3N 
Neat, r.t., 2 h 
8%[a] 
5 279 
 
3 equiv. benzyl alcohol 
Neat, r.t., 4 d 
36%[a] 
6 280  
3 equiv. allyl alcohol 
Neat, r.t., 4 d 
44%[b] 
7 281 
 
1.3 equiv. benzylamine, 1.3 equiv. K2CO3 
THF/H2O, r.t., 4 h 
38%[a] 
8 281 
 
3 equiv. benzylamine 
Neat, r.t., 2 h 
58%[b] 
9 282 
 
3 equiv. 1-naphthylmethylamine 
Neat, r.t., 4 d 
32%[c] 
10 283 
 
3 equiv. tert-butanol 
Neat, 30 °C, 4 d 
no conversion 
[a] Isolated yield after purification by reversed-phase chromatography. 
[b] Isolated yield after purification by normal-phase chromatography. 
[c] Isolated yield after purification by decantation. 
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A base such as triethylamine or K2CO3 was added to neutralize the HCl released during the reaction 
(entries 2-4, 6) and tetrahydrofuran was used as a solvent, since the starting material did not 
(re)dissolve in dichloromethane, acetonitrile or ethyl acetate. The use of a solvent slowed down the 
reaction tremendously. Both the addition of base and solvent ultimately proved unnecessary as the 
reactions proceeded well under neat conditions (entries 1, 5, 6, 8, 9). As a result, only liquid alcohols 
or amines were screened and an excess amount was used to allow the reaction to stir. In the case of 
compound 281 and 282, the viscous mixture precipitated shortly after the addition of the amine, 
showing that the amine acted as a base and formed an ammonium chloride precipitate. The reaction 
with tert-butanol was unsuccessful (entry 10). Despite the easy reaction of the carbamoyl chloride 
with amines, no dimeric products were observed during the synthesis of the carbamoyl chloride 277 
from reaction with amine 237b. 
The reaction of carbamoyl chloride 277 with benzyl alcohol was also performed using continuous 
flow technology. Syringe pumps were used to supply a flow of reagents to the tube reactor. The main 
advantages for using meso flow reactors versus batch are the better surface to product volume 
ratios, which improves heat transfer capabilities and better mixing efficiencies.[225] One syringe pump 
contained a 0.5 M solution of carbamoyl chloride 277 in dry THF. The second syringe pump was filled 
with benzyl alcohol. The tube reactor had a volume of 0.3 mL. Depending on the desired residence 
time and ratio of reagents the flow rates were calculated. 
 
Figure 31: Setup tube reactor with syringe pumps. Tube reactor with internal diameter of 0.508 mm. 
The solution of carbamoyl chloride was mixed at the T piece with an excess of benzyl alcohol at 60 °C 
(Table 36, entry 1). After a residence time of 5 minutes no conversion had taken place and the 
starting material remained. The temperature was elevated to 80 °C but still no product was obtained 
(entry 2). Finally, a large excess of benzyl alcohol was used and a trace of the carbamate 279 could be 
found (entry 3). Again the use of solvent is detrimental for the reaction. Since the reaction in batch 
was already successful using only 1.5-3 equivalents of benzyl alcohol, the application of the reaction 
in the meso reactor was not further pursued. 
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Table 36: Reaction of carbamoyl chloride 277 with benzyl alcohol. 
Entry Equiv. benzyl alcohol RT (min) T (°C) Result 
1 1.5 5 60 No conversion 
2 1.5 5 80 No conversion 
3 10 6 80 Trace of 279 
Reaction of the carbamoyl chloride 277 with benzyl alcohol resulted in the synthesis of a 
benzyloxycarbonyl (Cbz) group (279). This moiety can function as a protecting group to selectively 
shield the bridging amine, which is complementary to the earlier introduction of protecting groups at 
the indole-N (see 2.3.5), and can easily be deprotected by hydrogenolysis (Scheme 55). 
Hydrogenolysis of 279 also removed the chlorine atom yielding 284 after pHPLC. Analogously, if the 
reaction with tert-butanol would have been successful, a Boc protecting group would have been the 
result. It was assumed that the shielding of the amine function might facilitate purification by 
reducing the polarity of the compound. This would eventually lead to derivatives of compound 237b 
in a better yield despite the extra steps. However, compound 284 was obtained in low yield as a 
result of purification, which eliminated this presumed alternative route to derivatives of 237b.  
 
Scheme 55: Hydrogenolysis of the carbamate derivative 279. 
By transforming the carbamoyl chloride 277 to a carbamate or urea, a more stable compound is 
formed that can undergo further modification. The methyl carbamate 278 was subjected to similar 
conditions as 237b to assess the possibility of replacing the chlorine with different nucleophiles. Two 
compounds were synthesized and prove that this is indeed possible. The starting material 278 was 
converted to the desired compounds 286 and 287, next to a side product for which the chlorine atom 
is replaced with a hydroxyl group (285). No loss of the carbamate group was detected, neither were 
traces found of the product resulting from reaction of the nucleophile with the carbamate moiety.  
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Table 37: Substitution of the chlorine atom in carbamate derivative 278. 
  
Cpd Reaction conditions Ratio[a] Yield 286 or 287 
286 1.5 equiv. allyl alcohol + 1.5 equiv. NaH 
THF, r.t., 1 d 
285/286 
3/2 
9%[b] 
287 1.5 equiv. phenol + 1.5 equiv. NaH 
THF, r.t., 1 h 
278/285/287 
5/4/11 
38%[c] 
[a] Ratios obtained by integration of the MS-signals in the HPLC-MS chromatogram. 
[b] Isolated yield after purification by reversed-phase chromatography. 
[c] Isolated yield after crystallization 
One urea 282 and two carbamate 286 and 287 derivatives were also tested for their inhibitory 
activity against BCRP. No inhibitory activity was observed for any of the tested compounds. This may 
indicate the necessity of the bridging amine NH for activity (possible hydrogen bonding) or maybe 
the urea or carbamate groups are too bulky to allow the molecule to interact with the active site. 
Table 38: The values express the percentage inhibition of the control. 
BCRP (h) inhibition[a] 282 286 287 
5 µM 7.1 -5.5 8.2 
50 µM 13.3 -0.4 6.0 
All assays were run by Cerep, France. For more details, see Experimental procedures. All values are 
the mean of two replicates. The test concentrations that were used, are based on the IC50 values of 
the reference compounds and the hundredfold or tenfold thereof. [a] Reference: KO143 (IC50 = 
480 nM). 
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2.3.8. Mechanistic discussion for the substitution of chlorine 
The stability of the obtained α-chloroamine 237 originates from its bridged structure and can be 
explained by the rule of Bredt. The formation of an iminium ion on the bridgehead through 
elimination of chloride is prevented by the high degree of strain, which would be introduced by the 
E-double bond in a six-membered ring. Nevertheless, this does not correspond to the observed 
substitution of the chlorine atom.  
The α-chloroamine 237b did not readily react (over a period of 1-3 days) with nucleophiles 
(methanol, water or allylamine) under neutral conditions (vide supra). In contrast, basic nucleophiles 
reacted smoothly with 237b at room temperature. Thus, a stronger nucleophile seems to be 
necessary to mediate the replacement of chlorine. In the case of an E1 or SN1 type mechanism, the 
difference in nucleophilicity (e.g. water vs. hydroxide) does not have an influence on the reaction 
rate as the rate-determining step is the loss of chloride and the concomitant formation of a 
carbocation intermediate. 
Literature provides evidence for the participation of nitrogen in the solvolysis of bridgehead 
chlorides.[212] Possibly, the reactions of 237b with the nucleophiles go through a strained bridgehead 
imine or iminium intermediate, thereby exhibiting an anti-Bredt character.[212-218]  
These contradictory observations cannot be explained by Bredt’s rule and are a proof that Bredt’s 
rule is only an empirical observation and not an absolute rule. A better strategy for assessing the 
stability of the bridgehead alkene may involve the calculation of olefin strain energy.[226] The olefin 
strain (OS) corresponds to the difference in energy between the alkene and the corresponding 
alkane. Calibration using bridgehead olefins of known stability leads to the the definition of three 
olefin strain ranges: ‘isolable’, ‘observable’ or ‘unstable’. Through OS calculations, a compound of 
unknown stability can be allocated to one of these ranges to determine if a putative ‘anti-Bredt’ 
compound would be isolable. These calculations are ongoing and will be used to contribute to the 
discussion on the putative mechanism for the substitution. These results will be disclosed in due 
time. 
Maybe the basic conditions are required to deprotonate the intermediate iminium species, after 
expulsion of chloride (in an E1 or SN1 type mechanism), to the imine and to compensate for the 
hydrochloric acid that would be released. 
A base-promoted elimination like in an E2 type mechanism involving the deprotonation of the 
bridging secondary amine seems implausible, because no antiperiplanar conformation is possible in 
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the bicyclic structure. However, this mechanism was supported by an experiment with dimethylated 
247. When compound 247 was treated with sodium methoxide or sodium hydroxide at room 
temperature no reaction took place, in contrast to the easy conversion of 237b. If the reaction would 
proceed via an E1 or SN1 type of mechanism, the methyl group should not have influenced the 
outcome. In case of an E2 mechanism, the dimethylated 247 has no proton on the bridging amine, so 
no elimination can occur and indeed no reaction was observed. When 247 was refluxed in a sodium 
methoxide solution, substitution was observed, so maybe the SN1 or E1 mechanism prevailed at 
elevated temperature. 
The reactivity of carbamate 278 with the basic nucleophiles does not concur with the finding that 
dimethylated 247 does not react with basic nucleophiles at room temperature. Structure 278 
resembles the dimethylated structure 247, as both compounds are substituted at the bridging amine. 
This rules out the E2 mechanism playing a role for all the observed substitution reactions.  
Still, if an E1- or SN1-type of mechanism is assumed to prevail under these reactions, the presence of 
the more electron donating methyl group should have facilitated the intermediate imine formation 
more than the more electron withdrawing ester/carbamate group. 
 
Scheme 56: Observed reactivities of different α-chloroamine derivatives towards nucleophiles. 
Assuming that the basic conditions were necessary for quenching the hydrogen chloride released 
during the reaction, can account for the lack of conversion when only 1.2 equivalents of KCN or 
1.5 equivalents of benzylmagnesium bromide were used. In theory, one equivalent would be 
necessary to neutralize the HCl formed while another equivalent would be necessary to function as a 
nucleophile. When potassium cyanide or sodium azide get protonated the corresponding acids are 
gaseous and would evolve from the reaction explaining the lack of reaction. In the case of the O-, N- 
and S-nucleophiles, reducing the number of equivalents did not pose an issue since the neutral 
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amines, alcohols or thiol would have been nucleophilic enough to react with an intermediate imine. 
The neutral counterparts of the carbon nucleophiles, on the other hand, will not react. Reactions 
with the latter nucleophiles were unsuccessful using only 1.2-1.5 equivalents of nucleophile. 
However, both quenching and substitution reactions would occur simultaneously and not all HCl 
would be reacted first. Theoretically a conversion of 60-75% should still have been possible, but was 
never detected. Thus, no conclusive explanation was found for the differences in reactivity, leaving 
room for debate. 
2.3.9. Introducing the α-chloroamine in cyclo(Trp, Hyp) 
Introduction of the new 3,5-bridge was also investigated for the DKP cyclo(D-Trp, L-Hyp) 190b. This 
compound contains a free hydroxyl group, which holds promise for further derivatization studies. 
Subjecting 190b to an excess of diphosgene resulted in a complex reaction mixture (Scheme 57). This 
outcome was to be expected due to the presence of the free hydroxyl group. Introduction of a 
protecting group or preparation of a derivative that shields the alcohol could help to overcome this 
problem. Here, the selective introduction of a protecting group on the hydroxyl moiety in the 
presence of the indole-NH and amide, was the first challenge. According to patent literature, the 
protecting group, tert-butyldiphenylsilyl (TBDPS), has already been selectively introduced on the 
alcohol in cyclo(D-Trp, L-Hyp) 190b.[227] However, this group can be removed using HCl in 
methanol.[228] For the introduction of the α-chloroamine in 190b, excess diphosgene is used 
producing HCl. Therefore, the TBDPS group was not evaluated as it would unlikely remain stable 
under these conditions. 
 
Scheme 57: Unsuccessful synthesis of α-chloroamine 290. 
With cyclo(D-Trp, L-Hyp) 190b already in hand, this compound was used to perform an esterification 
with acetic acid or heptanoic acid in the presence of EDC∙HCl and DMAP. These coupling reactions 
were unsuccessful due to lack of conversion (Scheme 58). 
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Scheme 58: Unsuccessful coupling of the hydroxyl group in 190b with an acid. 
Next, the acetylation of cyclo(D-Trp, L-Hyp) 190b via the addition of acetic anhydride was examined. 
The reaction was not selective and partial conversion was observed to a di-acetylated DKP 293. After 
the addition of an extra equivalent of acetic anhydride full conversion of the starting material 190b 
was achieved, but this time the crude mixture was composed of di- and tri-acetylated DKPs 293 and 
294 (Scheme 59). Purification with reversed-phase chromatography yielded both compounds 293 
and 294. Spectral analysis revealed that the di-acetylated compound 293 possessed a non-protected 
indole nitrogen. Since an extra substituent on the amide nitrogen prevents reaction with diphosgene, 
as confirmed with dimethylated cyclo(L-Trp, L-Pro) 295 (Scheme 60), the di-acetylated 293 could not 
be used in further steps. The same goes for the tri-acetylated 294. 
 
Scheme 59: Acetylation of 190b. 
 
Scheme 60: Methylated DKP 295 is unreactive towards diphosgene. 
However, the dipeptide 182b was also available, which holds the advantage that already one position 
is protected by the Cbz group. This intermediate 182b was treated with one equivalent of Boc2O, but 
a mixture of mono- and di-Boc-protected dipeptide was obtained. This resulted in incomplete 
conversion, so an extra equivalent of Boc2O was added to transform all the material into the 
di-Boc--protected dipeptide 296 (Scheme 61). Upon deprotection by hydrogenolysis and column 
chromatography, DKP 297 was isolated in 52% yield over the two steps. 
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Scheme 61: Synthesis of N,O-diprotected 297. 
In a next step, selective deprotection of the Boc group on the indole amine from 297 was envisaged, 
since the presence of the Boc group would reduce the nucleophilicity of the indole. Selective removal 
of the Boc protective group from nitrogen atoms in conjugation with an aromatic or carbonyl group 
has been described employing silica gel.[229] However, after heating under reduced pressure for 
several hours, the starting material was retrieved (Scheme 62). 
 
Scheme 62: Unsuccessful selective deprotection of 297. 
The attempts to synthesize selectively protected cyclo(D-Trp, L-Hyp) 190b were unsuccessful so far. 
Hence, the synthetic route was adapted. The protecting group at the hydroxyl moiety was to be 
introduced in the starting amino acid, instead of trying to introduce it selectively later on in the 
synthesis. Starting from the commercially available L-4-hydroxyproline methyl ester hydrochloride 
299, a Boc protecting group was introduced on the amine (300, Scheme 63).[230]  
Subsequent alkylation of the hydroxyl group was attempted. Reaction with benzyl bromide resulted 
in a complex reaction mixture. Next, iodomethane was evaluated. Extra portions of iodomethane and 
sodium hydride were added when the conversion stagnated. The addition of excess sodium hydride 
caused partial isomerization resulting in diastereomeric 301.  
Next, the Boc protecting group was removed with hydrochloric acid in dioxane.[231] The proline 
methyl ester 302 was then coupled as such with N-Cbz-D-Trp 155b in the presence of EDC∙HCl. The 
resulting dipeptide 303 was subjected to hydrogenolysis without purification. Spontaneous ring 
closure of the deprotected dipeptide yielded the diketopiperazine 304.  
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The major diastereomer was obtained in 30% yield over the 3 last steps after column 
chromatography. In the final step DKP 304 was reacted with diphosgene, which yielded its 
3,5-bridged counterpart 305 after isolation with pHPLC. No further attempts were made to introduce 
another protecting group or functionality. Further studies to introduce an easily removable 
protecting group should make further derivatization at the hydroxyl function accessible. 
 
Scheme 63: Synthesis of α-chloroamine derivative 305.  
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2.3.10. Conclusions 
A method for the preparation of 3,5-bridged piperazin-2-ones containing an α-chloroamine 
functionality from cyclo(Trp, Pro) 2 was presented, by using diphosgene for the formation of the C-C 
bond affording the pentacyclic scaffold. Density functional theory (DFT) calculations suggest that the 
α-chloroamine is formed by direct attack by the C-2 atom of the indole group and not by C-3 attack 
and a subsequent 1,2-shift. The newly obtained bridged structure includes the remarkable feature of 
a chloro-substituent α to nitrogen, a structural unit which is mostly unstable. Derivatization of the 
pentacycle by substitution of the chlorine atom offers a new avenue towards synthetic analogues of 
brevianamides, fumitremorgins and (spiro)tryprostatins. To illustrate this opportunity, a small library 
of decorated pentacycles was synthesized using a range of O-, N-, S- and C-nucleophiles. A 
preliminary bioactivity screening of some of the newly developed diketopiperazines revealed 
significant inhibition of BCRP. Structural modifications to obtain higher BCRP inhibitory potency are 
possible, as the presence of the α–chloroamine provides an easy way to decorate the novel 
pentacyclic framework. Besides, other stereoisomers are easily accessible. 
In general purifications proved to be extremely cumbersome. To purify the compounds using 
chromatography a choice had to be made between the lesser of two evils. On the one hand, using 
normal-phase chromatography the polarity of the compounds causes tailing, resulting in co-elution 
and loss of the desired compounds. On the other hand, reversed-phase chromatography was well 
suited to separate the different products, but as the compounds poorly dissolve in acetonitrile or 
water, major product losses were encountered again. Generally, the successful reactions in this work 
gave good conversions and improving the purification methods would increase the isolated yields. 
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Further research towards structural modifications to the 3,5-bridged scaffold in view of obtaining a 
higher BCRP inhibitory potency are possible, as the presence of the α–chloroamine provides an easy 
way to decorate the novel pentacyclic framework 360 (Figure 32, modification a). Taking into account 
the diverse set of nucleophiles that can be used, a wide range of modifications remains to be 
investigated. Other isomers are also easily accessible (modification b). Alterations to the amino acids 
parts of the diketopiperazine e.g. substitution of tryptophan (modification c) or functionalization of 
hydroxyproline (modification d) remain to be investigated, and may reveal compounds with higher 
potency. The pentacyclic compound 360 also bears multiple nitrogen positions that are easily 
amenable to further modification (modifications e and f). When the reaction of the α–chloroamine 
with excess diphosgene proceeds, a carbamoyl chloride is obtained. This functional group enables 
the introduction of different substituents at the position of the bridging amine (modification e). The 
carbamate group is a key structural motif in many approved drugs and prodrugs.[232] 
 
Figure 32: Possible sites for modification of the novel 3,5-bridged structure. 
When a derivative would be found with improved activity, the multitude of modification sites can be 
very useful. They can serve as anchoring points for a tracer molecule to investigate the target of the 
derivative and can give an indication of the parts of the structure that are crucial for its activity.  
The use of DKPs as blood-brain barrier shuttle has also been described.[233] So, by introducing well-
chosen groups, one can easily modify the lipophilicity of the molecule while attaching the compound 
to be transported to another part of the molecule.  
Moreover, it would be interesting to investigate the substrate scope of the ring forming reaction with 
diphosgene. On the one hand proline could be replaced by other amino acids to obtain better 
bioactivities. On the other hand it would be very promising if the method can be applied on 
diketopiperazines containing an aromatic amino acid other than tryptophan, such as phenylalanine 
derivatives. Phenylalanine derivatives decorated with various alkoxy or alkylgroups are good 
nucleophiles and are most likely to react (308, Scheme 64). Tetracyclic compounds 307 would be 
easily accessible in this manner. 
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Scheme 64: Proposed intramolecular cyclization of phenylalanine-based diketopiperazines. 
This could open the way to simplified analogues of other complex natural products such as 
ecteinascidins (e.g. 309, Figure 33).[234] Ecteinascidin 743 (309) is a marine natural product and a 
potent antitumor drug. It was recently approved for the treatment of a number of soft tissue 
sarcomas and ovarian cancer and is known under the commercial name Yondelis® or Trabectedin.[235] 
Several total syntheses of ecteinascidin 743 (309) have been reported, since it cannot be obtained in 
adequate quantities from natural sources.[236-240] However, these syntheses require many steps and 
are therefore not suited for scale-up. Ecteinascidin 743 (309) is nowadays obtained through a lengthy 
semi-synthesis (21 steps) from cyanosafracin B 310, which is readily available through fermentation 
(Figure 33).[241]  
 
Figure 33: Ecteinascidin 743 (309) and cyanosafracin B 310. 
Compounds 307 show much resemblance to one of the key intermediates (314) in Fukuyama’s recent 
total synthesis of ecteinascidin 743 (309, Scheme 65). The intermediate 314 is synthesized from 
diketopiperazine 313 in 10 steps. Preparation of 313 itself required 4 steps starting from the natural 
amino acid, L-glutamic acid derived 311. From intermediate 314, the synthesis of Fukuyama describes 
another 14 steps to obtain ecteinascidin 743 (309).[242] The intermediate may be obtained through 
our reaction in fewer steps. 
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Scheme 65: Synthesis of ecteinascidin 743 (309) according to the group of Fukuyama. 
Ecteinascidin 743 (309) has a very complex structure and therefore it is not amenable to extensive 
SAR work. Based on our current methodology, simplified analogues can be proposed with a general 
structure 315 (Scheme 66). The critical structural features responsible for its activity as antitumor 
agent are rings A and B and the hemiaminal functionality (highlighted in Figure 33). This framework 
should be conserved when synthesizing ecteinascidin 743 (309) analogues. We therefore propose 
structure 315, which may be obtained through our newly discovered diphosgene-induced 
intramolecular cyclization reaction, as a template for SAR work. 
Diketopiperazines 318 can be synthesized from two phenylalanine derivatives 319 and 321. The 
amino acid derivative 320 is obtained from 321 via a Pictet-Spengler reaction. The reaction of 
diketopiperazine 318 with diphosgene should provide the pentacyclic α-chloroamine 317. The 
chlorine at the bridgehead position of 317 again leaves room for further modifications (316). The 
analogues 315 would result from enantioselective reduction of the amide unit. The two rings A and B 
and the hemiaminal, necessary for retaining activity, are present. 
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Scheme 66: Retrosynthetic analysis for the synthesis of simplified ecteinascidin 743 analogues 315. 
From the basic scaffold 322 alternative strategies can still be designed to prepare annulated or spiro-
derivatives with different ring sizes that are worthwhile to elaborate further such as in Scheme 67. 
The basic diketopiperazine 322 can, for example, be decorated with a propargyl unit. Subsequent 
intramolecular cyclization of 323 can be accomplished by means of a gold catalyst. The use of 
gold(III)chloride to mediate ring formation has been investigated at our department for the synthesis 
of isoindoles.[243] The resulting product is expected to be either a spiro-derivative 324 or an 
annulated pentacycle 325 obtained through a 1,2-shift in 324. These products possess an exocyclic 
double bond, which is amenable to further modifications via electrophilic addition reactions.  
 
Scheme 67: Cyclization of diketopiperazine 323 with a gold catalyst. 
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1. General methods 
Commercially available solvents and reagents were used as such without further purification unless 
stated otherwise. 
1.1. Solvents 
Dry diethyl ether (Et2O), tetrahydrofuran (THF) and toluene were freshly distilled from sodium or 
sodium/benzophenone ketyl. Dry dichloromethane (CH2Cl2) was freshly distilled over calcium hydride 
prior to use. Acetonitrile (ACN) was dried over 4Å molecular sieves. Methanol was dried by 
distillation over magnesium. Dry N,N-dimethylformamide (DMF) was obtained by distillation from 
magnesium sulfate and stored over 4Å molecular sieves. 
1.2. Column chromatography 
Purification by normal-phase column chromatography was performed in a glass column with silica gel 
(Aldrich, particle size 70-200 µm, pore diameter ca. 6 nm). Solvent systems were determined via thin 
layer chromatography (TLC) on glass plates coated with silica gel (Merck, Kieselgel 60F254, precoated 
0.25 mm). Visualization was performed by UV irradiation (254 nm and 366 nm), oxidation by a 
KMnO4 solution or elemental iodine. Reversed-phase column chromatography was performed on a 
Reveleris® X2 Flash Chromatography System with a Reveleris® C18 RP cartridge. 
1.3. Preparative TLC 
Preparative TLC was executed with TLC-plates (Analtech, Uniplate, 2000 µm 20 × 20 cm) in an elution 
chamber using an appropriate eluent. 
1.4. Liquid chromatography 
HPLC and HPLC-MS analysis were performed on an Agilent 1200 Series liquid chromatograph with a 
reversed-phase column (Eclipse plus C18 column, 50 × 4.6 mm, particle size 3.5 µm or a Supelco 
Ascentis Express C18 column, 30 × 4.6 mm, particle size 2.7 µm) connected to a UV/VIS detector and 
an Agilent 1100 Series LC/MSD type SL mass spectrometer with electrospray ionization (ESI, 70 eV) 
using a mass selective single quadrupole detector. A mixture of 5 mM NH4OAc in H2O and ACN was 
used as eluent. 
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1.5. Preparative HPLC 
Preparative HPLC was performed on an Agilent 1100 Series liquid chromatograph using a reversed 
phase column (Zorbax Eclipse XDB-C18 column, 150 × 21.2 mm, particle size 5 µm) that is 
thermostatized at 25 °C. The column is connected to a UV-VIS Variable Wavelength Detector (VWD). 
A mixture of H2O and ACN was used as eluent. 
1.6. Mass spectrometry 
Low-resolution mass spectra were recorded with an Agilent 1100 Series LC/MSD type SL mass 
spectrometer with electrospray ionization (ESI, 70 eV) using a mass selective single quadrupole 
detector. High-resolution mass spectra were obtained with an Agilent Technologies 6210 Time-Of-
Flight (TOF) mass spectrometer, equipped with ESI/APCI-multimode source. 
1.7. NMR spectroscopy 
High resolution 1H-NMR (300 or 400 MHz) and 13C-NMR (75 or 100 MHz) spectra were recorded on a 
Jeol Eclipse FT 300 NMR spectrometer or a Bruker Avance III Nanobay 400 MHz spectrometer at 
room temperature, unless otherwise noted. Peak were assigned with the aid of DEPT, COSY, HSQC, 
HMBC, H2BC and NOE experiments. The compounds were diluted in deuterated solvents with 
tetramethylsilane (TMS) as an internal standard. All chemical shifts are expressed as parts per million 
(ppm). 
1.8. Infrared spectroscopy 
Infrared spectra were recorded on a Perkin Elmer Spectrum BX FT-IR spectrophotometer with an ATR 
(Attenuated Total Reflectance) accessory. All compounds were analyzed in neat form and only 
selected absorbances (νmax, cm
-1) were reported. 
1.9. Melting point 
Melting points of crystalline compounds were determined using a Büchi B-540 apparatus or a Kofler 
bench, type WME Heizbank of Wagner & Munz (Tmax 260 °C). 
1.10. Microwave irradiation 
All microwave reactions were performed in a CEM Discover Benchmate with a continuous power 
output from 0 to 300 Watt and a self-adjusting, single mode microwave cavity. The reactions were 
performed in 10 mL thick-walled Pyrex reaction vessels, closed with a snap-cap and equipped with a 
small magnetic stirring bar. A ramp time of maximum five minutes was used during which the 
temperature was increased from room temperature to the desired temperature. This temperature 
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was maintained during the course of the reaction for the indicated time. The temperature control 
system used an external infrared sensor to measure the temperature on the bottom of the vessel 
and was used in a feedback loop with the on-board computer to regulate the temperature from 25 to 
250 °C by adjusting the power output (1 Watt increments). The pressure control, IntelliVent™ 
Pressure Control System, used an indirect measurement of the pressure by sensing changes in the 
external deflection of the septa on the top of the sealed pressure vessel. Stirring was performed by a 
rotating magnetic plate located below the floor of the microwave cavity. After the reaction the vial 
was cooled down by a stream of air onto the vial, which decreased the temperature of the vial from 
approximately 150 °C to 40 °C in less than 120 seconds. 
1.11. Optical rotation 
Optical rotations were recorded with a Jasco P-2000 polarimeter. 
1.12. X-ray analysis 
X-ray diffraction was performed using an Agilent Supernove Dual Source (Cu at zero) diffractometer 
equipped with an Atlas CCD detector using CuKα radiation (λ = 1.54178 Å) and ω scans. The images 
were interpreted and integrated with the program CrysAlisPro (Agilent Technologies). Using Olex2, 
the structure was solved by direct methods using the SheIXL program package. Non-hydrogen atoms 
were anisotropically refined and the hydrogen atoms in the riding mode and isotropic temperature 
factors fixed at 1.2 times U (eq) of the parent atoms. The amide and amine hydrogen atoms were 
located from a difference electron density map and were unrestrainedly refined.  
All X-ray diffraction analyses were performed in collaboration with Prof. Dr. Kristof Van Hecke, 
XStruct, Department of Inorganic and Physical Chemistry, Ghent University, Belgium. 
CCDC-1030976 and -1030977 contain the supplementary crystallographic data for this work and can 
be obtained free of charge from the Cambridge Crystallographic Data Centre via 
https://summary.ccdc.cam.ac.uk/structure-summary-form. 
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2. Safety 
2.1. General safety aspects 
The practical work during this thesis was conducted in agreement with the SynBioC Research Group 
Internal Guidelines and the internal safety document “Safety Instructions: How to work with 
chemicals”. All reactions were performed under a chemical fume hood, wearing protective clothes 
and eye protection. 
2.2. Specific safety aspects 
The Material Safety Data Sheet (MSDS) of the chemical provides a list of all the associated risks and 
procedures for handling that substance in a safe manner. These MSDS can be found on the website 
of the supplier. In certain cases reagents that show high risks were handled. The most important 
reagents are mentioned below.  
Halogenated solvent (dichloromethane and chloroform): cause damage to organs through 
prolonged or repeated exposure. Toxic if inhaled and the vapors may cause drowsiness or dizziness. 
Breathing the vapors should be avoided. Release in the environment was avoided by separately 
collecting the solvents as well as all aqueous phases that had been in contact with halogenated 
solvents. 
Non-halogenated solvent in general (THF, acetone, acetonitrile, methanol, …): are commonly used 
solvents. They cause acute toxicity after inhalation, specific target organ toxicity following single or 
repeated exposure. Keep them away from heat, fire, hot surfaces, sparks and ignition sources. Avoid 
inhalation and wear protective gloves and clothing. 
Organic acids (acetic acid, formic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, …): are 
corrosive substances that can cause severe skin burns and eye damage. 
Inorganic acids (HCl, …): are corrosive substances that can cause severe skin burns and eye damage 
and are corrosive to metals. The volatile acids may cause respiratory irritation. Wear protective 
gloves and protective clothing. 
Hydrogen gas: extremely flammable gas. The gas was used under pressure (5 bar) and it may explode 
if heated. Keep it away from heat, fire, hot surfaces, sparks and ignition sources. 
Sodium hydride (NaH): Do not allow contact with water. In contact with water releases flammable 
hydrogen gases which may ignite spontaneously. Keep away from sources of ignition. 
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Di- or triphosgene: Exposure to di- or triphosgene is similar in hazard to phosgene. The product is a 
corrosive material. Fatal if swallowed or inhaled and causes severe skin burns and eye damage 
(lachrymator). Decomposes in contact with water. 
Palladium-based catalysts: highly flammable solids. They should be kept away from heat, sparks, 
open flames or hot surfaces. 
EDC∙HCl: causes serious eye damage and skin irritation. May cause respiratory irritation so avoid 
breathing dust of the compound. Prolonged or repeated exposure may cause allergic reactions in 
certain sensitive individuals. It is considered a greener alternative to N,N'-dicyclohexylcarbodi-
imide.[244] 
Benzotriazole: is harmful if swallowed or if inhaled and causes serious eye irritation. The reagent is 
harmful to aquatic life with long lasting effects so release to the environment should be avoided. 
Thionyl chloride: is a corrosive substance which causes severe skin burns and eye damage. It reacts 
violently with water and liberates a toxic gas.  
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3. Diketopiperazine synthesis via benzotriazole-assisted coupling 
3.1. Synthesis of N-Cbz-D-Trp 155b[140] 
D-Tryptophan (1.0 equiv., 49 mmol, 10.0 g) was suspended in H2O (300 mL) and K2CO3 (2.0 equiv., 
98 mmol, 13.5 g) and NaHCO3 (1.0 equiv., 49 mmol, 4.11 g) were added. The addition of acetone 
(40 mL) gave a clear solution. CbzCl (1.25 equiv., 61 mmol, 8.7 mL) was slowly added to the solution 
while being cooled with an ice-water bath. Next, the mixture was warmed to 30 °C and after stirring 
for 3 hours the mixture was extracted with Et2O (50 mL). The aqueous layer was acidified to a pH of 2 
with 2 M HCl. The resulting precipitate was extracted by EtOAc. The organic phase was washed with 
H2O (100 mL), dried over magnesium sulfate and the solids were removed by filtration. The solution 
was concentrated under reduced pressure and provided a viscous oil. The oil was redissolved in 
CH2Cl2 and evaporated. N-Cbz-D-Trp 155b was obtained as a white powder (15.6 g, 94%) and was 
used in the next step without further purification.  
3.2. Benzotriazole-activation of N-protected amino acids[130] 
Thionyl chloride (1.1 equiv.) was added to a solution of 1H-benzotriazole (2.0 equiv.) in dry THF, and 
the reaction mixture was stirred for 20 min. The appropriate N-protected amino acid was added and 
the solution was stirred at room temperature for 2.5 hours. The solvent was then evaporated under 
reduced pressure and the residue was redissolved in CH2Cl2. The organic phase was washed twice 
with 2 M HCl and water and was dried over magnesium sulfate. Removal of the solvent under 
reduced pressure afforded the benzotriazole derivative as a yellow foam. The crude 
acylbenzotriazole was used for the coupling with an appropriate second amino acid.  
3.3. Dipeptide synthesis with benzotriazole-activated amino acids[133] 
A solution of benzotriazole-activated amino acid (1.0 equiv.), an appropriate second amino acid 
(1.0 equiv.) and triethylamine (1.0 equiv.) in dry ACN (4 mL/mmol amino acid) was subjected to 
microwave irradiation (70W, 50 °C, 10 min). Subsequently, the reaction mixture was concentrated 
under vacuum. The residue was redissolved in EtOAc and the solution was washed three times with 4 
M HCl and brine. Then, the organic phase was dried over magnesium sulfate and the dipeptide was 
obtained as a yellow foam after removal of the solvent under reduced pressure. The crude dipeptide 
was again activated via the introduction of a benzotriazole group.  
3.4. Benzotriazole activation of N-protected dipeptides[133] 
Thionyl chloride (1.0 equiv.) was added to a solution of 1H-benzotriazole (4.0 equiv.) in CH2Cl2, and 
the reaction mixture was stirred for 30 min. Next, the reaction mixture was cooled to -10 °C. The 
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appropriate dipeptide was added and stirred at -10 °C for one hour. Subsequently, the mixture was 
washed twice with 4 M HCl, twice with saturated aqueous NaHCO3 and with brine before the organic 
phase was dried over magnesium sulfate. The organic phase was concentrated in vacuo, which 
afforded the desired benzotriazole-activated dipeptides as yellow-orange foams. 
3.5. Trans-selective cyclization/epimerization for the synthesis of trans-
cyclo(N-Cbz-Trp, Pro) 
N-Cbz-protected dipeptidoyl benzotriazoles 163 were synthesized according to the general 
procedures (see 3.1 to 3.4). A solution of N-Cbz-protected dipeptidoyl benzotriazole 163 (1.0 equiv.) 
and triethylamine (1.0 equiv.) in dry ACN (4 mL/mmol 163) was subjected to microwave irradiation 
(70W, 80 °C, 35 min). Subsequently, the reaction mixture was concentrated under vacuum.[137] 
benzyl (3S,8aR)-3-((1H-indol-3-yl)methyl)-1,4-dioxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-
carboxylate 170a 
The general procedure was applied on the dipeptide isomer 163a (1.9 mmol, 
1.0 g). The crude mixture was redissolved in CH2Cl2 (25 mL) and washed 
three times with 4 M HCl (3×15ml). The organic layer was dried over 
magnesium sulfate and concentrated under reduced pressure, providing the 
trans-diketopiperazine 170a. Spectral data are in accordance with reported 
values.[137, 245] Yield 96% (0.75 g); yellow foam; [α]D
21 = +135.8 (c=0.2 in 
CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 1.11-1.28 (1H, m, CHaHb-14), 1.60-1.79 (2H, m, CHaHb-13, 
CHaHb-14), 1.87-1.99 (1H, m, CHaHb-13), 2.23-2.32 (1H, m, CH-12), 3.04-3.14 (1H, m, CHaHb-15), 3.36 
(1H, dd, J=15.0 Hz, J=5.2 Hz, CHaHb-8), 3.39-3.48 (1H, m, CHaHb-15), 3.59 (1H, dd, J=15.0 Hz, J=3.4 Hz, 
CHaHb-8), 5.10 (1H, dd, J=5.2 Hz, J=3.4 Hz, CH-9), 5.22 (1H, d, J=12.1 Hz, CHaHb-19), 5.34 (1H, d, 
J=12.1 Hz, CHaHb-19), 6.89 (1H, s, CH-2), 7.09 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.18 (1H, dd, J=7.5 Hz, 
J=7.5 Hz, CH-6), 7.31-7.43 (6H, m, CH-7, CH-21, CH-22, CH-23, CH-24, CH-25), 7.53 (1H, d, J=7.5 Hz, 
CH-4), 8.28 (1H, s, NH-1) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.6 (CH2-14), 28.4 (CH2-8), 29.3 (CH2-13), 
44.9 (CH2-15), 58.9 (CH-12), 62.1 (CH-9), 69.1 (CH2-19), 109.1 (Cq-3), 111.3 (CH-7), 118.9 (CH-4), 119.9 
(CH-5), 122.6 (CH-6), 124.6 (CH-2), 127.1 (Cq-3a), 128.4 (CH-21, CH-25), 128.7 (CH-22, CH-23, CH-24), 
134.7 (Cq-20), 136.1 (Cq-7a), 152.1 (CC=O-18), 164.9 (CC=O-17), 167.9 (CC=O-11) ppm. 
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benzyl (3R,8aS)-3-((1H-indol-3-yl)methyl)-1,4-dioxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-
carboxylate 170b 
The general procedure was applied on the dipeptide isomer 163b 
(3.7 mmol, 2.0 g). The crude mixture was directly purified by column 
chromatography (3/7 petroleum ether/EtOAc) to give the corresponding 
trans-diketopiperazine 170b.[245] Yield 41% (0.64 g); yellow foam; Rf=0.21 
(3/7 petroleum ether/EtOAc); [α]D
21 = -135.0 (c=0.2 in CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 1.09-1.28 (1H, m, CHaHb-14), 1.59-1.79 (2H, m, 
CHaHb-13, CHaHb-14), 1.86-1.95 (1H, m, CHaHb-13), 2.33 (1H, dd, J=10.2 Hz, J=6.3 Hz, CH-12), 3.05-3.15 
(1H, m, CHaHb-15), 3.36 (1H, dd, J=15.0 Hz, J=5.3 Hz, CHaHb-8), 3.39-3.48 (1H, m, CHaHb-15), 3.57 (1H, 
dd, J=15.0 Hz, J=3.8 Hz, CHaHb-8), 5.11 (1H, dd, J=5.3 Hz, J=3.8 Hz, CH-9), 5.19 (1H, d, J=12.1 Hz, 
CHaHb-19), 5.31 (1H, d, J=12.1 Hz, CHaHb-19), 6.86 (1H, s, CH-2), 7.07 (1H, dd, J=7.5 Hz, J=7.5 Hz, 
CH-5), 7.16 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-6), 7.27-7.43 (6H, m, CH-7, CH-21, CH-22, CH-23, CH-24, 
CH-25), 7.52 (1H, d, J=7.5 Hz, CH-4), 8.76 (1H, s, NH-1) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.7 
(CH2-14), 28.6 (CH2-8), 29.4 (CH2-13), 45.0 (CH2-15), 59.0 (CH-12), 62.2 (CH-9), 69.2 (CH2-19), 108.9 
(Cq-3), 111.5 (CH-7), 118.8 (CH-4), 119.9 (CH-5), 122.5 (CH-6), 124.8 (CH-2), 127.2 (Cq-3a), 128.5 
(CH-21, CH-25), 128.8 (CH-22, CH-23, CH-24), 134.7 (Cq-20), 136.2 (Cq-7a), 152.0 (CC=O-18), 165.0 
(CC=O-17), 168.1 (CC=O-11) ppm; IR (cm
-1): max = 3345 (NH), 1774 (C=O), 1725 (C=O), 1657 (C=O); MS 
(ES): m/z (%): 374 (100) [M - CO2 + H]
+; HRMS (ESI): calcd. for C24H24N3O4
+ [M+H]+: 418.1761; found: 
418.1874. 
4. Diketopiperazine synthesis via carbodiimide-assisted coupling 
4.1. Synthesis of the cyclo(Trp, Pro) isomers 
4.1.1. EDC-assisted coupling 
Proline methyl ester hydrochloride 183 (1 equiv.) was dissolved in anhydrous CH2Cl2 and 
N-benzyloxycarbonyltryptophan 155 (1 equiv.), EDC∙HCl (1 equiv.) and triethylamine (1 equiv.) were 
subsequently added under a nitrogen atmosphere. The reaction was stirred at room temperature for 
24 hours and was then washed three times with 1 M HCl and saturated aq. NaHCO3. The organic 
layer was dried over magnesium sulfate and concentrated under reduced pressure, yielding 
dipeptide 181 as a yellow foam.[125] 
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4.1.2. Hydrogenolysis and cyclization 
To a solution of dipeptide 181 in MeOH, 5 wt% of Pd/C was added. The reaction mixture was stirred 
under 5 atm of H2 for 2-3 hours at room temperature. The Pd/C catalyst was removed by filtration 
through a celite pad. In the case of the D,L- and L,D-isomers, the methanolic solution was stirred at 
room temperature until ring closure was complete. In the case of the cis-fused isomers, ammonia in 
methanol (7 M NH3) was added to induce ring formation. The reaction were monitored via HPLC-MS. 
The filtrate was concentrated in vacuo to give the crude diketopiperazine 2. The pure product 2 was 
obtained after recrystallization from methanol as colourless crystals. The structure of the products 
was confirmed by comparison of the spectroscopic data with literature values.[58, 115, 121] 
It should be noted that for further reactions with 2 it is advisable to redissolve the DKP 2 crystals in 
methanol and evaporate the solvent under reduced pressure to obtain 2 in its amorphic ‘foam’ state. 
That way the compound 2 dissolves more readily in the solvent used in the subsequent reaction. 
(3S,8aS)-3-((1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 2a 
Following general procedures 4.1.1 and 4.1.2 on a 20 mmol scale, isomer 
2a was obtained from 155a and 183a in 3 steps. Yield 70% (3.97 g); 
colourless crystals;  1H-NMR (300 MHz, CDCl3) δ 1.85-2.10 (3H, m, CHaHb-
13, CH2-14); 2.28-2.39 (1H, m, CHaHb-13); 2.97 (1H, dd, J=15.1 Hz, 10.7 Hz, 
CHaHb-8); 3.57-3.68 (2H, m, CH2-15); 3.72-3.81 (1H, m, CHaHb-8); 4.08 (1H, ddd, J=8.0 Hz, 8.0 Hz, 1.10 
Hz, CH-12); 4.38 (1H, dd, J=10.7 Hz, 2.5 Hz, CH-9); 5.73 (1H, br s, NH-10); 7.11 (1H, d, J=2.2 Hz, CH-2); 
7.15 (1H, ddd, J=7.7 Hz, 7.7 Hz, 1.10 Hz, CH-5); 7.24 (1H, ddd, J=7.7 Hz, 7.7 Hz, 1.7 Hz, CH-6); 7.40 (1H, 
br d, J=7.7 Hz, CH-7); 7.59 (1H, br d, J=7.7 Hz, CH-4); 8.26 (1H, br s, NH-1) ppm; 13C-NMR (75 MHz, 
CDCl3) δ 22.7 (CH2-14); 26.9 (CH2-8); 28.4 (CH2-13); 45.5 (CH2-15); 54.6 (CH-9); 59.3 (CH-12); 110.1 
(Cq-3); 111.7 (CH-7); 118.6 (CH-4); 120.1 (CH-5); 122.9 (CH-6); 123.4 (CH_2); 126.8 (Cq-3a); 136.8 
(Cq-7a); 165.6 (CC=O-17); 169.4 (CC=O-11) ppm. 
(3R,8aS)-3-((1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 2b 
Following general procedure 4.1.1 and 4.1.2 on a 46 mmol scale, isomer 2b 
was obtained from 155b and 183a in 2 steps. Yield 79% (10.32 g); 
colourless crystals;  1H-NMR (300 MHz, CDCl3) δ 1.33-1.47 (1H, m, 
CHaHb-14), 1.64-1.76 (1H, m, CHaHb-13), 1.78-1.87 (1H, m, CHaHb-14), 2.01-
2.10 (1H, m, CHaHb-13), 2.78 (1H, dd, J=10.9 Hz, J=6.3 Hz, CH-12), 3.13-3.21 (1H, m, CHaHb-15), 3.18 
(1H, dd, J=14.5 Hz, J=4.3 Hz, CHaHb-8), 3.41 (1H, dd, J=14.5 Hz, J=5.9 Hz, CHaHb-8), 3.50-3.58 (1H, m, 
CHaHb-15), 4.21-4.26 (1H, m, CH-9), 6.36 (1H, br s, NH-10), 7.03 (1H, s, CH-2), 7.12 (1H, dd, J=7.5 Hz, 
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J=7.5 Hz, CH-5), 7.19 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-6), 7.36 (1H, d, J=7.5 Hz, CH-7), 7.61 (1H, d, J=7.5 
Hz, CH-4), 8.46 (1H, br s, NH-1) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.4 (CH2-14), 28.8 (CH2-13), 30.4 
(CH2-8), 45.0 (CH2-15), 57.8 (CH-12), 58.2 (CH-9), 108.9 (Cq-3), 111.4 (CH-7), 118.8 (CH-4), 119.6 (CH-
5), 122.4 (CH-6), 124.6 (CH-2), 127.1 (Cq-3a), 136.2 (Cq-7a), 165.9 (CC=O-17), 170.0 (CC=O-11) ppm.  
(3S,8aR)-3-((1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 2c 
Following general procedure 4.1.1 and 4.1.2 on a 10 mmol scale, isomer 2c 
was obtained from 155a and 183b in 2 steps. Yield 74% (2.10 g); colourless 
crystals; 1H-NMR (300 MHz, CDCl3) δ 1.38-1.49 (1H, m, CHaHb-14), 1.67-1.76 
(1H, m, CHaHb-13), 1.80-1.89 (1H, m, CHaHb-14), 2.05-2.13 (1H, m, CHaHb-
13), 2.86 (1H, dd, J=10.7 Hz, J=6.6 Hz, CH-12), 3.15-3.23 (1H, m, CHaHb-15), 3.20 (1H, d, J=14.6 Hz, 
CHaHb-8), 3.41 (1H, dd, J=14.6 Hz, J=6.1 Hz, CHaHb-8), 3.52-3.61 (1H, m, CHaHb-15), 4.22-4.27 (1H, m, 
CH-9), 5.86 (1H, s, NH-10), 7.06 (1H, s, CH-2), 7.14 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.21 (1H, dd, 
J=7.5 Hz, J=7.5 Hz, CH-6), 7.36 (1H, d, J=7.5 Hz, CH-7), 7.62 (1H, d, J=7.5 Hz, CH-4), 8.17 (1H, s, NH-1) 
ppm; 13C-NMR (75 MHz, CDCl3) δ 21.6 (CH2-14), 29.0 (CH2-13), 30.6 (CH2-8), 45.1 (CH2-15), 58.0 (CH-
12), 58.4 (CH-9), 109.2 (Cq-3), 111.4 (CH-7), 118.9 (CH-4), 119.8 (CH-5), 122.4 (CH-6), 124.5 (CH-2), 
127.2 (Cq-3a), 136.3 (Cq-7a), 165.8 (CC=O-17), 170.0 (CC=O-11) ppm.  
 (3R,8aR)-3-((1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 2d 
Following general procedure 4.1.1 and 4.1.2 on a 10 mmol scale, isomer 2d 
was obtained from 155b and 183b in 3 steps. Yield 63% (1.78 g); colourless 
crystals; 1H-NMR (300 MHz, CDCl3) δ 1.86-2.07 (3H, m, CHaHb-13, CH2-14), 
2.27-2.38 (1H, m, CHaHb-13), 2.97 (1H, dd, J=14.9 Hz, J=10.9 Hz, CHaHb-8), 
3.53-3.69 (2H, m, CH2-15), 3.57 (1H, dd, J=14.9 Hz, J=3.4 Hz, CHaHb-8), 4.07 (1H, t, J=7.7 Hz, CH-12), 
4.37 (1H, dd, J=10.9 Hz, J=3.4 Hz, CH-9), 5.79 (1H, s, NH-10), 7.07 (1H, d, J=2.2 Hz, CH-2), 7.14 (1H, dd, 
J=7.8 Hz, J=7.8 Hz, CH-5), 7.23 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-6), 7.39 (1H, d, J=7.8 Hz, CH-7), 7.59 
(1H, d, J=7.8 Hz, CH-4), 8.45 (1H, s, NH-1) ppm; 13C-NMR (75 MHz, CDCl3) δ 22.7 (CH2-14), 26.9 
(CH2-8), 28.4 (CH2-13), 45.5 (CH2-15), 54.7 (CH-9), 59.3 (CH-12), 109.9 (Cq-3), 111.7 (CH-7), 118.6 
(CH-4), 120.0 (CH-5), 122.8 (CH-6), 123.5 (CH-2), 126.8 (Cq-3a), 136.8 (Cq-7a), 165.7 (CC=O-17), 169.5 
(CC=O-11) ppm. 
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4.2. Synthesis of the cyclo(Trp, Hyp) isomers 
4.2.1. EDC-assisted coupling 
Trans-4-hydroxy-L-proline methyl ester hydrochloride 299 (1 equiv., 10 mmol, 1.82 g) was dissolved 
in dry CH2Cl2 (80 mL) and N-benzyloxycarbonyltryptophan 155 (1 equiv., 10 mmol, 3.38 g), EDC∙HCl 
(1 equiv., 10 mmol, 1.96 g) and triethylamine (1 equiv., 10 mmol, 1.4 mL) were subsequently added 
under a nitrogen atmosphere. The reaction was stirred at room temperature for 24 hours and was 
then washed three times with 1 M HCl (80 mL) and saturated aq. NaHCO3 (80 mL). The organic layer 
was dried over magnesium sulfate and concentrated, yielding dipeptide 182 as a white foam.[125]  
4.2.2. Hydrogenolysis and cyclization 
To a solution of dipeptide 182 in MeOH (200 mL), 5 wt% of Pd/C was added. The reaction mixture 
was stirred under 5 atm of H2 for 2 hours at room temperature. The Pd/C catalyst was removed by 
filtration through a celite pad. In the case of the D,L-isomer 182b, the methanolic solution was stirred 
at room temperature until ring closure was complete. In the case of the L,L-isomer 182a, ammonia in 
methanol (7 M NH3) was added to induce ring formation. The reaction was monitored via HPLC-MS. 
The filtrate was concentrated in vacuo to give the crude diketopiperazine 190, which was purified via 
column chromatography or recrystallization.  
(3S,7R,8aS)-3-((1H-indol-3-yl)methyl)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 190a 
Applying general procedures 4.2.1 and 4.2.2 on 299 and 155a, isomer 
190a was obtained after column chromatography. Yield 40% (1.20 g); 
white amorphous powder; Rf=0.14 (3/1 EtOAc/acetone); m.p. 146-
150 °C; [α]D
25 = -74.2 (c=0.44 in DMSO); 1H-NMR (400 MHz, DMSO-d6) 
δ 1.47 (1H, dd, J=12.7 Hz, J=11.3 Hz, J=4.6 Hz, CHaHb-13), 1.90 (1H, dd, J=12.7 Hz, J=6.3 Hz, CHaHb-13), 
3.07 (1H, dd, J=14.9 Hz, J=5.8 Hz, CHaHb-8), 3.15 (1H, d, J=12.4 Hz, CHaHb-15), 3.25 (1H, dd, J=14.9 Hz, 
J=4.7 Hz, CHaHb-8), 3.51 (1H, dd, J=12.4 Hz, J=4.8 Hz, CHaHb-15), 4.08-4.13 (1H, m, CH-14), 4.30 (1H, 
dd, J=11.3 Hz, J=6.3 Hz, CH-12), 4.34-4.38 (1H, m, CH-9), 5.11 (1H, d, J=3.3 Hz, OH-18), 6.97 (1H, dd, 
J=7.6 Hz, J=7.6 Hz, CH-5), 7.06 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-6), 7.18 (1H, d, J=2.3 Hz, CH-2), 7.33 
(1H, d, J=7.6 Hz, CH-7), 7.57 (1H, d, J=7.6 Hz, CH-4), 7.72 (1H, s, NH-10), 10.85 (1H, s, NH-1) ppm; 
13C-NMR (100 MHz, DMSO-d6) δ 26.2 (CH2-8), 37.6 (CH2-13), 54.3 (CH2-15), 55.6 (CH-9), 57.4 (CH-12), 
67.2 (CH-14), 109.7 (Cq-3), 111.7 (CH-7), 118.7 (CH-5), 119.1 (CH-4), 121.4 (CH-6), 124.8 (CH-2), 127.8 
(Cq-3a), 136.4 (Cq-7a), 166.1 (CC=O-17), 169.9 (CC=O-11) ppm; IR (cm
-1): max = 3263 (NH), 1644 (C=O), 
1420; MS (ES): m/z (%): 300 (100) [M + H]+; HRMS (ESI): calcd. for C16H18N3O3
+ [M+H]+: 300.1343; 
found: 300.1336. 
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(3R,7R,8aS)-3-((1H-indol-3-yl)methyl)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 190b 
Applying general procedures 4.2.1 and 4.2.2 on 299 and 155b, isomer 
190b was obtained after recrystallization from methanol. Yield 40% 
(1.20 g); colourless crystals; m.p. >260 °C; [α]D
25 = -56.6 (c=0.44 in 
DMSO); 1H-NMR (400 MHz, DMSO-d6) δ 1.68 (1H, dd, J=12.5 Hz, 
J=11.8 Hz, J=4.4 Hz, CHaHb-13), 1.83 (1H, dd, J=12.5 Hz, J=6.2 Hz, CHaHb-13), 2.93 (1H, d, J=12.6 Hz, 
CHaHb-15), 3.04 (1H, dd, J=14.4 Hz, J=4.8 Hz, CHaHb-8), 3.18 (1H, dd, J=14.4 Hz, J=6.0 Hz, CHaHb-8), 
3.38 (1H, dd, J=11.8 Hz, J=6.2 Hz, CH-12), 3.58 (1H, dd, J=12.6 Hz, J=4.9 Hz, CHaHb-15), 3.93-3.98 (1H, 
m, CH-9), 4.12-4.17 (1H, m, CH-14), 4.84 (1H, d, J=2.8 Hz, OH-18), 6.96 (1H, dd, J=8.0 Hz, J=8.0 Hz, 
CH-5), 7.05 (1H, dd, J=8.0 Hz, J=8.0 Hz, CH-6), 7.09 (1H, d, J=2.3 Hz, CH-2), 7.33 (1H, d, J=8.0 Hz, CH-7), 
7.84 (1H, d, J=8.0 Hz, CH-4), 8.17 (1H, d, J=3.8 Hz, NH-10), 10.92 (1H, s, NH-1) ppm; 13C-NMR 
(100 MHz, DMSO-d6) δ 29.0 (CH2-8), 37.4 (CH2-13), 53.4 (CH2-15), 55.0 (CH-12), 57.3 (CH-9), 65.4 
(CH-14), 107.9 (Cq-3), 110.7 (CH-7), 117.7 (CH-4), 117.8 (CH-5), 120.3 (CH-6), 123.7 (CH-2), 126.8 
(Cq-3a), 135.4 (Cq-7a), 164.8 (CC=O-17), 168.0 (CC=O-11) ppm; IR (cm
-1): max = 3216 (NH), 1693 (C=O), 
1628 (C=O), 1455; MS (ES): m/z (%): 300 (100) [M + H]
+; HRMS (ESI): calcd. for C16H18N3O3
+ [M+H]+: 
300.1343; found: 300.1341. 
5. Synthesis of dimers via the Pictet-Spengler reaction 
General procedure: Diketopiperazine 2 (2 equiv.) was dissolved in dry CH2Cl2 at room temperature 
under a nitrogen atmosphere. The aldehyde (2.5 equiv.) was added and the mixture was cooled 
to -40 °C before trifluoroacetic acid (20 equiv.) was added. The mixture was stirred for one hour 
at -40 °C. The reaction mixture was quenched by the careful addition of saturated NaHCO3 solution 
and subsequently washed twice with saturated NaHCO3 solution and brine. The organic phase was 
dried over magnesium sulfate and concentrated under reduced pressure. Purification of the foam 
residue by chromatography provided the desired products. 
(3S,3'S,8aS,8a'S)-3,3'-((ethane-1,1-diylbis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 199a 
Using the general procedure with diketopiperazine isomer 2a 
and acetaldehyde on a 0.7 mmol scale, compound 199a was 
obtained after column chromatography. Yield 46% (0.191 g); 
yellow powder; Rf=0.01 (CH2Cl2/2% MeOH); m.p. 164-168 °C; 
[α]D
25 = -135.8 (c=0.72 in CH2Cl2); 
1H-NMR (300 MHz, CDCl3) δ 
0.11-0.26 (1H, m, CHaHb-13); 1.11-1.22 (1H, m, CHaHb-14); 
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1.34-1.48 (2H, m, CHaHb-13, CHaHb-14); 1.61-1.69 (1H, m, CHaHb-13‘); 1.79-1.89 (2H, m, CH2-14‘); 2.07 
(3H, d, J=6.6 Hz, CH3-19); 2.26-2.37 (1H, m, CHaHb-13‘); 3.09-3.18 (1H, m, CHaHb-15); 3.19 (1H, dd, 
J=14.9 Hz, J=4.7 Hz, CHaHb-8‘); 3.33-3.45 (3H, m, CH2-8, CHaHb-15); 3.45-3.69 (4H, m, CHaHb-8‘,CH-12, 
CH2-15‘); 4.05-4.17 (1H, m, CH-12‘); 4.34 (1H, br dd, J=4.7 Hz, J=4.7 Hz, CH-9‘); 4.47 (1H, br dd, 
J=4.4 Hz, J=4.4 Hz, CH-9); 6.85 (1H, br s, CH-2); 6.92 (1H, q, J=6.6 Hz, CH-18); 7.02 (1H, br s, CH-2‘); 
7.08-7.27 (4H, m, CH-5, CH-5‘,CH-6, CH-6‘); 7.36 (1H, d, J=9.1 Hz, CH-7‘); 7.39 (1H, d, J=9.1 Hz, CH-7); 
7.59-7.68 (3H, m, NH-10‘,CH-4, CH-4‘); 8.09 (1H, br s, NH-10) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.2 
(CH3-19); 21.4 (CH2-14); 22.3 (CH2-14‘); 26.9 (CH2-8); 28.1 (CH2-13); 28.8 (CH2-13‘); 29.1 (CH2-8‘); 44.9 
(CH2-15); 45.4 (CH2-15‘); 55.1 (CH-9); 55.5 (CH-9‘); 58.6 (CH-12); 59.2 (CH-12‘); 61.4 (CH-18); 
108.7 (Cq-3); 109.5 (Cq-3‘); 110.3 (CH-7); 110.4 (CH-7‘); 119.6 (CH-4); 120.2 (CH-5); 120.4 (CH-5‘); 
120.5 (CH-4‘); 122.4 (CH-2); 122.6 (CH-6); 123.0 (CH-6‘); 123.6 (CH-2‘); 127.6 (Cq-3a); 129.2 (Cq-3a‘); 
135.7 (Cq-7a); 135.8 (Cq-7a‘); 164.7 (CC=O-11*); 165.5 (CC=O-11‘*); 169.0 (CC=O-17*); 170.2 (CC=O-17‘*) 
ppm (The allocation of the signals CHy-X and CHy-X‘ as well as signals with the same superscript (*) 
may be interchanged); IR (cm-1): max = 1655 (C=O), 1455; MS (ES): m/z (%): 593 (100) [M + H]+, 310 
(70) [M–DKP+H]+; HRMS (ESI): calcd. for C34H37N6O4
+ [M+H]+: 593.2871; found: 593.2863. 
(3R,3'R,8aS,8a'S)-3,3'-((ethane-1,1-diylbis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 199b 
Using the general procedure with diketopiperazine isomer 2b 
and acetaldehyde on a 1.0 mmol scale, compound 199b was 
obtained after reversed-phase chromatography using a 
H2O/ACN gradient (2 column volumes (CVs) 15% ACN, over 30 
CVs to 40% ACN). Yield 32% (0.19 g); white foam; m.p. 184-
188 °C; [α]D
25 = +122.7 (c=0.72 in CH2Cl2); 
1H-NMR (400 MHz, 
CDCl3) δ 84-1.12 (2H, m, CHaHb-13, CHaHb-14), 1.14-1.22 (1H, m, CHaHb-13), 1.24-1.31 (1H, m, CH-12), 
1.50-1.59 (1H, m, CHaHb-14), 1.79-2.09 (3H, m, CHaHb-13’, CH2-14’), 2.10 (3H, d, J=6.6 Hz, CH3-19), 
2.34-2.43 (1H, m, CHaHb-13’), 2.76 (1H, ddd, J=12.0 Hz, J=9.6 Hz, J=2.5 Hz, CHaHb-15), 2.93 (1H, dd, 
J=14.8 Hz, J=5.0 Hz, CHaHb-8), 3.05 (1H, dd, J=14.2 Hz, J=11.1 Hz, CHaHb-8’), 3.30 (1H, dt, J=12.0 Hz, 
J=8.6 Hz, CHaHb-15), 3.47-3.58 (3H, m, CHaHb-8, CHaHb-8’, CHaHb-15’), 3.70 (1H, dt, J=11.8 Hz, J=8.5 Hz, 
CHaHb-15’), 3.88 (1H, dd, J=10.1 Hz, J=6.6 Hz, CH-12’), 4.16-4.20 (1H, m, CH-9), 4.52 (1H, ddd, 
J=11.1 Hz, J=4.2 Hz, J=4.2 Hz, CH-9’), 6.77 (1H, s, CH-2), 6.96 (1H, q, J=6.6 Hz, CH-18), 7.09-7.18 (3H, 
m, CH-5, CH-5’, CH-6’), 7.20 (1H, s, CH-2’), 7.22 (1H, d, J=7.7 Hz, CH-7’), 7.32 (1H, ddd, J=7.9 Hz, 
J=7.9 Hz, J=0.9 Hz, CH-6), 7.55 (1H, d, J=7.9 Hz, CH-4), 7.59 (1H, d, J=7.9 Hz, CH-7), 7.71 (1H, d, 
J=7.7 Hz, CH-4’), 7.97 (1H, d, J=2.9 Hz, NH-10), 9.05 (1H, d, J=4.2 Hz, NH-10’) ppm; 
13C-NMR (100 MHz, CDCl3) δ 21.1 (CH2-14), 21.2 (CH3-19), 22.1 (CH2-14’), 28.2 (CH2-13), 29.1 
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(CH2-13’), 30.2 (CH2-8), 30.6 (CH2-8’), 44.6 (CH2-15), 45.4 (CH2-15’), 56.3 (CH-9’), 57.0 (CH-12), 57.3 
(CH-9), 58.3 (CH-12’), 60.5 (CH-18), 107.9 (CH-7), 108.7 (CH-7’), 110.1 (Cq-3), 110.9 (Cq-3’), 119.8 
(CH-4), 120.0 (CH-5), 120.1 (CH-4’), 120.7 (CH-5’), 122.6 (CH-6’), 123.0 (CH-6), 123.1 (CH-2’), 123.4 
(CH-2), 127.4 (Cq-3a), 128.0 (Cq-3a’), 135.3 (Cq-7a), 136.4 (Cq-7a’), 165.1 (CC=O-17), 166.1 (CC=O-17’), 
170.2 (CC=O-11), 170.6 (CC=O-11’) ppm (The allocation of the signals CHy-X and CHy-X‘ may be 
interchanged); IR (cm-1): max = 3224 (NH), 1651 (C=O), 1452; MS (ES): m/z (%): 593 (100) [M + H]+; 
HRMS (ESI): calcd. for C34H37N6O4
+ [M+H]+: 593.2871; found: 593.2872. 
(3S,3'S,8aS,8a'S)-3,3'-((propane-1,1-diylbis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 200a 
Using the general procedure with diketopiperazine isomer 2a 
and propionaldehyde on a 0.7 mmol scale, compound 200a 
was obtained after column chromatography. Yield 16% 
(0.068 g); yellow powder; Rf=0.01 (CH2Cl2/5% MeOH); m.p. 
150-158 °C; [α]D
25 = -143.0 (c=0.42 in CH2Cl2); 
1H-NMR 
(300 MHz, CDCl3) δ -0.29-(-0.15) (1H, m, CHaHb-13); 0.87-0.97 (1H, m, CHaHb-14); 0.97 (3H, t, J=7.2 Hz, 
CH3-20); 1.11 (1H, m, CHaHb-13); 1.18-1.34 (1H, m, CHaHb-14); 1.70-2.08 (3H, m, CHaHb-13‘, CH2-14‘); 
2.29-2.59 (3H, m, CHaHb-13‘, CH2-19); 3.02 (1H, ddd, J=11.6 Hz, J=10.0 Hz, J=4.0 Hz, CHaHb-15); 3.11 
(1H, dd, J=14.6 Hz, 4.7 Hz, CHaHb-8‘); 3.31 (1H, ddd, J=11.6 Hz, J=8.0 Hz, J=8.0 Hz, CHaHb-15); 3.43 (2H, 
d, J=5.0 Hz, CH2-8); 3.49-3.64 (4H, m, CHaHb-8‘, CH-12, CH2-15‘); 4.08-4.16 (1H, m, CH-12‘); 4.31 (1H, 
br s, CH-9‘); 4.49 (1H, dd, J=5.0 Hz, J=3.9 Hz, CH-9); 6.60 (1H, dd, J=7.4 Hz, J=7.4 Hz, CH-18); 6.95 (1H, 
s, CH-2); 6.98 (1H, s, CH-2‘); 7.09 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-5); 7.10 (1H, dd, J=7.7 Hz, J=7.7 Hz, 
CH-5‘); 7.16 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6); 7.24 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6‘); 7.37 (1H, d, 
J=7.7 Hz, CH-7‘); 7.47 (1H, d, J=7.7 Hz, CH-7); 7.60 (1H, d, J=7.7 Hz, CH-4); 7.65 (1H, d, J=7.7 Hz, 
CH-4‘); 7.79 (1H, s, NH-10); 8.36 (1H, s, NH-10‘) ppm; 13C-NMR (75 MHz, CDCl3) δ 10.6 (CH3-20); 21.1 
(CH2-14); 22.5 (CH2-14‘); 26.6 (CH2-8); 27.9 (CH2-13); 28.6 (CH2-19*); 28.8 (CH2-13‘*); 29.6 (CH2-8‘); 
44.8 (CH2-15); 45.4 (CH2-15‘); 55.0 (CH-9); 55.7 (CH-9‘); 58.4 (CH-12); 59.3 (CH-12‘); 66.4 (CH-18); 
108.6 (CH-7); 109.4 (CH-7‘); 110.2 (Cq-3); 110.7 (Cq-3‘); 119.5 (CH-4); 120.0 (CH-5); 120.4 (CH-5‘); 
120.6 (CH-4‘); 122.2 (CH-2); 122.6 (CH-6); 122.9 (CH-6‘); 123.5 (CH-2‘); 127.4 (Cq-3a); 129.2 (Cq-3a‘); 
136.2 (Cq-7a); 136.4 (Cq-7a‘); 164.6 (CC=O-11**); 165.6 (CC=O-11‘**); 168.9 (CC=O-17**); 170.4 
(CC=O-17‘**) ppm (The allocation of the signals CHy-X and CHy-X‘ as well as signals with the same 
superscript (*, **) may be interchanged); IR (cm-1): max = 1654 (C=O), 1454; MS (ES): m/z (%): 607 
(100) [M + H]+, 324 (75) [M–DKP+H]+; HRMS (ESI): calcd. for C35H39N6O4
+ [M+H]+: 607.3027; found: 
607.3021. 
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(3R,3'R,8aS,8a'S)-3,3'-((propane-1,1-diylbis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 200b 
Using the general procedure with diketopiperazine isomer 2b 
and propionaldehyde on a 1.0 mmol scale, compound 200b 
was obtained after reversed-phase chromatography using a 
H2O/ACN gradient (2 CVs 15% ACN, over 30 CVs to 40% ACN). 
Yield 12% (0.070 g); white foam; m.p. 188-193 °C; [α]D
25 = 
+135.5 (c=0.43 in CH2Cl2); 
1H-NMR (400 MHz, CDCl3) δ 0.80-1.12 (7H, m, CH-12, CHaHb-14, CH2-13, 
CH3-20), 1.46-1.55 (1H, m, CHaHb-14), 1.84-2.12 (3H, m, CHaHb-13’, CH2-14’), 2.37-2.58 (3H, m, 
CHaHb-13’, CH2-19), 2.72 (1H, ddd, J=12.0 Hz, J=9.6 Hz, J=2.4 Hz, CHaHb-15), 2.91 (1H, dd, J=14.7 Hz, 
J=5.1 Hz, CHaHb-8), 3.01 (1H, dd, J=14.2 Hz, J=11.7 Hz, CHaHb-8’), 3.26 (1H, dt, J=12.0 Hz, J=8.6 Hz, 
CHaHb-15), 3.51-3.62 (3H, m, CHaHb-8, CHaHb-8’, CHaHb-15’), 3.67-3.76 (1H, m, CHaHb-15’), 4.01 (1H, 
dd, J=10.0 Hz, J=6.7 Hz, CH-12’), 4.13-4.17 (1H, m, CH-9), 4.52 (1H, ddd, J=11.7 Hz, J=4.2 Hz, J=4.2 Hz, 
CH-9’), 6.63 (1H, t, J=7.4 Hz, CH-18), 6.76 (1H, s, CH-2), 7.07-7.18 (3H, m, CH-5, CH-5’, CH-6’), 7.21 
(1H, d, J=7.8 Hz, CH-7’), 7.27 (1H, s, CH-2’), 7.32 (1H, ddd, J=7.9 Hz, J=7.9 Hz, J=1.0 Hz, CH-6), 7.54 
(1H, d, J=7.9 Hz, CH-4), 7.62 (1H, d, J=7.9 Hz, CH-7), 7.72 (1H, d, J=7.8 Hz, CH-4’), 7.92 (1H, d, J=2.8 Hz, 
NH-10), 9.14 (1H, d, J=4.2 Hz, NH-10’) ppm; 13C-NMR (100 MHz, CDCl3) δ 10.5 (CH3-20), 21.0 (CH2-14), 
22.2 (CH2-14’), 28.1 (CH2-13), 28.8 (CH2-19), 29.1 (CH2-13’), 30.3 (CH2-8), 30.7 (CH2-8’), 44.6 (CH2-15), 
45.4 (CH2-15’), 56.2 (CH-9’), 56.9 (CH-12), 57.4 (CH-9), 58.4 (CH-12’), 65.8 (CH-18), 108.0 (CH-7), 
108.6 (CH-7’), 110.1 (Cq-3), 111.1 (Cq-3’), 19.9 (CH-4, CH-5), 120.1 (CH-4’), 120.6 (CH-5’), 122.5 (CH-
6’), 122.9 (CH-6), 123.0 (CH-2’), 123.6 (CH-2), 127.2 (Cq-3a), 127.9 (Cq-3a’), 136.2 (Cq-7a), 136.8 (Cq-
7a’), 165.1 (CC=O-17), 166.2 (CC=O-17’), 170.2 (CC=O-11), 170.4 (CC=O-11’) ppm (The allocation of the 
signals CHy-X and CHy-X‘ may be interchanged); IR (cm
-1): max = 3219 (NH), 1645 (C=O), 1454; MS 
(ES): m/z (%): 607 (100) [M + H]+; HRMS (ESI): calcd. for C35H39N6O4
+ [M+H]+: 607.3027; found: 
607.3019. 
(3S,3'S,8aS,8a'S)-3,3'-(((phenylmethylene)bis(1H-indole-2,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 204a 
Using the general procedure with DKP isomer 2a and 
benzaldehyde on a 0.7 mmol scale, compound 204a was 
obtained after column chromatography. Yield 36% (0.165 g); 
orange/brown powder; Rf=0.03 (CH2Cl2/2% MeOH); m.p. 189-
195 °C; 1H-NMR (300 MHz, CDCl3) δ 1.57-1.89 (6H, m, CHaHb-13, 
CHaHb-13‘,CH2-14, CH2-14‘); 2.08-2.22 (2H, m, CHaHb-13, CHaHb-13‘); 2.98-3.11 (2H, m, CHaHb-8, 
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CHaHb-8‘); 3.32-3.58 (6H, m, CHaHb-8, CHaHb-8‘,CH2-15, CH2-15‘); 3.68-3.82 (2H, m, CH-12, CH-12‘); 
3.96 (1H, dd, J=8.0 Hz, J=5.2 Hz, CH-9); 4.05 (1H, dd, J=6.6 Hz, J=6.6 Hz, CH-9‘); 5.87 (1H, s, NH-10); 
6.17 (1H, s, NH_10‘); 6.34 (1H, s, CH-18); 7.11-7.38 (11H, m, CH-5, CH-5‘,CH-6, CH-6‘,CH-7, 
CH-7‘,CH-20, CH-21, CH-22, CH-23, CH-24); 7.51-7.58 (2H, m, CH-4, CH-4‘); 8.28 (2H, s, NH-1, NH-1‘) 
ppm; 13C-NMR (75 MHz, CDCl3) δ 22.4 (CH2-14); 22.6 (CH2-14‘); 25.7 (CH2-8); 25.9 (CH2-8‘); 28.1 
(CH2-13); 28.1 (CH2-13‘); 41.1 (CH-18); 45.2 (CH2-15); 45.4 (CH2-15‘); 54.7 (CH-9); 55.2 (CH-9‘); 59.1 
(CH-12, CH-12‘); 106.9 (Cq-3); 107.2 (Cq-3‘); 111.5 (CH-7); 111.6 (CH-7‘); 118.3 (CH-4); 118.6 (CH-4‘); 
120.5 (CH-5, CH-5‘); 122.6 (CH-6, CH-6‘); 128.0 (CH-22); 128.6 (CH-21, CH-23); 128.7 (Cq-3a); 128.8 
(Cq-3a‘); 129.5 (CH-20, CH-24); 135.3 (Cq-2*); 135.5 (Cq-2‘*); 135.6 (Cq-7a*); 136.0 (Cq-7a‘*); 139.8 
(Cq-19); 165.6 (CC=O-11**); 165.8 (CC=O-11‘**); 169.2 (CC=O-17**); 169.7 (CC=O-17‘**) ppm (The 
allocation of the signals CHy-X and CHy-X‘ as well as signals with the same superscript (*, **) may be 
interchanged); IR (cm-1): max = 3252 (NH), 1655 (C=O), 1457, 1432; MS (ES): m/z (%): 655 (100) 
[M + H]+, 327 (70) [M–DKP+H]+; HRMS (ESI): calcd. for C39H39N6O4
+ [M+H]+: 655.3033; found: 
655.3019. 
Using the general procedure with DKP isomer 2b and benzaldehyde on a 2.5 mmol scale, compounds 
204b and 205 were obtained after pHPLC using an isocratic H2O/ACN gradient (35% ACN).  
 (3R,3'R,8aS,8a'S)-3,3'-(((phenylmethylene)bis(1H-indole-2,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 204b 
Yield 8% (0.013 g); white amorphous powder; m.p. 150-154 °C; 
1H-NMR (400 MHz, CDCl3) δ 1.24-1.39 (2H, m, CHaHb-14, 
CHaHb-14’), 1.60-1.84 (4H, m, CHaHb-13, CHaHb-13’, CHaHb-14, 
CHaHb-14’), 1.96-2.09 (2H, m, CHaHb-13, CHaHb-13’), 2.65-2.81 
(3H, m, CHaHb-8, CH-12, CH-12’), 2.83 (1H, dd, J=14.6 Hz, 
J=5.0 Hz, CHaHb-8’), 3.01 (1H, dd, J=10.0 Hz, J=10.0 Hz, CHaHb-15’), 3.12-3.23 (2H, m, CHaHb-8, 
CHaHb-15’), 3.25-3.35 (1H, m, CHaHb-8’), 3.37-3.49 (2H, m, CH2-15), 3.93 (1H, br. s, CH-9), 4.16-4.23 
(1H, m, CH-9’), 6.05 (1H, s, CH-18), 7.03-7.33 (11H, m, CH-5, CH-5’, CH-6, CH-6’, CH-7, CH-7’, CH-20, 
CH-21, CH-22, CH-23, CH-24), 7.45-7.54 (2H, m, CH-4, CH-4’), 7.68 (1H, s, NH-10’), 8.09 (1H, s, NH-1’), 
8.16 (1H, s, NH-10), 8.36 (1H, s, NH-1) ppm; 13C-NMR (100 MHz, CDCl3) δ 21.5 (CH2-14), 21.6 
(CH2-14’), 28.9 (CH2-13, CH2-13’), 29.3 (CH2-8), 29.4 (CH2-8’), 41.9 (CH-18), 44.9 (CH2-15), 45.1 
(CH2-15’), 57.9 (CH-12, CH-12’), 58.1 (CH-9’), 58.2 (CH-9), 106.6 (Cq-3), 107.3 (Cq-3’), 111.1 (CH-7), 
111.3 (CH-7’), 118.6 (CH-4), 118.9 (CH-4’), 120.1 (CH-5, CH-5’), 122.1 (CH-6), 122.4 (CH-6’), 128.0 
(CH-22), 128.5 (Cq-3a), 128.9 (CH-20, CH-24), 129.3 (Cq-3a’), 129.4 (CH-21, CH-23), 134.6 (Cq-7a), 
134.9 (Cq-2), 135.1 (Cq-7a’), 135.8 (Cq-2), 139.3 (Cq-19), 165.9 (CC=O-17*, CC=O-17’*), 169.9 (CC=O-11*), 
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170.2 (CC=O-11’*) ppm (The allocation of the signals CHy-X and CHy-X‘ as well as signals with the same 
superscript (*) may be interchanged); IR (cm-1): max = 3250 (NH), 1651 (C=O), 1458; MS (ES): m/z 
(%): 655 (100) [M + H]+; HRMS (ESI): calcd. for C39H39N6O4
+ [M+H]+: 655.3027; found: 655.3036. 
(3R,3'R,8aS,8a'S)-3,3'-(((phenylmethylene)bis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydro-
pyrrolo[1,2-a]pyrazine-1,4-dione) 205 
Yield 11% (0.015 g); white amorphous powder; m.p. 190-
196 °C; 1H-NMR (400 MHz, CDCl3) δ 0.89-1.12 (2H, m, 
CHaHb-13, CHaHb-14), 1.18-1.27 (2H, m, CH-12, CHaHb-13), 1.51-
1.60 (1H, m, CHaHb-14), 1.78-2.10 (3H, m, CHaHb-13’, CH2-14’), 
2.33-2.41 (1H, m, CHaHb-13’), 2.67-2.75 (1H, m, CHaHb-15), 
2.86-2.98 (2H, m, CHaHb-8, CHaHb-8’), 3.30 (1H, dt, J=12.1 Hz, J=8.6 Hz, CHaHb-15’), 3.50-3.74 (4H, m, 
CHaHb-8, CHaHb-8’, CH2-15’), 3.99 (1H, dd, J=10.0 Hz, J=6.6 Hz, CH-12’), 4.16-4.21 (1H, m, CH-9), 4.56 
(1H, ddd, J=11.8 Hz, J=4.2 Hz, J=4.2 Hz, CH-9’), 6.71 (1H, s, CH-2), 6.81 (1H, s, CH-2’), 7.00 (2H, d, 
J=6.9 Hz, CH-20, CH-24), 7.14-7.25 (3H, m, CH-5, CH-5’, CH-6), 7.27-7.43 (5H, m, CH-6’, CH-7’, CH-21, 
CH-22, CH-23), 7.54 (1H, d, J=8.0 Hz, CH-7), 7.63 (1H, d, J=8.0 Hz, CH-4’), 7.77 (1H, d, J=8.0 Hz, CH-4), 
8.04 (1H, s, CH-18), 8.12 (1H, d, J=2.7 Hz, NH-10), 8.12 (1H, d, J=4.2 Hz, NH-10’) ppm; 
13C-NMR (100 MHz, CDCl3) δ 21.0 (CH2-14), 22.2 (CH2-14’), 28.2 (CH2-13), 29.0 (CH2-13’), 30.3 (CH2-8), 
30.7 (CH2-8’), 44.5 (CH2-15), 45.4 (CH2-15’), 56.1 (CH-9’), 57.1 (CH-12), 57.4 (CH-9), 58.3 (CH-12’), 66.5 
(CH-18), 108.2 (CH-7), 108.4 (CH-7’), 110.2 (Cq-3), 111.4 (Cq-3’), 119.9 (CH-4’), 120.4 (CH-4, CH-5), 
121.0 (CH-5’), 122.7 (CH-6), 123.2 (CH-6’), 124.9 (CH-2), 125.4 (CH-2’), 127.1 (CH-20, CH-24), 127.4 
(Cq-3a), 128.1 (Cq-3a’), 129.1 (CH-21, CH-23), 129.3 (CH-22), 136.2 (Cq-7a), 136.4 (Cq-19), 137.4 
(Cq-7a’), 165.0 (CC=O-17), 166.2 (CC=O-17’), 170.3 (CC=O-11), 170.4 (CC=O-11’) ppm (The allocation of the 
signals CHy-X and CHy-X‘ may be interchanged); IR (cm
-1): max = 3219 (NH), 1645 (C=O), 1454; MS 
(ES): m/z (%): 655 (100) [M + H]+; HRMS (ESI): calcd. for C39H39N6O4
+ [M+H]+: 655.3027; found: 
655.3040. 
6. Ring formation through metathesis of allyl groups 
6.1. Introduction of the allyl group at C-3 of the indole[189]  
Diketopiperazine 2 (1 equiv., 0.35 mmol, 0.10 g) and Pd(PPh3)4 (5 mol%, 0.018 mmol, 0.020 g) were 
dissolved in dry, degassed THF (5 mL) at room temperature under a nitrogen atmosphere. Allyl 
alcohol (1 equiv., 0.35 mmol, 0.024 mL) and Et3B (1 equiv., 0.35 mmol, 0.35 mL of 1 M hexane 
solution,) were successively added to this solution. The reaction mixture was stirred at 50 °C for 
5 hours, during which the reaction was monitored by means of HPLC-MS. After dilution with EtOAc 
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(5 mL), the mixture was washed twice with saturated aq. NaHCO3 (5 mL) and with brine (5 mL). The 
organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was 
subjected to reversed-phase pHPLC using an isocratic H2O/ACN gradient (35% ACN) to yield the 
desired compounds 222. 
(5aS,6aR,11aR,13aS)-6a-allyl-1,2,3,6,6a,11,11a,13a-octahydro-13H-pyrrolo[1'',2'':4',5']pyrazino-
[1',2':1,5]pyrrolo[2,3-b]indole-5,13(5aH)-dione 222a 
Following the general procedure using isomer 2a, compound 222a was 
obtained after purification by pHPLC. Yield 76% (0.086 g); colourless 
crystals; m.p. 85-87 °C; [α]D
25 = -302.8 (c=0.27 in CHCl3); 
1H-NMR (400 MHz, 
CDCl3) δ 1.63 (1H, br s, NH-1), 1.83-1.97 (1H, m, CHaHb-14), 1.97-2.09 (1H, m, 
CHaHb-14), 2.09-2.20 (1H, m, CHaHb-13), 2.26-2.35 (1H, m, CHaHb-13), 2.36 (1H, dd, J=13.0 Hz, J=11.1 
Hz, CHaHb-8), 2.45-2.49 (2H, m, CH2-18), 2.67 (1H, dd, J=13.0 Hz, J=6.3 Hz, CHaHb-8), 3.44-3.60 (2H, m, 
CH2-15), 4.04-4.11 (2H, m, CH-9, CH-12), 5.06-5.10 (1H, m, CHaHb-20), 5.11 (1H, br s, CHaHb-20), 5.30 
(1H, s, CH-2), 5.65-5.80 (1H, m, CH-19), 6.62 (1H, d, J=7.5 Hz, CH-7), 6.79 (1H, dd, J=7.5 Hz, J=7.5 Hz, 
CH-5), 7.07-7.13 (2H, m, CH-4, CH-6) ppm; 13C-NMR (100 MHz, CDCl3) δ 23.1 (CH2-14), 27.7 (CH2-13), 
37.8 (CH2-8), 41.9 (CH2-18), 45.2 (CH2-15), 55.5 (Cq-3), 60.3 (CH-9*), 60.5 (CH-12*), 79.2 (CH-2), 109.6 
(CH-7), 119.1 (CH2-20), 119.4 (CH-5), 123.5 (CH-4), 128.8 (CH-6), 130.8 (Cq-3a), 132.9 (CH-19), 148.9 
(Cq-7a), 165.9 (CC=O-17), 167.1 (CC=O-11) ppm; IR (cm
-1): max = 1665 (C=O), 1632 (C=O), 1426; MS 
(ES): m/z (%): 324 (100) [M + H]+; HRMS (ESI): calcd. for C19H22N3O2
+ [M+H]+: 324.1707; found: 
324.1703. 
(5aR,6aS,11aS,13aR)-6a-allyl-1,2,3,6,6a,11,11a,13a-octahydro-13H-pyrrolo[1'',2'':4',5']pyrazino-
[1',2':1,5]pyrrolo[2,3-b]indole-5,13(5aH)-dione 222b 
Following the general procedure using isomer 2d,compound 222b was 
obtained after purification by pHPLC. Yield 68% (0.077 g); colourless 
crystals; m.p. 85-87 °C; [α]D
25 = +302.5 (c=0.27 in CHCl3); 
1H-NMR (400 MHz, 
CDCl3) δ 1.78-1.96 (2H, m, NH-1, CHaHb-14), 1.96- 2.08 (1H, m, CHaHb-14), 
2.09-2.20 (1H, m, CHaHb-13), 2.26-2.34 (1H, m, CHaHb-13), 2.36 (1H, dd, J=12.6 Hz, J=11.9 Hz, CHaHb-
8), 2.45-2.55 (2H, m, CH2-18), 2.66 (1H, dd, J=12.6 Hz, J=6.3 Hz, CHaHb-8), 3.41-3.60 (2H, m, CH2-15), 
4.04-4.10 (1H, m, CH-9, CH-12), 5.05-5.15 (2H, m, CH2-20), 5.30 (1H, s, CH-2), 5.65-5.80 (1H, m, CH-
19), 6.61 (1H, d, J=7.5 Hz, CH-7), 6.79 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.07-7.14 (2H, m, CH-4, CH-
6); 13C-NMR (100 MHz, CDCl3) δ 23.1 (CH2-14), 27.7 (CH2-13), 37.8 (CH2-8), 41.9 (CH2-18), 45.2 (CH2-
15), 55.5 (Cq-3), 60.3 (CH-9*), 60.5 (CH-12*), 79.2 (CH-2), 109.5 (CH-7), 119.1 (CH2-20), 119.4 (CH-5), 
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123.5 (CH-4), 128.8 (CH-6), 130.8 (Cq-3a), 132.9 (CH-19), 148.9 (Cq-7a), 165.9 (CC=O-17), 167.1 (CC=O-11) 
ppm; IR (cm-1): max = 1666 (C=O), 1632 (C=O), 1425; MS (ES): m/z (%): 324 (100) [M + H]+; HRMS 
(ESI): calcd. for C19H22N3O2
+ [M+H]+: 324.1707; found: 324.1708. 
6.2. Selective synthesis of mono-allylated diketopiperazine 228a 
6.2.1. Synthesis of N’-Boc-protected dipeptide 229 
Crude dipeptide 181a (1 equiv., 1.0 mmol, 0.45 g) synthesized according to the general procedure in 
4.1.1 was dissolved in dry CH2Cl2 (20 mL) under a nitrogen atmosphere. Boc2O (1 equiv., 1.0 mmol, 
0.22 g), triethylamine (2 equiv., 2.0 mmol, 0.28 mL) and DMAP (0.2 equiv, 0.20 mmol, 24 mg) were 
added to the solution. After 4 hours the reaction mixture was washed three times with brine (15 mL). 
The organic layer was dried over magnesium sulfate and concentrated in vacuo yielding the 
N’-Boc-protected dipeptide 229 (quant., 1.0 mmol, 0.55 g) as a yellow foam. 
6.2.2. Hydrogenolysis and cyclization 
To a solution of N’-Boc-protected dipeptide 229 (1 equiv., 1.0 mmol, 0.55 g) in MeOH (25 mL), 10 
wt% of Pd/C (0.055 g) was added. The reaction mixture was stirred under 5 atm of H2 for 24 hours at 
room temperature. The Pd/C catalyst was removed by filtration through a celite pad. Next, the 
solution was transferred in a closed vessel and ammonia in methanol (7 M NH3) was added to induce 
ring formation. The filtrate was concentrated in vacuo to give the crude N’-Boc-protected 
diketopiperazine 230. The pure product 230 was obtained after column chromatography with EtOAc 
as eluent. 
tert-butyl 3-(((3S,8aS)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methyl)-1H-indole-1-
carboxylate 230 
Following the general procedures 6.2.1 and 6.2.2 afforded compound 
230. Yield 92% (0.35 g); colourless crystals; Rf=0.17 (EtOAc); m.p. 143-
145 °C; 1H-NMR (400 MHz, CDCl3) δ 1.69 (9H, s, 3×CH3-20), 1.83-1.99 
(1H, m, CHaHb-14), 2.00-2.13 (2H, m, CHaHb-13, CHaHb-14), 2.29-2.40 
(1H, m, CHaHb-13), 2.90 (1H, dd, J=15.1 Hz, J=11.0 Hz, CHaHb-8), 3.55-
3.69 (2H, m, CH2-15), 3.72 (1H, dd, J=15.1 Hz, J=2.8 Hz, CHaHb-8), 4.06-4.13 (1H, m, CH-12), 4.38 (1H, 
dd, J=11.0 Hz , J=2.8 Hz, CH-9), 5.77 (1H, s, NH-10), 7.26 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5), 7.36 (1H, 
dd, J=7.8 Hz, J=7.8 Hz, CH-6), 7.51 (1H, s, CH-2), 7.52 (1H, d, J=7.8 Hz, CH-4), 8.17 (1H, d, J=7.8 Hz, CH-
7) ppm; 13C-NMR (100 MHz, CDCl3) δ 22.7 (CH2-14), 26.6 (CH2-8), 28.2 (3×CH3-20), 28.3 (CH2-13), 45.5 
(CH2-15), 54.0 (CH-9), 59.2 (CH-12), 84.1 (Cq-19), 114.8 (Cq-3), 115.7 (CH-7), 118.7 (CH-4), 122.9 
(CH-5), 124.5 (CH-2), 125.1 (CH-6), 129.4 (Cq-3a), 135.9 (Cq-7a), 149.3 (CC=O-18), 165.1 (CC=O-17), 169.4 
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(CC=O-11) ppm; IR (cm
-1): max = 1736 (C=O), 1645 (C=O), 1370; MS (ES): m/z (%): 384 (100) [M + H]+; 
HRMS (ESI): calcd. for C21H26N3O4
+ [M+H]+: 384.1918; found: 384.1912. 
6.2.3. Allylation 
To a solution of N’-Boc-protected diketopiperazine 230 (1 equiv., 1.3 mmol, 0.50 g) in dry ACN 
(25 mL), sodium hydride was added in two separate portions (one portion every 15 minutes). 
Subsequently, two equivalents of allyl bromide (2 equiv., 2.6 mmol, 0.23 mL) were added. The 
mixture was stirred under a nitrogen atmosphere for 16 hours at room temperature. Then, the 
reaction was quenched by the addition of water and the solvent was evaporated under reduced 
pressure. Subsequently, the residue was dissolved in CH2Cl2 (30 mL). The solution was washed twice 
with saturated aq. NaHCO3 (30 mL). The organic phase was dried over magnesium sulfate and 
concentrated in vacuo. Purification of the residue by chromatography provided the desired product 
231. 
tert-butyl 3-(((3S,8aS)-2-allyl-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-yl)methyl)-1H-indole-1-
carboxylate 231 
Yield 87% (0.48 g); colourless crystals; Rf=0.25 (1/3 petroleum 
ether/EtOAc); m.p. 147-149 °C; 1H-NMR (400 MHz, CDCl3) δ 0.45-0.57 
(1H, m, CHaHb-13), 1.15-1.26 (1H, m, CHaHb-14), 1.48-1.60 (1H, m, 
CHaHb-14), 1.66 (9H, s, 3×CH3-20), 1.94-2.02 (1H, m, CHaHb-13), 3.13 
(1H, ddd, J=12.0 Hz, J=10.1 Hz, J= 4.5 Hz, CHaHb-15), 3.26 (1H, dd, J=15.4 
Hz, J=3.9 Hz, CHaHb-8), 3.51-3.63 (3H, m, CHaHb-8, CHaHb-21, CHaHb-15), 3.83 (1H, dd, J=11.3 Hz, J=6.2 
Hz, CH-12), 4.41 (1H, dd, J=3.9 Hz, J=3.9 Hz, CH-9), 4.90 (1H, dddd, J=15.3 Hz, J=4.6 Hz, J=1.7 Hz, J=1.7 
Hz, CHaHb-21), 5.29-5.35 (2H, m, CH2-23), 5.76-5.87 (1H, m, CH-22), 7.23 (1H, ddd, J=7.7 Hz, J=7.7 Hz, 
J=1.1 Hz, CH-5), 7.28-7.31 (2H, m, CH-2, CH-6), 7.55 (1H, dd, J=7.7 Hz, J=1.1 Hz, CH-4), 8.09 (1H, d, 
J=7.7 Hz, CH-7) ppm; 13C-NMR (100 MHz, CDCl3) δ 21.1 (CH2-14), 25.9 (CH2-8), 28.2 (3×CH3-20), 28.9 
(CH2-13), 44.6 (CH2-15), 45.5 (CH2-21), 59.1 (CH-12), 59.3 (CH-9), 83.9 (Cq-19), 113.9 (Cq-3), 115.1 
(CH-7), 119.2 (CH2-23), 119.4 (CH-4), 122.6 (CH-5), 124.7 (CH-2*), 124.8 (CH-6*), 130.2 (Cq-3a), 131.8 
(CH-22), 135.1 (Cq-7a), 149.4 (CC=O-18), 164.1 (CC=O-17), 165.9 (CC=O-11) ppm (The signals with the 
same superscript (*) may be interchanged); IR (cm-1): max = 1742 (C=O), 1644 (C=O), 1632 (C=O), 
1365; MS (ES): m/z (%): 424 (100) [M + H]+; HRMS (ESI): calcd. for C19H22N3O2
+ [M - Boc + 2H]+: 
324.1707; found: 324.1703. 
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6.2.4. Boc deprotection 
Acetyl chloride (5 equiv., 15.5 mmol, 1.1 mL) was added dropwise to a solution of compound 231 
(1 equiv., 3.1 mmol, 1.3 g) in 25 mL of methanol at 0 °C. After stirring at room temperature for 
24 hours the mixture was concentrated under reduced pressure. The mono-allylated product 228a 
was obtained through purification by column chromatography using a mixture of EtAOc and 
petroleum ether as eluent. 
(3S,8aR)-3-((1H-indol-3-yl)methyl)-2-allylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 228a 
Yield 82% (0.81 g); colourless crystals; Rf=0.23 (1/4 petroleum 
ether/EtOAc); m.p. 153-155 °C; [α]D
25 = +75.3 (c=0.59 in CHCl3); 
1H-NMR 
(400 MHz, CDCl3) δ 1.11-1.28 (1H, m, CHaHb-14), 1.55-1.67 (1H, m, CHaHb-
13), 1.67-1.78 (1 H, m, CHaHb-14), 1.88-1.96 (1H, m, CHaHb-13), 2.29 (1H, dd, 
J=10.8 Hz, J=6.3 Hz, CH-12), 3.03 (1H, ddd, J=11.8 Hz, J=9.7 Hz, J=2.2 Hz, CHaHb-15), 3.24 (1H, dd, 
J=14.9 Hz, J=4.5 Hz, CHaHb-8), 3.41-3.54 (3H, m, CHaHb-8, CHaHb-15, CHaHb-18), 4.27 (1H, dd, J=4.5 Hz, 
J=4.5 Hz , CH-9), 4.67 (1H, dd, J=15.0 Hz, J=5.0 Hz, CHaHb-18), 5.17-5.23 (2H, m, CH2-20), 5.78 (1H, 
dddd, J=17.0 Hz, J=10.0 Hz, J=7.2 Hz, J=5.0 Hz, CH-19), 6.92 (1H, d, J=2.1 Hz, CH-2), 7.09 (1H, dd, J=7.6 
Hz, J=7.6 Hz, CH-5), 7.16 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-6), 7.33 (1H, d, J=7.6 Hz, CH-7), 7.57 ( 1H, d, 
J=7.6 Hz, CH-4), 9.04 (1H, br s, NH-1) ppm; 13C-NMR (100 MHz, CDCl3) δ 21.6 (CH2-14), 27.1 (CH2-8), 
29.2 (CH2-13), 44.9 (CH2-15), 46.5 (CH2-18), 57.9 (CH-12), 62.1 (CH-9), 108.9 (Cq-3), 111.4 (CH-7), 
118.8 (CH-4), 119.1 (CH2-20), 119.6 (CH-5), 122.3 (CH-6), 124.2 (CH-2), 127.2 (Cq-3a), 131.9 (CH-19), 
136.2 (Cq-7a), 165.5 (CC=O-17), 167.8 (CC=O-11) ppm; IR (cm
-1): max = 1739 (C=O), 1455; MS (ES): m/z 
(%): 324 (100) [M + H]+; HRMS (ESI): calcd. for C19H22N3O2
+ [M + H]+: 324.1707; found: 324.1712. 
6.3. Synthesis of diallylated diketopiperazines[121] 
To a stirred solution of cyclo(D-Trp, L-Pro) 2b (1 equiv., 1.1 mmol, 300 mg) in 10 mL of dry DMF, 
sodium hydride (2.2 equiv., 2.3 mmol, 56 mg) was added at 0 °C. After stirring the mixture at 0 °C for 
15 min, allyl bromide (5 equiv., 5.3 mmol, 0.5 mL) was added. The reaction mixture was stirred at 
0 °C for another hour and was then allowed to warm to room temperature. The reaction was 
monitored using HPLC-MS. When the conversion stagnated, an extra portion of sodium hydride was 
added (1 equiv., 1.1 mmol, 25 mg). The reaction was then quenched with 5% aq. NaHCO3 (30 mL) and 
extracted two times with CH2Cl2 (2×25 mL). The combined organic phases were washed with brine 
(2×25 mL), and dried over magnesium sulfate. Removal of the solvent under reduced pressure gave 
the crude reaction product containing mono- and diallylated products, which were separated by 
means of column chromatography (1/1 petroleum ether/EtOAc). 
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(3R,8aS)-2-allyl-3-((1-allyl-1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 220b 
Yield 43% (0.165 g); yellow oil; Rf=0.27 (1/1 petroleum ether/EtOAc); 
1H-NMR (300 MHz, CDCl3) δ 1.13-1.38 (1H, m, CHaHb-14), 1.54-1.82 (2H, m, 
CHaHb-13, CHaHb-14), 1.90-2.00 (1H, m, CHaHb-13), 2.35 (1H, dd, J=10.7 Hz, 
J=6.3 Hz, CH-12), 3.00-3.10 (1H, m, CHaHb-15), 3.23 (1H, dd, J=14.9 Hz, J=4.6 
Hz, CHaHb-8), 3.39-3.53 (3H, m, CHaHb-8, CHaHb-15, CHaHb-21), 4.25 (1H, t, J=4.6 Hz, CH-9), 4.62-4.72 
(3H, m, CH2-18, CHaHb-21), 5.05 (1H, ddd, J=17.1 Hz, J=2.8 Hz, J=1.7 Hz, CHaHb-20), 5.14-5.28 (3H, m, 
CHaHb-20, CH2-23), 5.76 (1H, dddd, J=17.1 Hz, J=9.8 Hz, J=7.5 Hz, J=5.0 Hz, CH-22), 5.92 (1H, dddd, 
J=17.1 Hz, J=10.5 Hz, J=5.3 Hz, J=5.2 Hz, CH-19), 6.87 (1H, s, CH-2), 7.10 (1H, dd, J=7.5 Hz, J=7.5 Hz, 
CH-5), 7.18 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-6), 7.27 (1H, d, J=7.5 Hz, CH-7), 7.56 (1H, d, J=7.5 Hz, CH-4) 
ppm; 13C-NMR (75 MHz, CDCl3) δ 21.7 (CH2-14), 27.0 (CH2-8), 29.1 (CH2-13), 44.9 (CH2-15), 46.4 (CH2-
21), 48.7 (CH2-18), 57.9 (CH-12), 62.1 (CH-9), 108.3 (Cq-3), 109.6 (CH-7), 117.4 (CH2-20), 119.0 (CH2-
23), 119.1 (CH-4), 119.5 (CH-5), 122.2 (CH-6), 127.6 (CH-2), 128.0 (Cq-3a), 132.0 (CH-22), 133.3 (CH-
19), 136.3 (Cq-7a), 165.6 (CC=O-17), 167.4 (CC=O-11) ppm; IR (cm
-1): max = 1651 (C=O), 1451; MS (ES): 
m/z (%): 364 (100) [M + H]+; HRMS (ESI): calcd. for C22H26N3O2
+ [M + H]+: 364.1707; found: 364.2038. 
(3R,8aS)-3-((1H-indol-3-yl)methyl)-2-allylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 228b 
Yield 13% (0.044 g); colourless crystals; Rf=0.20 (1/1 petroleum 
ether/EtOAc); m.p. 163-165 °C; [α]D
25 = -95.2 (c=0.59 in CHCl3); 
1H-NMR 
(300 MHz, CDCl3) δ 1.10-1.34 (1H, m, CHaHb-14), 1.54-1.79 (2H, m, CHaHb-
13, CHaHb-14), 1.86-1.98 (1H, m, CHaHb-13), 2.29 (1H, dd, J=10.7 Hz, J=6.3 
Hz, CH-12), 2.97-3.09 (1H, m, CHaHb-15), 3.24 (1H, dd, J=14.9 Hz, J=4.5 Hz, CHaHb-8), 3.40-3.55 (3H, m, 
CHaHb-8, CHaHb-15, CHaHb-18), 4.27 (1H, dd, J=4.5 Hz, J=4.5 Hz, CH-9), 4.68 (1H, dd, J=15.7 Hz, J=5.0 
Hz, CHaHb-18), 5.21 (1H, d, J=16.9 Hz, CHaHb-20), 5.25 (1H, d, J=10.1 Hz, CHaHb-20), 5.76 (1H, dddd, 
J=16.9 Hz, J=10.1 Hz, J=7.6 Hz, J=5.0 Hz, CH-19), 6.92 (1H, s, CH-2), 7.09 (1H, dd, J=7.7 Hz, J=7.7 Hz, 
CH-5), 7.16 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.33 (1H, d, J=7.7 Hz, CH-7), 7.57 (1H, d, J=7.7 Hz, CH-4), 
9.02 (1H, s, NH-1) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.8 (CH2-14), 27.3 (CH2-8), 29.5 (CH2-13), 45.1 
(CH2-15), 46.7 (CH2-18), 58.1 (CH-12), 62.3 (CH-9), 109.1 (Cq-3), 111.6 (CH-7), 119.0 (CH-4), 119.3 
(CH2-20), 119.9 (CH-5), 122.6 (CH-6), 124.4 (CH-2), 127.5 (Cq-3a), 132.1 (CH-19), 136.4 (Cq-7a), 165.8 
(CC=O-17), 168.0 (CC=O-11) ppm; IR (cm
-1): max = 1657 (C=O), 1650 (C=O), 1456; MS (ES): m/z (%): 324 
(100) [M + H]+; HRMS (ESI): calcd. for C19H22N3O2
+ [M + H]+: 324.1707; found: 324.1738. 
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7. Synthesis of annulated analogues via other electrophiles 
7.1. Synthesis of a dimer with CDI  
Diketopiperazine 2b (1 equiv., 1.4 mmol, 0.40 g) was suspended in dry CH2Cl2 (20 mL) under a 
nitrogen atmosphere. Triethylamine (3 equiv., 4.2 mmol, 0.59 mL) was added and stirred for 
10 minutes before the addition of CDI (1.1 equiv., 1.5 mmol, 0.25 g). The mixture was refluxed for 
5 days. Subsequently, the organic phase was washed with 2 M HCl (3×30mL) and with water 
(3×30mL). The organic phase was dried over magnesium sulfate and concentrated in vacuo. 
Purification of the residue by pTLC provided the dimeric product 234. 
(3S,3'S,8aS,8a'S)-3,3'-((carbonylbis(1H-indole-1,3-diyl))bis(methylene))bis(hexahydropyrrolo[1,2-a]-
pyrazine-1,4-dione) 234 
Yield 65% (0.27 g); yellow foam; Rf=0.14 (CH2Cl2/4% MeOH); 
m.p. 194-196 °C; 1H-NMR (300 MHz, CDCl3) δ 1.28-1.47 (2H, m, 
CHaHb-14, CHaHb-14‘), 1.59-1.76 (2H, m, CHaHb-13, CHaHb-13‘), 
1.77-1.94 (2H, m, CHaHb-14, CHaHb-14‘), 2.06-2.17 (2H, m, 
CHaHb-13, CHaHb-13‘), 2.65 (2H, dd, J=11.6 Hz, J=6.1 Hz, CH-12, 
CH-12‘), 2.96-3.05 (2H, m, CHaHb-15, CHaHb-15‘), 3.10 (2H, dd, J=14.3 Hz, J=5.5 Hz, CHaHb-8, CHaHb-8‘), 
3.71-3.57 (4H, m, CHaHb-8, CHaHb-8‘, CHaHb-15, CHaHb-15‘), 4.42-4.48 (2H, m, CH-9, CH-9‘), 7.13 (2H, s, 
CH-2, CH-2‘), 7.32 (2H, dd, J=7.8 Hz, J=7.8 Hz, CH-5, CH-5‘), 7.39 (2H, dd, J=7.8 Hz, J=7.8 Hz, CH-6, 
CH-6‘), 7.63 (2H, d, J=7.8 Hz, CH-4, CH-4‘), 8.10 (2H, d, J=7.8 Hz, CH-7, CH-7‘), 8.55 (2H, d, J=7.8 Hz, 
NH-10, NH-10‘) ppm; 13C-NMR (75 MHz, CDCl3) δ 21.0 (CH2-14, CH2-14‘), 29.3 (CH2-13, CH2-13), 29.5 
(CH2-8, CH2-8‘), 44.8 (CH2-15, CH2-15‘), 57.3 (CH-9, CH-9‘), 58.3 (CH-12, CH-12‘), 114.7 (CH-7, CH-7‘), 
115.0 (Cq-3, Cq-3‘), 119.5 (CH-4, CH-4‘), 123.9 (CH-5, CH-5‘), 125.3 (CH-6, CH-6‘), 127.7 (CH-2, CH-2‘), 
129.7 (Cq-3a, Cq-3a‘), 136.3 (Cq-7a, Cq-7a‘), 148.0 (CC=O-18), 164.7 (CC=O-17, CC=O-17‘), 171.0 (CC=O-11, 
CC=O-11‘) ppm (The allocation of the signals CHy-X and CHy-X‘ may be interchanged); IR (cm
-1): max = 
1713 (C=O), 1645 (C=O), 1447; MS (ES): m/z (%): 593 (100) [M + H]+; HRMS (ESI): calcd. for 
C33H33N6O5
+ [M + H]+: 593.2507; found: 593.2499. 
7.2. Synthesis of 3,5-bridged α-chloroamines 237a-d 
1,3-diethyl-1,3-diisopropylurea 
DIPEA (2 equiv., 4.0 mmol, 0.72 mL) was dissolved in dry CH2Cl2 (10 mL) and 
diphosgene (1 equiv., 2.0 mmol, 0.24 mL) was slowly added at room temperature as 
the reaction is exothermic. After 3 hours, the organic phase was washed with 
saturated aq. NaHCO3 (3×5 mL), brine (2×5 mL) and with water (2×5 mL). The organic phase was 
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dried over magnesium sulfate and concentrated under reduced pressure yielding a yellow liquid. 
1H NMR revealed the presence of two rotamers in a 1:1.6 ratio. 
Yield 70% (0.28 g); yellow liquid; 1H NMR (400 MHz, CDCl3) δ (rotamer 1) 1.18-1.31 (18H, m, 6×CH3), 
3.32 (4H, q, J=6.91 Hz, 2×CH2), 4.54 (2H, septet, J=6.18 Hz, 2×CH) ppm; (rotamer 2) 1.18-1.31 (18H, 
m, 6×CH3), 3.41 (4H, q, J=7.06 Hz, 2×CH2), 4.29 (2H, septet, J=6.55 Hz, 2×CH) ppm; 
13C NMR (100 
MHz, CDCl3) δ (rotamer 1) 14.2 (CH3), 20.7 (6×CH3), 39.6 (2×CH2), 52.2 (2×CH), 148.2 (CC=O) ppm; 
(rotamer 2) 15.4 (CH3), 20.2 (6×CH3), 41.8 (2×CH2), 51.6 (2×CH), 148.7 (CC=O) ppm; MS (ES): m/z (%): 
88 (100) [C5H14N]
+; 
General procedure: Diketopiperazine 2 (1 equiv.) was suspended in dry CH2Cl2 and cooled with an 
ice-bath to 0 °C under a nitrogen atmosphere. Diphosgene (3 equiv.), dissolved in dry CH2Cl2, was 
added dropwise to the suspension. The mixture was heated to reflux. The reaction was monitored 
using HPLC-MS and after complete conversion, the organic phase was washed with saturated aq. 
NaHCO3 and with water. The organic phase was dried over magnesium sulfate and concentrated 
under reduced pressure. Purification of the residue by chromatography provided the desired 
products 237. 
(6S,13R,13aS)-13-chloro-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 237a.  
Using the general procedure with isomer 2a on a 0.7 mmol scale, compound 
237a was obtained after pTLC. Yield 40% (0.084 g); white powder; Rf=0.20 
(CH2Cl2/4% MeOH); m.p. 224-230 °C; [α]D
25 = +102.8 (c=0.51 in CHCl3); 
1H NMR 
(300 MHz, CDCl3) δ 1.76-2.16 (4H, m, CH2-13, CH2-14), 2.71 (1H, s, NH-10), 
2.92-3.01 (1H, m, CHaHb-15), 3.05 (1H, d, J=16.4 Hz, CHaHb-8), 3.18 (1H, dd, J=16.4 Hz, J=5.9 Hz, 
CHaHb-8), 3.79 (1H, dd, J=11.0 Hz, J=5.0 Hz, CH-12), 4.04-4.15 (1H, m, CHaHb-15), 4.23 (1H, d, J=5.9 Hz, 
CH-9), 7.14 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-5), 7.24 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.37 (1H, d, 
J=7.7 Hz, CH-7), 7.48 (1H, d, J=7.7 Hz, CH-4), 8.25 (1H, s, NH-1) ppm; 13C NMR (75 MHz, CDCl3) δ 21.2 
(CH2-14), 24.9 (CH2-8), 28.2 (CH2-13), 44.4 (CH2-15), 58.1 (CH-9), 68.5 (CH-12), 77.4 (Cq-11), 109.3 
(Cq-3), 111.5 (CH-7), 119.3 (CH-4), 120.4 (CH-5), 123.6 (CH-6), 126.5 (Cq-3a), 134.3 (Cq-2), 136.0 
(Cq-7a), 169.3 (CC=O-17) ppm; IR (cm
-1): max = 3151 (NH), 1624 (C=O); MS (ES): m/z (%): 302/304 
(100/35) [M + H]+; HRMS (ESI): calcd. for C16H17ClN3O
+ [M + H]+: 302.1055; found: 302.1057. 
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(6R,13S,13aS)-13-chloro-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 237b.  
Apllying the general procedure on isomer 2b on a 10 mmol scale, compound 
237b was obtained after column chromatography. Yield 50% (1.51 g); 
colourless crystals; Rf=0.25 (4/6 petroleum ether/EtOAc + 4% Et3N); m.p. 248-
250 °C; [α]D
25 = -115.3 (c=0.50 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.78-2.19 
(4H, m, CH2-13, CH2-14), 2.70 (1H, s, NH-10), 2.93-3.02 (1H, m, CHaHb-15), 3.05 (1H, d, J=16.5 Hz, 
CHaHb-8), 3.20 (1H, dd, J=16.5 Hz, J=6.6 Hz, CHaHb-8), 3.80 (1H, dd, J=11.0 Hz, J=5.0 Hz, CH-12), 4.05-
4.16 (1H, m, CHaHb-15), 4.24 (1H, d, J=6.6 Hz, CH-9), 7.15 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-5), 7.25 (1H, 
dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.38 (1H, d, J=7.7 Hz, CH-7), 7.50 (1H, d, J=7.7 Hz, CH-4), 8.14 (1H, s, 
NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.3 (CH2-14), 24.9 (CH2-8), 28.2 (CH2-13), 44.4 (CH2-15), 
58.2 (CH-9), 68.5 (CH-12), 77.0 (Cq-11), 109.3 (Cq-3), 111.5 (CH-7), 119.3 (CH-4), 120.4 (CH-5), 123.6 
(CH-6), 126.6 (Cq-3a), 134.3 (Cq-2), 136.0 (Cq-7a), 169.3 (CC=O-17) ppm; IR (cm
-1): max = 3150 (NH), 
1621 (C=O), 1461, 1450; MS (ES): m/z (%): 302/304 (100/35) [M + H]+; HRMS (ESI): calcd. for 
C16H17ClN3O
+ [M + H]+: 302.1055; found: 302.1067. 
CCDC-1030976 and -1030977 contain the supplementary crystallographic data for this compound 
and can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
https://summary.ccdc.cam.ac.uk/structure-summary-form. 
(6S,13R,13aR)-13-chloro-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 237c.  
Using the general procedure on isomer 2c on a 0.7 mmol scale, compound 
237c was obtained after pTLC. Yield 24% (0.051 g); white powder; Rf=0.17 
(CH2Cl2/4% MeOH); m.p. 240-246 °C; [α]D
25 = +115.3 (c=0.50 in CHCl3); 
1H NMR 
(300 MHz, CDCl3) δ 1.68-2.20 (4H, m, CH2-13, CH2-14), 2.69 (1H, s, NH-10), 
2.92-3.02 (1H, m, CHaHb-15), 3.05 (1H, d, J=16.5 Hz, CHaHb-8), 3.19 (1H, dd, J=16.5 Hz, J=6.3 Hz, 
CHaHb-8), 3.79 (1H, dd, J=11.0 Hz, J=5.0 Hz, CH-12), 4.03-4.16 (1H, m, CHaHb-15), 4.24 (1H, d, J=6.3 Hz, 
CH-9), 7.14 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.25 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-6), 7.37 (1H, d, 
J=7.5 Hz, CH-7), 7.49 (1H, d, J=7.5 Hz, CH-4), 8.20 (1H, s, NH-1) ppm; 13C NMR (75 MHz, CDCl3) δ 21.2 
(CH2-14), 24.9 (CH2-8), 28.2 (CH2-13), 44.4 (CH2-15), 58.1 (CH-9), 68.5 (CH-12), 77.4 (Cq-11), 109.3 
(Cq-3), 111.5 (CH-7), 119.3 (CH-4), 120.4 (CH-5), 123.6 (CH-6), 126.6 (Cq-3a), 134.3 (Cq-2), 136.0 
(Cq-7a), 169.2 (CC=O-17) ppm; IR (cm
-1): max = 3171 (NH), 1624 (C=O), 1451; MS (ES): m/z (%): 
302/304 (100/35) [M + H]+; HRMS (ESI): calcd. for C16H17ClN3O
+ [M + H]+: 302.1055; found: 302.1065. 
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(6R,13S,13aR)-13-chloro-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 237d.  
Following the general procedure on isomer 2d on a 0.7 mmol scale, 
compound 237d was obtained after pTLC. Yield 46% (0.097 g); white powder; 
Rf=0.22 (CH2Cl2/2% MeOH); m.p. 210-218 °C; [α]D
25 = -102.5 (c=0.51 in CHCl3); 
1H NMR (300 MHz, CDCl3) δ 1.76-2.18 (4H, m, CH2-13, CH2-14), 2.68 (1H, s, 
NH-10), 2.92-3.01 (1H, m, CHaHb-15), 3.04 (1H, d, J=16.5 Hz, CHaHb-8), 3.18 (1H, dd, J=16.5 Hz, J=6.3 
Hz, CHaHb-8), 3.79 (1H, dd, J=10.7 Hz, J=4.7 Hz, CH-12), 4.03-4.15 (1H, m, CHaHb-15), 4.23 (1H, d, J=6.3 
Hz, CH-9), 7.14 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5), 7.24 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-6), 7.37 (1H, d, 
J=7.8 Hz, CH-7), 7.48 (1H, d, J=7.8 Hz, CH-4), 8.25 (1H, s, NH-1) ppm; 13C NMR (75 MHz, CDCl3): δ 21.3 
(CH2-14), 24.9 (CH2-8), 28.2 (CH2-13), 44.4 (CH2-15), 58.2 (CH-9), 68.5 (CH-12), 77.0 (Cq-11), 109.3 (Cq-
3), 111.5 (CH-7), 119.3 (CH-4), 120.4 (CH-5), 123.6 (CH-6), 126.6 (Cq-3a), 134.3 (Cq-2), 136.0 (Cq-7a), 
169.3 (CC=O-17) ppm; IR (cm
-1): max = 3222 (NH), 1613 (C=O), 1446; MS (ES): m/z (%): 302/304 
(100/35) [M + H]+; HRMS (ESI): calcd. for C16H17ClN3O
+ [M + H]+: 302.1055; found: 302.1062. 
7.3. Introduction of protecting groups on the α-chloroamine 
7.3.1. Boc protecting group 
To a solution of α-chloroamine 237b (1 equiv., 1.2 mmol, 0.35 g) in anhydrous ACN (5 mL) were 
added DMAP (0.02 equiv., 0.23 mmol, 28 mg) and (Boc)2O (3 equiv., 3.5 mmol, 0.76 g). After stirring 
for 3 hours at room temperature, the solvent was removed under reduced pressure and the residue 
was diluted with CH2Cl2 (15 mL). The organic phase was subsequently washed with brine (3×30 mL). 
Drying the organic phase over magnesium sulfate and concentration of the solvent under reduced 
pressure yielded the N’-protected α-chloroamine 241 as a yellow foam. 
tert-Butyl (6R,13S,13aS)-13-chloro-5-oxo-1,2,3,5,6,7,13,13a-octahydro-12H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-12-carboxylate 241 
Yield 98% (0.46 g); yellow foam; m.p. 221-223 °C; 1H NMR (400 MHz, CDCl3) δ 
1.71 (9H, s, 3×CH3-20), 1.85-2.08 (3H, m, CHaHb-13, CH2-14), 2.18-2.28 (1H, m, 
CHaHb-13), 2.49 (1H, s, NH-10), 3.00-3.09 (1H, m, CHaHb-15), 3.03 (1H, d, 
J=16.8 Hz, CHaHb-8), 3.13 (1H, dd, J=16.8 Hz, J=6.3 Hz, CHaHb-8), 4.09-4.19 (1H, 
m, CHaHb-15), 4.19 (1H, d, J=6.3 Hz, CH-9), 4.61 (1H, dd, J=10.9 Hz, J=4.9 Hz, 
CH-12), 7.25 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-6), 7.35 (1H, dd, J=7.6 Hz, J=7.6 Hz, 
CH-5), 7.45 (1H, d, J=7.6 Hz, CH-7), 7.94 (1H, d, J=7.6 Hz, CH-4) ppm; 13C NMR (100 MHz, CDCl3) δ 
21.4 (CH2-14), 25.3 (CH2-8), 27.5 (CH2-13), 28.2 (3×CH3-20), 44.3 (CH2-15), 56.1 (CH-9), 66.4 (CH-12), 
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76.1 (Cq-11), 84.7 (Cq-19), 114.8 (CH-4), 116.4 (Cq-3), 119.0 (CH-7), 122.9 (CH-6), 125.7 (CH-5), 127.1 
(Cq-3a), 135.3 (Cq-2), 136.1 (Cq-7a), 149.8 (CC=O-18), 168.7 (CC=O-17) ppm; IR (cm
-1): max = 1735 
(C=O), 1638 (C=O), 1452; MS (ES): m/z (%): 402/404 (100/35) [M + H]+; HRMS (ESI): calcd. for 
C21H25ClN3O3
+ [M + H]+: 402.1579; found: 402.1590. 
7.3.2. Benzyl protecting group 
A solution of α-chloroamine 237b (1 equiv., 0.33 mmol, 100 mg) in dry DMF (5 mL) was cooled to 0 °C 
and sodium hydride (2.5 equiv., 0.83 mmol, 33 mg) was added. After 15 minutes benzyl bromide 
(2.5 equiv., 0.83 mmol, 0.10 mL) was added to the solution. The mixture was allowed to warm to 
room temperature and was stirred for one day. Then, EtOAc (15 mL) was added and the organic 
phase was washed with brine (5×10 mL) and water (2×10 mL). Drying the organic phase over 
magnesium sulfate and concentration of the solvent under reduced pressure yielded the crude 
product. Compound 244 was isolated with pTLC as a white foam. 
(6R,13S,13aS)-12-benzyl-13-chloro-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 244 
Yield 56% (73 mg); white foam; m.p. 209-211 °C; 1H NMR (400 MHz, CDCl3) δ 
1.50-1.62 (1H, m, CHaHb-14), 1.80-1.95 (3H, m, CH2-13, CHaHb-14), 2.67 (1H, s, 
NH-10), 2.27-2.80 (1H, m, CHaHb-15), 3.13 (1H, d, J=16.3 Hz, CHaHb-8), 3.26 
(1H, dd, J=16.3 Hz, J=6.5 Hz, CHaHb-8), 3.38 (1H, dd, J=11.2 Hz, J=5.2 Hz, 
CH-12), 3.96-4.20 (1H, m, CHaHb-15), 4.19 (1H, d, J=6.5 Hz, CH-9), 5.66 (1H, d, 
J=17.0 Hz, CHaHb-18), 5.74 (1H, d, J=17.0 Hz, CHaHb-18), 6.98-7.02 (2H, m, CH-20, CH-24), 7.12-7.27 
(6H, m, CH-5, CH-6, CH-7, CH-21, CH-22, CH-23), 7.54 (1H, d, J=7.9 Hz, CH-4) ppm; 13C NMR (100 MHz, 
CDCl3) δ 21.2 (CH2-14), 25.7 (CH2-8), 27.8 (CH2-13), 44.1 (CH2-15), 47.9 (CH2-18), 57.7 (CH-9), 67.5 
(CH-12), 77.0 (Cq-11), 110.2 (CH-7), 110.4 (Cq-3), 119.3 (CH-4), 120.3 (CH-5), 123.7 (CH-6), 125.6 
(Cq-3a), 126.3 (CH-20, CH-24), 127.4 (CH-22), 128.7 (CH-21, CH-23), 133.9 (Cq-2), 137.6 (Cq-7a*), 137.8 
(Cq-19*), 169.0 (CC=O-17) ppm (Signals with the same superscript (*) may be interchanged); IR (cm
-1): 
max = 1632 (C=O), 1454; MS (ES): m/z (%): 392/394 (100/35) [M + H]+; HRMS (ESI): calcd. for 
C23H23ClN3O
+ [M + H]+: 392.1524; found: 392.1532. 
7.3.3. Methyl groups 
A solution of α-chloroamine 237b (1 equiv., 2.0 mmol, 604 mg) in dry DMF (10 mL) was cooled to 0 °C 
and sodium hydride (2.5 equiv., 5.0 mmol, 200 mg) was added. After 15 minutes methyl iodide 
(2.5 equiv., 5.0 mmol, 0.31 mL)was added. The mixture was allowed to warm to room temperature 
and was stirred for one day. Then EtOAc (20 mL) was added and the organic phase was washed with 
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brine (5×15 mL) and water (2×15 mL). Drying the organic phase over magnesium sulfate and 
removal of the solvent under reduced pressure yielded the crude product. Compound 247 was 
isolated as a white foam via column chromatography using EtOAc as eluent. 
(6R,13S,13aS)-13-chloro-12,14-dimethyl-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 247 
Yield 48% (317 mg); white foam; m.p. 230-232 °C; 1H NMR (400 MHz, CDCl3) δ 
1.75-1.90 (1H, m, CHaHb-14), 1.95-2.22 (3H, m, CH2-13, CHaHb-14), 2.68 (3H, s, 
CH3-19), 2.92 (1H, d, J=16.8 Hz, CHaHb-8), 2.89-2.98 (1H, m, CHaHb-15), 3.35 
(1H, dd, J=16.8 Hz, J=6.4 Hz, CHaHb-8), 3.74 (1H, dd, J=11.1 Hz, J=5.1 Hz, 
CH-12), 3.94 (3H, s, CH3-18), 4.03 (1H, d, J=6.4 Hz, CH-9), 4.09-4.18 (1H, m, CHaHb-15), 7.13 (1H, dd, 
J=7.7 Hz, J=7.7 Hz, CH-5), 7.28 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.34 (1H, d, J=7.7 Hz, CH-7), 7.51 
(1H, d, J=7.7 Hz, CH-4) ppm; 13C NMR (100 MHz, CDCl3) δ 19.8 (CH2-8), 21.5 (CH2-14), 28.6 (CH2-13), 
32.3 (CH3-18), 36.6 (CH3-19), 44.4 (CH2-15), 64.2 (CH-9), 68.8 (CH-12), 82.2 (Cq-11), 108.6 (Cq-3), 109.4 
(CH-7), 119.2 (CH-4), 119.9 (CH-5), 123.2 (CH-6), 125.3 (Cq-3a), 131.3 (Cq-2), 137.9 (Cq-7a), 169.4 
(CC=O-17) ppm; IR (cm
-1): max = 1634 (C=O), 1466; MS (ES): m/z (%): 330/332 (100/33) [M + H]+; 
HRMS (ESI): calcd. for C18H21ClN3O
+ [M + H]+: 330.1368; found: 330.1372. 
7.4. Synthesis of α-chloroamine derivatives 
7.4.1. Procedure for the synthesis of derivative 253 
α-Chloroamine 237b (1.0 equiv., 1 mmol, 302 mg) was suspended in 10 mL of 2 M aq. NaOH and 
refluxed until the conversion was complete. The aqueous phase was then neutralized with 2 M HCl 
(10 mL), resulting in a suspension which was extracted three times with chloroform (10 mL). The 
white precipitate moved to the organic phase (suspension). The layers were separated and the 
organic phase was filtered off to yield compound 253 as a white powder (65%). 
(6R,13S,13aS)-13-hydroxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 253 
Yield 65% (184 mg); white powder; m.p. >260 °C; [α]D
20 = +92.8 (c=0.42 in 
DMF); 1H NMR (400 MHz, DMSO-d6) δ 1.21-1.34 (1H, m, CHaHb-13), 1.54-1.72 
(2H, m, CH2-14), 2.04-2.13 (1H, m, CHaHb-13), 2.81 (1H, dd, J=15.1 Hz, J=1.4 Hz, 
CHaHb-8), 2.91 (1H, dd, J=15.1 Hz, J=5.1 Hz, CHaHb-8), 3.07 (1H, ddd, J=11.6 Hz, 
J=9.3 Hz, J=9.3 Hz, CHaHb-15), 3.17 (1H, ddd, J=11.6 Hz, J=9.0 Hz, J=2.5 Hz, CHaHb-15), 3.34 (1H, s, 
NH-10), 3.79 (1H, dd, J=11.2 Hz, J=5.1 Hz, CH-12), 3.85 (1H, d, J=5.1 Hz, CH-9), 6.48 (1H, s, OH-18), 
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6.93 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=1.0 Hz, CH-5), 7.04 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=1.0 Hz, CH-6), 
7.31 (1H, d, J=7.7 Hz, CH-7), 7.37 (1H, d, J=7.7 Hz, CH-4), 11.04 (1H, s, NH-1) ppm; 13C NMR (100 MHz, 
DMSO-d6) δ 21.7 (CH2-14), 26.6 (CH2-8), 28.2 (CH2-13), 44.7 (CH2-15), 56.1 (CH-9), 68.2 (CH-12), 80.1 
(Cq-11), 108.2 (Cq-3), 111.5 (CH-7), 118.1 (CH-4), 118.3 (CH-5), 121.0 (CH-6), 126.1 (Cq-3a), 133.6 
(Cq-2), 136.0 (Cq-7a), 169.9 (CC=O-17) ppm; IR (cm
-1): max = 3262 (NH), 1593 (C=O), 1452; MS (ES): 
m/z (%) = 284 (100) [M + H]+; HRMS (ESI): calcd. for C16H18N3O2
+
 [M + H]
+: 284.1394; found: 284.1401. 
7.4.2. Procedure for the synthesis of derivative 240 
α-Chloroamine 237b (1 equiv., 1 mmol, 302 mg) was suspended in MeOH (10 mL). A sodium 
methoxide solution in MeOH (1 equiv., 1 mmol, 0.25 mL of 4 M solution) was added and the mixture 
was refluxed for two and a half hours. Next, the reaction was quenched by the addition of water and 
the solvent was evaporated under reduced pressure. The residual white precipitate was redissolved 
in chloroform (10 mL) and washed three times with water. After drying the organic phase over 
MgSO4, the solvent was removed by evaporation to give compound 240 as a white solid (96%). 
(6R,13S,13aS)-13-methoxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 240 
Yield 96% (285 mg); white solid; m.p. >260 °C; [α]D
20 = -69.8 (c=0.35 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.55-1.68 (1H, m, CHaHb-13), 1.72-1.86 (1H, m, 
CHaHb-14), 1.92-2.04 (2H, m, CHaHb-13, CHaHb-14), 2.23 (1H, s, NH-10), 2.93 
(1H, ddd, J=12.2 Hz, J=10.1 Hz, J=4.8 Hz, CHaHb-15), 3.02 (1H, dd, J=15.9 Hz, 
J=1.3 Hz, CHaHb-8), 3.20 (1H, dd, J=15.9 Hz, J=6.5 Hz, CHaHb-8), 3.35 (3H, s, CH3-18), 3.58 (1H, dd, 
J=11.8 Hz, J=4.9 Hz, CH-12), 3.94-4.03 (1H, m, CHaHb-15); 4.17 (1H, dd, J=6.5 Hz, J=1.3 Hz, CH-9), 7.13 
(1H, ddd, J=7.8 Hz, J=7.8 Hz, J=1.0 Hz, CH-5), 7.21 (1H, ddd, J=7.8 Hz, J=7.8 Hz, J=1.0 Hz, CH-6), 7.36 
(1H, d, J=7.8 Hz, CH-7), 7.50 (1H, d, J=7.8 Hz, CH-4), 8.09 (1H, s, NH-1) ppm; 13C NMR (100 MHz, 
CDCl3) δ 21.5 (CH2-14), 24.4 (CH2-8), 25.5 (CH2-13), 43.5 (CH2-15), 51.3 (CH3-18), 57.8 (CH-9), 66.6 
(CH-12), 83.6 (Cq-11), 111.2 (Cq-3), 111.3 (CH-7), 119.0 (CH-4), 120.0 (CH-5), 122.8 (CH-6), 126.9 
(Cq-3a), 133.2 (Cq-2), 136.1 (Cq-7a), 171.3 (CC=O-17) ppm; IR (cm
-1): max = 3150 (NH), 1620 (C=O), 
1462; MS (ES): m/z (%) = 298 (100) [M + H]+, 595 (75); HRMS (ESI): calcd. for C17H20N3O2
+ [M + H]+: 
298.1550; found: 298.1556. 
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7.4.3. General procedure for the synthesis of derivatives 254-262 and 265  
The nucleophile (3 equiv., 1.5 mmol or 1.5 equiv., 0.75 mmol) was dissolved in THF (10 mL) at room 
temperature. The solution was cooled to 0 °C and sodium hydride (3 equiv., 1.5 mmol, 60 mg or 
1.5 equiv., 0.75 mmol, 30 mg respectively, 60% in mineral oil) was added. After stirring for 
15 minutes at 0 °C, α-chloroamine 237b (1 equiv., 0.5 mmol, 151 mg) was added to the mixture. The 
mixture was allowed to warm up to room temperature and was stirred until the conversion was 
complete. An ammonia chloride solution (10 mL) and EtOAc (15 mL) were added subsequently. The 
layers were separated and the aqueous phase was extracted with 10 mL EtOAc. The combined 
organic phases were washed 3 times with water (10 mL). The organic phase was dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. When necessary, further 
purification was done by normal-phase chromatography using (a mixture of) EtOAc (and methanol) 
as eluent or reversed-phase chromatography using a gradient of water and acetonitrile as eluent to 
provide the desired compound. 
(6R,13S,13aS)-13-allyloxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 254  
Using the general procedure with 3 equivalents of allyl alcohol, compound 
254 was obtained without further purification. Yield 86% (140 mg); yellow 
powder; m.p. 258-260 °C; [α]D
20 = -28.4 (c=0.32 in CHCl3); 
1H NMR (400 MHz, 
CDCl3) δ 1.58-1.71 (1H, m, CHaHb-13), 1.71-1.83 (1H, m, CHaHb-14), 1.91-2.05 
(2H, m, CHaHb-13, CHaHb-14), 2.60 (1H, s, NH-10), 2.90 (1H, ddd, J=12.1 Hz, 
J=10.3 Hz, J=4.6 Hz, CHaHb-15), 3.01 (1H, dd, J=15.9 Hz, J=1.0 Hz, CHaHb-8), 3.18 (1H, dd, J=15.9 Hz, 
J=6.4 Hz, CHaHb-8), 3.61 (1H, dd, J=11.7 Hz, J=4.9 Hz, CH-12), 3.92 (1H, ddt, J=13.7 Hz, J=5.1 Hz, 
J=1.7 Hz, CHaHb-18), 3.96 (1H, ddd, J=12.1 Hz, J=9.4 Hz, J=6.1 Hz, CHaHb-15), 4.15 (1H, dd, J=5.1 Hz, 
J=1.0 Hz, CH-9), 4.31 (ddt, J=13.7 Hz, J=4.9 Hz, J=1.7 Hz, 1H, CHaHb-18), 5.14 (1H, ddt, J=10.5 Hz, 
J=1.7 Hz, J=1.7 Hz, CHaHb-20), 5.28 (1H, ddt, J=17.1 Hz, J=1.7 Hz, J=1.7 Hz, CHaHb-20), 5.92 (1H, dddd, 
J=17.1 Hz, J=10.5 Hz, J=5.1 Hz, J=4.9 Hz, CH-19), 7.10 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=0.6 Hz, CH-5), 
7.18 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=0.6 Hz, CH-6), 7.33 (1H, d, J=7.7 Hz, CH-7), 7.48 (1H, d, J=7.7 Hz, 
CH-4), 8.45 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.5 (CH2-14), 24.4 (CH2-8), 25.6 (CH2-13), 
43.6 (CH2-15), 57.9 (CH-9), 64.4 (CH2-18), 66.7 (CH-12), 83.6 (Cq-11), 110.8 (Cq-3), 111.4 (CH-7), 115.6 
(CH2-20), 119.0 (CH-4), 119.9 (CH-5), 122.7 (CH-6), 126.9 (Cq-3a), 133.6 (Cq-2), 135.3 (CH-19), 136.2 
(Cq-7a), 171.4 (CC=O-17) ppm; IR (cm
-1): max = 3266 (NH), 1628 (C=O), 1457; MS (ES): m/z (%) = 324 
(100) [M + H]+, 647 (65); HRMS (ESI): calcd. for C19H22N3O2
+ [M + H]+: 324.1707; found: 324.1700.  
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(6R,13S,13aS)-13-(3-methylbut-2-en-1-yl)oxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-
epiminopyrrolo[1',2':1,2]azocino[4,5-b]indol-5-one 255  
Following the general procedure using 1.5 equivalents of prenyl alcohol, 255 
was obtained after purification by reversed-phase chromatography 
(2 column volumes (CVs) 10% ACN, over 16 CVs to 40% ACN then during 
8 CVs 40% ACN) as a yellow powder. Yield 33% (58 mg); yellow powder; m.p. 
116-124 °C; [α]D
20 = -66.5 (c=0.53 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.53 
(3H, s, CH3-21*), 1.57-1.70 (1H, m, CHaHb-13), 1.73 (3H, s, CH3-22*), 1.71-1.84 
(1H, m, CHaHb-14), 1.93-2.04 (2H, m, CHaHb-13, CHaHb-14), 2.31 (1H, s, NH-10), 2.88-2.96 (1H, m, 
CHaHb-15), 3.02 (1H, d, J=15.9 Hz, CHaHb-8), 3.20 (1H, dd, J=15.9 Hz, J=6.0 Hz, CHaHb-8), 3.58 (1H, dd, 
J=11.8 Hz, J=4.9 Hz, CH-12), 3.90-4.02 (2H, m, CHaHb-18, CHaHb-15), 4.17 (1H, d, J=6.0 Hz, CH-9), 4.27 
(1H, dd, J=11.9 Hz, J=6.5 Hz, CHaHb-18), 5.34 (1H, t, J=6.5 Hz, CH-19), 7.12 (1H, dd, J=7.7 Hz, J=7.7 Hz, 
CH-5), 7.21 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.35 (1H, d, J=7.7 Hz, CH-7), 7.35 (1H, d, J=7.7 Hz, CH-4), 
8.10 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 18.1 (CH3-21*), 21.5 (CH2-14), 24.5 (CH2-8), 25.6 
(CH2-13), 25.8 (CH3-22*), 43.6 (CH2-15), 57.9 (CH-9), 60.7 (CH2-18), 66.7 (CH-12), 83.4 (Cq-11), 110.9 
(Cq-3), 111.2 (CH-7), 119.0 (CH-4), 119.9 (CH-5), 121.3 (CH-19), 122.7 (CH-6), 126.9 (Cq-3a), 133.8 
(Cq-2), 136.1 (Cq-7a**), 136.5 (Cq-20**), 171.3 (CC=O-17) ppm (The signals with the same superscript 
(*) may be interchanged); IR (cm-1): max = 3252 (NH), 1627 (C=O), 1446; MS (ES): m/z (%) = 352 
(100) [M + H]+, 703 (30); HRMS (ESI): calcd. for C21H26N3O2
+ [M + H]+: 352.2020; found: 352.2029. 
(6R,13S,13aS)-13-phenoxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 256 
Following the general procedure using 3 equivalents of phenol, 256 was 
obtained as the insoluble residue from rinsing the crude with acetone and 
methanol. Yield 19% (55 mg); white powder; m.p. 136-140 °C; [α]D
20 = -34.1 
(c=0.26 in THF); 1H NMR (400 MHz, DMSO-d6) δ 1.74-1.87 (1H, m, CHaHb-14), 
1.88-2.10 (3H, m, CH2-13, CHaHb-14), 2.79 (1H, d, J=15.7 Hz, CHaHb-8), 2.87 
(1H, ddd, J=11.7 Hz, J=10.2 Hz, J=4.8 Hz, CHaHb-15), 3.08 (1H, dd, J=15.7 Hz, J=6.1 Hz, CHaHb-8), 3.71 
(1H, dd, J=11.2 Hz, J=5.3 Hz, CH-12), 3.82 (1H, ddd, J=11.7 Hz, J=9.2 Hz, J=6.2 Hz, CHaHb-15), 3.95 (1H, 
ddd, J=6.1 Hz, J=4.1 Hz, J=1.3 Hz, CH-9), 4.10 (1H, d, J=4.1 Hz, NH-10), 6.86 (1H, td, J=6.8 Hz, J=1.7 Hz, 
CH-21), 6.98 (1H, ddd, J=7.8 Hz, J=7.8 Hz, J=1.0 Hz, CH-5), 7.04-7.14 (5H,m, 1H, m, CH-6, CH-19, 
CH-20, CH-22, CH-23), 7.26 (1H, d, J=7.8 Hz, CH-7), 7.43 (1H, d, J=7.8 Hz, CH-4), 11.14 (1H, s, NH-1) 
ppm; 13C NMR (100 MHz, DMSO-d6) δ 21.2 (CH2-14), 23.9 (CH2-8), 24.9 (CH2-13), 43.3 (CH2-15), 57.5 
(CH-9), 66.9 (CH-12), 85.1 (Cq-11), 108.3 (Cq-3), 111.7 (CH-7), 118.3 (CH-4), 118.8 (CH-5), 119.4 (CH-
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19, CH-23), 121.6 (CH-6, CH-21), 126.1 (Cq-3a), 128.6 (CH-20, CH-22), 134.3 (Cq-2), 136.3 (Cq-7a), 
155.0 (Cq-18), 170.6 (CC=O-17) ppm; IR (cm
-1): max = 3164 (NH), 1610 (C=O), 1456; MS (ES): m/z (%) = 
360 (100) [M + H]+; HRMS (ESI): calcd. for C22H22N3O2
+ [M + H]+: 360.1707; found: 360.1700. 
(6R,13S,13aS)-13-benzyloxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 257  
Following the general procedure using 1.5 equivalents of benzyl alcohol, 257 
was obtained via purification by pTLC as a white solid. Yield 26% (49 mg); 
white solid; Rf=0.41 (EtOAc); m.p. 134-138 °C; [α]D
20 = -20.9 (c=0.42 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.67-1.86 (2H, m, CHaHb-13, CHaHb-14), 1.96-2.12 
(2H, m, CHaHb-13, CHaHb-14), 2.37 (1H, s, NH-10), 2.95 (1H, ddd, J=12.2 Hz, 
J=10.2 Hz, J=4.7 Hz, CHaHb-15), 3.04 (1H, dd, J=15.9 Hz, J=1.4 Hz, CHaHb-8), 
3.23 (1H, dd, J=15.9 Hz, J=6.5 Hz, CHaHb-8), 3.66 (1H, dd, J=11.7 Hz, J=4.9 Hz, CH-12), 3.99 (1H, ddd, 
J=12.2 Hz, J=9.4 Hz, J=6.1 Hz, CHaHb-15), 4.18 (1H, dd, J=6.1 Hz, J=1.4 Hz, CH-9), 4.45 (1H, d, J=12.5 Hz, 
CHaHb-18), 4.91 (1H, d, J=12.5 Hz, CHaHb-18), 7.14 (1H, ddd, J=7.6 Hz, J=7.6 Hz, J=1.1 Hz, CH-5), 7.21 
(1H, ddd, J=7.6 Hz, J=7.6 Hz, J=1.1 Hz, CH-6), 7.29-7.38 (6H, m, CH-7, CH-20, CH-21, CH-22, CH-23, 
CH-24), 7.52 (1H, d, J=7.6 Hz, CH-4), 8.05 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.5 
(CH2-14), 24.4 (CH2-8), 25.7 (CH2-13), 43.6 (CH2-15), 57.9 (CH-9), 65.4 (CH2-18), 66.7 (CH-12), 83.8 
(Cq-11), 111.2 (Cq-3), 111.4 (CH-7), 119.0 (CH-4), 120.0 (CH-5), 122.8 (CH-6), 126.9 (CH-20, CH-24, 
Cq-3a), 127.5 (CH-22), 128.5 (CH-21, CH-23), 133.4 (Cq-2), 136.1 (Cq-7a), 138.7 (Cq-19), 171.3 (CC=O-17) 
ppm; IR (cm-1): max = 3258 (NH), 1620 (C=O), 1454; MS (ES): m/z (%) = 374 (100) [M + H]+, 747 (25); 
HRMS (ESI): calcd. for C23H24N3O2
+ [M + H]+: 374.1863; found: 374.1861. 
(6R,13R,13aS)-13-allylamino-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 258  
Using the general procedure using 3 equivalents of allylamine, compound 258 
was obtained without further purification. Yield 77% (124 mg); yellow 
powder; m.p. 206-210 °C; [α]D
20 = -28.3 (c=0.34 in CHCl3); 
1H NMR (400 MHz, 
CDCl3) δ 1.50-1.73 (2H, m, CHaHb-13, NH-10), 1.73-1.88 (1H, m, CHaHb-14), 
1.88-1.97 (1H, m, CHaHb-13), 1.97-2.12 (2H, m, 1H, m, CHaHb-14, NH-18), 2.94 
(1H, ddd, J=12.2 Hz, J=10.2 Hz, J=4.6 Hz, CHaHb-15), 3.03 (1H, dd, J=16.1 Hz, J=1.4 Hz, CHaHb-8), 3.02-
3.13 (1H, m, CHaHb-19), 3.13 (1H, dd, J=16.1 Hz, J=6.4 Hz, CHaHb-8), 3.39 (1H, ddt, J=14.6 Hz, J=6.4 Hz, 
J=1.5 Hz, CHaHb-19), 3.50 (1H, dd, J=11.9 Hz, J=4.6 Hz, CH-12), 4.01 (1H, ddd, J=12.2 Hz, J=9.5 Hz, 
J=6.2 Hz, CHaHb-15), 4.18 (1H, dd, J=6.4 Hz, J=1.4 Hz, CH-9), 5.11 (1H, ddt, J=10.3 Hz, J=1.5 Hz, 
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J=1.5 Hz, CHaHb-21), 5.23 (1H, ddt, J=17.1 Hz, J=1.5 Hz, J=1.5 Hz, CHaHb-21), 5.92 (1H, dddd, J=17.1 Hz, 
J=10.3 Hz, J=6.4 Hz, J=4.8 Hz, CH-20), 7.11 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=1.0 Hz, CH-5), 7.19 (1H, ddd, 
J=7.7 Hz, J=7.7 Hz, J=1.0 Hz, CH-6), 7.35 (1H, d, J=7.7 Hz, CH-7), 7.49 (1H, d, J=7.7 Hz, CH-4), 8.20 (1H, 
s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.5 (CH2-14), 25.1 (CH2-8, CH2-13), 43.2 (CH2-15), 44.7 
(CH2-19), 57.1 (CH-9), 67.1 (CH-12), 67.8 (Cq-11), 110.0 (Cq-3), 111.2 (CH-7), 115.6 (CH2-21), 118.8 
(CH-4), 119.7 (CH-5), 122.5 (CH-6), 127.3 (Cq-3a), 134.9 (Cq-2), 135.6 (Cq-7a), 136.9 (CH-20), 170.9 
(CC=O-17) ppm; IR (cm
-1): max = 3273 (NH), 1613 (C=O), 1455; MS (ES): m/z (%) = 323 (100) [M + H]+; 
HRMS (ESI): calcd. for C19H23N4O
+ [M + H]+: 323.1866; found: 323.1881. 
(6R,13S,13aS)-13-phenylamino-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 259  
Following the general procedure using 3 equivalents of aniline, 259 was 
obtained as the insoluble residue from rinsing the crude with acetonitrile. 
Yield 24% (43 mg); brown powder; m.p. 198-202 °C; [α]D
20 = +108.9 (c=0.21 in 
THF); 1H NMR (400 MHz, DMSO-d6) δ 1.78-1.82 (1H, m, CHaHb-14), 1.82-1.98 
(2H, m, 1H, m, CHaHb-13, CHaHb-14), 2.12-2.21 (1H, m, CHaHb-13), 2.74-2.86 
(2H, m, CHaHb-8, CHaHb-15), 3.07 (1H, dd, J=15.5 Hz, J=6.2 Hz, CHaHb-8), 3.51 
(1H, d, J=3.8 Hz, NH-10), 3.53 (1H, dd, J=11.2 Hz, J=4.7 Hz, CH-12), 3.78-3.88 (2H, m, CH-9, CHaHb-15), 
5.51 (1H, s, NH-18), 6.44-6.56 (1H, m, CH-22), 6.86-6.92 (4H, m, CH-20, CH-21, CH-23, CH-24), 6.94 
(1H, ddd, J=7.6 Hz, J=7.6 Hz, J=1.2 Hz, CH-5), 7.00 (1H, ddd, J=7.6 Hz, J=7.6 Hz, J=1.2 Hz, CH-6), 7.25 
(1H, d, J=7.6 Hz, CH-7), 7.39 (1H, d, J=7.6 Hz, CH-4), 10.63 (1H, s, NH-1) ppm; 13C NMR (100 MHz, 
DMSO-d6) δ 21.2 (CH2-14), 24.4 (CH2-8), 24.6 (CH2-13), 42.8 (CH2-15), 56.0 (CH-9), 66.1 (Cq-11), 67.2 
(CH-12), 107.4 (Cq-3), 111.6 (CH-7), 116.2 (CH-20, CH-24), 117.3 (CH-22), 117.9 (CH-4), 118.5 (CH-5), 
120.9 (CH-6), 126.5 (Cq-3a), 127.9 (CH-21, CH-23), 135.8 (Cq-7a), 136.9 (Cq-2), 145.8 (Cq-19), 170.9 
(CC=O-17) ppm; IR (cm
-1): max = 3195 (NH), 1601 (C=O), 1498, 1456; MS (ES): m/z (%) = 359 (100) 
[M + H]+, 717 (25); HRMS (ESI): calcd. for C22H23N4O
+ [M + H]+: 359.1866; found: 359.1877. 
(6R,13R,13aS)-13-benzylamino-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 260  
Following the general procedure using 1.5 equivalents of benzylamine, 260 
was obtained on purification by pTLC as a white powder. Yield 28% (52 mg); 
white powder ; Rf=0.37 (EtOAc + 5% MeOH); m.p. 142-148 °C; [α]D
20 = +0.4 
(c=0.40 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.58-1.72 (1H, m, CHaHb-13), 
1.72-1.85 (1H, m, CHaHb-14), 1.85-2.21 (4H, m, NH-10, CHaHb-13, CHaHb-14, 
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NH-18), 2.92 (1H, ddd, J=12.2 Hz, J=10.2 Hz, J=4.6 Hz, CHaHb-15), 3.05 (1H, dd, J=16.1 Hz, J=1.3 Hz, 
CHaHb-8), 3.17 (1H, dd, J=16.1 Hz, J=6.5 Hz, CHaHb-8), 3.53 (1H, dd, J=11.8 Hz, J=4.6 Hz, CH-12), 3.62 
(1H, d, J=13.5 Hz, CHaHb-19), 3.98 (1H, d, J=13.5 Hz, CHaHb-19), 3.95-4.03 (1H, m, CHaHb-15), 4.19 (1H, 
dd, J=6.4 Hz, J=1.3 Hz, CH-9), 7.11 (1H, ddd, J=7.6 Hz, J=7.6 Hz, J=1.1 Hz, CH-5), 7.19 (1H, ddd, J=7.6 
Hz, J=7.6 Hz, J=1.1 Hz, CH-6), 7.25-7.36 (6H, m, CH-7, CH-21, CH-22, CH-23, CH-24, CH-25), 7.50 (1H, 
d, J=7.6 Hz, CH-4), 8.32 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.5 (CH2-14), 25.1 (CH2-8*), 
25.2 (CH2-13*), 43.2 (CH2-15), 46.2 (CH2-19), 57.1 (CH-9), 67.2 (CH-12), 67.9 (Cq-11), 110.1 (Cq-3), 
111.2 (CH-7), 118.7 (CH-4), 119.7 (CH-5), 122.5 (CH-6), 127.2 (CH-23), 127.3 (Cq-3a), 127.7 (CH-21, 
CH-25), 128.6 (CH-22, CH-24), 134.8 (Cq-2), 135.7 (Cq-7a), 140.2 (Cq-20), 170.9 (CC=O-17) ppm (The 
signals with the same superscript (*) may be interchanged); IR (cm-1): max = 3291 (NH), 1622 (C=O), 
1456; MS (ES): m/z (%) = 373 (100) [M + H]+; HRMS (ESI): calcd. for C23H25N4O
+ [M + H]+: 373.2023; 
found: 373.2019. 
(6R,13R,13aS)-13-((naphthalen-1-ylmethyl)amino)-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-
epiminopyrrolo[1',2':1,2]azocino[4,5-b]indol-5-one 261 
Following the general procedure using 3 equivalents of 
1-napthylmethylamine, 261 was obtained on purification by reversed-phase 
chromatography using a H2O/ACN gradient (during 10 CV 30% ACN, over 
20 CV to 80% ACN) as a white powder. Yield 36% (76 mg); white powder ; 
m.p. >260 °C; [α]D
25 = -44.5 (c=0.64 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 
1.60-2.06 (5H, m, CH2-13, CH2-14, NH-10*), 2.22 (1H, br s, NH-18*), 2.90-2.98 
(1H, m, CHaHb-15), 3.09 (1H, d, J=15.9 Hz, CHaHb-8), 3.24 (1H, dd, J=15.9 Hz, J=6.3 Hz, CHaHb-8), 3.52-
3.59 (H, m, CH-12), 3.96-4.06 (2H, m, CHaHb-15, CHaHb-19), 4.24 (1H, d, J=6.3 Hz, CH-9), 4.53 (1H, d, 
J=13.9 Hz, CHaHb-19), 7.13 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-5), 7.21 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-6), 
7.33 (1H, d, J=7.6 Hz, CH-7), 7.42-7.57 (5H, m, CH-4, CH-21, CH-22, CH-25, CH-26), 7.79 (1H, d, 
J=8.2 Hz, CH-23), 7.85-7.90 (1H, m, CH-24), 7.94-8.00 (1H, m, CH-27), 8.19 (1H, s, NH-1) ppm; 
13C NMR (100 MHz, CDCl3) δ 21.5 (CH2-14), 25.1 (CH2-8, CH2-13), 43.3 (CH2-15), 43.4 (CH2-19), 57.1 
(CH-9), 67.2 (CH-12), 68.1 (Cq-11), 110.1 (Cq-3), 111.3 (CH-7), 118.8 (CH-4), 119.8 (CH-5), 122.5 (CH-6), 
123.2 (CH-27), 125.3 (CH-21*), 125.5 (CH-22*), 125.9 (CH-25*), 126.4 (CH-26*), 127.3 (Cq-3a), 128.0 
(CH-23), 128.9 (CH-24), 131.4 (Cq-27a), 133.8 (Cq-23a), 134.9 (Cq-2), 135.7 (Cq-7a**), 135.9 (Cq-20**), 
171.1 (CC=O-17) ppm (The signals with the same superscript (*,**) may be interchanged); IR (cm
-1): 
max = 1609 (C=O), 1457; MS (ES): m/z (%) = 423 (100) [M + H]+; HRMS (ESI): calcd. for C27H27N4O
+ 
[M + H]+: 423.2179; found: 423.2209. 
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(6R,13R,13aS)-13-((2-(1H-indol-3-yl)ethyl)amino)-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-
epiminopyrrolo[1',2':1,2]azocino[4,5-b]indol-5-one 262 
Following the general procedure using 3 equivalents of tryptamine, 262 was 
obtained on purification by reversed-phase chromatography using a 
H2O/ACN gradient (during 10 CV 10% ACN, over 20 CV to 50% ACN, during 10 
CV 50% ACN) as a white powder. Yield 31% (66 mg); white powder ; m.p. 
248-250 °C; [α]D
25 = -118.6 (c=0.41 in CHCl3); 
1H NMR (400 MHz, DMSO-d6) δ 
1.63-1.80 (3H, m, CH2-13, CHaHb-14), 1.81-1.92 (1H, m, CHaHb-14), 2.28-2.35 
(1H, m, NH-18), 2.50-2.58 (1H, m, CHaHb-19), 2.66 (1H, d, J=15.2 Hz, CHaHb-20), 2.75-3.05 (5H, m, 
CH2-8, CHaHb-15, CHaHb-19, CHaHb-20), 3.14 (1H, d, J=3.5 Hz, NH-10), 3.35-3.41 (1H, m, CH-12), 3.72-
3.85 (1H, m, CH-9), 6.88 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5), 6.94 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5’), 
6.98-7.07 (3H, m, CH-2’, CH-6, CH-6’), 7.29 (1H, d, J=7.8 Hz, CH-7’), 7.34 (2H, d, J=7.8 Hz, CH-4’, CH-7), 
7.47 (1H, d, J=7.8 Hz, CH-4), 10.72 (1H, s, NH-1’), 10.77 (1H, s, NH-1) ppm; 13C NMR (100 MHz, 
DMSO-d6) δ 21.7 (CH2-14), 25.0 (CH2-13, CH2-20), 27.0 (CH2-8), 43.3 (CH2-15), 43.6 (CH2-19), 56.6 (CH-
9), 67.6 (CH-12), 68.0 (Cq-11), 108.1 (Cq-3’), 111.7 (CH-7’), 111.9 (CH-7), 113.2 (Cq-3), 118.2 (CH-4’), 
118.5 (CH-5), 118.8 (CH-5’), 118.9 (CH-4), 121.3 (CH-6, CH-6’), 122.7 (CH-2’), 127.1 (Cq-3a’), 127.7 
(Cq-3a), 136.3 (Cq-7a’), 136.7 (Cq-2, Cq-7a), 171.5 (CC=O-17) ppm (The allocation of the signals CHy-X 
and CHy-X‘ may be interchanged); IR (cm
-1): max = 1622 (C=O), 1456; MS (ES): m/z (%) = 426 (100) 
[M + H]+, 703 (30); HRMS (ESI): calcd. for C26H28N5O
+ [M + H]+: 426.2288; found: 426.2300. 
(6R,13S,13aS)-13-allylthio-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 265  
Using general procedure B using 3 equivalents of allyl mercaptan, 265 was 
obtained after purification by pTLC as a white powder. Yield 32% (55 mg); 
white powder; Rf=0.22 (EtOAc); m.p. 136-140 °C; [α]D
20 = -165.26 (c=0.38 in 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.63-1.76 (1H, m, CHaHb-13), 1.76-1.87 
(1H, m, CHaHb-14), 1.91-1.99 (1H, m, CHaHb-13), 1.99-2.07 (1H, m, CHaHb-14), 
2.45 (1H, s, NH-10), 2.95 (1H, ddd, J=12.2 Hz, J=10.2 Hz, J=4.6 Hz, CHaHb-15), 3.01 (1H, dd, J=16.0 Hz, 
J=1.3 Hz, CHaHb-8), 3.02 (1H, ddt, J=13.6 Hz, J=7.4 Hz, J=1.2 Hz, CHaHb-18), 3.16 (1H, dd, J=16.0 Hz, 
J=6.5 Hz, CHaHb-8), 3.29 (1H, ddt, J=13.3 Hz, J=7.0 Hz, J=1.2 Hz, CHaHb-18), 3.58 (1H, dd, J=11.9 Hz, 
J=4.7 Hz, CH-12), 3.99 (1H, ddd, J=12.2 Hz, J=9.5 Hz, J=6.3 Hz, CHaHb-15), 4.06 (1H, dd, J=6.5 Hz, 
J=1.3 Hz, CH-9), 5.01 (1H, ddt, J=9.9 Hz, J=1.2 Hz, J=1.2 Hz, CHaHb-20), 5.04 (1H, ddt, J=17.0 Hz, 
J=1.2 Hz, J=1.2 Hz, CHaHb-20), 5.79 (1H, dddd, J=17.0 Hz, J=9.9 Hz, J=7.4 Hz, J=7.0 Hz, CH-19), 7.13 
(1H, ddd, J=7.8 Hz, J=7.8 Hz, J=1.1 Hz, CH-5), 7.21 (1H, ddd, J=7.8 Hz, J=7.8 Hz, J=1.1 Hz, CH-6), 7.36 
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(1H, d, J=7.8 Hz, CH-7), 7.48 (1H, d, J=7.8 Hz, CH-4), 8.16 (1H, s, NH-1) ppm; 13C NMR (100 MHz, 
CDCl3) δ 21.7 (CH2-14), 24.8 (CH2-8), 26.2 (CH2-13), 31.9 (CH2-18), 43.1 (CH2-15), 55.9 (CH-9), 63.1 
(Cq-11), 67.0 (CH-12), 110.4 (Cq-3), 111.2 (CH-7), 117.9 (CH2-20), 118.9 (CH-4), 120.0 (CH-5), 122.7 
(CH-6), 127.2 (Cq-3a), 134.0 (CH-19), 134.3 (Cq-2), 135.5 (Cq-7a), 170.9 (CC=O-17) ppm; IR (cm
-1): max 
= 3262 (NH), 1614 (C=O), 1448; MS (ES): m/z (%) = 340 (100) [M + H]+, 679 (25); HRMS (ESI): calcd. for 
C19H22N3OS
+ [M + H]+: 340.1478; found: 340.1490. 
7.4.4. Procedure for the synthesis of derivative 267 
A solution of α-chloroamine 237b (1 equiv., 0.5 mmol, 151 mg) in dry THF (10 mL) was cooled 
to -78 °C. Butyllithium (3 equiv, 1.5 mmol, 0.8 mL of 2 M BuLi in hexanes) was added and the mixture 
was allowed to warm to room temperature. After 30 minutes the reaction was quenched by the 
careful addition of water (10 mL). EtOAc (15 mL) was added subsequently and the layers were 
separated. The aqueous layer was extracted with EtOAc (10 mL). The combined organic phases were 
washed 3 times with water (10 mL) and dried over magnesium sulfate. Concentration of the solution 
under reduced pressure yielded a yellow powder. Purification by pTLC using EtOAc as eluent gave 
compound 267 as a white powder. 
(6R,13R,13aS)-13-butyl-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 267 
Yield 12% (19 mg); white powder; Rf=0.11 (EtOAc); m.p. 204-206 °C; 
[α]D
20 = -29.6 (c=0.27 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 0.85 (3H, t, 
J=7.1 Hz, CH3-21), 1.05-1.17 (1H, m, CHaHb-19), 1.24-1.38 (3H, m, CHaHb-19, 
CH2-20), 1.58-2.04 (7H, m, NH-10, CH2-13, CH2-14, CH2-18), 2.87 (1H, ddd, 
J=12.1 Hz, J=9.8 Hz, J=4.4 Hz, CHaHb-15), 3.03 (1H, dd, J=16.1 Hz, J=1.7 Hz, 
CHaHb-8), 3.09 (1H, dd, J=16.1 Hz, J=6.0 Hz, CHaHb-8), 3.33 (1H, dd, J=11.6 Hz, J=4.5 Hz, CH-12), 3.98 
(1H, ddd, J=12.1 Hz, J=9.5 Hz, J=6.0 Hz, CHaHb-15), 4.10 (1H, dd, J=6.0 Hz, J=1.7 Hz, CH-9), 7.09 (1H, 
ddd, J=7.7 Hz, J=7.7 Hz, J=1.1 Hz, CH-5), 7.15 (1H, ddd, J=7.7 Hz, J=7.7 Hz, J=1.1 Hz, CH-6), 7.32 (1H, d, 
J=7.7 Hz, CH-7), 7.46 (1H, d, J=7.7 Hz, CH-4), 8.26 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 14.1 
(CH3-21), 21.7 (CH2-14), 23.3 (CH2-20), 25.7 (CH2-8), 25.8 (CH2-19), 26.0 (CH2-13), 35.0 (CH2-18), 43.0 
(CH2-15), 53.1 (Cq-11), 55.0 (CH-9), 67.9 (CH-12), 108.5 (Cq-3), 111.1 (CH-7), 118.6 (CH-4), 119.8 
(CH-5), 122.1 (CH-6), 127.3 (Cq-3a), 136.0 (Cq-7a), 136.9 (Cq-2), 171.2 (CC=O-17) ppm; IR (cm
-1): max = 
3254 (NH), 1614 (C=O), 1455; MS (ES): m/z (%) = 324 (100) [M + H]+, 647 (85); HRMS (ESI): calcd. for 
C20H26N3O
+ [M + H]+: 324.2070; found: 324.2082. 
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7.4.5. Procedure for the synthesis of derivative 270 
A solution of α-chloroamine 237b (1 equiv., 1.5 mmol, 453 mg) in dry THF (25 mL) was cooled 
to -78 °C. Phenyllithium (2 equiv., 3.0 mmol, 2.0 mL of 1.5 M PhLi in dibutyl ether) was added and the 
mixture was allowed to warm to room temperature. After 3 hours the reaction was quenched by the 
careful addition of ammonia chloride solution (20 mL). The layers were separated and the organic 
phase was washed another 2 times with ammonia chloride solution (20 mL) and dried over 
magnesium sulfate. Concentration under reduced pressure yielded an orange foam. Purification by 
reversed-phase chromatography using a H2O/ACN gradient (during 2 CV 30% ACN, over 20 CV to 80% 
ACN) gave compound 270 as an orange powder. 
(6R,13R,13aS)-13-phenyl-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 270 
Yield 12% (62 mg); orange amorphous powder; m.p. >260 °C; [α]D
20 = -67 
(c=0.2 in DMSO); 1H NMR (400 MHz, DMSO-d6) δ 1.34-1.47 (1H, m, CHaHb-13), 
1.56-1.65 (1H, m, CHaHb-13), 1.70-1.81 (2H, m, CH2-14), 2.79 (1H, d, J=15.5 Hz, 
CHaHb-8), 2.79-2.85 (1H, m, CHaHb-15), 3.04 (1H, dd, J=15.5 Hz, J=6.5 Hz, 
CHaHb-8), 3.80 (1H, d, J=3.8 Hz, NH-10), 3.89-3.98 (2H, m, CH-9, CHaHb-15), 
4.10 (1H, dd, J=11.6 Hz, J=4.8 Hz, CH-12), 6.93 (1H, dd, J=7.5 Hz, J=7.5 Hz, J=0.8 Hz, CH-5), 7.00 (1H, 
dd, J=7.5 Hz, J=7.5 Hz, J=0.8 Hz, CH-6), 7.29-7.38 (3H,m, 1H, m, CH-4, CH-7, CH-21), 7.45 (2H, dd, 
J=7.5 Hz, J=7.5 Hz, CH-20, CH-22), 7.81 (2H, d, J=7.5 Hz, CH-19, CH-23), 10.08 (1H, s, NH-1) ppm; 
13C NMR (100 MHz, DMSO-d6) δ 22.0 (CH2-14), 25.4 (CH2-8), 26.5 (CH2-13), 43.4 (CH2-15), 54.7 
(Cq-11), 55.6 (CH-9), 67.2 (CH-12), 105.9 (Cq-3), 112.1 (CH-7), 118.1 (CH-4), 119.2 (CH-5), 121.5 (CH-6), 
126.8 (Cq-3a), 126.9 (CH-19, CH-23), 127.7 (CH-21), 128.8 (CH-20, CH-22), 136.4 (Cq-7a), 137.9 (Cq-2), 
142.0 (Cq-18), 171.4 (CC=O-17) ppm; IR (cm
-1): max = 3274 (NH), 1633 (C=O), 1456; MS (ES): m/z (%) = 
344 (100) [M + H]+, 687 (85); HRMS (ESI): calcd. for C22H22N3O
+ [M + H]+: 344.1757; found: 344.1765. 
7.4.6. Procedure for the synthesis of derivative 274 
To a solution of α-chloroamine 237b (1 equiv., 1.0 mmol, 302 mg) in dry THF (15 mL), 
vinylmagnesium bromide (3 equiv., 3.0 mmol, 3.0 mL of 1.0M vinylmagnesium bromide in THF) was 
added. After one hour stirring at room temperature, the reaction was quenched by the careful 
addition of ammonia chloride solution (15 mL). The layers were separated and the organic phase was 
washed another two times with ammonia chloride solution (15 mL) and dried over magnesium 
sulfate. Concentration under reduced pressure yielded an brown oil. Purification by reversed-phase 
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chromatography using a H2O/ACN gradient (during 10 CV 10% ACN, over 20 CV to 50% ACN) gave 
compound 274 as a yellow powder. 
(6R,13R,13aS)-13-vinyl-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo[1',2':1,2]azocino-
[4,5-b]indol-5-one 274 
Yield 27% (80 mg); yellow amorphous powder; m.p. >260 °C; [α]D
25 = -56 
(c=0.1 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.54-2.04 (5H, m, CH2-13, CH2-14, 
NH-10), 2.86-2.95 (1H, m, CHaHb-15), 3.10 (1H, d, J=2.3 Hz, CHaHb-8), 3.11 (1H, 
d, J=5.9 Hz, CHaHb-8), 3.54 (1H, dd, J=11.9 Hz, J=4.7 Hz, CH-12), 4.02-4.10 (1H, 
m, CHaHb-15), 4.19 (1H, dd, J=5.9 Hz, J=2.3 Hz, CH-9), 5.43 (1H, d, J=10.9 Hz, CHaHb-19), 5.51 (1H, d, 
J=17.3 Hz, CHaHb-19), 6.30 (1H, dd, J=17.3 Hz, J=10.9 Hz, CH-18), 7.11 (1H, dd, J=7.4 Hz, J=7.4 Hz, CH-
5), 7.18 (1H, dd, J=7.4 Hz, J=7.4 Hz, CH-6), 7.32 (1H, d, J=7.4 Hz, CH-7), 7.48 (1H, d, J=7.4 Hz, CH-4), 
7.97 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.7 (CH2-14), 25.5 (CH2-8), 26.8 (CH2-13), 43.2 
(CH2-15), 54.3 (Cq-11), 54.9 (CH-9), 66.7 (CH-12), 107.9 (Cq-3), 111.0 (CH-7), 117.2 (CH2-19), 118.7 
(CH-4), 119.9 (CH-5), 122.4 (CH-6), 127.1 (Cq-3a), 135.8 (Cq-2*), 135.9 (Cq-7a*), 136.6 (CH-18), 170.6 
(CC=O-17) ppm (The signals with the same superscript (*,**) may be interchanged); IR (cm
-1): max = 
3155 (NH), 1613 (C=O), 1467; MS (ES): m/z (%) = 294 (100) [M + H]+, 587 (65); HRMS (ESI): calcd. for 
C18H20N3O
+ [M + H]+: 294.1601; found: 294.1610. 
7.5. Carbamate and urea derivatives of the α-chloroamine 327b 
7.5.1. Synthesis of the carbamoyl chloride 277 
Diketopiperazine 2b (1 equiv., 3.0 mmol, 0.85 g) was suspended in dry CH2Cl2 (50 mL) and cooled 
with an ice-bath to 0 °C under a nitrogen atmosphere. Diphosgene (3 equiv., 9.0 mmol, 1.1 mL), 
dissolved in dry CH2Cl2 (30 mL), was added dropwise to the suspension. The mixture was heated to 
reflux. The reaction was monitored using HPLC-MS and after complete conversion (ca. 36 h) of the 
intermediate α-chloroamine 237b, the organic phase was washed with saturated NaHCO3 solution 
and with water. The organic phase was dried over magnesium sulfate and concentrated in vacuo to 
yield the crude carbamoyl chloride 277 as a brown foam. 
(6R,13S,13aS)-13-chloro-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carbonyl chloride 277 
Crude yield 90% (0.98 g, ±90% pure); brown foam; 1H NMR (400 MHz, CDCl3) 
δ 1.77-1.91 (1H, m, CHaHb-14), 1.95-2.10 (2H, m, CHaHb-13, CHaHb-14), 2.22-
2.31 (1H, m, CHaHb-13), 3.00-3.08 (1H, m, CHaHb-15), 3.21 (1H, d, J=16.4 Hz, 
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CHaHb-8), 3.39 (1H, dd, J=16.4 Hz, J=6.0 Hz, CHaHb-8), 3.87 (1H, dd, J=11.2 Hz, J=4.7 Hz, CH-12), 3.97-
4.06 (1H, m, CHaHb-15), 5.65 (1H, d, J=6.0 Hz, CH-9), 7.17 (1H, dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.27 (1H, 
dd, J=7.5 Hz, J=7.5 Hz, CH-5), 7.38 (1H, d, J=7.5 Hz, CH-7), 7.49 (1H, d, J=7.5 Hz, CH-4), 8.37 (1H, s, NH-
1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.2 (CH2-14), 24.0 (CH2-8), 28.4 (CH2-13), 44.6 (CH2-15), 64.2 
(CH-9), 69.9 (CH-12), 76.4 (Cq-11), 109.2 (Cq-3), 111.8 (CH-7), 119.4 (CH-4), 120.9 (CH-5), 124.3 (CH-6), 
125.8 (Cq-3a), 131.7 (Cq-2), 136.3 (Cq-7a), 146.7 (CC=O-18), 166.1 (CC=O-17) ppm. 
7.5.2. Carbamate derivatives 
methyl (6R,13S,13aS)-13-chloro-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxylate 278 
Following the general procedure 7.5.1, the crude carbamoyl chloride 277 
was dissolved in a minimal amount of methanol and colourless crystals of 
278 were formed, which turned white after drying to air. Fine fibrous 
crystals were formed. Yield 65% (0.70 g); colourless, fibrous crystals; m.p. 
166-168 °C; [α]D
25 = -74.5 (c=0.51 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.73-1.89 (1H, m, CHaHb-14), 
1.94-2.09 (2H, m, CHaHb-13, CHaHb-14), 2.18-2.28 (1H, m, CHaHb-13), 2.96-3.05 (1H, m, CHaHb-15), 
3.12 (1H, dd, J=16.3 Hz, J=1.3 Hz, CHaHb-8), 3.29 (1H, dd, J=16.3 Hz, J=6.2 Hz, CHaHb-8), 3.77 (3H, s, 
CH3-19), 3.79-3.85 (1H, m, CH-12), 3.97-4.06 (1H, m, CHaHb-15), 5.48 (1H, dd, J=6.2 Hz, J=1.3 Hz, CH-
9), 7.14 (1H, dd, J=8.0 Hz, J=8.0 Hz, CH-5), 7.24 (1H, dd, J=8.0 Hz, J=8.0 Hz, CH-6), 7.36 (1H, d, J=8.0 
Hz, CH-7), 7.48 (1H, d, J=8.0 Hz, CH-4), 8.38 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.3 
(CH2-14), 23.8 (CH2-8), 28.4 (CH2-13), 44.4 (CH2-15), 53.3 (CH3-19), 60.5 (CH-9), 70.1 (CH 12), 74.9 (Cq-
11), 109.5 (Cq-3), 111.6 (CH-7), 119.3 (CH-4), 120.6 (CH-5), 123.9 (CH-6), 126.3 (Cq-3a), 133.2 (Cq-2), 
136.1 (Cq-7a), 155.1 (CC=O-18), 167.7 (CC=O-17) ppm. IR (cm
-1): max = 3177 (NH), 1722 (C=O), 1620 
(C=O), 1439; MS (ES): m/z (%) = 360/362 (100/33) [M + H]+; HRMS (ESI): calcd. for C18H19ClN3O3
+ [M + 
H]+: 360.1109; found: 360.1112. 
benzyl (6R,13S,13aS)-13-chloro-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxylate 279 
Following general procedure 7.5.1 on a 2.0 mmol scale, the crude 
carbamoyl chloride 277 was dissolved in benzyl alcohol (3 equiv., 
6.0 mmol, 0.62 mL). After 4 days the product was isolated as a white 
powder with reversed-phase chromatography using a H2O/ACN 
gradient (during 2 CV 30% ACN, over 20 CV to 80% ACN).Yield 36% 
(0.31 g); colourless crystals; m.p. 144-150 °C; [α]D
25 = -54.5 (c=0.35 in CHCl3); 
1H NMR (400 MHz, 
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CDCl3) δ 1.74-1.88 (1H, m, CHaHb-14), 1.90-2.05 (2H, m, CHaHb-13, CHaHb-14), 2.18-2.26 (1H, m, 
CHaHb-13), 2.96-3.04 (1H, m, CHaHb-15), 3.10 (1H, dd, J=16.3 Hz, J=1.2 Hz, CHaHb-8), 3.26 (1H, dd, 
J=16.3 Hz, J=6.2 Hz, CHaHb-8), 3.81 (1H, dd, J=11.1 Hz, J=4.9 Hz, CH-12), 3.94-4.03 (1H, m, CHaHb-15), 
5.15 (1H, d, J=12.2 Hz, CHaHb-19), 5.22 (1H, d, J=12.2 Hz, CHaHb-19), 5.52 (1H, dd, J=6.2 Hz, J=1.2 Hz, 
CH-9), 7.14 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-5), 7.22-7.28 (1H, m, CH-6), 7.30-7.39 (6H, m, CH-7, CH-21, 
CH-22, CH-23, CH-24, CH-25), 7.47 (1H, d, J=7.6 Hz, CH-4), 8.19 (1H, s, NH-1) ppm; 13C NMR (100 
MHz, CDCl3) δ 21.3 (CH2-14), 23.8 (CH2-8), 28.4 (CH2-13), 44.4 (CH2-15), 60.5 (CH-9), 68.2 (CH2-19), 
70.2 (CH-12), 75.1 (Cq-11), 109.5 (Cq-3), 111.6 (CH-7), 119.3 (CH-4), 120.6 (CH-5), 123.9 (CH-6), 126.3 
(Cq-3a), 128.3 (CH-21, CH-25), 128.4 (CH-23), 128.6 (CH-22, CH-24), 133.1 (Cq-2), 135.5 (Cq-20), 136.1 
(Cq-7a), 154.5 (CC=O-18), 167.6 (CC=O-17) ppm; IR (cm
-1): max = 3264 (NH), 1725 (C=O), 1636 (C=O), 
1451; MS (ES): m/z (%) = 436/438 (100/30) [M + H]+; HRMS (ESI): calcd. for C24H23ClN3O3
+ [M + H]+: 
436.1422; found: 436.1418. 
allyl (6R,13S,13aS)-13-chloro-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxylate 280 
Following general procedure 7.5.1 on a 2.0 mmol scale, the crude 
carbamoyl chloride 277 was dissolved in allyl alcohol (3 equiv., 
6.0 mmol, 0.41 mL). After 4 days the product 280 was isolated as a 
yellow powder with column chromatography using a mixture of EtOAc 
and petroleum ether as eluent. Yield 44% (0.34 g); yellow powder; Rf=0.15 (2/8 petroleum 
ether/EtOAc); m.p. 107-109 °C; [α]D
25 = -67.7 (c=0.64 in CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.73-1.90 
(1H, m, CHaHb-14), 1.94-2.10 (2H, m, CHaHb-13, CHaHb-14), 2.18-2.29 (1H, m, CHaHb-13), 2.96-3.05 (1H, 
m, CHaHb-15), 3.13 (1H, dd, J=16.3 Hz, J=1.2 Hz, CHaHb-8), 3.31 (1H, dd, J=16.3 Hz, J=6.2 Hz, CHaHb-8), 
3.82 (1H, dd, J=11.1 Hz, J=4.9 Hz, CH-12), 3.93-4.06 (1H, m, CHaHb-15), 4.59-4.73 (2H, m, CH2-19), 5.26 
(1H, dd, J=10.4 Hz, J=1.3 Hz, CHaHb-21), 5.34 (1H, dd, J=17.2 Hz, J=1.3 Hz, CHaHb-21), 5.52 (1H, dd, 
J=6.2 Hz, J=1.2 Hz, CH-9), 5.88-6.00 (1H, m, CH-20), 7.14 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-5), 7.24 (1H, 
dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.36 (1H, d, J=7.7 Hz, CH-7), 7.48 (1H, d, J=7.7 Hz, CH-4), 8.37 (1H, s, NH-
1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.3 (CH2-14), 23.8 (CH2-8), 28.4 (CH2-13), 44.4 (CH2-15), 60.5 
(CH-9), 67.1 (CH2-19), 70.2 (CH-12), 75.0 (Cq-11), 109.4 (Cq-3), 111.6 (CH-7), 118.7 (CH2-21), 119.3 
(CH-4), 120.6 (CH-5), 123.8 (CH-6), 126.2 (Cq-3a), 131.9 (CH-20), 133.2 (Cq-2), 136.2 (Cq-7a), 154.3 
(CC=O-18), 167.7 (CC=O-17) ppm; IR (cm
-1): max = 3265 (NH), 1728 (C=O), 1634 (C=O), 1451; MS (ES): 
m/z (%) = 386/388 (100/35) [M + H]+; HRMS (ESI): calcd. for C20H21ClN3O3
+ [M + H]+: 386.1266; found: 
386.1276. 
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7.5.3. Urea derivatives 
(6R,13S,13aS)-N-benzyl-13-chloro-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxamide 281 
Following general procedure 7.5.1 on a 2.0 mmol scale, benzylamine 
(3 equiv., 6.0 mmol, 0.66 mL) was added to the crude carbamoyl 
chloride 277. A brown precipitate is formed and the product 281 was 
isolated as a brown foam with column chromatography using a 
mixture of EtOAc and petroleum ether as eluent. Yield 58% (0.34 g); 
brown foam; Rf=0.40 (2/8 petroleum ether/EtOAc); m.p. >260 °C; [α]D
25 = -344.0 (c=0.53 in DMSO); 
1H NMR (400 MHz, CDCl3) δ 1.72-1.85 (1H, m, CHaHb-14), 1.93-2.05 (2H, m, CHaHb-13, CHaHb-14), 
2.08-2.16 (1H, m, CHaHb-13), 2.95-3.03 (1H, m, CHaHb-15), 3.08 (1H, dd, J=16.4 Hz, J=1.1 Hz, CHaHb-8), 
3.28 (1H, dd, J=16.4 Hz, J=6.4 Hz, CHaHb-8), 3.83 (1H, dd, J=11.1 Hz, J=4.9 Hz, CH-12), 4.01-4.10 (1H, 
m, CHaHb-15), 4.40 (1H, dd, J=14.7Hz, J=5.4 Hz, CHaHb-20), 4.50 (1H, dd, J=14.7Hz, J=5.4 Hz, CHaHb-
20), 5.18 (1H, dd, J=6.4 Hz, J=1.1 Hz, CH-9), 6.06 (1H, t, J=5.4 Hz, NH-19), 7.14 (1H, dd, J=7.6 Hz, J=7.6 
Hz, CH-5), 7.22-7.38 (7H, m, CH-6, CH-7, CH-22, CH-23, CH-24, CH-25, CH-26), 7.48 (1H, d, J=7.6 Hz, 
CH-4), 8.17 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.4 (CH2-14), 23.7 (CH2-8), 28.4 (CH2-13), 
44.4 (CH2-15), 45.3 (CH2-20), 61.5 (CH-9), 70.1 (CH-12), 78.4 (Cq-11), 110.3 (Cq-3), 111.5 (CH-7), 119.5 
(CH-4), 120.6 (CH-5), 123.8 (CH-6), 126.4 (Cq-3a), 127.6 (CH-24), 127.8 (CH-22, CH-26), 128.8 (CH-23, 
CH-25), 132.8 (Cq-2), 136.2 (Cq-7a), 137.9 (Cq-21), 158.3 (CC=O-18), 168.2 (CC=O-17) ppm; IR (cm
-1): 
max = 3174 (NH), 1609 (C=O), 1457; MS (ES): m/z (%) = 435/437 (15/5) [M + H]+, 302/304 (25/8), 
241 (100); HRMS (ESI): calcd. for C24H24ClN4O2
+ [M + H]+: 435.1582; found: 435.1591. 
(6R,13S,13aS)-13-chloro-N-(naphthalen-1-ylmethyl)-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-
epiminopyrrolo[1',2':1,2]azocino[4,5-b]indole-14-carboxamide 282 
Following general procedure 7.5.1 on a 4.0 mmol scale, 
1-napthylmethylamine (3 equiv., 12.0 mmol, 1.8 mL) was added 
to the crude carbamoyl chloride 277. A brown precipitate is 
formed. Compound 282 was obtained as a white powder after 
rinsing the product with methanol. Yield 32% (0.62 g); white 
powder; m.p. >260 °C; [α]D
25 = -248.1 (c=0.83 in DMSO); 1H NMR (400 MHz, DMSO-d6) δ 1.70-1.87 
(2H, m, CH2-14), 1.95-2.10 (2H, m, CH2-13), 2.77 (1H, d, J=16.1 Hz, CHaHb-8), 2.89-2.98 (1H, m, 
CHaHb-15), 3.04 (1H, dd, J=16.1 Hz, J=6.2 Hz, CHaHb-8), 3.76-3.87 (2H, m, CH-12, CHaHb-15), 4.62-4.82 
(3H, m, CH-9, CH2-20), 7.01 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5), 7.14 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-6), 
7.39 (1H, d, J=7.8 Hz, CH-7), 7.42 (1H, d, J=7.8 Hz, CH-4), 7.45-7.50 (2H, m, CH-22, CH-23), 7.53-7.57 
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(2H, m, CH-26, CH-27), 7.87 (1H, dd, J=7.3 Hz, J=1.7 Hz, CH-24), 7.95-7.98 (1H, m, CH-25), 8.09-8.13 
(1H, m, CH-28), 8.25 (1H, t, J=5.7 Hz, NH-19), 11.24 (1H, s, NH-1) ppm; 13C NMR (100 MHz, DMSO-d6) 
δ 21.3 (CH2-14), 23.6 (CH2-8), 28.5 (CH2-13), 42.2 (CH2-20), 44.4 (CH2-15), 63.0 (CH-9), 69.6 (CH-12), 
76.5 (Cq-11), 107.4 (Cq-3), 112.3 (CH-7), 118.9 (CH-4), 119.7 (CH-5), 122.7 (CH-6), 124.0 (CH-28), 125.8 
(CH-22*), 126.1 (Cq-3a), 126.2 (CH-23*), 126.3 (CH-26), 126.6 (CH-27), 128.1 (CH-24), 129.0 (CH-25), 
131.4 (Cq-28a), 133.8 (Cq-24a), 134.7 (Cq-2), 135.1 (Cq-21), 136.5 (Cq-7a), 158.6 (CC=O-18), 167.9 
(CC=O-17) ppm (The signals with the same superscript (*) may be interchanged); IR (cm
-1): max = 
3172 (NH), 1665 (C=O), 1630 (C=O), 1505, 1456; MS (ES): m/z (%) = 485/487 (10/3) [M + H]+, 302/304 
(30/10), 141 (100); HRMS (ESI): calcd. for C28H26ClN4O2
+ [M + H]+: 485.1739; found: 485.1744. 
7.5.4. Hydrogenolysis of 279 
To a solution of compound 279 (0.089 mmol, 39 mg) in MeOH, 10 wt% of Pd/C (4 mg) was added. 
The reaction mixture was stirred under 5 atm of H2 for 4 hours at room temperature. The Pd/C 
catalyst was removed by filtration through a celite pad. The filtrate was concentrated in vacuo to give 
the crude product 284. The pure product 284 was obtained after pHPLC using an isocratic gradient of 
H2O/ACN (20% ACN). 
Yield 17% (4 mg); white powder; 1H NMR (400 MHz, CDCl3) δ 1.78-2.06 (5H, 
m, CH2-13, CH2-14, NH-10), 2.91-2.99 (1H, m, CHaHb-15), 3.05 (1H, d, 
J=16.3 Hz, CHaHb-8), 3.14 (1H, dd, J=16.3 Hz, J=6.6 Hz, CHaHb-8), 3.44 (1H, dd, 
J=11.2 Hz, J=5.1 Hz, CH-12), 4.00-4.09 (1H, m, CHaHb-15), 4.10 (1H, d, 
J=6.6 Hz, CH-9), 4.34 (1H, s, CH-11), 7.11 (1H, dd, J=7.3 Hz, J=7.3 Hz, CH-5), 7.18 (1H, dd, J=7.3 Hz, 
J=7.3 Hz, CH-6), 7.33 (1H, d, J=7.3 Hz, CH-7), 7.49 (1H, d, J=7.3 Hz, CH-4), 7.87 (1H, s, NH-1) ppm; 
13C NMR (100 MHz, CDCl3) δ 22.1 (CH2-14), 25.1 (CH2-8), 28.4 (CH2-13), 43.0 (CH2-15), 46.9 (CH-11), 
53.9 (CH-9), 63.7 (CH-12), 107.0 (Cq-3), 111.0 (CH-7), 118.5 (CH-4), 120.0 (CH-5), 122.3 (CH-6), 127.1 
(Cq-3a), 134.6 (Cq-2), 135.6 (Cq-7a), 171.0 (CC=O-17) ppm; MS (ES): m/z (%) = 286 (100) [M + H]
+; HRMS 
(ESI): calcd. for C16H18N3O
+ [M + H]+: 286.1444; found: 286.1445. 
7.5.5. Substitution of chlorine in carbamate 278 
The nucleophile (1.5 equiv., 0.75 mmol) was dissolved in THF (5 mL) at room temperature. The 
solution was cooled to 0 °C and sodium hydride (1.5 equiv., 0.75 mmol, 30 mg, 60% in mineral oil) 
was added. After stirring for 15 minutes at 0 °C, carbamate 278 (1 equiv., 0.5 mmol, 180 mg) was 
added to the mixture. The mixture was allowed to warm up to room temperature and was kept 
stirring until the conversion was complete. The reaction was monitored using HPLC-MS. An ammonia 
chloride solution (10 mL) and EtOAc (15 mL) were added subsequently. The layers were separated 
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and the aqueous phase was extracted with 10 mL EtOAc. The combined organic phases were washed 
3 times with water (10 mL). The organic phase was dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure to remove the solvent. When necessary, further purification 
was done by reversed-phase chromatography using a gradient of water and acetonitrile as eluent or 
recrystallization to provide the desired compound. 
methyl (6R,13S,13aS)-13-(allyloxy)-5-oxo-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxylate 286 
Following general procedure 7.5.5 using 1.5 equivalents of allyl alcohol, 286 
was obtained after purification by reversed-phase chromatography (2 CVs 
30% ACN, over 20 CVs to 80% ACN) as a white powder. Yield 9% (17 mg); 
white powder; m.p. 152-156 °C; [α]D
25 = -30.5 (c=0.16 in CHCl3); 
1H NMR 
(400 MHz, CDCl3) δ 1.70-1.86 (2H, m, CHaHb-13, CHaHb-14), 1.94-2.05 (1H, 
m, CHaHb-14), 2.10-2.19 (1H, m, CHaHb-13), 2.92-3.01 (1H, m, CHaHb-15), 3.14 (1H, dd, J=16.1 Hz, 
J=1.8 Hz, CHaHb-8), 3.22 (1H, dd, J=16.1 Hz, J=5.8 Hz, CHaHb-8), 3.66 (1H, dd, J=11.3 Hz, J=4.8 Hz, 
CH-12), 3.76 (3H, s, CH3-19), 3.85-3.96 (2H, m, CHaHb-15, CHaHb-20), 4.25-4.32 (1H, m, CHaHb-20), 5.23 
(1H, dd, J=10.5 Hz, J=1.6 Hz, CHaHb-22), 5.34 (1H, dd, J=17.3 Hz, J=1.6 Hz, CHaHb-22), 5.50 (1H, dd, 
J=5.8 Hz, J=1.8 Hz, CH-9), 5.94-6.05 (1H, m, CH-21), 7.14 (1H, dd, J=7.8 Hz, J=7.8 Hz, CH-5), 7.24 (1H, 
dd, J=7.8 Hz, J=7.8 Hz, CH-6), 7.35 (1H, d, J=7.8 Hz, CH-7), 7.51 (1H, d, J=7.8 Hz, CH-4), 8.10 (1H, s, 
NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.7 (CH2-14), 23.9 (CH2-8), 26.2 (CH2-13), 43.6 (CH2-15), 
53.0 (CH3-19), 59.7 (CH-9), 66.5 (CH2-20), 67.9 (CH-12), 87.0 (Cq-11), 111.4 (CH-7), 111.7 (Cq-3), 116.4 
(CH2-22), 119.2 (CH-4), 120.3 (CH-5), 123.3 (CH-6), 126.3 (Cq-3a), 132.5 (Cq-2), 134.3 (CH-21), 136.2 
(Cq-7a), 155.6 (CC=O-18), 168.8 (CC=O-17) ppm; IR (cm
-1): max = 3258 (NH), 1692 (C=O), 1634 (C=O), 
1439; MS (ES): m/z (%) = 382 (100) [M + H]+, 763 (40); HRMS (ESI): calcd. for C21H24N3O4
+ [M + H]+: 
382.1761; found: 382.1761. 
methyl (6R,13S,13aS)-5-oxo-13-phenoxy-2,3,5,6,7,12,13,13a-octahydro-1H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indole-14-carboxylate 287 
Following general procedure 7.5.5 using 1.5 equivalents of phenol, 287 was 
obtained after recrystallization in methanol. Yield 38% (79 mg); colourless 
crystals; m.p. 221-223 °C; [α]D
25 = +14.8 (c=0.36 in CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 1.76-2.11 (3H, m, CHaHb-13, CH2-14), 2.28-2.36 (1H, m, 
CHaHb-13), 2.97-3.05 (1H, m, CHaHb-15), 3.26 (1H, dd, J=16.3 Hz, J=1.4 Hz, 
CHaHb-8), 3.38 (1H, dd, J=16.3 Hz, J=6.1 Hz, CHaHb-8), 3.51 (3H, s, CH3-19), 
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3.82 (1H, dd, J=11.4 Hz, J=4.9 Hz, CH-12), 3.92-4.01 (1H, m, CHaHb-15), 5.61 (1H, dd, J=6.1 Hz, J=1.4 
Hz, CH-9), 6.81-6.94 (3H, m, CH-21, CH-23, CH-25), 7.08-7.24 (5H, m, CH-5, CH-6, CH-7, CH-22, 
CH-24), 7.53 (1H, d, J=7.6 Hz, CH-4), 7.80 (1H, s, NH-1) ppm; 13C NMR (100 MHz, CDCl3) δ 21.6 (CH2-
14), 23.8 (CH2-8), 26.6 (CH2-13), 43.7 (CH2-15), 53.0 (CH3-19), 59.7 (CH-9), 68.5 (CH-12), 85.8 (Cq-11), 
111.0 (Cq-3), 111.7 (CH-7), 116.4 (CH-21, CH-25), 119.2 (CH-4), 120.4 (CH-5), 122.1 (CH-23), 123.3 
(CH-6), 126.3 (Cq-3a), 129.4 (CH-22, CH-24), 132.0 (Cq-2), 136.6 (Cq-7a), 155.1 (CC=O-18, Cq-20), 168.4 
(CC=O-17) ppm; IR (cm
-1): max = 3058 (NH), 1698 (C=O), 1627 (C=O), 1439; MS (ES): m/z (%) = 418 
(100) [M + H]+, 834 (80); HRMS (ESI): calcd. for C24H24N3O4
+ [M + H]+: 418.1761; found: 418.1794. 
7.6. Introducing the α-chloroamine in cyclo(D-Trp, L-Hyp) 190b 
7.6.1. Introduction of acetyl groups on cyclo(D-Trp, L-Hyp) 190b 
Diketopiperazine cyclo(D-Trp, L-Hyp) 190b (1 equiv., 1.0 mmol, 0.30 g) was dissolved in dry CH2Cl2 
(20 mL) under a nitrogen atmosphere. Triethylamine (1.1 equiv., 1.1 mmol, 0.15 mL), DMAP 
(0.05 equiv., 0.05 mmol, 6 mg) and Ac2O (1.1 equiv., 1.1 mmol, 0.10 mL) were added to the solution. 
When the conversion stagnated, a supplementary amount of Ac2O (1.1 equiv., 1.1 mmol, 0.10 mL) 
was added and the mixture was left to stir overnight. Next, the solution was washed three times with 
1 M HCl (3×15 mL), saturated aq. NaHCO3 (3×15 mL) and water (15 mL). The organic layer was dried 
over magnesium sulfate and concentrated in vacuo yielding a mixture of di- and tri-acetylated 
diketopiperazine. Both compounds were isolated using reversed-phase chromatography (2 CVs 20% 
ACN, over 20 CVs to 60% ACN). 
(3R,7R,8aS)-3-((1H-indol-3-yl)methyl)-2-acetyl-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-7-yl 
acetate 293 
Yield 34% (0.13 g); white foam; m.p. 198-204 °C; 1H-NMR (400 MHz, 
CDCl3) δ 1.76-1.83 (1H, m, CHaHb-13), 1.83 (3H, s, CH3-21), 2.04 (1H, 
dd, J=13.8 Hz, J=5.9 Hz, CHaHb-13), 2.50 (1H, dd, J=11.7 Hz, J=5.9 Hz, 
CH-12), 2.60 (3H, s, CH3-19), 3.08 (1H, d, J=14.0 Hz, CHaHb-15), 3.35 
(1H, dd, J=15.0 Hz, J=5.3 Hz, CHaHb-8), 3.63 (1H, dd, J=15.0 Hz, J=2.9 Hz, CHaHb-8), 3.76 (1H, dd, 
J=14.0 Hz, J=5.1 Hz, CHaHb-15), 5.03 (1H, dd, J=5.1 Hz, J=5.1 Hz, CH-14), 5.31 (1H, dd, J=5.3 Hz, 
J=2.9 Hz, CH-9), 6.91 (1H, s, CH-2), 7.12 (1H, dd, J=8.0 Hz, J=8.0 Hz, CH-5), 7.18 (1H, dd, J=8.0 Hz, 
J=8.0 Hz, CH-6), 7.37 (1H, d, J=8.0 Hz, CH-7), 7.57 (1H, d, J=8.0 Hz, CH-4), 8.20 (1H, s, NH-1) ppm; 
13C NMR (100 MHz, CDCl3) δ 20.9 (CH3-21), 27.8 (CH3-19), 28.0 (CH2-8), 35.9 (CH2-13), 51.7 (CH2-15), 
57.4 (CH-12), 59.7 (CH-9), 69.8 (CH-14), 109.8 (Cq-3), 111.1 (CH-7), 119.2 (CH-4), 120.1 (CH-5), 122.8 
(CH-6), 124.2 (CH-2), 127.2 (Cq-3a), 136.1 (Cq-7a), 165.1 (CC=O-17), 169.8 (CC=O-11, CC=O-20), 171.9 
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(CC=O-18) ppm; IR (cm
-1): max = 3299 (NH), 1737 (C=O), 1710 (C=O), 1660 (C=O); MS (ES): m/z (%) = 
384 (100) [M + H]+, 766 (20); HRMS (ESI): calcd. for C20H22N3O5
+ [M + H]+: 384.1554; found: 384.1548. 
(3R,7R,8aS)-2-acetyl-3-((1-acetyl-1H-indol-3-yl)methyl)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-7-
yl acetate 294 
Yield 18% (0.076 g); white powder; m.p. 90-96 °C; 1H-NMR (400 
MHz, CDCl3) δ 1.87 (3H, s, CH3-23), 1.87-1.95 (1H, m, CHaHb-13), 2.16 
(1H, dd, J=13.9 Hz, J=5.8 Hz, CHaHb-13), 2.60 (6H, s, CH3-19, CH3-21), 
3.00 (1H, dd, J=11.5 Hz, J=5.9 Hz, CH-12), 3.17 (1H, d, J=14.0 Hz, 
CHaHb-15), 3.33 (1H, dd, J=15.0 Hz, J=5.5 Hz, CHaHb-8), 3.50 (1H, dd, J=15.0 Hz, J=3.4 Hz, CHaHb-8), 
3.78 (1H, dd, J=14.0 Hz, J=5.0 Hz, CHaHb-15), 5.12 (1H, dd, J=5.0 Hz, J=5.0 Hz, CH-14), 5.33 (1H, dd, 
J=5.5 Hz, J=3.4 Hz, CH-9), 7.20 (1H, s, CH-2), 7.29 (1H, dd, J=7.4 Hz, J=7.4 Hz, CH-5), 7.36 (1H, dd, 
J=7.4 Hz, J=7.4 Hz, CH-6), 7.49 (1H, d, J=7.4 Hz, CH-4), 8.43 (1H, d, J=7.4 Hz, CH-7) ppm; 
13C NMR (100 MHz, CDCl3) δ 20.9 (CH3-23), 24.1 (CH3-19), 27.8 (CH2-8, CH3-21), 36.0 (CH2-13), 51.7 
(CH2-15), 57.6 (CH-12), 59.1 (CH-9), 69.8 (CH-14), 116.3 (Cq-3), 116.7 (CH-7), 119.0 (CH-4), 123.9 
(CH-5), 124.8 (CH-2), 126.0 (CH-6), 129.9 (Cq-3a), 135.7 (Cq-7a), 164.6 (CC=O-17), 168.4 (CC=O-18), 169.3 
(CC=O-11), 169.8 (CC=O-22), 171.9 (CC=O-20) ppm; IR (cm
-1): max = 1738 (C=O), 1704 (C=O), 1668 (C=O), 
1452; MS (ES): m/z (%) = 426 (100) [M + H]+; HRMS (ESI): calcd. for C22H24N3O6
+ [M + H]+: 424.1509; 
found: 424.1533.  
7.6.2. Introduction of Boc groups on dipeptide 182b 
Dipeptide 182b (1 equiv., 8.0 mmol, 3.7 g), synthesized according to the general procedure in 4.2.1, 
was dissolved in dry ACN (50 mL) under a nitrogen atmosphere. DMAP (0.2 equiv, 1.6 mmol, 0.20 g) 
and Boc2O (1.2 equiv., 9.6 mmol, 2.10 g) were added to the solution. To obtain the fully diprotected 
product, a supplementary amount of Boc2O (1 equiv., 8.0 mmol, 1.75 g) was added and the mixture 
was left to stir overnight. Next, the mixture was concentrated under reduced pressure and the 
residue was dissolved in CH2Cl2 (50 mL). The organic layer was washed three times with brine (3×15 
mL) and subsequently dried over magnesium sulfate. Evaporation of the solvent under reduced 
pressure provided the crude dipeptide 296 (4.95 g).  
7.6.3. Hydrogenolysis and cyclization of Boc-protected dipeptide 296 
To a solution of dipeptide 296 in MeOH (100 mL), 5 wt% of Pd/C (0.25 g) was added. The reaction 
mixture was stirred under 5 atm of H2 overnight at room temperature. The Pd/C catalyst was 
removed by filtration through a celite pad. The methanolic solution was stirred at room temperature 
until ring closure was complete, which was monitored with HPLC-MS. The filtrate was concentrated 
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in vacuo to give the crude diketopiperazine 297. The pure product 297 was obtained as a white foam 
after column chromatography using a mixture of EtOAc and petroleum ether as eluent. 
tert-butyl 3-(((3R,7R,8aS)-7-((tert-butoxycarbonyl)oxy)-1,4-dioxooctahydropyrrolo[1,2-a]pyrazin-3-
yl)methyl)-1H-indole-1-carboxylate 297 
Yield 52% over 2 steps (2.08 g); white foam; Rf = 0.20 (1/1 
petroleum ether/EtOAc) ; m.p. 118-120 °C; 1H-NMR 
(400 MHz, CDCl3) δ 1.50 (9H, s, 3×CH3-23),1.67 (9H, s, 
3×CH3-20), 2.02-2.12 (1H, m, CHaHb-13), 2.49 (1H, dd, 
J=14.0 Hz, J=4.8 Hz, CHaHb-13), 3.14 (1H, dd, J=14.5 Hz, 
J=8.5 Hz, CHaHb-8), 3.29 (1H, dd, J=14.5 Hz, J=3.6 Hz, CHaHb-8), 3.50 (1H, d, J=11.3 Hz, CHaHb-15),3.93-
4.04 (2H, m, CHaHb-15, CH-12), 4.23 (1H, ddd, J=8.5 Hz, J=3.6 Hz, J=3.6 Hz, CH-9), 5.14 (1H, t, J=4.8 Hz, 
CH-14), 6.07 (1H, d, J=3.6 Hz, NH-10), 7.25 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-5), 7.34 (1H, dd, J=7.7 Hz, 
J=7.7 Hz, CH-6), 7.48 (1H, s, CH-2), 7.55 (1H, d, J=7.7 Hz, CH-4), 8.16 (1H, d, J=7.7 Hz, CH-7) ppm; 
13C NMR (100 MHz, CDCl3) δ 27.7 (3×CH3-23), 28.2 (3×CH3-20), 30.5 (CH2-8), 35.6 (CH2-13), 52.3 
(CH2-15), 56.4 (CH-12), 57.9 (CH-9), 72.7 (CH-14), 83.1 (Cq-22), 84.1 (Cq-19), 114.2 (Cq-3), 115.5 (CH-7), 
118.8 (CH-4), 122.9 (CH-5), 125.0 (CH-6, CH-2), 129.4 (Cq-3a), 135.6 (Cq-7a), 149.4 (C=O-18), 152.4 
(C=O-21), 165.1 (C=O-17), 168.1 (C=O-11) ppm; IR (cm-1): max = 1733 (C=O), 1670 (C=O), 1451; MS 
(ES): m/z (%) = 344 (100) [M + H]+, 522 (10) [M + Na]+; HRMS (ESI): calcd. for C26H33N3NaO7
+ [M + Na]+: 
522.2211; found: 522.2220.  
7.6.4. Selective synthesis of O-methylated cyclo(Trp, Hyp) 304 
7.6.4.1. N-Boc protection of HypOMe∙HCl 299 
To a solution of 4-hydroxyproline methyl ester hydrochloride 299 (1 equiv., 24 mmol, 4.4 g) in 
acetone and water (3:2, 30 mL) were added triethylamine (2 equiv., 48 mmol, 6.8 mL), DMAP (0.05 
equiv., 1.2 mmol, 147 mg) and (Boc)2O (1.4 equiv., 34 mmol, 7.4 g). The mixture was stirred 
overnight. The acetone was removed under reduced pressure and the residue was diluted with 
EtOAc (50 mL). The organic phase was subsequently washed with 0.5 M HCl (30 mL), water (30 mL) 
and brine (30 mL). Drying the organic phase over magnesium sulfate and concentration of the 
solvent under reduced pressure yielded the N-protected hydroxyproline methyl ester 300 as a 
colourless oil.[230] Yield 64% (3.93 g); colourless oil. 
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7.6.4.2. O-methylation of N-Boc-HypOMe 300 
Next, N-protected hydroxyproline methyl ester 300 (1 equiv., 6.4 mmol, 1.58 g) was dissolved in dry 
DMF (10 mL) and cooled to 0 °C. Sodium hydride (1.25 equiv., 8.1 mmol, 0.32 g, 60% in mineral oil) 
and after 15 minutes methyl iodide (1.25 equiv., 8.1 mmol, 0.50 mL) were added at 0 °C. The mixture 
was allowed to warm up to room temperature and was monitored using HPLC-MS. To obtain full 
conversion, an extra portion of sodium hydride (0.5 equiv., 3.2 mmol, 0.13 g, 60% in mineral oil) and 
methyl iodide (1.0 equiv., 6.4 mmol, 0.40 mL) were added. After the careful addition of some 
droplets of water, EtOAc (25 mL) was added. The organic phase was washed with saturated 
aq. NaHCO3 (20 mL) and 4 times with brine (4×20 mL). After drying over magnesium sulfate, the 
solution was concentrated under reduced pressure. The crude product was purified with column 
chromatography using a mixture of EtOAc and petroleum ether as eluent. The compound 301 was 
obtained as yellow oil. Yield 59% (0.98 g, de = 26%); yellow oil; Rf=0.56 (1/1 petroleum ether/EtOAc). 
7.6.4.3. Boc deprotection from 301 
The removal of the Boc protecting group was accomplished by dissolving compound 301 (1 equiv., 
3.8 mmol, 0.98 g) in 4 M HCl in dioxane (65 mL).[231] After stirring the solution for 1.5 hour at room 
temperature, the conversion was complete. The solution was concentrated under reduced pressure 
providing the 4-methoxyproline methyl ester hydrochloride 302. Crude yield quant. (0.74 g); yellow 
oil. 
7.6.4.4. Dipeptide synthesis 
4-Methoxyproline methyl ester hydrochloride 302 (1 equiv., 3.8 mmol, 0.74 g,) was dissolved in dry 
CH2Cl2 (50 mL) and N-benzyloxycarbonyltryptophan 155b (1 equiv., 3.8 mmol, 1.28 g) and EDC∙HCl 
(1 equiv., 0.73 g, 3.8 mmol) were subsequently added under a nitrogen atmosphere. The mixture was 
stirred at room temperature for 16 hours and was then washed three times with 1 M HCl (40 mL) and 
saturated aq. NaHCO3 (40 mL). The organic layer was dried over magnesium sulfate and evaporated, 
yielding dipeptide 303.  
7.6.4.5. Hydrogenolysis and cyclization 
To a solution of dipeptide 303 in MeOH (250 mL), 5 wt% of Pd/C was added. The reaction mixture 
was stirred under 5 atm of H2 for 3 hours at room temperature. The Pd/C catalyst was removed by 
filtration through a celite pad. The filtrate was concentrated in vacuo to give the crude 
diketopiperazine. The pure product 304 was obtained after purification by reversed-phase 
chromatography (10 CVs 10% ACN, over 10 CVs to 20% ACN) as a white foam.  
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(3R,7R,8aS)-3-((1H-indol-3-yl)methyl)-7-methoxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 304 
Yield 30% over 3 steps (0.54 g); colourless crystals; m.p. 94-98 °C; [α]D
25 
= +40.0 (c=0.39 in CHCl3); 
1H-NMR (400 MHz, CDCl3) δ 1.71-1.81 (1H, m, 
CHaHb-13), 2.26-2.33 (1H, m, CHaHb-13), 3.15 (3H, s, CH3-18), 3.20-3.40 
(4H, m, CH-12, CH2-8, CHaHb-15), 3.65-3.72 (1H, m, CHaHb-15), 3.81-3.86 
(1H, m, CH-14), 4.18-4.24 (1H, m, CH-9), 6.13 (1H, s, NH-10), 7.02 (1H, s, CH-2), 7.13 (1H, dd, J=7.7 Hz, 
J=7.7 Hz, CH-5), 7.20 (1H, dd, J=7.7 Hz, J=7.7 Hz, CH-6), 7.37 (1H, d, J=7.7 Hz, CH-7), 7.61 (1H, d, 
J=7.7 Hz, CH-4), 8.30 (1H, s, NH-1) ppm; 13C-NMR (100 MHz, CDCl3) δ 30.6 (CH2-8), 35.0 (CH2-13), 51.0 
(CH2-15), 56.1 (CH3-18), 56.2 (CH-12), 58.5 (CH-9), 76.2 (CH-14), 109.4 (Cq-3), 111.3 (CH-7), 118.8 
(CH-4), 120.0 (CH-5), 122.5 (CH-6), 123.8 (CH-2), 126.9 (Cq-3a), 136.2 (Cq-7a), 165.5 (CC=O-17), 169.4 
(CC=O-11) ppm; IR (cm
-1): max = 3237 (NH), 1643 (C=O), 1453; MS (ES): m/z (%): 314 (100) [M + H]
+; 
HRMS (ESI): calcd. for C17H20N3O3
+ [M+H]+: 314.1499; found: 314.1514. 
7.6.5. Introduction of the α-chloroamine 
Diketopiperazine 304 (1 equiv., 3.0 mmol, 93.0 mg) was suspended in dry CH2Cl2 (3 mL) and cooled 
with an ice-bath to 0 °C under a nitrogen atmosphere. Diphosgene (3 equiv., 8.9 mmol, 0.11 mL), 
dissolved in dry CH2Cl2 (2 mL), was added dropwise to the suspension. The mixture was heated to 
reflux. After complete conversion (HPLC-MS) the organic phase was washed with saturated NaHCO3 
solution and with water. The organic phase was dried over magnesium sulfate and concentrated 
under reduced pressure. Purification of the residue by pHPLC using an isocratic H2O/ACN gradient 
(30% ACN) provided the desired product 305 as a white foam. 
(2R,6R,13S,13aS)-13-chloro-2-methoxy-1,2,3,6,7,12,13,13a-octahydro-5H-6,13-epiminopyrrolo-
[1',2':1,2]azocino[4,5-b]indol-5-one 305 
Yield 36% (35 mg); white foam; m.p. 236-238 °C; [α]D
25 = -160.7 (c=0.17 in 
CHCl3); 
1H-NMR (400 MHz, CDCl3) δ 2.03 (1H, ddd, J=12.6 Hz, J=12.6 Hz, 
J=6.4 Hz, CHaHb-13), 2.24 (1H, dd, J=12.6 Hz, J=4.6 Hz, CHaHb-13), 2.65 (1H, 
s, NH-10), 2.94 (1H, dd, J=13.3 Hz, J=2.1 Hz, CHaHb-15), 3.03 (1H, d, 
J=16.4 Hz, CHaHb-8), 3.16 (1H, dd, J=16.4 Hz, J=6.4 Hz, CHaHb-8), 3.30 (3H, s, CH3-18), 3.94-4.00 (1H, 
m, CH-14), 4.05 (1H, dd, J=12.6 Hz, J=4.6 Hz, CH-12), 4.21 (1H, d, J=6.4 Hz, CH-9), 4.37 (1H, dd, 
J=13.3 Hz, J=6.7 Hz, CHaHb-15), 7.13 (1H, dd, J=7.6 Hz, J=7.6 Hz, CH-5), 7.24 (1H, dd, J=7.6 Hz, J=7.6 Hz, 
CH-6), 7.36 (1H, d, J=7.6 Hz, CH-7), 7.47 (1H, d, J=7.6 Hz, CH-4), 8.27 (1H, s, NH-1) ppm; 
13C-NMR (100 MHz, CDCl3) δ 24.9 (CH2-8), 35.5 (CH2-13), 52.1 (CH2-15), 56.7 (CH3-18), 58.0 (CH-9), 
66.5 (CH-12), 76.4 (Cq-11), 77.2 (CH-14), 109.2 (Cq-3), 111.6 (CH-7), 119.3 (CH-4), 120.4 (CH-5), 123.6 
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(CH-6), 126.5 (Cq-3a), 134.1 (Cq-2), 136.0 (Cq-7a), 169.1 (C=O-17) ppm; IR (cm
-1): max = 3273 (NH), 
1638 (C=O), 1454; MS (ES): m/z (%): 332/334 (100/33) [M + H]
+; HRMS (ESI): calcd. for 
C17H20ClN3O2
+ [M+H]+: 332.1160; found: 332.1169. 
7.7. In vitro assays 
7.7.1. Single-cell collagen invasion assay procedure cited from De Wever et al.[162]  
The collagen invasion assays were assessed by the Laboratory of Experimental Cancer Research, 
Ghent University. Further details, critical points, timing, troubleshooting or suggestions can be found 
in the article from De Wever et al.  
Preparation of a collagen gel:  
1) Prepare collagen type I solution with a final concentration of 1 mg/mL collagen type I by 
mixing the following precooled (stored at 4 °C) components: 4 volumes collagen type I (stock 
is 3.49 mg/mL), 5 volumes of calcium- and magnesium-free Hank’s balanced salt solution, 1 
volume of minimal essential medium (10x), 1 volume of 0.25 M NaHCO3, 2.65 volumes of 
standard medium and 0.3 volumes of 1 M NaOH to make the solution alkaline. 
2) Add, for each test-condition, 1.25 mL of collagen type I solution to one well of a 6-well plate, 
spread homogeneously and let gelify on a flat surface in a humidified atmosphere of 10% CO2 
in air at 37 °C for at least 1 h to obtain a collagen gel with a 250 μm central thickness in the 
well. 
Preparation of single-cells: 
3) Prepare a single-cell suspension in standard medium by mild enzymatic dissociation, using a 
Ca2+- and Mg2+-free phosphate-buffered saline wash followed by incubation with a 
trypsin/ethylenediaminetetraacetic acid solution, of an exponentially growing culture 
(usually 70% confluence is used). 
4) Count a small aliquot of the cell suspension after staining with Trypan blue (0.04% Trypan 
blue in phosphate-buffered saline) to exclude dead cells. 
Initiation of invasion model: 
5) Prepare 1-2x105 viable, single-cells in 1 mL standard medium in 15 mL polypropylene tubes. 
Add test products such as growth factors (transforming growth factor-α) or drugs for 
preclinical (gefitinib) validation in desired concentration. Gently seed this mixture on top of 
blindcoded collagen type I gels. 
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6) Incubate cells in a humidified atmosphere with 10% CO2 in air at 37 °C for 24 h. 
Evaluation of single-cell invasion: 
7) Focus an inverted phase-contrast microscope (with objective 10x or 20x) downwards from 
the culture medium to the top of the gel onto a single focal plane. The edges of the cells 
appear brighter (cells have a ‘halo’ of light) compared to the background. The degree of 
reduction in brightness depends on the refractive index. Dense structures such as the 
nucleus or fibrillar collagen appear dark. Cellular extensions invading the collagen matrix 
appear dark because they are located out of phase (focal plane). Occasionally and dependent 
from cell-line to cell-line whole single-cells have migrated into the gel and appear dark. 
8) Take a digital image from 10-15 microscope fields. 
Calculation of invasion index (manual cell counting): 
9) Calculate the invasion index (cells with invasive extensions versus total number of cells x 100) 
by manual counting the number of invading and non-invading cells present in 10-15 
microscope fields. 
7.7.2. α2 (non-selective)  
The binding activity towards the α2 receptor obtained from rat cerebral cortex, was assessed by 
CEREP (France).[221, 246] Radiolabeled [3H]RX 821002 (0.5 nM) was used as ligand. Unlabeled RX 
821002 was used as a reference compound (IC50 = 58.7 nM). Test compounds were incubated at 
room temperature for one hour. The decrease in binding of radiolabeled RX 821002 in the presence 
of the tested compounds is measured by scintillation counting. 
7.7.3. D1 (antagonist radioligand)  
The binding activity towards the D1 receptor of human origin, obtained by recombinant production 
in CHO cells, was assessed by CEREP (France).[247-248] Radiolabeled [3H]SCH 23390 (0.3 nM) was used 
as ligand. Unlabeled SCH 23390 was used as a reference compound (IC50 = 0.242 nM). Test 
compounds were incubated at room temperature for a one hour period. The decrease in binding of 
radiolabeled SCH 23390 in the presence of the tested compounds is measured by scintillation 
counting. 
7.7.4. N neuronal α7  
The binding activity towards the N neuronal α7 receptor of human origin, obtained by recombinant 
production in SH-SY5Y cells, was assessed by CEREP (France).[249-250] Radiolabeled [125I]α-bungarotoxin 
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(0.5 nM) was used as ligand. Unlabeled α-bungarotoxin was used as a reference compound (IC50 = 0.7 
nM). Test compounds were incubated at 37 °C for 2 hours. The decrease in binding of radiolabeled α-
bungarotoxin in the presence of the tested compounds is measured by scintillation counting. 
7.7.5. N muscle-type (h) (antagonist radioligand) 
The activity towards the N muscle-type receptor originating from TE671 cells was assessed by CEREP 
(France).[251-252] Radiolabeled [125I]α-bungarotoxin (0.5 nM) was used as ligand. Unlabeled 
α-bungarotoxin was used as a reference compound (IC50 = 2 nM). Test compounds were incubated at 
room temperature for 2 hours. The decrease in binding of radiolabeled α-bungarotoxin in the 
presence of the tested compounds is measured by scintillation counting. 
7.7.6. Serotonin 5-HT1 (non-selective)  
The activity towards the serotonin 5-HT1 receptor originating from rat cerebral cortex was assessed 
by CEREP (France).[253-254] [3H]Serotonin (2 nM) was used as ligand. Unlabeled serotonin was used as a 
reference compound (IC50 = 0.0011 µM). Test compounds were incubated at 37 °C for 10 min. The 
decrease in binding of radiolabeled serotonin in the presence of the tested compounds is reflected in 
the percentage inhibition of control specific binding measured by scintillation counting. 
7.7.7. PDE5(h) (non-selective) 
This assay was run by CEREP (France),[223, 255] using PDE5 from human platelets. [3H]cGMP and cGMP 
(1 µM) were used as substrate. cGMP is broken down by the enzyme into guanosine-5'-triphosphate 
(GMP). The decrease in conversion of radiolabeled cGMP to GMP in the presence of the tested 
compounds is reflected in the percentage inhibition measured by scintillation counting. Incubation 
with the test compound was performed at room temperature over a one hour period. Dipyridamole 
served as a reference compound (IC50 = 0.7 µM). 
7.7.8. Tubulin polymerization 
Microtubule polymerization was assessed by CEREP (France).[256-257] Tubulin protein was obtained 
from porcine brain. Test compounds were incubated at 37 °C for 15 min, in the presence of 1mM of 
guanosine-5'-triphosphate (GTP) as a tubulin polymerization inducer. The assembly of microtubule 
was followed using DAPI as a fluorescent probe. Vinblastine served as a reference compound 
(IC50 = 1.2 µM). 
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7.7.9. BCRP (h) inhibition 
This assay was run by CEREP (France),[258-259] using BCRP of human origin, obtained by recombinant 
production in CHO-K1 cells. HOECHST 33342 (5 µM) was used as substrate and enzyme activity was 
determined by fluorimetry. Incubation with the test compound was performed at 37 °C, over a 
period of 20 minutes. KO143 served as a reference compound (IC50 = 480 nM). 
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Brevianamide F or cyclo(L-Pro, L-Trp) ia is a fungal secondary metabolite that is made up of two 
amino acids, proline and tryptophan (Figure 34). It is also a basic skeleton which can be found in 
several other natural products such as tryprostatins A and B, fumitremorgin C and stephacidin A, 
which display a wide range of biological activities. These compounds are mostly isolated from 
Streptomyces and Aspergillus species. The goal of this dissertation was to synthesize a library of less 
complex, physiologically active analogues based on these natural compounds. 
 
Figure 34: Diketopiperazine cyclo(L-Trp, L-Pro) ia. 
The first objective was to develop an efficient route for the synthesis of the basic skeleton, 
cyclo(Pro, Trp) i, starting from the L- and D-enantiomers of proline and tryptophan. Retention of the 
stereochemistry of these starting materials is essential. Different synthetic routes to obtain the 
desired compounds were evaluated. Most attention was paid to the coupling of the amino acids, but 
also the choice of the protecting group and the coupling order of the amino acids were examined. A 
first strategy was based on phosphorus-assisted amide formation and microwave heating. Next, 
benzotriazole activation was used, in which the amino acids were activated as their acylbenzotriazole 
counterparts to perform the coupling. A third strategy used 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC∙HCl) as a coupling reagent.  
The phosphite-promoted condensation of unprotected amino acids only provided the homocoupling 
product of proline. The synthetic route based on the benzotriazole methodology required more steps 
than EDC mediated coupling, resulting in lower overall yields. The procedure with EDC∙HCl appeared 
to be the best strategy for the coupling of the amino acids and was used to synthesize all four 
isomers in a limited number of steps and in good yields (Scheme 68). Spontaneous cyclization of the 
dipeptides towards the L,D and D,L isomers ib and ic occurred after Cbz-removal, but an extra 
cyclization step was required to obtain the cis-isomers ia and id. 
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Scheme 68: Synthesis of all isomers of cyclo(Trp, Pro) i. 
Having the basic skeleton i in hand, the objective was to decorate this framework i with biologically 
relevant substituents to obtain a diverse set of functionalized brevianamide analogues. The main 
goal was to introduce a supplementary ring in the basic skeleton i, connecting the diketopiperazine 
ring with the indole moiety. The introduction of such an extra bridge leads to a higher 
conformational rigidity of the scaffold, which often results in increased receptor specificity. To 
achieve this, several modifications can be examined. 
A first strategy that was attempted to achieve annulated derivatives was the Pictet-Spengler 
reaction. This reaction is usually performed on tryptamine or similar arylethylamines where the 
‘extra’ ring is introduced first by the condensation with an aldehyde or a ketone. This 1,2,3,4-
tetrahydro-β-carboline is then used as an intermediate that is modified to form a diketopiperazine. In 
the present work, the Pictet-Spengler reaction was performed on the available diketopiperazine i, 
which avoided the formation of different intermediates depending on the aldehyde used. A range of 
reaction conditions were tested but in all cases mixtures were obtained (Scheme 69). Based on HPLC-
MS these mixtures presumably contained the desired Pictet-Spengler products v. However, these 
compounds could never be isolated. The only isolated products from these reaction mixtures are 
dimers vi and vii. Several new dimers of i that are linked by an alkyl bridge between the indole 
nitrogens were obtained under Pictet-Spengler conditions (Table 39). 
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Scheme 69: Pictet-Spengler reaction of cyclo(Trp, Pro) i with an aldehyde. 
Table 39: Isolated yields of the dimeric products. 
 
 
 
 
Another strategy to modify the diketopiperazine scaffold i was through alkylation using an 
unsaturated electrophile such as allyl bromide. These compounds might be suitable for further 
transformation by metathesis. The formation of a spiro-annulated derivative viii was aspired through 
metathesis of the diallylated piperazin-2,5-dione ix (Scheme 70).  
 
Scheme 70: Aspired spiro-derivative viii via metathesis of diallylated ix. 
The introduction of an allyl group at the indole C-3 in the cis-isomers ia and id using palladium 
catalysis succeeded, but concomitant ring formation took place yielding the allylated and annulated 
derivatives xa and xb (Figure 35). Their stereochemistry was confirmed using NOE experiments.  
 
Figure 35: Allylated pentacyclic derivatives x. 
Cpd Starting compound Yield (%) 
via Cyclo(L-Trp, L-Pro) ia 46% 
vib Cyclo(D-Trp, L-Pro) ib 32% 
viia Cyclo(L-Trp, L-Pro) ia 16% 
viib Cyclo(D-Trp, L-Pro) ib 12% 
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Therefore, in our subsequent attempt the allyl group was first introduced at the amide nitrogen. To 
selectively introduce the allyl group at the amide nitrogen, several protecting and deprotecting steps 
at the indole nitrogen were necessary earlier in the synthesis. Unfortunately, epimerization took 
place during the synthesis of the mono-allylated product xi. Subsequent introduction of the allyl 
group at C-3 of the xi using the previously tested reaction conditions failed (Scheme 71). 
 
Scheme 71: Unsuccessful C-3 allylation of mono-allylated product xi. 
The diketopiperazine scaffold i was also subjected to several difunctionalized electrophilic reagents 
to accomplish the formation of an extra ring by forming a bridge between the amide nitrogen and 
the indole moiety. Only the reaction with CDI (1,1'-carbonylbis-1H-imidazole) gave a (clean) 
conversion and resulted in the formation of a dimer xii (Scheme 72).  
 
Scheme 72: Dimer xii from ib obtained with CDI. 
Another electrophile that was evaluated is phosgene, in the form of tri- or diphosgene. This resulted 
in the formation of pentacyclic compounds xiv and xv containing an α-chloroamine. Density 
functional theory (DFT) calculations suggest that the α-chloroamine is formed by direct attack by the 
C-2 atom of the indole group and not by C-3 attack and a subsequent 1,2-shift. The purification of xiv 
proved to be difficult and an optimization of the reaction conditions was performed. Modification of 
this rigid 3,5-bridged piperazin-2-one xivb was possible by substitution of the chlorine atom in xivb, 
which offers a new avenue towards synthetic analogues of brevianamides, fumitremorgins and 
(spiro)tryprostatins. A range of O-, N-, S- and C-nucleophiles (Nu-) was introduced under basic 
conditions, affording compounds xvi (Scheme 73). The purification of these derivatives xvi was 
troublesome, resulting in low isolated yields. A preliminary bioactivity screening of selected 
compounds revealed that the novel pentacyclic derivatives xvi possess significant breast cancer 
resistance protein (BCRP) inhibition. 
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Scheme 73: Synthesis of α-chloroamines xiv-xv and their derivatives xvi. 
Additionally, the carbamoyl chloride xvii was obtained when the pentacyclic xiv was left to react with 
diphosgene for a longer reaction time. This carbamoyl chloride xvii could easily be converted into the 
corresponding carbamate or urea xviii, by reaction with an alcohol or an amine, respectively. On 
their turn, these compounds could be modified by substitution of the chlorine atom, affording 
derivatives xix (Scheme 74). 
 
Scheme 74: Synthesis of carbamate and urea derivatives xviii. Further substitution of the chlorine atom yields 
compounds xix. 
In conclusion, a novel class of brevianamide F analogues, which possess interesting BCRP inhibitory 
activity, was synthesized. The presence of the α-chloroamine functionality provides an easy way to 
modify these 3,5-bridged structures, which may yield derivatives with a better BCRP inhibitory 
activity.  
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Brevianamide F of cyclo(L-Pro, L-Trp) ia is een secundair metaboliet van fungale oorsprong en is 
opgebouwd uit de aminozuren proline en tryptofaan (Figuur 1). Het vormt eveneens het basisskelet 
van verschillende andere natuurproducten zoals tryprostatines A en B, fumitremorgine C en 
stefacidine A, die een brede waaier aan biologische activiteiten vertonen. Deze verbindingen worden 
meestal geïsoleerd uit Streptomyces en Aspergillus species. Het doel van dit doctoraat bestond erin 
om een bibliotheek aan minder complexe, maar toch fysiologisch actieve verbindingen te 
synthetiseren die gebaseerd zijn op deze natuurproducten. 
 
Figuur 1: Diketopiperazine cyclo(L-Trp, L-Pro) ia. 
De eerste doelstelling was om een efficiënte route te ontwikkelen voor de synthese van het 
basisskelet cyclo(Pro, Trp) i, uitgaande van de verschillende isomeren van proline en tryptofaan. 
Hierbij is de retentie van de stereochemie van de startproducten van essentieel belang. Verschillende 
syntheseroutes om de gewenste verbindingen te bekomen werden vergeleken. De meeste aandacht 
werd geschonken aan de koppeling van de aminozuren, maar ook de invloed van de beschermende 
groepen en van de volgorde waarin de aminozuren werden gekoppeld, werden onderzocht. Een 
eerste strategie was gebaseerd op fosforgeassisteerde amidevorming en microgolfverwarming. 
Vervolgens werd de benzotriazoolmethodologie gebruikt, waarbij de aminozuren werden 
geactiveerd als hun overeenkomstige acylbenzotriazolen om de koppeling te bewerkstelligen. Een 
alternatieve strategie maakte gebruik van EDC∙HCl als koppelingsreagens. 
De fosfietgemedieerde condensatie van onbeschermde aminozuren leverde enkel het 
homogekoppelde product afgeleid van proline. De syntheseroute gebaseerd op de 
benzotriazoolmethodologie vereiste beduidend meer stappen dan de EDC-geassisteerde koppeling, 
wat resulteerde in lagere rendementen. De procedure met EDC∙HCl bleek de beste strategie te zijn 
voor de koppeling van de aminozuren, en werd gebruikt om de vier isomeren te synthetiseren in een 
beperkt aantal stappen en met goede rendementen (Schema 1). Er vond een spontane ringsluiting 
plaats van de dipeptiden bekomen na ontscherming van de Cbz-groep, met vorming van de L,D en D,L 
isomeren ib en ic. Een extra stap was echter nodig om de ringsluiting te bewerkstelligen bij de 
cis-isomeren ia en id. 
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Schema 1: Synthese van alle isomeren van cyclo(Trp, Pro) i. 
Met het skelet i ter beschikking, was het doel vervolgens om deze basisstructuur i te decoreren met 
relevante substituenten, teneinde op die manier een gevarieerde reeks aan gefunctionaliseerde 
analogen te verkrijgen. De hoofddoelstelling bestond uit het introduceren van een extra ring in het 
basisskelet i, die een verbinding maakt tussen de diketopiperazinering en de indoolgroep. Het 
invoegen van een extra brug leidt tot een grotere conformationele rigiditeit van het skelet, wat vaak 
aanleiding geeft tot een toegenomen selectiviteit voor een receptor. Om deze doelstelling te 
bereiken werden verschillende modificaties onderzocht. 
Een eerste strategie die werd getest, bestond erin om geannuleerde derivaten te bekomen door 
middel van een Pictet-Spenglerreactie. Deze reactie wordt doorgaans uitgevoerd op tryptamine of 
gelijkaardige arylethylamines, waarbij de ‘extra’ ring eerst wordt geïntroduceerd door de 
condensatie met een aldehyde of een keton. Dit 1,2,3,4-tetrahydro-β-carboline kan dan als 
intermediair dienen dat verder wordt omgezet in een diketopiperazine i. De Pictet-Spengler reactie 
werd in dit werk echter uitgevoerd op het reeds gevormde diketopiperazine i, waardoor de nood aan 
verschillende intermediairen, afhankelijk van het gebruikte aldehyde, werd vermeden. Verschillende 
reactiecondities werden onderzocht, maar keer op keer werden mengsels bekomen (Schema 2). Op 
basis van HPLC-MS-analyse bevatten deze mengsels wel degelijk het beoogde Pictet-Spengler 
product v. Deze verbindigen konden echter nooit geïsoleerd worden. De enige producten die werden 
bekomen uit deze reactiemengsels zijn de dimeren vi en vii. Verschillende nieuwe dimeren van i, die 
een alkylbrug bevatten tussen de indoolstikstofatomen, werden verkregen gebruik makende van 
reactiecondities die typisch zijn voor een Pictet-Spenglerreactie (Tabel 1). 
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Schema 2: Pictet-Spenglerreactie van cyclo(Trp, Pro) i met een aldehyde. 
Tabel 1: De rendementen van de opgezuiverde dimere producten. 
 
 
 
 
Een andere strategie om het diketopiperazineskelet i te wijzigen bestond uit een alkylering door 
middel van onverzadigde elektrofielen zoals allylbromide. Deze verbindingen zouden geschikte 
substraten moeten zijn voor een verdere omzetting door middel van metathese. De vorming van een 
spirogeannuleerd derivaat viii werd beoogd door middel van metathese van het digeallyleerde 
piperazin-2,5-dion ix (Schema 3). 
 
Schema 3: Beoogde spiro-derivaten viii met behulp van metathese van het digeallyleerd ix. 
Het invoeren van een allylgroep op C-3 van de indoolgroep in cis-isomeren ia en id gebruik makende 
van palladiumkatalyse was succesvol, maar tegelijkertijd vond een ringsluiting plaats die de 
geallyleerde en ringgesloten derivaten xa en xb opleverde (Figuur 2). De stereochemie van deze 
verbindingen werd bevestigd met behulp van NOE experimenten. 
Verbinding Startverbinding Rendement(%) 
via Cyclo(L-Trp, L-Pro) ia 46% 
vib Cyclo(D-Trp, L-Pro) ib 32% 
viia Cyclo(L-Trp, L-Pro) ia 16% 
viib Cyclo(D-Trp, L-Pro) ib 12% 
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Figuur 2: Geallyleerde pentacyclische derivaten x. 
Om deze ringsluiting te voorkomen werd de allylgroep eerst ingevoerd op het amidestikstofatoom. 
Om de allylgroep selectief op de amidestikstof te introduceren waren eerder in de synthesesequentie 
verschillende beschermings- en ontschermingsstappen nodig. Er werd echter epimerisatie 
vastgesteld tijdens de synthese van het monogeallyleerde product xi. De daaropvolgende invoering 
van de allylgroep op C-3 van xi, gebruik makende van de eerder geteste reactiecondities, faalde 
echter (Schema 4). 
 
Schema 4: Gefaalde C-3 allylering van het monogeallyleerd product xi. 
Het diketopiperazineskelet i werd eveneens behandeld met verschillende digefunctionaliseerde 
elektrofiele reagentia om de vorming van een extra ring, door middel van een brug tussen het 
amidestikstofatoom en de indoolgroep te bewerkstelligen. De reactie met CDI gaf conversie met 
vorming van slechts één product, opnieuw een dimeer xii (Schema 5). 
 
Schema 5: Dimeer xii van ib verkregen door middel van CDI. 
Een ander elektrofiel dat eveneens werd geëvalueerd was fosgeen, in de vorm van tri- of difosgeen. 
Hier werden pentacyclische verbindingen xiv en xv bekomen, die een α-chlooramine bevatten. 
‘Density functional theory’ (DFT) berekeningen suggereren dat het α-chlooramine wordt gevormd 
door directe aanval van het C-2 atoom van de indoolgroep, en niet door C-3-aanval en 
daaropvolgende 1,2-shift. De isolatie van xiv verliep moeizaam en een optimalisatie van de 
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reactiecondities werd uitgevoerd. Het modificeren van het rigide 3,5-gebrugde piperazin-2-on xiv 
was mogelijk door middel van substitutie van het chlooratoom. Dit creëert een nieuwe mogelijkheid 
voor het bereiden van synthetische analogen van de brevianamides, fumitremorgines en 
(spiro)tryprostatines. Een gamma aan O-, N-, S- en C-nucleofielen (Nu-) werden ingevoerd onder 
basische omstandigheden, met substitutie van het chlooratoom op het bruggenhoofd van xivb. Dit 
resulteerde in een reeks derivaten xvi (Schema 6). De isolatie van deze producten xvi verliep 
eveneens moeizaam, wat resulteerde in lage rendementen. Een eerste screening van de biologische 
activiteit van enkele verbindingen toonde aan dat deze nieuwe pentacyclische derivaten xvi een 
significante inhibitie uitoefenen van het ‘Breast Cancer Resistance Protein’ (BCRP). 
 
Schema 6: Synthese van α-chloroamines xiv-xv en verdere derivaten xvi. 
Daarenboven werd het carbamoylchloride van xvii bekomen wanneer ib lang genoeg werd 
gereageerd met difosgeen. Dit carbamoylchloride xvii kon gemakkelijk omgezet worden in het 
overeenkomstige carbamaat of ureum xviii, respectievelijk door reactie met een alcohol of een 
amine. Deze verbindingen konden op hun beurt verder gemodifieerd worden door substitutie van 
het chlooratoom, met vorming van derivaten xix (Schema 7). 
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Schema 7: Synthese van carbamaten en urea xviii. Verdere substitutie van het chlooratoom levert verbindingen xix. 
Samengevat, werd een nieuwe klasse van brevianamide F-analogen ontwikkeld die een inhiberende 
werking uitoefenen op BCRP. De aanwezigheid van het α-chlooramine maakt de synthese van een 
reeks aan derivaten mogelijk teneinde een betere BCRP-inhiberende activiteit te bekomen.  
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